<SEC-DOCUMENT>0001564590-15-003914.txt : 20150511
<SEC-HEADER>0001564590-15-003914.hdr.sgml : 20150511
<ACCEPTANCE-DATETIME>20150511161731
ACCESSION NUMBER:		0001564590-15-003914
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20150331
FILED AS OF DATE:		20150511
DATE AS OF CHANGE:		20150511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Versartis, Inc.
		CENTRAL INDEX KEY:			0001513818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				244106690
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36361
		FILM NUMBER:		15850956

	BUSINESS ADDRESS:	
		STREET 1:		4200 BOHANNON DRIVE
		STREET 2:		SUITE 250
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		6509638580

	MAIL ADDRESS:	
		STREET 1:		4200 BOHANNON DRIVE
		STREET 2:		SUITE 250
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vsar-10q_20150331.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<!-- NG Converter v3.0.3.5 -->
<body>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:center;border-top:Solid 1pt;padding-top:1pt;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="margin-top:3pt;text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;line-height:4pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-Q </p>
<p style="margin-top:3pt;text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;line-height:4pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#120;</font></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the quarterly period ended March&#160;31, 2015 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from<font style="color:#;"> </font><font style="text-decoration:underline;color:#;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#;"> </font>to<font style="color:#;"> </font><font style="text-decoration:underline;color:#;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission file number: 001-36361</p>
<p style="margin-top:3pt;text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;line-height:4pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Versartis, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter) </p>
<p style="margin-top:3pt;text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;line-height:4pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2834</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">26-4106690</p></td>
</tr>
<tr>
<td valign="top"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Primary Standard Industrial</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Classification Code Number)</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification Number)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4200 Bohannon Drive, Suite 250 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Menlo Park, California 94025 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(650) 963-8580 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </p>
<p style="margin-top:3pt;text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;line-height:4pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#120;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></font> </p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12 months (or for such shorter period than the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#120;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></font> </p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act. (Check one): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:21.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="bottom"  style="width:0.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:47.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></p></td>
<td valign="bottom"  style="width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:26.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="bottom"  style="width:0.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:2.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#120;</font></p></td>
</tr>
<tr style="height:3.75pt;">
<td valign="middle"  style="width:21.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:48.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:27.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:21.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="bottom"  style="width:0.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:47.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font><font style="font-family:Times New Roman;">&#160;&#160;(Do not check if a smaller reporting company)</font></p></td>
<td valign="bottom"  style="width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:26.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="bottom"  style="width:0.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:2.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></p></td>
</tr>
</table></div>
<p style="margin-top:3pt;text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;line-height:4pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in&#160;Rule&#160;12b-2&#160;of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160; <font style="font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#120;</font></font> </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of April&#160;30, 2015, there were 29,266,236 outstanding shares of common stock, par value $0.0001 per share, of Versartis, Inc. </p>
<p style="margin-top:3pt;text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;line-height:4pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:9pt;text-align:center;border-top:Solid 1pt;padding-top:1pt;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">VERSARTIS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">QUARTERLY REPORT ON FORM 10-Q </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FOR THE QUARTERLY PERIOD ENDED March&#160;31, 2015<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I. FINANCIAL INFORMATION </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Item</font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Page</font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Financial_Statements"><font style="text-decoration:underline;">Financial Statements (unaudited):</font></a></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Condensed_Balance_Sheets"><font style="text-decoration:underline;">a. Condensed Consolidated Balance Sheets at March 31, 2015 and December&#160;31, 2014</font></a></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Condensed_Statements_of_Operations"><font style="text-decoration:underline;">b. Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2015 and 2014</font></a></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Condensed_Statements_of_Cash_Flows"><font style="text-decoration:underline;">c. Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2015 and 2014</font></a></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Notes_to_Condensed"><font style="text-decoration:underline;">d. Notes to Condensed Consolidated Financial Statements</font></a></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Managements_Discussion"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Quantitative_and_Qualitative"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Controls_and_Procedures"><font style="text-decoration:underline;">Controls and Procedures</font></a></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td colspan="5" valign="bottom"  style="width:auto;">
<p style="text-align:center;margin-bottom:1pt;margin-top:9pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II. OTHER INFORMATION</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Legal_Proceedings"><font style="text-decoration:underline;">Legal Proceedings</font></a></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1A.</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Risk_Factors"><font style="text-decoration:underline;">Risk Factors</font></a></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Unregistered_Sales"><font style="text-decoration:underline;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Exhibits"><font style="text-decoration:underline;">Exhibits</font></a></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td colspan="3" valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Signatures"><font style="text-decoration:underline;">Signatures</font></a></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Financial_Statements"></a>PART I. FINANCIAL INFORMATION</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1. Financial Statements </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Condensed_Balance_Sheets"></a>VERSARTIS, INC. </p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CONDENSED CONSOLIDATED BALANCE SHEETS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(unaudited) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current Assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,261</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170,566</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,186</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,398</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234,447</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,964</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">616</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">664</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">714</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235,395</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174,294</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, convertible preferred stock and stockholders' equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts Payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">601</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,259</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,219</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,666</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Current Liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,820</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,925</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,820</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,925</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 6)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders' equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $0.0001 par value; 5,000,000 shares authorized at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; March 31, 2015 and December 31, 2014, respectively;&nbsp;&nbsp;zero shares issued</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and outstanding at&nbsp;&nbsp;March 31, 2015 and December 31, 2014, respectively</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.0001 par value, 50,000,000 shares authorized at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; March 31, 2015 and December 31, 2014; 29,257,836 and 24,245,437 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issued and outstanding at March 31, 2015 and December 31, 2014, respectively</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360,838</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">278,626</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(133,266</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(111,259</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,575</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167,369</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235,395</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174,294</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Condensed_Statements_of_Operations"></a>VERSARTIS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(unaudited) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands, except per share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,100</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,869</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,181</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,714</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,281</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,583</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,281</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,583</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,843</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss and comprehensive loss</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,006</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,426</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend related to beneficial conversion</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; feature of convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,559</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,006</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,985</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per basic and diluted share attributable to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.79</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16.13</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares used to compute</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted net loss per share</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,810</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,788</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Condensed_Statements_of_Cash_Flows"></a>VERSARTIS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(unaudited) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,006</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,426</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,988</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">426</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remeasurement of convertible preferred stock call option liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,560</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remeasurement of convertible preferred stock warrant liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,279</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in assets and liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,456</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(127</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(657</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">665</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities and other liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,553</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">810</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,524</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,808</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock in initial public offering, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,188</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock in follow-on offering, net of issuance costs</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,208</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of convertible preferred stock, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,793</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of convertible preferred stock warrants</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">570</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of common stock options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,224</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197,555</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,695</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,709</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at beginning of period</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170,566</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,288</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at end of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,261</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204,997</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of noncash items</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of preferred stock call option liability to additional paid in capital</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,581</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of preferred stock warrant liability to additional paid in capital</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,752</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of preferred stock to common stock and additional paid in capital</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122,290</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Offering issuance costs</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,293</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0.17%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">VERSARTIS, INC.</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<font style="text-transform:uppercase;">&#160;(CONTINUED)</font> <font style="font-style:italic;font-weight:normal;">(unaudited)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Notes_to_Condensed"></a>VERSARTIS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS <font style="font-style:italic;font-weight:normal;">(unaudited)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Formation and Business of the Company </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Versartis, Inc. (the &#8220;Company&#8221;) was incorporated on December&#160;10, 2008 in the State of Delaware. The Company is an endocrine-focused biopharmaceutical company initially developing long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. The Company is developing drug candidates that it has licensed from Amunix Operating Inc. (&#8220;Amunix&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s headquarters and operations are in Menlo Park, California. Since incorporation, the Company has been primarily performing research and development activities, including early clinical trials, filing patent applications, obtaining regulatory approvals, hiring personnel, and raising capital to support and expand these activities. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Unaudited Interim Financial Information<font style="font-style:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial information as of March 31, 2015 is unaudited. The condensed consolidated financial statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that management considers necessary for the fair presentation of the results of operations for the interim periods covered and of the financial condition of the Company at the date of the interim balance sheet. The December 31, 2014 condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America, or GAAP. The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December&#160;31, 2014 included in the Company&#8217;s annual report on Form 10-K filed on March&#160;6, 2015 with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Secondary Offering </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2015, we completed a secondary public offering of common stock, pursuant to which we issued 4,999,999 shares of common stock, which includes shares issued pursuant to the underwriters&#8217; exercise of their over-allotment option, and received net proceeds of approximately $80.2 million, after underwriting discounts, commissions and estimated offering expenses. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation and Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The preparation of the accompanying condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements are consolidated for the quarter ended March 31, 2015 and year ended December 31, 2014 and include the accounts of Versartis, Inc. and its wholly-owned subsidiary, Versartis Cayman Holdings Company, established in the fourth quarter of 2014. All intercompany accounts and transactions have been eliminated. The U.S. dollar is the functional currency for all of the Company's consolidated operations. All other accompanying condensed financial statements for the quarter ended March 31, 2014 include only the accounts of Versartis, Inc.</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, the Company has incurred net losses and negative cash flows from operations. At March&#160;31, 2015, the Company had an accumulated deficit of $133.3&#160;million and working capital of $226.6&#160;million. The Company expects to continue to incur losses from costs related to the continuation of research and development and administrative activities for the foreseeable future. Although management has been successful in raising capital in the past, most recently in January 2015, there can be no assurance that the Company will be successful or that any needed financing will be available in the future at terms acceptable to the Company. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segments </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. All long-lived assets are maintained in the United States of America. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0.17%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">VERSARTIS, INC.</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<font style="text-transform:uppercase;">&#160;(CONTINUED)</font> <font style="font-style:italic;font-weight:normal;">(unaudited)</font></p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reclassification</p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain amounts within the consolidated balance sheet for the prior period have been reclassified to conform with the current period presentation. These reclassifications had no impact on the Company&#8217;s previously reported financial position.</p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of credit risk </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. All of the Company&#8217;s cash and cash equivalents are held at five financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risk and Uncertainties </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#8217;s potential drug candidates, uncertainty of market acceptance of the Company&#8217;s products, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Products developed by the Company require clearances from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the products will receive the necessary clearances. If the Company was denied clearance, clearance was delayed or the Company was unable to maintain clearance, it could have a materially adverse impact on the Company. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be at terms acceptable by the Company. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and <font style="text-transform:uppercase;">c</font>ash <font style="text-transform:uppercase;">e</font>quivalents </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. At March 31, 2015 and December 31, 2014 the Company&#8217;s cash and cash equivalents were held in five institutions in the United States and include deposits in money market funds which were unrestricted as to withdrawal or use.</p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and <font style="text-transform:uppercase;">e</font>quipment, Net </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, generally between three and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of their useful life or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by the comparison of the carrying amount to the undiscounted future net cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value (i.e. determined through estimating projected discounted future net cash flows or other acceptable methods of determining fair value) arising from the asset. There have been no such impairments of long-lived assets as of March 31, 2015 or December&#160;31, 2014.</p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying value of the Company&#8217;s cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to the short-term nature of these items. Convertible preferred stock call option liability and convertible preferred stock warrant liability, which were outstanding through the completion of the Company&#8217;s initial public offering during the three months ended March 31, 2014, were carried at fair value. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0.17%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">VERSARTIS, INC.</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<font style="text-transform:uppercase;">&#160;(CONTINUED)</font> <font style="font-style:italic;font-weight:normal;">(unaudited)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:9pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4.5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:91%;">
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;I</p></td>
<td valign="bottom"  style="width:0.94%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:92.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unadjusted quoted prices in active markets for identical assets or liabilities;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;II</p></td>
<td valign="bottom"  style="width:0.94%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:92.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;III</p></td>
<td valign="bottom"  style="width:0.94%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:92.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial instruments consist of Level I assets. Level I securities are comprised of a highly liquid money market fund. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preclinical and Clinical Trial Accruals </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s clinical trial accruals are based on estimates of patient enrollment and related costs at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and clinical research organizations (&#8220;CROs&#8221;) that conduct and manage clinical trials on the Company&#8217;s behalf. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates preclinical and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of patient enrollment and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and <font style="text-transform:uppercase;">d</font>evelopment </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are charged to operations as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, laboratory supplies, consulting costs, external research and development expenses and allocated overhead, including rent, equipment depreciation, and utilities. Costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use are expensed to research and development costs when incurred. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income <font style="text-transform:uppercase;">t</font>axes </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i)&#160;the factors underlying the sustainability assertion have changed and (ii)&#160;the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0.17%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">VERSARTIS, INC.</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<font style="text-transform:uppercase;">&#160;(CONTINUED)</font> <font style="font-style:italic;font-weight:normal;">(unaudited)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based <font style="text-transform:uppercase;">c</font>ompensation </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For stock options granted to employees, the Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair value. The value of the portion of the award that is ultimately expected to vest is recognized as expense ratably over the requisite service period. The fair value of stock options is determined using the Black-Scholes option pricing model. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions regarding a number of complex and subjective variables. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense, net of estimated forfeitures, is reflected in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">604</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,384</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,988</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">426</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:3pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company&#8217;s comprehensive loss was the same as its reported net loss. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Share of Common Stock </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, convertible preferred stock, stock options and convertible preferred stock warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss for all of the periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#8217;s financial position or results of operations upon adoption. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-10<font style="font-style:italic;">, Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation</font>, or ASU 2014-10, which eliminates the definition of a development stage entity, the development stage presentation and disclosure requirements under ASC 915, <font style="font-style:italic;">Development Stage Entities</font>, and amends provisions of existing variable interest entity guidance under ASC 810, <font style="font-style:italic;">Consolidation</font>. As a result of the changes, the financial statements of entities which meet the former definition of a development stage entity will no longer: (1)&#160;present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2)&#160;label the financial statements as those of a development stage entity, (3)&#160;disclose a description of the development stage activities in which the entity is engaged, and (4)&#160;disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. Furthermore, ASU 2014-10 clarifies disclosures about risks and uncertainties under ASC Topic 275, <font style="font-style:italic;">Risks and Uncertainties</font> that apply to companies that have not commenced planned principal operations. Finally, variable interest entity rules no longer contain an exception for development stage entities and, as a result, development stage entities will have to be evaluated for consolidation in the same manner as non-development stage entities. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0.17%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">VERSARTIS, INC.</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<font style="text-transform:uppercase;">&#160;(CONTINUED)</font> <font style="font-style:italic;font-weight:normal;">(unaudited)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASU 2014-10, entities are no longer required to apply the presentation and disclosure provisions of ASC 915 during annual periods beginning after December&#160;15, 2014. In addition, the revisions to the consolidation standards are effective for annual periods beginning after December&#160;15, 2015 for public companies and are effective for annual periods beginning after December&#160;15, 2016 for nonpublic entities. Early adoption is permitted for any annual reporting period or interim period for which the entity&#8217;s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). The Company has adopted ASU 2014-10, effective January 1, 2015, but there was no impact on its financial position, results of operations or cash flows.</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2014, the FASB issued new guidance related to the disclosures around going concern. The new standard provides guidance around management&#8217;s responsibility to evaluate whether there is substantial doubt about an entity&#8217;s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The Company will apply the guidance and disclosure provisions of the new standard upon adoption.</p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Balance Sheet Components </p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Prepaid expenses (in thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and clinical <sup style="font-size:85%; vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,669</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,216</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">517</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,186</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,398</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">(1)</sup></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><sup style="font-size:85%; vertical-align:top"></sup>These prepayments consist primarily of advances to our contract manufacturers and contract research organizations</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Liabilities (in thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and related</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,143</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,737</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and clinical</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,489</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,259</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional services</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">411</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,219</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,666</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the Company&#8217;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at March 31, 2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,162</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,162</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,125</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,125</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0.17%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">VERSARTIS, INC.</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<font style="text-transform:uppercase;">&#160;(CONTINUED)</font> <font style="font-style:italic;font-weight:normal;">(unaudited)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Commitments and Contingencies </p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Facility Leases </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2014, the Company entered into an operating facility lease agreement to lease 12,943 square feet in Menlo Park, California for its new headquarters building for a period of thirty-nine months. The total obligation for the Company under this lease is approximately $1.9 million as of March&#160;31, 2015. </p>
<p style="margin-bottom:0pt;margin-top:3pt;margin-left:10.27%;text-indent:-10.27%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Equity Incentive Plans </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Board of Directors, or Board, and stockholders previously approved the 2009 Stock Plan, or the 2009 Plan. In March 2014, the stockholders approved the 2014 Equity Incentive Plan, or the 2014 Plan. As of March&#160;21, 2014, the effective date of the 2014 Plan, the Company suspended the 2009 Plan and no additional awards may be granted under the 2009 Plan. Any shares of common stock covered by awards granted under the 2009 Plan that terminate after March&#160;21, 2014 by expiration, forfeiture, cancellation or other means without the issuance of such shares, will be added to the 2014 Plan reserve. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2015, the total number of shares of common stock available for issuance under the 2014 Plan was approximately 2,031,000.  Unless the Board provides otherwise, beginning on January&#160;1, 2015, and continuing until the expiration of the 2014 Plan, the total number of shares of common stock available for issuance under the 2014 Plan will automatically increase annually on January&#160;1 by 4.5% of the total number of issued and outstanding shares of common stock as of December&#160;31 of the immediately preceding year. As of March 31, 2015, approximately 2,947,000 shares of common stock were subject to outstanding awards under the 2014 Plan. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2014, the Board and stockholders approved the 2014 Employee Stock Purchase Plan, or the ESPP, which became effective as of March&#160;5, 2014. The Company has reserved a total of approximately 392,000 shares of common stock for issuance under the ESPP. Unless the Board provides otherwise, beginning on January&#160;1, 2015, and continuing until the expiration of the ESPP, the total number of shares of common stock available for issuance under the ESPP will automatically increase annually on January&#160;1 by the lesser of (i)&#160;1% of the total number of issued and outstanding shares of common stock as of December&#160;31 of the immediately preceding year, or (ii)&#160;300,000 shares of common stock. As of March 31, 2015, the Company has approximately 9,000 shares of common stock under the ESPP. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. Net loss per share of Common Stock </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except per share data): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders - basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,006</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,985</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,810</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,788</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares used to compute basic and diluted net</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; loss per share</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,810</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,788</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per common share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.79</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16.13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss attributable to common stockholders per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period, determined using the treasury-stock method and the as-if converted method, for convertible securities, if inclusion of these is dilutive. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0.17%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">VERSARTIS, INC.</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<font style="text-transform:uppercase;">&#160;(CONTINUED)</font> <font style="font-style:italic;font-weight:normal;">(unaudited)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive securities outstanding at the end of the periods presented have been excluded from the computation of diluted shares outstanding: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,761,967</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,188,896</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185,514</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:13.3%;">
<tr>
<td valign="bottom"  style="width:100%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Managements_Discussion"></a>Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following management&#8217;s discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and notes thereto included in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q and with our audited financial statements and notes thereto for the year ended December&#160;31, 2014, included in our annual report on Form 10-K filed on March 6, 2015 with the U.S. Securities and Exchange Commission (SEC).</p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Special note regarding forward-looking statements </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This report contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed in the forward-looking statements. The statements contained in this report that are not purely historical are forward-looking statements within the meaning of Section&#160;27A of the Securities Act and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements are often identified by the use of words such as, but not limited to, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;strategy,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section titled &#8220;Risk Factors&#8221; included under Part II, Item&#160;1A below. Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements. </p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Versartis, Inc. (the &#8220;Company&#8221; &#8220;We&#8221; &#8220;Our&#8221;) is an endocrine-focused biopharmaceutical company initially developing our novel long-acting recombinant human growth hormone, VRS-317, for growth hormone deficiency, or GHD, an orphan disease. A key limitation to current recombinant human growth hormone, or rhGH, products is that they impose the burden of daily injections over multiple years, often resulting in poor compliance, which in turn can lead to suboptimal treatment outcomes in GHD patients. VRS-317 is intended to reduce the burden of daily treatment by requiring significantly fewer dosing events and injections, potentially improving compliance and, therefore, treatment outcomes. We have completed the Phase 2a stage of our pediatric GHD clinical trial, have analyzed 12 month safety and efficacy data from our ongoing Extension Study and have received feedback from various authorities, including the FDA and the EMA, providing guidance on the design of our Phase 3 clinical trial. We have submitted to the FDA the protocol for a pediatric GHD Phase 3 registration trial, which we refer to as the VELOCITY trial, and we initiated this Phase 3 trial in early 2015. As part of our on-going dialogue with the FDA, the agency recently requested additional bioanalytical data and placed our Phase 3 clinical trial on partial clinical hold (PCH) pending receipt and analysis of those data. We continue to administer VRS-317 to patients enrolled in our ongoing Extension Study and we continue to initiate U.S. sites and screen potential trial participants in the VELOCITY trial. We have received feedback from the Japanese regulatory agency, Pharmaceuticals Medicines and Devices Agency, or the PMDA, on our plans for a pediatric GHD Phase 2/3 registration trial in Japan. We submitted to the PMDA the agreed upon protocol for the pediatric GHD Phase 2/3 trial and a complete Clinical Trial Notification, or CTN, and initiated this Phase 2/3 trial in April 2015. In the first half of 2015, we received input from the FDA and the EMA and as a result we will conduct a Phase 2 trial in GHD adults prior to Phase 3 for this population, and we anticipate initiation of the Phase 2 trial in the second half of 2015. We have global rights to VRS-317 and, if VRS-317 is approved, given the highly concentrated prescriber base, we intend to commercialize it with our own specialty sales force in the United States and Canada, and potentially other geographies.</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VRS-317 is a fusion protein consisting of rhGH and a proprietary half-life extension technology known as XTEN, which we in-licensed from Amunix Operating, Inc., or Amunix. Amunix has granted us an exclusive license under its patents and know-how related to the XTEN technology to develop and commercialize up to four licensed products, including VRS-317. Once we start commercializing a licensed product, we will owe to Amunix a royalty on net sales of the licensed products until the later of the expiration of all licensed patents or ten years from the first commercial sale in the relevant country. The royalty payable is one percent of net sales for the first two marketed products, but higher single-digit royalties are payable if we market additional products, or if we substitute one marketed product for another. If we elect to substitute one marketed product for another, in addition to royalties, we would also be required to make milestone and other payments totaling up to $40 million per marketed product. </p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">First Three Months of 2015 and Other Recent Highlights </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2015, we completed a public offering of common stock, in which we issued 4,999,999 shares of common stock, which includes shares issued pursuant to the underwriters&#8217; exercise of their option to purchase additional shares, and received net proceeds of approximately $80.2 million, after underwriting discounts, commissions and estimated offering expenses. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial overview </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Summary </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not generated net income from operations, and, at March&#160;31, 2015, we had an accumulated deficit of $133.3 million, primarily as a result of research and development and general and administrative expenses. While we may in the future generate revenue from a variety of sources, including license fees, milestone payments and research and development payments in connection with potential future strategic partnerships, we have not yet generated any revenue. VRS-317 is at an early stage of development and may never be successfully developed or commercialized. Accordingly, we expect to incur significant and increasing losses from operations for the foreseeable future as we seek to advance VRS-317 through its on-going and planned Phase 2 and 3 clinical trials, and there can be no assurance that we will ever generate significant revenue or profits. </p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and development expenses </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize both internal and external research and development expenses as incurred. Our external research and development expenses consist primarily of: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:4pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of acquiring and manufacturing clinical trial and other materials, including expenses incurred under agreements with contract manufacturing organizations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:4pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">expenses incurred under agreements with contract research organizations, investigative sites, and consultants that conduct our clinical trials and a substantial portion of our preclinical activities; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:4pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">other costs associated with development activities, including additional studies. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal research and development costs consist primarily of salaries and related fringe benefit costs for our employees (such as workers&#8217; compensation and health insurance premiums), stock-based compensation charges, travel costs, and allocated overhead expenses. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to incur substantial expenses related to our development activities for the foreseeable future as we conduct our pediatric GHD Phase 3, our on-going Extension Study, our GHD Phase 2/3 registration trial in Japan, and our Phase 2 and 3 Adult GHD trials. As product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials, we expect that our research and development expenses will increase substantially in the future. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and administrative expenses </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist principally of personnel-related costs, professional fees for legal, consulting, audit and tax services, rent and other general operating expenses not included in research and development. We anticipate general and administrative expenses will increase in future periods, reflecting an expanding infrastructure, other administrative expenses and increased professional fees associated with being a public reporting company. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other income (expense), net </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net is comprised of changes in the fair value of the convertible preferred stock warrant and call option liabilities.  In addition, other income (expense), net includes any potential gains and losses on foreign currency transactions primarily related to third-party contracts with foreign based contract manufacturing organizations.</p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical accounting policies, significant judgments and use of estimates </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. On an ongoing basis, we evaluate our critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions. Our significant accounting policies are more fully described in Note 2 of the accompanying unaudited condensed consolidated financial statements and in Note 2 to our audited consolidated financial statements contained in the Annual Report on Form 10-K filed on March&#160;6, 2015 with the SEC. There have been no significant or material changes in our critical accounting policies during the three months ended March 31, 2015, as compared to those disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8211; Critical Accounting Policies and Use of Estimates&#8221; in the Annual Report on Form 10-K. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of operations </p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comparison of the Three Months Ended March&#160;31, 2015 and 2014 </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our net loss during the periods indicated (in thousands, except percentages): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase/</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Decrease)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">&nbsp;</sup></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,100</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,869</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,231</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">&nbsp;</sup></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,181</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,714</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,467</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">&nbsp;</sup></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,281</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,583</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,698</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">&nbsp;</sup></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NM</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">(1)</sup></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,843</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,069</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-102</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">&nbsp;</sup></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not loss and comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,006</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,426</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,580</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">&nbsp;</sup></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:13.3%;">
<tr>
<td valign="bottom"  style="width:100%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</p></td>
<td valign="top" style="width:94.27%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Not meaningful. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and development expense </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense increased $12.2 million, or 251%, to $17.1 million for the three months ended March 31, 2015 from $4.9 million for the same period in 2014. The increase in research and development expense was primarily due to a $10.3 million increase related to manufacturing costs to support our ongoing Extension Study and prepare for our Phase 3 clinical trial.&nbsp;&nbsp;Additionally, clinical costs increased $1.9 million related to the initiation of our global Phase 3 trial and our Phase 2/3 trial in Japan. For the three months ended March 31, 2015 and 2014, substantially all of our research and development expense related to our VRS-317 drug development activity. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and administrative expense </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense increased $2.5 million, or 91%, to $5.2 million for the three months ended March 31, 2015 from $2.7 million for the same period in 2014. The increase in general and administrative expense was primarily due to additional payroll, including an increase in stock-based compensation of $1.1 million, consulting, and professional services expenses as we continue to expand our infrastructure to support our growth. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other income (expense), net </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net decreased $12.1 million to $0.3 million of other income for the three months ended March 31, 2015 from other expense of $11.8 million for the same period in 2014. This decrease was primarily due to a change in the fair value of the preferred stock call option liability associated with the Series D convertible preferred stock financing of approximately $9.6&#160;million as measured immediately prior to the Series D-2 financing completed in February 2014. Other expense in the three months ended March&#160;31, 2014 also includes a $2.3 million change in the fair value of the warrant liability associated with the Series B convertible preferred stock financings in January and May 2012 as measured immediately prior to the close of our IPO on March&#160;26, 2014. </p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and capital resources </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2015, we completed a public offering of common stock, in which we issued 4,999,999 shares of common stock, which includes shares issued pursuant to the underwriters&#8217; exercise of their option to purchase additional shares, and received net proceeds of approximately $80.2 million, after underwriting discounts, commissions and estimated offering expenses. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have financed our operations through private placements of our equity securities, debt financing and, more recently, our initial public offering in 2014 and our secondary offering in January 2015. At March&#160;31, 2015, we had cash and cash equivalents of $230.3&#160;million, a majority of which is invested in money market funds at several highly rated financial institutions. We expect to incur substantial expenditures in the foreseeable future for the development and potential commercialization of VRS- 317 and any additional product candidates. Specifically, we have incurred substantial expenses in connection with our Phase&#160;2a clinical trial and we expect to continue to incur substantial expenses in connection with our Extension Study and additional Phase 2 and 3 clinical trials that we have initiated or plan to conduct. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our on-going and planned Phase&#160;2 and Phase 3 clinical trials for VRS-317 are successful, we will continue to require additional financing to further develop our product candidates and fund operations for the foreseeable future and we will continue to seek funds through equity or debt financings, collaborative or other arrangements with corporate sources, or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:9pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. We anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:4pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the rate of progress and cost of our clinical studies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:4pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the timing of, and costs involved in, seeking and obtaining approvals from the FDA and other regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:4pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of preparing to manufacture VRS-317 on a larger scale; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:4pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of commercialization activities if VRS-317 or any future product candidate is approved, including product sales, marketing, manufacturing and distribution; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:4pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the degree and rate of market acceptance of any products launched by us or future partners; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:4pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:4pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to enter into additional collaboration, licensing, commercialization or other arrangements and the terms and timing of such arrangements; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:4pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:96.67%;">
<p style="margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the emergence of competing technologies or other adverse market developments. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to others technologies or clinical product candidates or programs that we would prefer to develop and commercialize ourselves. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash flows </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,524</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,808</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing Activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,224</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197,555</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,695</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,709</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:3pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cash used in operating activities </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities was $20.5&#160;million and $5.8&#160;million in the three months ended March 31, 2015 and 2014, respectively, which was primarily due to the use of funds in our operations related to the development of our product candidates. Cash used in operating activities in 2015 increased compared to 2014 primarily due to a higher net loss from operations as we continued to increase our research and development expenditures to develop VRS-317.</p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cash used in investing activitie<font style="font-style:normal;">s</font> </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in investing activities consisted primarily of investment in equipment and leasehold improvements made to our new corporate headquarters in Menlo Park, California, which commenced in May 2014. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities was $80.2&#160;million in the three months ended March 31, 2015, compared to $197.6&#160;million in the same period of 2014. Cash provided by financing activities for 2015 and 2014 consisted of net proceeds from our follow-on offering and initial public offering, respectively.</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2015, we had cash and cash equivalents of approximately $230.3&#160;million. We believe that our existing cash and cash equivalents will be sufficient to sustain operations for at least the next 12&#160;months based on our existing business plan. If our potential Phase&#160;3 clinical trials are successful, we will need to raise additional capital in order to further advance our product candidates towards regulatory approval and potential commercialization. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual obligations and commitments </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2015, there were no material changes to our contractual obligations and commitments described under Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in the Annual Report on Form 10-K for the year ended December 31, 2014. </p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Off-balance sheet arrangements </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC. </p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">JOBS Act accounting election </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We are choosing to &#8220;opt out&#8221; of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted. This decision to opt out of the extended transition period under the JOBS Act is irrevocable. </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Quantitative_and_Qualitative"></a>Item&#160;3. Quantitative and qualitative disclosures about market risk </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary objective of our investment activities is to preserve our capital to fund our operations. We also seek to maximize income from our cash and cash equivalents without assuming significant risk. To achieve our objectives, we invest our cash and cash equivalents in money market funds. As of March 31, 2015, we had cash and cash equivalents of $230.3&#160;million consisting of cash and investments in highly liquid U.S. money market funds. A portion of our investments may be subject to interest rate risk and could fall in value if market interest rates increase. However, because our investments are substantially all short-term in duration, we believe that our exposure to interest rate risk is not significant and a 1% movement in market interest rates would not have a significant impact on the total value of our portfolio. We actively monitor changes in interest rates. </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Controls_and_Procedures"></a>Item&#160;4. Controls and Procedures </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-family:inherit;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An evaluation as of&#160;March&#160;31, 2015&#160;was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our &#8220;disclosure controls and procedures,&#8221; which are defined in Rule 13a-15(e) under the Securities Exchange Act&#160;of&#160;1934, as amended (the Exchange Act), as controls and other procedures of a company that are designed to ensure that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to the company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at&#160;March 31, 2015.</p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-family:inherit;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, including our Chief Executive Officer and Chief Financial Officer, has evaluated any changes in our internal control over financial reporting that occurred during the quarter ended&#160;March 31, 2015, and has concluded that there was no change during such quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-family:inherit;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Limitations on the Effectiveness of Controls</p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our Chief&#160;Executive Officer and Chief Financial Officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II: OTHER INFORMATION </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.27%;text-indent:-10.27%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.27%;text-indent:-10.27%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Legal_Proceedings"></a>Item&#160;1. Legal proceedings </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not currently subject to any material legal proceedings. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Risk_Factors"></a>Item&#160;1A. Risk Factors. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. You should consider carefully the following risks, together with all the other information in this Form 10-Q, including our condensed consolidated financial statements and notes thereto. If any of the following risks actually materializes, our operating results, financial condition and liquidity could be materially adversely affected. As a result, the trading price of our common stock could decline and you could lose part or all of your investment. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to the development and commercialization of our product candidate </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our success depends heavily on the successful development, regulatory approval and commercialization of our only product candidate, VRS-317. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any products that have gained regulatory approval. Our only clinical-stage product candidate is VRS-317, a novel, long-acting recombinant human growth hormone. We have completed the Phase 2a stage of a Phase 1b/2a clinical trial in children with growth hormone deficiency, or GHD, and initiated our North American and European Phase 3 pediatric GHD clinical trial for VRS-317 in early 2015. We also initiated a Phase 2/3 pediatric GHD clinical trial of VRS-317 in Japan in April 2015 and plan to initiate a Phase 2 adult GHD clinical trial of VRS-317 in the second half of 2015. As a result, our near-term prospects, including our ability to finance our operations and generate revenue, are substantially dependent on our ability to obtain regulatory approval for and, if approved, to successfully commercialize VRS-317 in a timely manner. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot commercialize VRS-317 or any future product candidates in the United States without first obtaining regulatory approval for the product from the U.S. Food and Drug Administration, or FDA, nor can we commercialize VRS-317 or any future product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. The FDA review process typically takes years to complete and approval is never guaranteed. Before obtaining regulatory approvals for the commercial sale of VRS-317 for a target pediatric GHD indication or our future product candidates, we generally must demonstrate with substantial evidence gathered in preclinical and well-controlled clinical studies that the product candidate is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate. We are pursuing the same regulatory pathway for VRS-317 followed by most of the approved rhGH products for pediatric GHD patients: a dose-finding study and a Phase 3 registration trial with a primary endpoint of 12 month mean height velocity. In addition, while the available growth data from published studies of approved rhGH therapy products suggest that three, six and twelve month mean height velocities are well correlated within the same clinical trial, it is possible that VRS-317, due to its unique properties, will produce different results. If 12 month mean height velocities that we observed for VRS-317 in the ongoing Extension Study do not correlate to 12 month mean height velocities that we ultimately observe in any Phase 3 clinical trial that we may conduct, VRS-317 may not achieve the required primary endpoint in the Phase 3 clinical trial, and VRS-317 may not receive regulatory approval. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, obtaining regulatory approval for marketing of VRS-317 in one country does not ensure we will be able to obtain regulatory approval in other countries, while a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in other countries. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if VRS-317 or any of our future product candidates were to successfully obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for VRS-317 in one or more jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding or generate sufficient revenue to continue to fund our operations. Also, any regulatory approval of VRS-317 or our future product candidates, once obtained, may be withdrawn. Furthermore, even if we obtain regulatory approval for VRS-317, the commercial success of VRS-317 will depend on a number of factors, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">development of our own commercial organization or establishment of a commercial collaboration with a commercial infrastructure; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">establishment of commercially viable pricing and obtaining approval for adequate reimbursement from third-party and government payors; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the ability of our third-party manufacturers to manufacture quantities of VRS-317 using commercially viable processes at a scale sufficient to meet anticipated demand and reduce our cost of manufacturing, and that are compliant with current Good Manufacturing Practices, or cGMP, regulations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our success in educating physicians and patients about the benefits, administration and use of VRS-317; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the effectiveness of our own or our potential strategic collaborators&#8217; marketing, sales and distribution strategy and operations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">acceptance of VRS-317 as safe and effective by patients, caregivers and the medical community; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">a continued acceptable safety profile of VRS-317 following approval; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">continued compliance with our obligations in our intellectual property licenses with third parties upon favorable terms. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of these factors are beyond our control. If we or our commercialization collaborators are unable to successfully commercialize VRS-317, we may not be able to earn sufficient revenues to continue our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">VRS-317 is a new chemical entity, and although it contains the same rhGH composition used in currently approved rhGH products, it has been genetically modified to extend its half-life, creating uncertainty about its long-term safety profile. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VRS-317 utilizes the same rhGH amino acid sequence as in currently approved rhGH products, but combined with sequences of hydrophilic amino acids genetically fused to the rhGH protein to extend its half-life. This proprietary in-licensed half-life extension technology, XTEN, has been used in VRS-317 to potentially enable less frequent administration of rhGH. We have limited clinical data on product candidates utilizing XTEN technology indicating whether they are safe or effective for long-term treatment in humans. The long term safety and efficacy of the XTEN technology and the extended half-life and exposure profile of VRS-317 compared to currently approved rhGH products is unknown, and it is possible it may increase the risk of unforeseen reactions to VRS-317 following extended treatment relative to other currently approved rhGH products. Elevated levels of rhGH and IGF-I together can lead to acromegaly, a rare disease that occurs when the body produces excess growth hormone, leading to an increase in the size of bones and organs and which can result in disfigurement and other complications, with an associated increased cancer risk. It is unknown whether long-term repeated administration of VRS-317 could result in an increased immune response to rhGH, leading to a loss of efficacy or potential safety issues. If extended treatment with VRS-317 in our ongoing or future clinical trials results in any concerns about its safety or efficacy, we may be unable to successfully develop or commercialize VRS-317. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because the results of preclinical testing and earlier clinical trials and the results to date in our Extension Study are not necessarily predictive of future results, VRS-317 may not have favorable results in later clinical trials or receive regulatory approval. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Success in preclinical testing and early clinical trials and the results to date in our Extension Study do not ensure that later clinical trials will generate adequate data to demonstrate the efficacy and safety of an investigational drug. A number of companies in the pharmaceutical and biotechnology industries, including those with greater resources and experience, have suffered significant setbacks in clinical trials, even after seeing promising results in earlier clinical trials. Despite the results to date in our ongoing Extension Study of VRS-317 in GHD children and the results reported in earlier trials, we do not know whether the clinical trials we are conducting, or may conduct, will demonstrate adequate efficacy and safety to result in regulatory approval to market VRS-317. Even if we believe that we have adequate data to support an application for regulatory approval to market our product candidates, the FDA, European Medicines Agency, or EMA, or other applicable foreign regulatory authorities may not agree and may require that we conduct additional clinical trials. If our Phase 3 clinical trial of VRS-317 in GHD children or other later-stage clinical trials do not produce favorable results, our ability to achieve regulatory approval for VRS-317 may be adversely impacted. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There can be no assurance that VRS-317 will not exhibit new or increased safety risks in the Phase 3 clinical trial as compared to the Phase 1b/2a clinical trial or ongoing Extension Study. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many other companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain regulatory approval for the marketing of their products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have not yet confirmed that the selected Phase 3 dose of VRS-317 administered for 12 months will provide adequate efficacy to support registration. There can be no guarantee that the dose studied in the Phase 3 clinical trial will be efficacious or, if it is, whether it will be the optimal dose. There cannot be any guarantee that any of these studies will be successful in determining a dose or dose regimen of VRS-317 suitable for marketing approval. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">As an organization, we have never conducted a Phase 3 clinical trial or submitted an NDA or BLA before, and may be unsuccessful in doing so for VRS-317. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we have completed the Phase 2a stage of a Phase 1b/2a clinical trial of VRS-317, the conduct of our Phase 3 clinical trial and the submission of a successful Biologics License Application, or BLA, is a complicated process. As an organization, we have never conducted a Phase 3 clinical trial, have limited experience in preparing, submitting and prosecuting regulatory filings, and have not submitted a BLA before. Consequently, even though the Phase 2a stage of our Phase 1b/2a clinical trial was successful, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to BLA submission and approval of VRS-317. Failure to complete, or delays in our clinical trials would prevent us from or delay us in commercializing VRS-317. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Long-acting rhGH products and product candidates no longer in development or marketed have failed to generate commercial success or obtain regulatory approval, and we cannot predict whether VRS-317 will achieve success where others have failed. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many attempts have been made to develop sustained release formulations of rhGH. For example, Nutropin Depot, a long-acting form of rhGH developed by Genentech that uses Alkermes&#8217; ProLease<font style="font-size:8.5pt;"><sup style="font-size:85%; vertical-align:top">&#174;</sup></font> injectable extended-release drug delivery system, was approved by the FDA in 1999 and withdrawn from the market in 2004 by Genentech and Alkermes due to the significant resources required to continue manufacturing and commercializing the product. Additional attempts at sustained release formulations have not yet led to globally marketed products, due to manufacturing, regulatory, efficacy and/or safety reasons. Even if we obtain all requisite regulatory approvals, no assurance can be given that VRS-317 will achieve commercial success or market adoption. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Delays in the enrollment of patients in any of our clinical studies could increase our development costs and delay completion of the study. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to initiate or continue clinical studies for VRS-317 or any future product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these studies as required by the FDA or other regulatory authorities. Even if we are able to enroll a sufficient number of patients in our clinical studies, if the pace of enrollment is slower than we expect, the development costs for our product candidates may increase and the completion of our studies may be delayed or our studies could become too expensive to complete. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, we enrolled 48 patients in the United States over approximately eight months in the Phase 1b stage of our Phase 1b/2a clinical trial of VRS-317. The last patient was enrolled in the Phase 2a stage of the trial in November 2013, and the trial was completed by mid-2014. As the outcome of the Phase 2a stage of the trial was successful, we initiated a Phase 3 clinical trial in the United States, Western Europe and Canada in early 2015. As we expect to study only pre-pubertal na&#239;ve to treatment subjects in the Phase 3 clinical trial, we will need to seek participation of additional patients in that trial. We will need to activate new clinical sites and enroll patients at forecasted rates at both new and existing clinical sites. Our forecasts regarding the rates of clinical site activation and patient enrollment at those sites are based on a number of assumptions, including assumptions based on past experience with the Phase 1b stage of the Phase 1b/2a clinical trial. However, there can be no assurance that those forecasts will be accurate or that we will not face delays in our Phase&#160;3 clinical trial. As with all global clinical trials, enrollment in our Phase 3 clinical trial is dependent on obtaining clearance from regulatory authorities in each country in which it will be conducted. To date, authorities in several countries have requested additional data or information prior to authorizing treatment of patients at sites located in those countries. For example, the FDA has recently placed the Investigational New Drug Application, or IND, for VRS-317 on partial clinical hold, or PCH, pending our provision of additional bioanalytical data. Under the PCH, we may continue to administer VRS-317 to patients enrolled in our ongoing Extension Study but may not enroll new patients in the United States until it is lifted. If we are unable to provide sufficient responses to the FDA and other regulatory authorities or additional authorities make requests prior to permitting enrollment, the Phase 3 trial may be delayed significantly.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There may be concurrent competing pediatric GHD clinical trials that will inhibit or slow our enrollment in the Phase 3 clinical trial. If we experience delays in enrollment, our ability to complete our Phase&#160;3 clinical trial could be impaired and the costs of conducting the trial could increase, either of which could have a material adverse effect on our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If clinical studies of VRS-317 and any future product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA or similar regulatory authorities outside the United States or do not otherwise produce positive results, we may incur additional costs, experience delays in completing or ultimately fail in completing the development and commercialization of VRS-317 or our future product candidates. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before obtaining regulatory approval for the sale of any product candidate, we must conduct extensive clinical studies to demonstrate the safety and efficacy of our product candidates in humans. Clinical studies are expensive, difficult to design and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">implement, can take many years to complete and are uncertain as to outcome. A failure of one or more of our clinical studies could occur at any stage of testing. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may experience numerous unforeseen events during, or as a result of, clinical studies that could delay or prevent our ability to receive regulatory approval or commercialize VRS-317 or any future product candidates, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">clinical studies may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical studies or abandon product development programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the number of patients required for clinical studies may be larger than we anticipate, enrollment in these clinical studies may be insufficient or slower than we anticipate or patients may drop out of these clinical studies at a higher rate than we anticipate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of clinical studies or the manufacturing of our product candidates may be greater than we anticipate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">we might have to suspend or terminate clinical studies of our product candidates for various reasons, including a PCH such as the one that is currently in effect or a finding that our product candidates have unanticipated serious side effects or other unexpected characteristics or that the patients are being exposed to unacceptable health risks; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">regulators may not approve our proposed clinical development plans; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">regulators or institutional review boards may not authorize us or our investigators to commence a clinical study or conduct a clinical study at a prospective study site; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the supply or quality of our product candidates or other materials necessary to conduct clinical studies of our product candidates may be insufficient or inadequate. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are required to conduct additional clinical studies or other testing of VRS-317 or any future product candidates beyond those that we contemplate, if we are unable to successfully complete clinical studies or other testing, if the results of these studies or tests are not positive or are only modestly positive or if there are safety concerns, we may: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">be delayed in obtaining marketing approval for our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">not obtain marketing approval at all; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">obtain approval for indications that are not as broad as intended; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">have the product removed from the market after obtaining marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">be subject to additional post-marketing testing requirements; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">be subject to restrictions on how the product is distributed or used. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product development costs will also increase if we experience delays in testing or approvals. We do not know whether any clinical studies will begin as planned, will need to be restructured or will be completed on schedule, or at all. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant clinical study delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which would impair our ability to commercialize our product candidates and harm our business and results of operations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">VRS-317 or our future product candidates may cause serious adverse side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any marketing approval. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidate, VRS-317, has not completed clinical development. The risk of failure of clinical development is high. It is impossible to predict when or if this or any future product candidates will prove safe enough to receive regulatory approval. Undesirable side effects caused by VRS-317 or any future product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authority. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric subjects taking VRS-317 have reported certain adverse effects, such as mild and transient injection site discomfort, headaches and sore extremities, consistent with known adverse effects of rhGH therapy. No serious side effects have been reported to date. However, we cannot assure you that side effects from VRS-317 in current or future clinical trials will continue to be mild or that side effects in general will not prompt the discontinued development of VRS-317 or any future product candidates. As a result of these side effects or further safety or toxicity issues that we may experience in our clinical trials in the future, we may not receive approval to market VRS-317 or any future product candidates, which could prevent us from ever generating revenue or achieving profitability. Results of our trials could reveal an unacceptably high severity or prevalence of side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Any drug-related side effects could affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Any of these occurrences may have a material adverse effect on our business, results of operations, financial condition, cash flows and future prospects. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if VRS-317 or any of our future product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">we may be forced to suspend the marketing of such product; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory authorities may withdraw their approvals of such product; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory authorities may require additional warnings on the label that could diminish the usage or otherwise limit the commercial success of such products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or other regulatory bodies may issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings about such product; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA may require the establishment or modification of Risk Evaluation Mitigation Strategies, or REMS, or a comparable foreign regulatory authority may require the establishment or modification of a similar strategy that may, for instance, restrict distribution of our products and impose burdensome implementation requirements on us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">we may be required to change the way the product is administered or conduct additional clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">we could be sued and held liable for harm caused to subjects or patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">we may be subject to litigation or product liability claims; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our reputation may suffer. </font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if our clinical trials demonstrate acceptable safety and efficacy of VRS-317 for growth in pediatric GHD patients based on a twice-monthly dosing regimen, the FDA or similar regulatory authorities outside the United States may not approve VRS-317 for marketing or may approve it with restrictions on the label, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming the success of our clinical trials, we anticipate seeking regulatory approval for VRS-317 in the United States, Europe and Canada for treatment of pediatric GHD patients based on a twice-monthly dosing regimen. It is possible that the FDA, the EMA or Health Canada may not consider the results of our clinical trials to be sufficient for approval of VRS-317 for this indication. In general, the FDA suggests that sponsors complete two adequate and well-controlled clinical studies to demonstrate effectiveness because a conclusion based on two persuasive studies will be more compelling than a conclusion based on a single study. Even if we achieve favorable results in our Phase 3 clinical trial, and considering that VRS-317 is a new chemical entity, the FDA may nonetheless require that we conduct additional clinical studies, possibly using a different clinical study design. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, even if the FDA or other regulatory authorities approve VRS-317 for treatment of pediatric GHD patients based on twice-monthly dosing, the approval may include additional restrictions on the label that could make VRS-317 less attractive to physicians and patients compared to other products that may be approved for broader indications, which could limit potential sales of VRS-317. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to obtain FDA or other regulatory approval of VRS-317 or if the approval is narrower than what we seek, it could have a material adverse effect on our business, financial condition, results of operations and growth prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if VRS-317 or any future product candidates receive regulatory approval, they may fail to achieve the degree of market acceptance by physicians, patients, caregivers, healthcare payors and others in the medical community necessary for commercial success. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If VRS-317 or any future product candidates receive regulatory approval, they may nonetheless fail to gain sufficient market acceptance by physicians, hospital administrators, patients, healthcare payors and others in the medical community. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the prevalence and severity of any side effects; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">their efficacy and potential advantages compared to alternative treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the price we charge for our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the willingness of physicians to change their current treatment practices; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">convenience and ease of administration compared to alternative treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the strength of marketing and distribution support; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the availability of third-party coverage or reimbursement. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, a number of companies offer therapies for treatment of pediatric GHD patients based on a daily regimen, and physicians, patients or their families may not be willing to change their current treatment practices in favor of VRS-317 even if it is able to offer less frequent dosing. If VRS-317 or any future product candidates, if approved, do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable on a sustained basis or at all. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">VRS-317 has never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale. In addition, to successfully commercialize VRS-317, we must also design, manufacture, and gain regulatory approval of a delivery device to safely, effectively, and conveniently administer VRS-317 in relevant patient types. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VRS-317 has never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, lot consistency and timely availability of raw materials. Even if we could otherwise obtain regulatory approval for VRS-317, there is no assurance that our manufacturer will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. For example, in February 2014, the FDA notified us that it would require additional information before allowing us to use a newly manufactured lot of VRS-317 produced by our new manufacturer intended for our ongoing Extension Study. The FDA subsequently issued a PCH related to the use of any material produced by this new manufacturer and requested additional information prior to allowing us to use the newly manufactured lot.&#160;We responded to the FDA&#8217;s requests, and the FDA ultimately lifted the PCH in June 2014, and the new supply is currently being used in the Extension Study. There can be no assurance, however, that we will not be subject to similar FDA actions in the future. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our manufacturer is unable to produce sufficient quantities of the approved product for commercialization, our commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VRS-317 is a biological molecule, or biologic, rather than a small molecule chemical compound, and as a result we face special uncertainties and risks associated with scaling up manufacturing. The manufacture of biologics involves complex processes, including developing cells or cell systems to produce the biologic, growing large quantities of such cells and harvesting and purifying the biologic produced by them. As a result, the cost to manufacture biologics is generally far higher than traditional small molecule chemical compounds, and the manufacturing process is less reliable and is difficult to reproduce. VRS-317 was previously produced for us by a third-party contract manufacturer using a small-scale process that was too expensive and inefficient to support the dosages necessary for our ongoing and planned clinical trials. We have entered into an agreement with a new third-party manufacturer to develop a more efficient, larger-scale manufacturing process. However, scaling up and improving a biologic manufacturing process is a difficult and uncertain task, and we can give no assurance that we will be successful in developing and implementing this new process. Additionally, if we receive regulatory approval for VRS-317, in order to successfully commercialize VRS-317, we will need to manufacture quantities of VRS-317 using commercially viable processes at a scale sufficient to meet anticipated demand. Even if </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we are able to do so, if the therapeutically effective dosage of VRS-317 is higher than we anticipate or the obtainable sales price is lower than we anticipate, we may not be able to successfully commercialize VRS-317. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To commercialize VRS-317, we must design, manufacture, and gain regulatory approval of a delivery device to safely, effectively and conveniently administer VRS-317. We have engaged third-party manufacturers to design a suitable prototype for commercial purposes. There can be no assurance that these efforts will be successful. If we are unsuccessful in developing a suitable delivery device, our commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our failure to successfully identify, acquire, develop and commercialize additional products or product candidates could impair our ability to grow. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although a substantial amount of our efforts will focus on the continued clinical testing and potential approval of our most advanced product candidate, VRS-317, a key element of our long-term growth strategy is to acquire, develop and/or market additional products and product candidates. We currently have one other potential product candidate that is in the preclinical study stage, but its development is at a preliminary stage and there can be no certainty that we will choose to advance it. Research programs to identify product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Because our internal research capabilities are limited, we may be dependent upon pharmaceutical and biotechnology companies, academic scientists and other researchers to sell or license products or technology to us. The success of this strategy depends partly upon our ability to identify, select and acquire promising pharmaceutical product candidates and products. The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. Any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of pharmaceutical product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot provide assurance that any products that we develop or approved products that we acquire will be manufactured profitably or achieve market acceptance. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We currently have no sales or distribution personnel and only limited marketing capabilities. If we are unable to develop a sales and marketing and distribution capability on our own or through collaborations or other marketing partners, we will not be successful in commercializing VRS-317 or other future products. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have a significant sales or marketing infrastructure and have no experience in the sale, marketing or distribution of therapeutic products. To achieve commercial success for any approved product, we must either develop a sales and marketing organization or outsource these functions to third parties. If VRS-317 is approved, we intend to commercialize it with our own specialty sales force in the United States, Canada and potentially other geographies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also may not be successful entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively and could damage our reputation. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development and commercialization of new therapeutic products is highly competitive. We face competition with respect to VRS-317, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are several large pharmaceutical and biotechnology companies that currently market and sell rhGH therapies to our target patient group. These companies typically have a greater ability to reduce prices for their competing drugs in an effort to gain or retain market share and undermine the value proposition that we might otherwise be able to offer to payors. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. Many of these competitors are attempting to develop therapeutics for our target indications. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing our lead product candidate, VRS-317, for treatment of pediatric GHD patients based on a twice-monthly dosing regimen. The current standard of care for growth therapies for patients in the United States is a daily subcutaneous injection of rhGH. There are a variety of currently marketed daily rhGH therapies administered by daily subcutaneous injection and used for the treatment of GHD, principally Norditropin<font style="font-size:8.5pt;"><sup style="font-size:85%; vertical-align:top">&#174;</sup></font> (Novo Nordisk), Humatrope<font style="font-size:8.5pt;"><sup style="font-size:85%; vertical-align:top">&#174;</sup></font> (Eli Lilly), Nutropin-AQ<font style="font-size:8.5pt;"><sup style="font-size:85%; vertical-align:top">&#174;</sup></font> (Roche/Genentech), Genotropin<font style="font-size:8.5pt;"><sup style="font-size:85%; vertical-align:top">&#174;</sup></font> (Pfizer), Saizen<font style="font-size:8.5pt;"><sup style="font-size:85%; vertical-align:top">&#174;</sup></font> (Merck Serono), Tev-tropin<font style="font-size:8.5pt;"><sup style="font-size:85%; vertical-align:top">&#174;</sup></font> (Teva Pharmaceuticals), Omnitrope<font style="font-size:8.5pt;"><sup style="font-size:85%; vertical-align:top">&#174;</sup></font> (Sandoz GmbH) and Valtropin<font style="font-size:8.5pt;"><sup style="font-size:85%; vertical-align:top">&#174;</sup></font> (LG Life Science). These rhGH drugs, with the exception of Valtropin<font style="font-size:8.5pt;"><sup style="font-size:85%; vertical-align:top">&#174;</sup></font>, are well-established therapies and are widely accepted by physicians, patients, caregivers, third-party payors and pharmacy benefit managers, or PBMs, as the standard of care for the treatment of GHD. Physicians, patients, third-party payors and PBMs may not accept the addition of VRS-317 to their current treatment regimens for a variety of potential reasons, including concerns about incurring potential additional costs related to VRS-317, the perception that the use of VRS-317 will be of limited additional benefit to patients, or limited long-term safety data compared to currently available rhGH treatments. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the currently approved and marketed daily rhGH therapies, there are a variety of experimental therapies that are in various stages of clinical development by companies both already participating in the rhGH market as well as potential new entrants, principally Aileron Therapeutics, Althea, Ambrx, Ascendis, Bioton S.A., Critical Pharmaceuticals, Dong-A, GeneScience, Hanmi, LG Life Science, OPKO Health, Inc. (via Prolor acquisition) and all of the existing global and regional rhGH franchises. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors, including a number of large pharmaceutical companies that compete directly with us, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical study sites and patient registration for clinical studies, as well as in acquiring technologies complementary to, or necessary for, our programs. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may form strategic alliances in the future, and we may not realize the benefits of such alliances. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may form strategic alliances, create joint ventures or collaborations or enter into licensing arrangements with third parties that we believe will complement or augment our existing business. These relationships or those like them may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for VRS-317 or any future product candidates and programs because our research and development pipeline may be insufficient, our product candidates and programs may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates and programs as having the requisite potential to demonstrate safety and efficacy. If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction or license, we will achieve the revenues or specific net income that justifies such transaction. Any delays in entering into new strategic partnership agreements related to our product candidates could also delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are able to commercialize VRS-317 or any future product candidates, the products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, thereby harming our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulations that govern marketing approvals, pricing and reimbursement for new therapeutic products vary widely from country to country. Some countries require approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain regulatory approval. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to commercialize VRS-317 or any future products successfully also will depend in part on the extent to which reimbursement for these products and related treatments becomes available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and these third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Reimbursement may impact the demand for, or the price of, any product for which we obtain marketing approval. Obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with products administered under the supervision of a physician. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate that we successfully develop. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There may be significant delays in obtaining reimbursement for approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or regulatory authorities in other countries. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the product and the clinical setting in which it is used, may be based on payments allowed for lower cost products that are already reimbursed and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the United&#160;States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government funded and private payors for new products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. In some foreign countries, including major markets in the European Union and&#160;Japan, the&#160;pricing&#160;of prescription pharmaceuticals is subject to governmental control. In these countries,&#160;pricing&#160;negotiations with governmental authorities can take nine to twelve months or longer after the receipt of regulatory marketing approval for a product. To obtain reimbursement or&#160;pricing&#160;approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. Our business could be materially harmed if reimbursement of our approved products, if any, is unavailable or limited in scope or amount or if&#160;pricing&#160;is set at unsatisfactory levels. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability exposure related to the testing of VRS-317 and any future product candidates in human clinical studies and will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">decreased demand for any product candidates or products that we may develop; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">injury to our reputation and significant negative media attention; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">withdrawal of patients from clinical studies or cancellation of studies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">significant costs to defend the related litigation; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">substantial monetary awards to patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">loss of revenue; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the inability to commercialize any products that we may develop. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently hold $5 million in product liability insurance coverage, which may not be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our financial condition and need for additional capital </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have a limited operating history and have incurred significant losses since our inception, and we anticipate that we will continue to incur substantial and increasing losses for the foreseeable future. We have only one product candidate and no commercial sales, which, together with our limited operating history, makes it difficult to evaluate our business and assess our future viability. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company with a limited operating history. We do not have any products approved for sale, and to date we have focused principally on developing our only product candidate, VRS-317. Evaluating our performance, viability or future success will be more difficult than if we had a longer operating history or approved products on the market. We continue to incur significant research and development and general and administrative expenses related to our operations. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval or become commercially viable. We have incurred significant operating losses in each year since our inception and expect to incur substantial and increasing losses for the foreseeable future. As of March 31, 2015, we had an accumulated deficit of $133.3 million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have financed our operations primarily through private placements of our convertible preferred stock and, the initial public offering of our common stock in March 2014, and a follow-on offering of our common stock in January 2015. We have devoted substantially all of our efforts to research and development, including clinical studies, but have not completed development of any product candidate. We anticipate that our expenses will increase substantially as we: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">continue the research and development of our only product candidate, VRS-317, and any future product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">continue clinical studies of VRS-317, including the Phase 3, Phase 2/3, and Phase 2 clinical trials of VRS-317 that we initiated or expect to initiate in 2015, which will be our most expensive clinical trials to date; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">seek to discover or in-license additional product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">seek regulatory approvals for VRS-317 and any future product candidates that successfully complete clinical studies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize VRS-317 or other future product candidates if they obtain regulatory approval, including process improvements in order to manufacture VRS-317 at commercial scale; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">enhance operational, financial and information management systems and hire more personnel, including personnel to support development of VRS-317 and any future product candidates and, if a product candidate is approved, our commercialization efforts. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To be profitable in the future, we must succeed in developing and eventually commercializing VRS-317 as well as other products with significant market potential. This will require us to be successful in a range of activities, including advancing VRS-317 and any future product candidates, completing clinical studies of these product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling those products for which we may obtain regulatory approval. We are only in the preliminary stages of some of these activities. We may not succeed in these activities and may never generate revenue that is sufficient to be profitable in the future. Even if we are profitable, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to achieve sustained profitability would depress the value of our company and could impair our ability to raise capital, expand our business, diversify our product candidates, market our product candidates, if approved, or continue our operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We currently have no source of product revenue and may never become profitable. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not generated any revenues from commercial product sales, or otherwise. Even if we are able to successfully achieve regulatory approval for VRS-317 or any future product candidates, we do not know when any of these products will generate revenue from product sales for us. Our ability to generate revenue from product sales and achieve profitability will depend upon our ability, alone or with any future collaborators, to successfully commercialize products, including VRS-317 or any product candidates that we may develop, in-license or acquire in the future. Our ability to generate revenue from product sales from VRS-317 or any future product candidates also depends on a number of additional factors, including our or any future collaborators&#8217; ability to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">complete development activities, including our ongoing Extension Study and Phase&#160;3, Phase 2/3, and Phase 2 clinical trials of VRS-317, successfully and on a timely basis; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">demonstrate the safety and efficacy of VRS-317 to the satisfaction of the FDA and obtain regulatory approval for VRS-317 and future product candidates, if any, for which there is a commercial market; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">complete and submit applications to, and obtain regulatory approval from, foreign regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">set a commercially viable price for our products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">establish and maintain supply and manufacturing relationships with reliable third parties, and ensure adequate and legally compliant manufacturing of bulk drug substances and drug products to maintain that supply; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">develop a commercial organization capable of sales, marketing and distribution of any products for which we obtain marketing approval in markets where we intend to commercialize independently; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">find suitable distribution partners to help us market, sell and distribute our approved products in other markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">obtain coverage and adequate reimbursement from third-party payors, including government and private payors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">achieve market acceptance of our products, if any; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">establish, maintain and protect our intellectual property rights and avoid third-party patent interference or patent infringement claims; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">attract, hire and retain qualified personnel. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, because of the numerous risks and uncertainties associated with pharmaceutical product development, including that VRS-317 or any future product candidates may not advance through development or achieve the endpoints of applicable clinical trials, we are unable to predict the&#160;timing or amount of increased expenses, or when or if we will be able to achieve or maintain profitability. In addition, our expenses could increase beyond expectations if we decide to or are required by the FDA or foreign regulatory authorities to perform studies or trials in addition to those that we currently anticipate. Even if we are able to complete the development and regulatory process for VRS-317 or any future product candidates, we anticipate incurring significant costs associated with commercializing these products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we are able to generate revenues from the sale of VRS-317 or any future product candidates that may be approved, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or shut down our operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. From time to time, we may enter into collaboration agreements with other companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue. Accordingly, our revenue may depend on development funding and the achievement of development and clinical milestones under any potential future collaboration and license agreements and sales of our products, if approved. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a significant fluctuation in our operating results from one period to the next. In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award as determined by our board of directors, and recognize the cost as an expense over the employee&#8217;s requisite service period. As the variables that we use as a basis for valuing these awards change over time, our underlying stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly. Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the timing and cost of, and level of investment in, research and development activities relating to VRS-317 and any future product candidates, which will change from time to time; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to enroll patients in clinical trials and the timing of enrollment; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of manufacturing VRS-317 and any future product candidates, which may vary depending on FDA guidelines and requirements, the quantity of production and the terms of our agreements with manufacturers; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">expenditures that we will or may incur to acquire or develop additional product candidates and technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the timing and outcomes of clinical studies for VRS-317 and any future product candidates or competing product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">changes in the competitive landscape of our industry, including consolidation among our competitors or partners; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">any delays in regulatory review or approval of VRS-317 or any of our future product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the level of demand for VRS-317 and any future product candidates, should they receive approval, which may fluctuate significantly and be difficult to predict; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the risk/benefit profile, cost and reimbursement policies with respect to our products candidates, if approved, and existing and potential future drugs that compete with our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">competition from existing and potential future drugs that compete with VRS-317 or any of our future product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to commercialize VRS-317 or any future product candidate inside and outside of the United States, either independently or working with third parties; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to establish and maintain collaborations, licensing or other arrangements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to adequately support future growth; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">potential unforeseen business disruptions that increase our costs or expenses; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">future accounting pronouncements or changes in our accounting policies; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the changing and volatile global economic environment. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue and/or earnings guidance we may provide. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will need additional funds to support our operations, and such funding may not be available to us on acceptable terms, or at all, which would force us to delay, reduce or suspend our research and development programs and other operations or commercialization efforts. Raising additional capital may subject us to unfavorable terms, cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates and technologies. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The completion of the development and the potential commercialization of VRS-317 and any future product candidates, should they receive approval, will require substantial funds. As of March 31, 2015, we had approximately $230.3 million in cash and cash equivalents. We believe that our existing cash and cash equivalents will be sufficient to sustain operations for at least the next 12 months based on our existing business plan. Our future financing requirements will depend on many factors, some of which are beyond our control, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the rate of progress and cost of our clinical studies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the timing of, and costs involved in, seeking and obtaining approvals from the FDA and other regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of preparing to manufacture VRS-317 on a larger scale; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of commercialization activities if VRS-317 or any future product candidate is approved, including product sales, marketing, manufacturing and distribution; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the degree and rate of market acceptance of any products launched by us or future partners; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to enter into additional collaboration, licensing, commercialization or other arrangements and the terms and timing of such arrangements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the emergence of competing technologies or other adverse market developments; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of attracting, hiring and retaining qualified personnel. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any material committed external source of funds or other support for our development efforts. Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. Additional financing may not be available to us when we need it or it may not be available on favorable terms. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to VRS-317 or potential future product candidates, technologies, future revenue streams or research programs, or grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend one or more of our clinical studies or research and development programs or our commercialization efforts. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our reliance on third parties </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third parties to conduct our clinical studies, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such studies. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not independently conduct clinical studies of our lead product candidate. We rely on third parties, such as contract research organizations, or CROs, clinical data management organizations, medical institutions and clinical investigators, to perform this function. For example, we currently rely on ResearchPoint Global to oversee and manage the Extension Study and global Phase 3 pediatric trial of VRS-317. Our reliance on these third parties for clinical development activities reduces our control over these activities but does not relieve us of our responsibilities. We remain responsible for ensuring that each of our clinical studies is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as good clinical practices, for conducting, recording and reporting the results of clinical studies to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of patients in clinical studies are protected. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical studies in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, regulatory approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely on other third parties to store and distribute supplies for our clinical studies. Any performance failure on the part of our existing or future distributors could delay clinical development or regulatory approval of our product candidates or commercialization of our products, producing additional losses and depriving us of potential product revenue. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third-party contract manufacturing organizations to manufacture and supply VRS-317. If our manufacturers and suppliers fail to perform adequately or fulfill our needs, we may be required to incur significant costs and devote significant efforts to find a new supplier or manufacturer. We may also face delays in the development and commercialization of our product candidates. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have limited experience in, and we do not own facilities for, clinical-scale manufacturing of our product candidates and we currently rely upon third-party contract manufacturing organizations to manufacture and supply drug product for our clinical studies of VRS-317. The manufacture of pharmaceutical products in compliance with the FDA&#8217;s cGMPs requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical products often encounter difficulties in production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced cGMP requirements, other federal and state regulatory requirements and foreign regulations. If our manufacturers were to encounter any of these difficulties or otherwise fail to comply with their obligations to us or under applicable regulations, our ability to provide study drugs in our clinical studies would be jeopardized. Any delay or interruption in the supply of clinical study materials could delay the completion of our clinical studies, increase the costs associated with maintaining our clinical study programs and, depending upon the period of delay, require us to commence new studies at significant additional expense or terminate the studies completely. For example, in February 2014, the FDA notified us that it would require additional information before allowing us to use a newly manufactured lot of VRS-317 produced by our new manufacturer and intended for our ongoing Extension Study. The FDA subsequently issued a partial clinical hold related to the use of any material produced by this new manufacturer and requested additional information prior to allowing us to use the newly manufactured lot. We responded to the FDA&#8217;s requests, and the FDA ultimately lifted the partial clinical hold in June 2014, and the new supply is currently being used in the Extension Study. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All manufacturers of our product candidates must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. Manufacturers of our product candidates may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. The FDA or similar foreign regulatory agencies may also implement new standards at any time, or change their interpretation and enforcement of existing standards for manufacture, packaging or testing of products. We have little control over our manufacturers&#8217; compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall or withdrawal of product approval. If the safety of any product supplied is compromised due to our manufacturers&#8217; failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical studies, regulatory submissions, approvals or commercialization of our product candidates, entail higher costs or impair our reputation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidate, VRS-317, is a biologic and therefore requires a complex production process. In October, 2012, we transferred production of VRS-317 to a new manufacturer, Boehringer Ingelheim. In connection with the transfer of production, we made certain changes to the manufacturing process in order to increase its scale and efficiency. We cannot assure that the FDA and the EMA will agree to the changes in the manufacturing process to support commercialization. In addition, current agreements with our manufacturer do not provide for the entire supply of the drug product necessary for full scale commercialization. If we and our manufacturer cannot agree to the terms and conditions necessary for our commercial supply needs, or if our manufacturer terminates the agreement in response to a material breach by us or otherwise becomes unable to fulfill its supply obligations, we would not be able to manufacture VRS-317 until a qualified alternative manufacturer is identified, which could also delay the development of, and impair our ability to commercialize, VRS-317. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of third-party manufacturers with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for alternative suppliers, which could have a material adverse effect on our business. New manufacturers of any product candidate would be required to qualify under applicable regulatory requirements and would need to have sufficient rights under applicable intellectual property laws to the method of manufacturing the product candidate. Obtaining the necessary FDA approvals or other qualifications under applicable regulatory requirements and ensuring non-infringement of third-party intellectual property rights could result in a significant interruption of supply and could require the new manufacturer to bear significant additional costs that may be passed on to us. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any future collaboration agreements we may enter into for VRS-317 or any other product candidate may place the development of VRS-317 or other product candidates outside our control, may require us to relinquish important rights or may otherwise be on terms unfavorable to us. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may enter into additional collaboration agreements with third parties with respect to VRS-317 for the commercialization of this candidate outside the United States, or with respect to future product candidates for commercialization in or outside the United States. Our likely collaborators for any distribution, marketing, licensing or other collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. We will have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend in part on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborations involving our product candidates are subject to numerous risks, which may include the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators have significant discretion in determining the efforts and resources that they will apply to any such collaborations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical study results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may delay clinical studies, provide insufficient funding for a clinical study program, stop a clinical study, abandon a product candidate, repeat or conduct new clinical studies or require a new formulation of a product candidate for clinical testing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and distribution; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">disputes may arise between us and a collaborator that causes the delay or termination of the research, development or commercialization of our product candidates or that results in costly litigation or arbitration that diverts management attention and resources; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any termination or disruption of collaborations could result in delays in the development of product candidates, increases in our costs to develop the product candidates or the termination of development of a product candidate. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to the operation of our business </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain our chief executive officer and other key executives and to attract, retain and motivate qualified personnel. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on our chief executive officer and the other principal members of our executive team, all of whom joined our company prior to May 2015, when our current chief executive officer began serving in that role. Under the terms of their employment, our executives may terminate their employment with us at any time. The loss of the services of any of these people or instability in our executive team, which may be more likely due to our recent leadership changes, could impede the achievement of our research, development and commercialization objectives. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of April 30, 2015, we had 39 employees. Over the next several years, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Future growth would impose significant added responsibilities on members of management, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">managing our clinical trials effectively, which we anticipate being conducted at numerous clinical sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">identifying, recruiting, maintaining, motivating and integrating additional employees with the expertise and experience we will require; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">managing our internal development efforts effectively while complying with our contractual obligations to licensors, licensees, contractors and other third parties; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">managing additional relationships with various strategic partners, suppliers and other third parties; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">improving our managerial, development, operational and finance reporting systems and procedures; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">expanding our facilities. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our failure to accomplish any of these tasks could prevent us from successfully growing our company. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act, or the JOBS Act, which was enacted in April 2012. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an emerging growth company for up to five years, although circumstances could cause us to lose that status earlier. We will remain an emerging growth company until the earlier of (1)&#160;December&#160;31, 2019, (2)&#160;the last day of the fiscal year (a)&#160;in which we have total annual gross revenue of at least $1.0 billion or (b)&#160;in which we are deemed to be a large accelerated filer, which means, among other things, that the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June&#160;30th, and (3)&#160;the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may suffer or be more volatile. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations could be subject to earthquakes, power shortages, telecommunications failures, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions. The </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. Our corporate headquarters are located in California and certain clinical sites for our product candidate, operations of our existing and future partners are or will be located in California near major earthquake faults and fire zones. The ultimate impact on us, our significant partners, suppliers and our general infrastructure of being located near major earthquake faults and fire zones and being consolidated in certain geographical areas is unknown, but our operations and financial condition could suffer in the event of a major earthquake, fire or other natural or manmade disaster. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we obtain approval to commercialize VRS-317 outside the United States, we will be subject to additional risks. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we obtain approval to commercialize any products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">different regulatory requirements for drug approvals in foreign countries; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">reduced protection for intellectual property rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">unexpected changes in tariffs, trade barriers and regulatory requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">economic weakness, including inflation or political instability in particular foreign economies and markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">foreign taxes, including withholding of payroll taxes; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">workforce uncertainty in countries where labor unrest is more common than in the United&#160;States; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires. </font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our drug development programs. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical study data from completed or ongoing clinical studies for a product candidate could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of any product candidates could be delayed. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to intellectual property </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with our obligations in our intellectual property licenses with third parties, we could lose license rights that are important to our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to intellectual property license agreements with third parties, including with respect to VRS-317, and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that our future license agreements will impose, various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, our licensors may have the right to terminate these agreements, in which event we may not be able to develop and market any product that is covered by these agreements. For example, we license substantially all of the intellectual property relating to VRS-317 from Amunix, and the loss of our license agreement with Amunix would therefore materially adversely affect our ability to proceed with any development or potential commercialization of our product candidates as currently planned. Amunix has the right to terminate the license upon 30 days&#8217; written notice with respect to a particular target and the related products if (i)&#160;during any consecutive 18 month period our cumulative funding of research, development and commercialization activities in respect of such target is not at least $250,000, in which case we would have the right to extend the applicable 18 month period by paying Amunix $150,000; or (ii)&#160;if we do not use commercially reasonable measures to develop and commercialize licensed products based on such </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">target. Termination of this license, or reduction or elimination of our licensed rights under it or any other license, may result in our having to negotiate new or reinstated licenses on less favorable terms or our not having sufficient intellectual property rights to operate our business. The occurrence of such events could materially harm our business and financial condition. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risks described elsewhere pertaining to our intellectual property rights also apply to the intellectual property rights that we license, and any failure by us or our licensors to obtain, maintain, defend and enforce these rights could have a material adverse effect on our business. In some cases we do not have control over the prosecution, maintenance or enforcement of the patents that we license, and may not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents, and our licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents. We are also required to reimburse Amunix for certain costs incurred in prosecuting, maintaining, defending and enforcing the licensed patents. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to successfully commercialize our technology and products may be materially adversely affected if we are unable to obtain and maintain effective intellectual property rights for our technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends in large part on our and our licensors&#8217; ability to obtain and maintain patent and other intellectual property protection in the United States and in other countries with respect to our proprietary technology and products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We license substantially all of the intellectual property relating to VRS-317 from Amunix. We do not presently own any issued patents or pending patent applications, and our license agreement with Amunix provides that inventions relating to VRS-317 are owned by Amunix. We are therefore dependent on Amunix to apply for, prosecute, maintain, defend and, in some cases, enforce the patent rights necessary to conduct our business. However, we cannot be certain this will be done in a manner consistent with the best interests of our business. The process of applying for patents is expensive and time-consuming, and Amunix may not, or may not be able to, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or Amunix will fail to identify patentable aspects of our respective research and development output before it is too late to obtain patent protection. While Amunix has obtained a number of patents relating to the XTEN technology, and applied for a number of other patents relating to the XTEN technology in general, and VRS-317 in particular, we cannot assure you that the pending applications will result in issued patents, and the existing Amunix patents that we license, and any future patents they obtain may not be sufficiently broad to prevent others from using our technologies or from developing competing products and technologies. Under our license agreement with Amunix, we are obligated to use commercially reasonable efforts to develop and commercialize certain products that we license from Amunix and to maintain minimum rates of spending on research, development and commercialization. In exchange, we retain a limited, exclusive license to relevant patents and know-how related to XTEN technology. If we fail to fulfill our obligations under the agreement, Amunix could terminate the agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain unresolved. In recent years patent rights have been the subject of significant litigation. As a result, the issuance, scope, validity, enforceability and commercial value of the patent rights we rely on are highly uncertain. Pending and future patent applications may not result in patents being issued which protect our technology or products or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of the patents we rely on or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that our licensors were the first to make the inventions claimed in our licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. Assuming the other requirements for patentability are met, prior to March&#160;16, 2013, in the United States, the first to make the claimed invention is entitled to the patent, while outside the United States, the first to file a patent application is entitled to the patent. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if the patent applications we rely on issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and the patents we rely on may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights to exclude others from commercializing products similar or identical to ours or otherwise provide us with a competitive advantage. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, certain of Amunix&#8217;s activities have been funded, and may in the future be funded, by the U.S. government. When new technologies are developed with U.S. government funding, the government obtains certain rights in any resulting patents, including the right to a nonexclusive license authorizing the government to use the invention. These rights may permit the government to disclose our confidential information to third parties and to exercise &#8220;march-in&#8221; rights to use or allow third parties to use Amunix&#8217;s patented technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the U.S. government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, U.S. government-funded inventions must be reported to the government, U.S. government funding must be disclosed in any resulting patent applications, and Amunix&#8217;s rights in such inventions may be subject to certain requirements to manufacture products in the United States. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may become involved in legal proceedings to protect or enforce our intellectual property rights, which could be expensive, time-consuming and unsuccessful. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe or otherwise violate the patents we rely on, or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims that we assert against perceived infringers could also provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property rights. In addition, in an infringement proceeding, a court may decide that a patent we are asserting is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that the patents we are asserting do not cover the technology in question. An adverse result in any litigation proceeding could put one or more patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interference or derivation proceedings provoked by third parties or brought by the United States Patent and Trademark Office, or USPTO, or any foreign patent authority may be necessary to determine the priority of inventions or other matters of inventorship with respect to patents and patent applications. We or our licensers may become involved in proceedings, including oppositions, interferences, derivation proceedings inter partes reviews, patent nullification proceedings, or re-examinations, challenging our patent rights or the patent rights of others, and the outcome of any such proceedings are highly uncertain. For example, Novo Nordisk A/S and XL-protein GmbH filed oppositions to an issued European patent relating to the XTEN technology. An adverse determination in any such proceeding could reduce the scope of, or invalidate, important patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Our business also could be harmed if a prevailing party does not offer us a license on commercially reasonable terms, if any license is offered at all. Litigation or other proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may also become involved in disputes with others regarding the ownership of intellectual property rights. For example, we hold material service agreements with certain parties, including Amunix, and disagreements may therefore arise as to the ownership of any intellectual property developed pursuant to these relationships. If we are unable to resolve these disputes, we could lose valuable intellectual property rights. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and/or management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the proprietary rights or intellectual property of third parties. We may become party to, or be threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology. Third parties may assert infringement claims against us based on existing or future intellectual property rights. If we are found to infringe a third-party&#8217;s intellectual property rights, we could be required to obtain a license from such third-party to continue developing and marketing our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products and technology. We may also elect to enter into such a license in order to settle pending or threatened litigation. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us, and could require us to pay significant royalties and other fees. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. These and other claims that we have misappropriated the confidential information or trade secrets of third parties can have a similar negative impact on our business to the infringement claims discussed above. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we are successful in defending against intellectual property claims, litigation or other legal proceedings relating to such claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of litigation or other intellectual property related proceedings could have a material adverse effect on our ability to compete in the marketplace. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected, harming our business and competitive position. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our patented technology and products, we rely upon confidential proprietary information, including trade secrets, unpatented know-how, technology and other proprietary information, to develop and maintain our competitive position. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in the market. We seek to protect our confidential proprietary information, in part, by confidentiality agreements with our employees and our collaborators and consultants. We also have agreements with our employees and selected consultants that obligate them to assign their inventions to us. These agreements are designed to protect our proprietary information, however, we cannot be certain that our trade secrets and other confidential information will not be disclosed or that competitors will not otherwise gain access to our trade secrets, or that technology relevant to our business will not be independently developed by a person that is not a party to such an agreement. Furthermore, if the employees, consultants or collaborators that are parties to these agreements breach or violate the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets through such breaches or violations. Further, our trade secrets could be disclosed, misappropriated or otherwise become known or be independently discovered by our competitors. In addition, intellectual property laws in foreign countries may not protect trade secrets and confidential information to the same extent as the laws of the United States. If we are unable to prevent disclosure of the intellectual property related to our technologies to third parties, we may not be able to establish or maintain a competitive advantage in our market, which would harm our ability to protect our rights and have a material adverse effect on our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to protect and/or enforce our intellectual property rights throughout the world. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive to us and to our licensors. Competitors may use our technologies in jurisdictions where we or our licensors have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as in the United States. These products may compete with our products in jurisdictions where we or our licensors do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. The following examples are illustrative: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Others may be able to make products that are similar to our product candidates but that are not covered by the claims of the patents that we license; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Our licensors or collaborators might not have been the first to make the inventions covered by an issued patent or pending patent application; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Our licensors or collaborators might not have been the first to file patent applications covering an invention; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Others may independently develop similar or alternative technologies or duplicate any of our or our licensors&#8217; technologies without infringing our intellectual property rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Pending patent applications may not lead to issued patents; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Issued patents may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">Our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">We may not develop or in-license additional proprietary technologies that are patentable; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">The patents of others may have an adverse effect on our business. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, they could significantly harm our business, results of operations and prospects. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our or our licensors&#8217; patent protection could be reduced or eliminated for non-compliance with these requirements. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid by us and/or our licensors to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the licensed patents and/or applications. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to use our technologies and those technologies licensed to us and this circumstance would have a material adverse effect on our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of our issued patents. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2013, under the America Invents Act, or AIA, the United States moved to a first-to-file system and made certain other changes to its patent laws. The effects of these changes are currently unclear as the USPTO must still implement various regulations, the courts have yet to address these provisions and the applicability of the act and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. Accordingly, it is not yet clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents, all of which could have a material adverse effect on our business and financial condition. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our third party licensor does not obtain a patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for our product candidates, our business may be materially harmed. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, if any, one or more of the U.S. patents covering our approved product(s) or the use thereof may be eligible for up to five years of patent term restoration under the Hatch-Waxman Act. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA approved product. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent term extension also may be available in certain foreign countries upon regulatory approval of our product candidates. Nevertheless, we or our licensor may not be granted patent term extension either in the United States or in any foreign country because of, for example, we or our licensors failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our licensors are unable to obtain patent term extension or restoration, or the term of any such extension is less than requested, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to government regulation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The regulatory approval process is expensive, time consuming and uncertain and may prevent us or our collaboration partners from obtaining approvals for the commercialization of our product candidates.<font style="font-weight:normal;font-style:normal;"> </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, which regulations differ from country to country. Neither we nor our collaboration partners are permitted to market our product candidates in the United States until we receive approval of a BLA from the FDA. Neither we nor our collaboration partners have submitted an application or received marketing approval for VRS-317 or any future product candidates. Obtaining approval of a BLA can be a lengthy, expensive and uncertain process. In addition, failure to comply with FDA and other applicable U.S. and foreign regulatory requirements may subject us to administrative or judicially imposed sanctions, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">warning letters; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">civil or criminal penalties and fines; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">injunctions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">suspension or withdrawal of regulatory approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">suspension of any ongoing clinical studies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">voluntary or mandatory product recalls and publicity requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">refusal to accept or approve applications for marketing approval of new drugs or biologics or supplements to approved applications filed by us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">restrictions on operations, including costly new manufacturing requirements; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">seizure or detention of our products or import bans. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in February 2014, the FDA notified us that it would require additional information before allowing us to use a newly manufactured lot of VRS-317 produced by our new manufacturer and intended for our ongoing Extension Study. The FDA subsequently issued a PCH related to the use of any material produced by this new manufacturer and requested additional information prior to allowing us to use the newly manufactured lot and the new supply is currently being used in the Extension Study. We responded to the FDA&#8217;s requests, and the FDA ultimately lifted the PCH in June 2014. Prior to receiving approval to commercialize any of our product candidates in the United States or abroad, we and our collaboration partners must demonstrate with substantial evidence from well-controlled clinical studies, and to the satisfaction of the FDA and other regulatory authorities abroad, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical studies can be interpreted in different ways. Even if we and our collaboration partners believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. Administering any of our product candidates to humans may produce undesirable side effects, which could interrupt, delay or cause suspension of clinical studies of our product candidates and result in the FDA or other regulatory authorities denying approval of our product candidates for any or all targeted indications. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory approval of a BLA is not guaranteed, and the approval process is expensive and may take several years. The FDA also has substantial discretion in the approval process. Despite the time and expense exerted, failure can occur at any stage, and we could encounter problems that cause us to abandon or repeat clinical studies, or perform additional preclinical studies and clinical studies. The number of preclinical studies and clinical studies that will be required for FDA approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address and the regulations applicable to any particular product candidate. The FDA can delay, limit or deny approval of a product candidate for many reasons, including, but not limited to, the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">a product candidate may not be deemed safe or effective; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">FDA officials may not find the data from preclinical studies and clinical studies sufficient; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA might not approve our or our third-party manufacturer&#8217;s processes or facilities; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA may change its approval policies or adopt new regulations. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If VRS-317 or any future product candidates fail to demonstrate safety and efficacy in clinical studies or do not gain regulatory approval, our business and results of operations will be materially and adversely harmed. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we receive regulatory approval for a product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to penalties if we fail to comply with applicable regulatory requirements. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once regulatory approval has been granted, the approved product and its manufacturer are subject to continual review by the FDA and/or non-U.S. regulatory authorities. Any regulatory approval that we or any future collaboration partners receive for VRS-317 or any future product candidates may be subject to limitations on the indicated uses for which the product may be marketed or contain requirements for potentially costly post-marketing follow-up studies to monitor the safety and efficacy of the product. In addition, if the FDA and/or non-U.S. regulatory authorities approve VRS-317 or any future product candidates, we will be subject to extensive and ongoing regulatory requirements by the FDA and other regulatory authorities with regard to the labeling, packaging, adverse event reporting, storage, advertising, promotion and recordkeeping for our products. In addition, manufacturers of our drug products are required to comply with cGMP regulations, which include requirements related to quality control and quality assurance as well as the corresponding maintenance of records and documentation. Further, regulatory authorities must approve these manufacturing facilities before they can be used to manufacture our drug products, and these facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations. If we or a third party discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with regulatory requirements of the FDA and/or other non-U.S. regulatory authorities, we could be subject to administrative or judicially imposed sanctions, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">warning letters; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">civil or criminal penalties and fines; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">injunctions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">suspension or withdrawal of regulatory approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">suspension of any ongoing clinical studies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">voluntary or mandatory product recalls and publicity requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">refusal to accept or approve applications for marketing approval of new drugs or biologics or supplements to approved applications filed by us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">restrictions on operations, including costly new manufacturing requirements; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">seizure or detention of our products or import bans. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulatory requirements and policies may change and additional government regulations may be enacted with which we may also be required to comply. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or in other countries. If we are not able to maintain regulatory compliance, we may not be permitted to market our future products and our business may suffer. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Failure to obtain regulatory approvals in foreign jurisdictions will prevent us from marketing our products internationally. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to seek a distribution and marketing partner for VRS-317 outside the United States and may market future products in international markets. In order to market our future products in regions such as the European Economic Area, or EEA, Asia Pacific, or APAC, and many other foreign jurisdictions, we must obtain separate regulatory approvals. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA. Before granting the MA, the European Medicines Agency or the competent authorities of the member states of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. In Japan, the Pharmaceuticals and Medical Devices Agency, or the PMDA, of the Ministry of Health Labour and Welfare, or MHLW, must approve an application under the Pharmaceutical Affairs Act before a new drug product may be marketed in Japan. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have had limited interactions with foreign regulatory authorities. The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Moreover, clinical studies conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not obtain foreign regulatory approvals on a timely basis, if at all. We may not be able to file for regulatory approvals and even if we file we may not receive necessary approvals to commercialize our products in any market. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Healthcare reform measures could hinder or prevent our product candidates&#8217; commercial success. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, there have been and we expect there will continue to be a number of legislative and regulatory changes to the healthcare system in ways that could affect our future revenue and profitability and the future revenue and profitability of our potential customers. Federal and state lawmakers regularly propose and, at times, enact legislation that would result in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. For example, one of the most significant healthcare reform measures in decades, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, collectively, the ACA, was enacted in 2010. The ACA contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse measures, all of which will impact existing government healthcare programs and will result in the development of new programs. The ACA, among other things: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">imposes a non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded prescription drugs,&#8221; effective 2011; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">increases the minimum level of Medicaid rebates payable by manufacturers of brand-name drugs from 15.1% to 23.1%, effective 2011; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">could result in the imposition of injunctions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">requires collection of rebates for drugs paid by Medicaid managed care organizations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">requires manufacturers to participate in a coverage gap discount program, under which they must agree to offer 50% point-of-sale discounts off negotiated prices of applicable branded drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">creates a process for approval of biologic therapies that are similar or identical to approved biologics. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While the U.S. Supreme Court upheld the constitutionality of most elements of the ACA in June 2012, other legal challenges are still pending final adjudication in several jurisdictions. In addition, Congress has also proposed a number of legislative initiatives, including possible repeal of the ACA. At this time, it remains unclear whether there will be any changes made to the ACA, whether to certain provisions or its entirety. We cannot assure you that the ACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend proposals for spending reductions to Congress. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, which triggered the legislation&#8217;s automatic reduction to several government programs, including aggregate reductions to Medicare payments to providers of up to 2%&#160;per fiscal year, starting in 2013. In January 2013, President </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obama signed into law the American Taxpayer Relief Act of 2012, or the ATRA, which delayed for another two months the budget cuts mandated by the sequestration provisions of the Budget Control Act of 2011. The ATRA, among other things, also reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. In March 2013, the President signed an executive order implementing sequestration, and in April&#160;2013, the 2% Medicare reductions went into effect. We cannot predict whether any additional legislative changes will affect our business. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There likely will continue to be legislative and regulatory proposals at the federal and state levels directed at containing or lowering the cost of health care. We cannot predict the initiatives that may be adopted in the future or their full impact. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of health care may adversely affect: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to set a price that we believe is fair for our products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to generate revenue and achieve or maintain profitability; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the availability of capital. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, changes in regulatory requirements and guidance may occur and we may need to amend clinical study protocols to reflect these changes. Amendments may require us to resubmit our clinical study protocols to Institutional Review Boards for reexamination, which may impact the costs, timing or successful completion of a clinical study. In light of widely publicized events concerning the safety risk of certain drug products, regulatory authorities, members of Congress, the Governmental Accounting Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the recall and withdrawal of drug products, revisions to drug labeling that further limit use of the drug products and establishment of risk management programs that may, for instance, restrict distribution of drug products or require safety surveillance and/or patient education. The increased attention to drug safety issues may result in a more cautious approach by the FDA to clinical studies and the drug approval process. Data from clinical studies may receive greater scrutiny with respect to safety, which may make the FDA or other regulatory authorities more likely to terminate or suspend clinical studies before completion, or require longer or additional clinical studies that may result in substantial additional expense and a delay or failure in obtaining approval or approval for a more limited indication than originally sought. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the serious public health risks of high profile adverse safety events with certain drug products, the FDA may require, as a condition of approval, costly risk evaluation and mitigation strategies, which may include safety surveillance, restricted distribution and use, patient education, enhanced labeling, special packaging or labeling, expedited reporting of certain adverse events, preapproval of promotional materials and restrictions on direct-to-consumer advertising. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our business. We could be subject to healthcare fraud and abuse and patient privacy regulation by both the federal government and the states in which we conduct our business. The regulations that may affect our ability to operate include, without limitation: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs, such as the Medicare and Medicaid programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs, such as the Medicare and Medicaid programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the federal False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, false claims, or knowingly using false statements, to obtain payment from the federal government, and which may apply to entities like us which provide coding and billing advice to customers; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the federal transparency requirements under the Health Care Reform Law requires manufacturers of drugs, devices, biologics and medical supplies to report to the Department of Health and Human Services information related to physician payments and other transfers of value and physician ownership and investment interests; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ACA, among other things, amends the intent requirement of the Federal Anti-Kickback Statute and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. In addition, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the Federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security and fraud laws may prove costly. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to ownership of our common stock </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our stock price may be volatile, and investors in our common stock could incur substantial losses. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock price has fluctuated in the past and may be volatile in the future. From March&#160;21, 2014, the first date of trading of our common stock, through April 30, 2015 the reported sale price of our common stock has fluctuated between $16.15 and $36.86 per share. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may experience losses on their investment in our common stock. The market price for our common stock may be influenced by many factors, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the success of competitive products or technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">results of clinical studies of VRS-317 or future product candidates or those of our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to our products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">introductions and announcements of new products by us, our commercialization partners, or our competitors, and the timing of these introductions or announcements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">actions taken by regulatory agencies with respect to our products, clinical studies, manufacturing process or sales and marketing terms; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">variations in our financial results or those of companies that are perceived to be similar to us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the success of our efforts to acquire or in-license additional products or product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">developments concerning our collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization partners; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">developments concerning our ability to bring our manufacturing processes to scale in a cost-effective manner; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our ability or inability to raise additional capital and the terms on which we raise it; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the recruitment or departure of key personnel; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">changes in the structure of healthcare payment systems; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">market conditions in the pharmaceutical and biotechnology sectors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">trading volume of our common stock; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">sales of our common stock by us or our stockholders; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">general economic, industry and market conditions; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">the other risks described in this &#8220;Risk factors&#8221; section. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial costs and diversion of management&#8217;s attention and resources, which could materially and adversely affect our business, financial condition, results of operations and growth prospects.&nbsp;&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our executive officers, directors and principal stockholders will continue to maintain the ability to control or significantly influence all matters submitted to stockholders for approval. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of April 30, 2015, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock, in the aggregate, beneficially own shares representing approximately&#160;61% of our common stock. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these stockholders, if they choose to act together, will control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders may desire. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We incur significant costs as a result of operating as a newly public company, and our management devotes substantial time to new compliance initiatives. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a newly public company, we are incurring significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, the other rules and regulations of the Securities and Exchange Commission, or SEC, and the rules and regulations of The NASDAQ Global Select Market, or NASDAQ. The expenses required in order to adequately prepare for being a public company have been and will be material, and compliance with the various reporting and other requirements applicable to public companies requires considerable time and attention of management. For example, the Sarbanes-Oxley Act and the rules of the SEC and national securities exchanges have imposed various requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls. Our management and other personnel are devoting and will continue to need to devote a substantial amount of time to these compliance initiatives. These rules and regulations will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly. The impact of these events could also make it more difficult for us to attract and retain qualified personnel to serve on our board of directors, our board committees, or as executive officers. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting and disclosure controls and procedures. In particular, we must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting, as required by Section&#160;404 of the Sarbanes-Oxley Act, beginning with our annual report on Form 10-K for the fiscal year ended December&#160;31, 2015. In addition, we will be required to have our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting beginning with our annual report on Form 10-K following the date on which we are no longer an emerging growth company. Our compliance with Section&#160;404 of the Sarbanes-Oxley Act will require that we incur substantial accounting expense and expend significant management efforts. If we are not able to comply with the requirements of Section&#160;404 in a timely manner, or if we or our independent registered public accounting firm identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline and we could be subject to sanctions or investigations by NASDAQ, the SEC or other regulatory authorities, which would require additional financial and management resources. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to successfully implement our business plan and comply with Section&#160;404 requires us to be able to prepare timely and accurate condensed consolidated financial statements. We expect that we will need to continue to improve existing, and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">implement new operational and financial systems, procedures and controls to manage our business effectively. Any delay in the implementation of, or disruption in the transition to, new or enhanced systems, procedures or controls, may cause our operations to suffer and we may be unable to conclude that our internal control over financial reporting is effective and to obtain an unqualified report on internal controls from our auditors as required under Section&#160;404 of the Sarbanes-Oxley Act. This, in turn, could have an adverse impact on trading prices for our common stock, and could adversely affect our ability to access the capital markets. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">In connection with our preparations for becoming a public company, we identified a material weakness in our internal control over financial reporting and may identify additional material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our condensed consolidated financial statements. If we fail to remediate one or more of our material weaknesses in the future or if we fail to establish and maintain effective control over financial reporting, our ability to accurately and timely report our financial results could be adversely affected. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of condensed consolidated financial statements in accordance with U.S. generally accepted accounting principles. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of annual or interim condensed consolidated financial statements will not be prevented or detected on a timely basis. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the completion of our initial public offering, we were a private company with limited accounting personnel and other resources to address our internal control over financial reporting. During the course of preparing for our initial public offering, we determined that material adjustments to various accounts were necessary, which required us to restate the financial statements as of and for the years ended December&#160;31, 2012 and 2011 and for the period from inception (December 10, 2008) through December&#160;31, 2012 that had been previously audited by another independent audit firm. These adjustments leading to a restatement of those financial statements led us to conclude that we had a material weakness in internal control over financial reporting as of December&#160;31, 2012. The material weakness that we identified was that we did not maintain a sufficient complement of resources with an appropriate level of accounting knowledge, experience and training commensurate with our structure and financial reporting requirements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This material weakness contributed to adjustments to previously issued financial statements principally, but not limited to, the following areas: equity accounting in connection with our issuance of Series A and B convertible preferred stock and period-end cutoff for clinical trial related expenses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we have been successful in our efforts to remediate this particular material weakness we cannot assure you that we will be able to prevent or remediate any additional weaknesses in the future, which could impair our ability to accurately and timely report our financial position, results of operations or cash flows. If we are unable to successfully prevent or remediate any additional material weaknesses in the future, and if we are unable to produce accurate and timely consolidated financial statements, including our filing of quarterly reports with the SEC on a timely and accurate basis, our stock price may be adversely affected and we may be unable to maintain compliance with applicable NASDAQ listing requirements. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">An active trading market for our common stock may not be maintained. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is currently traded on NASDAQ, but we can provide no assurance that we will be able to maintain an active trading market for our shares on NASDAQ or any other exchange in the future. If there is no active market for our common stock, it may be difficult for our stockholders to sell shares without depressing the market price for the shares or at all. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts may cease to publish research on our company at any time in their discretion. If one or more of these analysts cease coverage of our company, or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our stock price and trading volume to decline. In addition, if one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If our operating results fail to meet the forecast of analysts, our stock price would likely decline. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. Among others, these provisions include the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our board of directors is divided into three classes with staggered three-year terms which may delay or prevent a change of our management or a change in control; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our board of directors has the right to elect directors to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our stockholders are not able to act by written consent or call special stockholders&#8217; meetings; as a result, a holder, or holders, controlling a majority of our capital stock are not able to take certain actions other than at annual stockholders&#8217; meetings or special stockholders&#8217; meetings called by the board of directors, the chairman of the board, the chief executive officer or the president; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our certificate of incorporation prohibits cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our stockholders are required to provide advance notice and additional disclosures in order to nominate individuals for election to the board of directors or to propose matters that can be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of our company; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:95.46%;margin-left:4.54%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Symbol';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top" style="width:97.73%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Symbol';font-size:10pt;"><font style="font-family:Times New Roman;">our board of directors are able to issue, without stockholder approval, shares of undesignated preferred stock, which makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to acquire us. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employment arrangements with our executive officers may require us to pay severance benefits to any of those persons who are terminated in connection with a change in control of us, which could harm our financial condition or results. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our executive officers are parties to employment or other agreements or participants under plans that contain change in control and severance provisions providing for aggregate cash payments for severance and other benefits and acceleration of vesting of stock options in the event of a termination of employment in connection with a change in control of us. The accelerated vesting of options could result in dilution to our existing stockholders and harm the market price of our common stock. The payment of these severance benefits could harm our financial condition and results. In addition, these potential severance payments may discourage or prevent third parties from seeking a business combination with us. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be our stockholders&#8217; sole source of gain. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of existing or any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be our stockholders&#8217; sole source of gain for the foreseeable future. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Unregistered_Sales"></a>Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Exhibits"></a>Item&#160;6. Exhibits </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:7.98%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="3" valign="bottom"  style="width:56.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="7" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:32.94%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporation by Reference</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:7.98%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br><font style="text-decoration:underline;">Number</font></p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:21.8%;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:13.4%;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit Description</font></p></td>
<td valign="bottom"  style="width:21.76%;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:5.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Form</font></p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SEC <br><font style="text-decoration:underline;">File No.</font></p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:4.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit</font></p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:8.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Filing Date</font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="3" valign="bottom"  style="width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amended and Restated Certificate of Incorporation of Versartis, Inc.</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:5.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36361</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:4.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:8.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/26/2014</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="3" valign="bottom"  style="width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amended and Restated Bylaws of Versartis, Inc.</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:5.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-193997</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:4.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:8.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/06/2014</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="3" valign="bottom"  style="width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Stock Certificate</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:5.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36361</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:4.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:8.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">05/14/2014</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="3" valign="bottom"  style="width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of 2014 Equity Incentive Plan Stock Option Grant Notice and Stock Option Agreement</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:5.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-8</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-194949</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:4.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.5</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:8.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">04/01/2014</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="3" valign="bottom"  style="width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of 2014 Equity Incentive Plan Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:5.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36361</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:4.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:8.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">04/17/2014</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1*</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="3" valign="bottom"  style="width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification required by Rule&#160;13a-14(a) or Rule&#160;15d-14(a).</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:5.52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:10.56%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:4.94%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:8.72%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2*</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="3" valign="bottom"  style="width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification required by Rule&#160;13a-14(a) or Rule&#160;15d-14(a).</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:5.52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:10.56%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:4.94%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:8.72%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1*+</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="3" valign="bottom"  style="width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification required by Rule&#160;13a-14(b) or Rule&#160;15d-14(b) and Section&#160;1350 of Chapter&#160;63 of Title&#160;18 of the United States Code (18&#160;U.S.C. &#167;1350)</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:5.52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:10.56%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:4.94%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:8.72%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="3" valign="bottom"  style="width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:5.52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:10.56%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:4.94%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:8.72%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="3" valign="bottom"  style="width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:5.52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:10.56%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:4.94%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:8.72%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="3" valign="bottom"  style="width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:5.52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:10.56%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:4.94%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:8.72%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="3" valign="bottom"  style="width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:5.52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:10.56%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:4.94%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:8.72%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="3" valign="bottom"  style="width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:5.52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:10.56%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:4.94%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:8.72%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="3" valign="bottom"  style="width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:5.52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:10.56%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:4.94%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:8.72%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed Herewith. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This certification accompanies the Quarterly Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed &#8220;filed&#8221; by the Registrant for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.53%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.53%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Signatures"></a>SIGNATURES </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:49%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">VERSARTIS, INC.</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Registrant)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 11, 2015</p></td>
<td valign="bottom"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jay Shepard&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jay Shepard</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 11, 2015</p></td>
<td valign="bottom"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Joshua T. Brumm&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joshua T. Brumm</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>vsar-ex311_201503316.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<!-- NG Converter v3.0.3.5 -->
<body>
<p style="text-align:right;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;31.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Certification of President and Chief Executive Officer </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Jay Shepard, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:94.33%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of Versartis, Inc. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:94.33%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:94.33%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top" style="width:94.33%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) for the registrant and have: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.4%;margin-left:5.6%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.4%;margin-left:5.6%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.4%;margin-left:5.6%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top" style="width:94.33%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.4%;margin-left:5.6%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.4%;margin-left:5.6%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 11, 2015</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jay Shepard&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jay Shepard</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;<font style="font-size:8pt;">&#160;</font></p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>vsar-ex312_201503317.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<!-- NG Converter v3.0.3.5 -->
<body>
<p style="text-align:right;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;31.2 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Certification of President and Chief Executive Officer </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Joshua Brumm, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top" style="width:94.33%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of Versartis, Inc. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top" style="width:94.33%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top" style="width:94.33%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top" style="width:94.33%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)) for the registrant and have: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.4%;margin-left:5.6%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.4%;margin-left:5.6%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.4%;margin-left:5.6%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top" style="width:94.33%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.4%;margin-left:5.6%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.4%;margin-left:5.6%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May&#160;11, 2015</p></td>
<td valign="bottom"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Joshua Brumm</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joshua Brumm</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>vsar-ex321_201503318.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<!-- NG Converter v3.0.3.5 -->
<body>
<p style="text-align:right;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Jay Shepard, Chief Executive Officer of Versartis, Inc. (the &#8220;Company&#8221;), and Joshua Brumm, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. The Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2015, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Exchange Act; and </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: May 11, 2015 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Witness Whereof, the undersigned have set their hands hereto as of the 11th day of May, 2015. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:46.6%;">
<tr>
<td valign="bottom"  style="width:100%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;/s/ Jay Shepard</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:100%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jay Shepard</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:100%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;/s/ Joshua Brumm</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:100%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joshua Brumm</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>vsar-20150331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RRD ActiveDisclosure(SM) XBRL Instance Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2015-05-06T18:23:29.7602757+00:00 -->
<!-- Version            : 2.0.5.0 -->
<!-- Package ID         : 5D450A663E0E1D6253DC3DA711642366-0001513818-001504 -->
<!-- Copyright (c) 2015 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<xbrl xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.xbrl.org/2003/instance" xmlns:vsar="http://www.versartis.com/20150331" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="vsar-20150331.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <unit id="U_shares">
    <measure>shares</measure>
  </unit>
  <unit id="U_iso4217USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="U_iso4217USD_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="U_vsarSegment">
    <measure>vsar:Segment</measure>
  </unit>
  <unit id="U_pure">
    <measure>pure</measure>
  </unit>
  <unit id="U_utrsqft">
    <measure>utr:sqft</measure>
  </unit>
  <context id="C_0001513818_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001513818_20150430">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
    </entity>
    <period>
      <instant>2015-04-30</instant>
    </period>
  </context>
  <context id="C_0001513818_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001513818_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001513818_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001513818_20131231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="C_0001513818_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="C_0001513818_us-gaapFairValueByLiabilityClassAxis_vsarConvertiblePreferredStockCallOptionLiabilityMember_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" xmlns="http://xbrl.org/2006/xbrldi">vsar:ConvertiblePreferredStockCallOptionLiabilityMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001513818_us-gaapFairValueByLiabilityClassAxis_vsarConvertiblePreferredStockWarrantLiabilityMember_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" xmlns="http://xbrl.org/2006/xbrldi">vsar:ConvertiblePreferredStockWarrantLiabilityMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001513818_us-gaapFairValueByLiabilityClassAxis_vsarConvertiblePreferredStockToCommonStockMember_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" xmlns="http://xbrl.org/2006/xbrldi">vsar:ConvertiblePreferredStockToCommonStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001513818_us-gaapSubsidiarySaleOfStockAxis_vsarSecondaryOfferingMember_20150101_20150131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">vsar:SecondaryOfferingMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-01-31</endDate>
    </period>
  </context>
  <context id="C_0001513818_us-gaapRangeAxis_us-gaapMinimumMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001513818_us-gaapRangeAxis_us-gaapMaximumMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001513818_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0001513818_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001513818_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001513818_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001513818_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001513818_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByAssetClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MoneyMarketFundsMember</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueMeasurementsRecurringMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001513818_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByAssetClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MoneyMarketFundsMember</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel1Member</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueMeasurementsRecurringMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001513818_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByAssetClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MoneyMarketFundsMember</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueMeasurementsRecurringMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001513818_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByAssetClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MoneyMarketFundsMember</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel1Member</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueMeasurementsRecurringMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001513818_us-gaapStatementGeographicalAxis_vsarMenloParkCaliforniaMember_20140301_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementGeographicalAxis" xmlns="http://xbrl.org/2006/xbrldi">vsar:MenloParkCaliforniaMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-03-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001513818_us-gaapStatementGeographicalAxis_vsarMenloParkCaliforniaMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementGeographicalAxis" xmlns="http://xbrl.org/2006/xbrldi">vsar:MenloParkCaliforniaMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001513818_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_vsarTwoThousandNineStockOptionPlanMember_20140321">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xmlns="http://xbrl.org/2006/xbrldi">vsar:TwoThousandNineStockOptionPlanMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-03-21</instant>
    </period>
  </context>
  <context id="C_0001513818_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_vsarStockOptionPlanTwoThousandFourteenMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xmlns="http://xbrl.org/2006/xbrldi">vsar:StockOptionPlanTwoThousandFourteenMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001513818_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_vsarStockOptionPlanTwoThousandFourteenMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xmlns="http://xbrl.org/2006/xbrldi">vsar:StockOptionPlanTwoThousandFourteenMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001513818_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_vsarEmployeeStockPurchasePlanMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xmlns="http://xbrl.org/2006/xbrldi">vsar:EmployeeStockPurchasePlanMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001513818_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_vsarEmployeeStockPurchasePlanMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xmlns="http://xbrl.org/2006/xbrldi">vsar:EmployeeStockPurchasePlanMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001513818_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_vsarOptionsToPurchaseCommonStockMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">vsar:OptionsToPurchaseCommonStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="C_0001513818_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_vsarOptionsToPurchaseCommonStockMember_20140101_20140331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">vsar:OptionsToPurchaseCommonStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="C_0001513818_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20150101_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001513818</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockUnitsRSUMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <dei:DocumentType id="F_000000" contextRef="C_0001513818_20150101_20150331">10-Q</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001513818_20150101_20150331">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001513818_20150101_20150331">2015-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0001513818_20150101_20150331">2015</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000004" contextRef="C_0001513818_20150101_20150331">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol id="F_000005" contextRef="C_0001513818_20150101_20150331">VSAR</dei:TradingSymbol>
  <dei:EntityRegistrantName id="F_000006" contextRef="C_0001513818_20150101_20150331">Versartis, Inc.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000007" contextRef="C_0001513818_20150101_20150331">0001513818</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate id="F_000008" contextRef="C_0001513818_20150101_20150331">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory id="F_000009" contextRef="C_0001513818_20150101_20150331">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityCommonStockSharesOutstanding id="F_000010" contextRef="C_0001513818_20150430" decimals="INF" unitRef="U_shares">29260236</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000011" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">230261000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000012" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">170566000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000013" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">4186000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000014" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">2398000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000015" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">234447000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000016" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">172964000</us-gaap:AssetsCurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000017" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">284000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000018" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">616000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000019" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">664000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000020" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">714000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets id="F_000021" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">235395000</us-gaap:Assets>
  <us-gaap:Assets id="F_000022" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">174294000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000023" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">601000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000024" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">1259000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000025" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">7219000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000026" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">5666000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000027" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">7820000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000028" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">6925000</us-gaap:LiabilitiesCurrent>
  <us-gaap:Liabilities id="F_000029" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">7820000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000030" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">6925000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000031" xsi:nil="true" contextRef="C_0001513818_20150331" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000032" xsi:nil="true" contextRef="C_0001513818_20141231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000033" xsi:nil="true" contextRef="C_0001513818_20150331" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000034" xsi:nil="true" contextRef="C_0001513818_20141231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000035" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000036" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital id="F_000037" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">360838000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital id="F_000038" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">278626000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000039" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">-133266000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000040" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">-111259000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000041" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">227575000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000042" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">167369000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000043" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">235395000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000044" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">174294000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000045" contextRef="C_0001513818_20150331" decimals="INF" unitRef="U_iso4217USD_shares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000046" contextRef="C_0001513818_20141231" decimals="INF" unitRef="U_iso4217USD_shares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000047" contextRef="C_0001513818_20150331" decimals="INF" unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000048" contextRef="C_0001513818_20141231" decimals="INF" unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000049" contextRef="C_0001513818_20150331" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000050" contextRef="C_0001513818_20141231" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000051" contextRef="C_0001513818_20150331" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000052" contextRef="C_0001513818_20141231" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000053" contextRef="C_0001513818_20150331" decimals="INF" unitRef="U_iso4217USD_shares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000054" contextRef="C_0001513818_20141231" decimals="INF" unitRef="U_iso4217USD_shares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000055" contextRef="C_0001513818_20150331" decimals="INF" unitRef="U_shares">50000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000056" contextRef="C_0001513818_20141231" decimals="INF" unitRef="U_shares">50000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000057" contextRef="C_0001513818_20150331" decimals="INF" unitRef="U_shares">29257836</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000058" contextRef="C_0001513818_20141231" decimals="INF" unitRef="U_shares">24245437</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000059" contextRef="C_0001513818_20150331" decimals="INF" unitRef="U_shares">29257836</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000060" contextRef="C_0001513818_20141231" decimals="INF" unitRef="U_shares">24245437</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000061" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">17100000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000062" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">4869000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000063" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">5181000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000064" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">2714000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000065" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">22281000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000066" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">7583000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000067" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-22281000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000068" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">-7583000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InvestmentIncomeInterest id="F_000069" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">49000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000070" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">226000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000071" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">-11843000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss id="F_000072" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-22006000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000073" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">-19426000</us-gaap:NetIncomeLoss>
  <us-gaap:OtherPreferredStockDividendsAndAdjustments id="F_000074" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">25559000</us-gaap:OtherPreferredStockDividendsAndAdjustments>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000075" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-22006000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000076" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">-44985000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000077" contextRef="C_0001513818_20150101_20150331" decimals="2" unitRef="U_iso4217USD_shares">-0.79</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000078" contextRef="C_0001513818_20140101_20140331" decimals="2" unitRef="U_iso4217USD_shares">-16.13</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000079" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_shares">27810000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000080" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_shares">2788000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000081" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">54000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000082" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">5000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ShareBasedCompensation id="F_000083" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">1988000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000084" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">426000</us-gaap:ShareBasedCompensation>
  <vsar:RemeasurementOfCallOptionAndPreferredStockLiability id="F_000085" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">-9560000</vsar:RemeasurementOfCallOptionAndPreferredStockLiability>
  <us-gaap:FairValueAdjustmentOfWarrants id="F_000086" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">2279000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000087" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">1456000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000088" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">127000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000089" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-657000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000090" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">665000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities id="F_000091" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">1553000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities id="F_000092" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">810000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="F_000093" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-20524000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="F_000094" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">-5808000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000095" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">5000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000096" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">38000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="F_000097" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">-5000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="F_000098" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">-38000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="F_000099" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">132188000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000100" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">80208000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000101" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">64793000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromWarrantExercises id="F_000102" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">570000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000103" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">16000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000104" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="F_000105" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">80224000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="F_000106" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">197555000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000107" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">59695000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000108" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">191709000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000109" contextRef="C_0001513818_20131231" decimals="-3" unitRef="U_iso4217USD">13288000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000110" contextRef="C_0001513818_20140331" decimals="-3" unitRef="U_iso4217USD">204997000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3 id="F_000111" contextRef="C_0001513818_us-gaapFairValueByLiabilityClassAxis_vsarConvertiblePreferredStockCallOptionLiabilityMember_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">9581000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3 id="F_000112" contextRef="C_0001513818_us-gaapFairValueByLiabilityClassAxis_vsarConvertiblePreferredStockWarrantLiabilityMember_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">2752000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3>
  <us-gaap:ConversionOfStockAmountConverted1 id="F_000113" contextRef="C_0001513818_us-gaapFairValueByLiabilityClassAxis_vsarConvertiblePreferredStockToCommonStockMember_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">122290000</us-gaap:ConversionOfStockAmountConverted1>
  <vsar:InitialPublicOfferingCosts id="F_000114" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">1293000</vsar:InitialPublicOfferingCosts>
  <vsar:FormationAndBusinessOfCompanyTextBlock id="F_000115" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. Formation and Business of the Company &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Versartis, Inc. (the &amp;#8220;Company&amp;#8221;) was incorporated on December&amp;#160;10, 2008 in the State of Delaware. The Company is an endocrine-focused biopharmaceutical company initially developing long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. The Company is developing drug candidates that it has licensed from Amunix Operating Inc. (&amp;#8220;Amunix&amp;#8221;). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s headquarters and operations are in Menlo Park, California. Since incorporation, the Company has been primarily performing research and development activities, including early clinical trials, filing patent applications, obtaining regulatory approvals, hiring personnel, and raising capital to support and expand these activities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Unaudited Interim Financial Information&lt;font style="font-style:normal;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying financial information as of March 31, 2015 is unaudited. The condensed consolidated financial statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that management considers necessary for the fair presentation of the results of operations for the interim periods covered and of the financial condition of the Company at the date of the interim balance sheet. The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December&amp;#160;31, 2014 included in the Company&amp;#8217;s annual report on Form 10-K filed on March&amp;#160;6, 2015 with the U.S. Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Secondary Offering &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2015, we completed a secondary public offering of common stock, pursuant to which we issued 4,999,999 shares of common stock, which includes shares issued pursuant to the underwriters&amp;#8217; exercise of their over-allotment option, and received net proceeds of approximately $80.2 million, after underwriting discounts, commissions and estimated offering expenses. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3.5pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</vsar:FormationAndBusinessOfCompanyTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="F_000116" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. Summary of Significant Accounting Policies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation and Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;). The preparation of the accompanying condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying condensed consolidated financial statements are consolidated for the quarter ended March 31, 2015 and year ended December 31, 2014 and include the accounts of Versartis, Inc. and its wholly-owned subsidiary, Versartis Cayman Holdings Company, established in 2014. All intercompany accounts and transactions have been eliminated. The U.S. dollar is the functional currency for all of the Company&apos;s consolidated operations. All other accompanying condensed financial statements for the quarter ended March 31, 2014 include only the accounts of Versartis, Inc.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since inception, the Company has incurred net losses and negative cash flows from operations. At March&amp;#160;31, 2015, the Company had an accumulated deficit of $133.3&amp;#160;million and working capital of $226.6&amp;#160;million. The Company expects to continue to incur losses from costs related to the continuation of research and development and administrative activities for the foreseeable future. Although management has been successful in raising capital in the past, most recently in January 2015, there can be no assurance that the Company will be successful or that any needed financing will be available in the future at terms acceptable to the Company. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. All long-lived assets are maintained in the United States of America. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of &lt;font style="text-transform:uppercase;"&gt;c&lt;/font&gt;redit &lt;font style="text-transform:uppercase;"&gt;r&lt;/font&gt;isk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. All of the Company&amp;#8217;s cash and cash equivalents are held at five financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Risk and Uncertainties &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&amp;#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&amp;#8217;s potential drug candidates, uncertainty of market acceptance of the Company&amp;#8217;s products, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Products developed by the Company require clearances from the U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the products will receive the necessary clearances. If the Company was denied clearance, clearance was delayed or the Company was unable to maintain clearance, it could have a materially adverse impact on the Company. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be at terms acceptable by the Company. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and &lt;font style="text-transform:uppercase;"&gt;c&lt;/font&gt;ash &lt;font style="text-transform:uppercase;"&gt;e&lt;/font&gt;quivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. At March 31, 2015 and December 31, 2014 the Company&amp;#8217;s cash and cash equivalents were held in five institutions in the United States and include deposits in money market funds which were unrestricted as to withdrawal or use.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and &lt;font style="text-transform:uppercase;"&gt;e&lt;/font&gt;quipment, Net &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, generally between three and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of their useful life or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by the comparison of the carrying amount to the undiscounted future net cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value (i.e. determined through estimating projected discounted future net cash flows or other acceptable methods of determining fair value) arising from the asset. There have been no such impairments of long-lived assets as of March 31, 2015 or December&amp;#160;31, 2014.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying value of the Company&amp;#8217;s cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to the short-term nature of these items. Convertible preferred stock call option liability and convertible preferred stock warrant liability were carried at fair value. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4.5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:91%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;I&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.94%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:92.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;II&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.94%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:92.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;III&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.94%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:92.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s financial instruments consist of Level I assets. Level I securities are comprised of a highly liquid money market fund. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Preclinical and Clinical Trial Accruals &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s clinical trial accruals are based on estimates of patient enrollment and related costs at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and clinical research organizations (&amp;#8220;CROs&amp;#8221;) that conduct and manage clinical trials on the Company&amp;#8217;s behalf. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates preclinical and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of patient enrollment and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and &lt;font style="text-transform:uppercase;"&gt;d&lt;/font&gt;evelopment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are charged to operations as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, laboratory supplies, consulting costs, external research and development expenses and allocated overhead, including rent, equipment depreciation, and utilities. Costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use are expensed to research and development costs when incurred. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income &lt;font style="text-transform:uppercase;"&gt;t&lt;/font&gt;axes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes under the asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&amp;#8217;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i)&amp;#160;the factors underlying the sustainability assertion have changed and (ii)&amp;#160;the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based &lt;font style="text-transform:uppercase;"&gt;c&lt;/font&gt;ompensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For stock options granted to employees, the Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair value. The value of the portion of the award that is ultimately expected to vest is recognized as expense ratably over the requisite service period. The fair value of stock options is determined using the Black-Scholes option pricing model. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions regarding a number of complex and subjective variables. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense, net of estimated forfeitures, is reflected in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;604&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;124&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,384&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;302&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,988&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;426&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:3pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company&amp;#8217;s comprehensive loss was the same as its reported net loss. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss per Share of Common Stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, convertible preferred stock, stock options and convertible preferred stock warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss for all of the periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&amp;#8217;s financial position or results of operations upon adoption. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-10&lt;font style="font-style:italic;"&gt;, Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation&lt;/font&gt;, or ASU 2014-10, which eliminates the definition of a development stage entity, the development stage presentation and disclosure requirements under ASC 915, &lt;font style="font-style:italic;"&gt;Development Stage Entities&lt;/font&gt;, and amends provisions of existing variable interest entity guidance under ASC 810, &lt;font style="font-style:italic;"&gt;Consolidation&lt;/font&gt;. As a result of the changes, the financial statements of entities which meet the former definition of a development stage entity will no longer: (1)&amp;#160;present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2)&amp;#160;label the financial statements as those of a development stage entity, (3)&amp;#160;disclose a description of the development stage activities in which the entity is engaged, and (4)&amp;#160;disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. Furthermore, ASU 2014-10 clarifies disclosures about risks and uncertainties under ASC Topic 275, &lt;font style="font-style:italic;"&gt;Risks and Uncertainties&lt;/font&gt; that apply to companies that have not commenced planned principal operations. Finally, variable interest entity rules no longer contain an exception for development stage entities and, as a result, development stage entities will have to be evaluated for consolidation in the same manner as non-development stage entities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2014, the FASB issued new guidance related to the disclosures around going concern. The new standard provides guidance around management&amp;#8217;s responsibility to evaluate whether there is substantial doubt about an entity&amp;#8217;s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The Company will apply the guidance and disclosure provisions of the new standard upon adoption.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under ASU 2014-10, entities are no longer required to apply the presentation and disclosure provisions of ASC 915 during annual periods beginning after December&amp;#160;15, 2014. In addition, the revisions to the consolidation standards are effective for annual periods beginning after December&amp;#160;15, 2015 for public companies and are effective for annual periods beginning after December&amp;#160;15, 2016 for nonpublic entities. Early adoption is permitted for any annual reporting period or interim period for which the entity&amp;#8217;s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). The Company has adopted ASU 2014-10, effective January 1, 2015, but there was no impact on its financial position, results of operations or cash flows. &lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock id="F_000117" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. Balance Sheet Components &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets (in thousands) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preclinical and clinical &lt;sup style="font-size:85%; vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,669&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,216&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;517&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,186&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,398&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;sup style="font-size:85%; vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:95.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;sup style="font-size:85%; vertical-align:top"&gt;&lt;/sup&gt;A substantial majority of these prepayments consist of advances to our contract manufacturers. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accrued Liabilities (in thousands) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and related&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,143&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,737&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preclinical and clinical&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,489&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,259&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;188&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;411&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;399&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;259&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,219&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,666&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000118" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. Fair Value Measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table sets forth the Company&amp;#8217;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements at March 31, 2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160,162&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160,162&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements at December 31, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160,125&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160,125&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3.5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000119" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. Commitments and Contingencies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Facility Leases &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2014, the Company entered into an operating facility lease agreement to lease 12,943 square feet in Menlo Park, California for its new headquarters building for a period of thirty-nine months. The total obligation for the Company under this lease is approximately $1.9 million as of March&amp;#160;31, 2015. &lt;/p&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock id="F_000120" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. Equity Incentive Plans &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s Board of Directors, or Board, and stockholders previously approved the 2009 Stock Plan, or the 2009 Plan. In March 2014, the stockholders approved the 2014 Equity Incentive Plan, or the 2014 Plan. As of March&amp;#160;21, 2014, the effective date of the 2014 Plan, the Company suspended the 2009 Plan and no additional awards may be granted under the 2009 Plan. Any shares of common stock covered by awards granted under the 2009 Plan that terminate after March&amp;#160;21, 2014 by expiration, forfeiture, cancellation or other means without the issuance of such shares, will be added to the 2014 Plan reserve. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31, 2015, the total number of shares of common stock available for issuance under the 2014 Plan was approximately 2,031,000.  Unless the Board provides otherwise, beginning on January&amp;#160;1, 2015, and continuing until the expiration of the 2014 Plan, the total number of shares of common stock available for issuance under the 2014 Plan will automatically increase annually on January&amp;#160;1 by 4.5% of the total number of issued and outstanding shares of common stock as of December&amp;#160;31 of the immediately preceding year. As of March 31, 2015, approximately 2,947,000 shares of common stock were subject to outstanding awards under the 2014 Plan. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2014, the Board and stockholders approved the 2014 Employee Stock Purchase Plan, or the ESPP, which became effective as of March&amp;#160;5, 2014. The Company has reserved a total of approximately 392,000 shares of common stock for issuance under the ESPP. Unless the Board provides otherwise, beginning on January&amp;#160;1, 2015, and continuing until the expiration of the ESPP, the total number of shares of common stock available for issuance under the ESPP will automatically increase annually on January&amp;#160;1 by the lesser of (i)&amp;#160;1% of the total number of issued and outstanding shares of common stock as of December&amp;#160;31 of the immediately preceding year, or (ii)&amp;#160;300,000 shares of common stock. As of March 31, 2015, the Company has approximately 9,000 shares of common stock under the ESPP. &lt;/p&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000121" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. Net loss per share of Common Stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except per share data): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders - basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,006&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(44,985&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,810&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,788&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares used to compute basic and diluted net&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; loss per share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,810&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,788&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted net loss per common share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.79&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16.13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss attributable to common stockholders per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period, determined using the treasury-stock method and the as-if converted method, for convertible securities, if inclusion of these is dilutive. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following potentially dilutive securities outstanding at the end of the periods presented have been excluded from the computation of diluted shares outstanding: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,761,967&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,188,896&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;185,514&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:13.3%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:100%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:4pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <vsar:BasisOfPresentationAndUseOfEstimatesTextBlock id="F_000122" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation and Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;). The preparation of the accompanying condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying condensed consolidated financial statements are consolidated for the quarter ended March 31, 2015 and year ended December 31, 2014 and include the accounts of Versartis, Inc. and its wholly-owned subsidiary, Versartis Cayman Holdings Company, established in 2014. All intercompany accounts and transactions have been eliminated. The U.S. dollar is the functional currency for all of the Company&apos;s consolidated operations. All other accompanying condensed financial statements for the quarter ended March 31, 2014 include only the accounts of Versartis, Inc.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since inception, the Company has incurred net losses and negative cash flows from operations. At March&amp;#160;31, 2015, the Company had an accumulated deficit of $133.3&amp;#160;million and working capital of $226.6&amp;#160;million. The Company expects to continue to incur losses from costs related to the continuation of research and development and administrative activities for the foreseeable future. Although management has been successful in raising capital in the past, most recently in January 2015, there can be no assurance that the Company will be successful or that any needed financing will be available in the future at terms acceptable to the Company. &lt;/p&gt;&lt;/div&gt;</vsar:BasisOfPresentationAndUseOfEstimatesTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="F_000123" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. All long-lived assets are maintained in the United States of America. &lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk id="F_000124" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of &lt;font style="text-transform:uppercase;"&gt;c&lt;/font&gt;redit &lt;font style="text-transform:uppercase;"&gt;r&lt;/font&gt;isk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. All of the Company&amp;#8217;s cash and cash equivalents are held at five financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. &lt;/p&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <vsar:SignificantRisksAndUncertaintiesPolicyPolicyTextBlock id="F_000125" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Risk and Uncertainties &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The Company&amp;#8217;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&amp;#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&amp;#8217;s potential drug candidates, uncertainty of market acceptance of the Company&amp;#8217;s products, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Products developed by the Company require clearances from the U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the products will receive the necessary clearances. If the Company was denied clearance, clearance was delayed or the Company was unable to maintain clearance, it could have a materially adverse impact on the Company. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be at terms acceptable by the Company. &lt;/p&gt;&lt;/div&gt;</vsar:SignificantRisksAndUncertaintiesPolicyPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="F_000126" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and &lt;font style="text-transform:uppercase;"&gt;c&lt;/font&gt;ash &lt;font style="text-transform:uppercase;"&gt;e&lt;/font&gt;quivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. At March 31, 2015 and December 31, 2014 the Company&amp;#8217;s cash and cash equivalents were held in five institutions in the United States and include deposits in money market funds which were unrestricted as to withdrawal or use.&lt;/p&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="F_000127" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and &lt;font style="text-transform:uppercase;"&gt;e&lt;/font&gt;quipment, Net &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, generally between three and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of their useful life or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized. &lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock id="F_000128" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by the comparison of the carrying amount to the undiscounted future net cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value (i.e. determined through estimating projected discounted future net cash flows or other acceptable methods of determining fair value) arising from the asset. There have been no such impairments of long-lived assets as of March 31, 2015 or December&amp;#160;31, 2014.&lt;/p&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="F_000129" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The carrying value of the Company&amp;#8217;s cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to the short-term nature of these items. Convertible preferred stock call option liability and convertible preferred stock warrant liability were carried at fair value. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4.5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:91%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;I&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.94%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:92.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;II&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.94%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:92.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;III&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.94%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:92.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s financial instruments consist of Level I assets. Level I securities are comprised of a highly liquid money market fund. &lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <vsar:PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock id="F_000130" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Preclinical and Clinical Trial Accruals &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The Company&amp;#8217;s clinical trial accruals are based on estimates of patient enrollment and related costs at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and clinical research organizations (&amp;#8220;CROs&amp;#8221;) that conduct and manage clinical trials on the Company&amp;#8217;s behalf. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates preclinical and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of patient enrollment and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. &lt;/p&gt;&lt;/div&gt;</vsar:PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="F_000131" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and &lt;font style="text-transform:uppercase;"&gt;d&lt;/font&gt;evelopment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are charged to operations as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, laboratory supplies, consulting costs, external research and development expenses and allocated overhead, including rent, equipment depreciation, and utilities. Costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use are expensed to research and development costs when incurred. &lt;/p&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:IncomeTaxPolicyTextBlock id="F_000132" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income &lt;font style="text-transform:uppercase;"&gt;t&lt;/font&gt;axes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes under the asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&amp;#8217;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i)&amp;#160;the factors underlying the sustainability assertion have changed and (ii)&amp;#160;the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. &lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock id="F_000133" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based &lt;font style="text-transform:uppercase;"&gt;c&lt;/font&gt;ompensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For stock options granted to employees, the Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair value. The value of the portion of the award that is ultimately expected to vest is recognized as expense ratably over the requisite service period. The fair value of stock options is determined using the Black-Scholes option pricing model. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions regarding a number of complex and subjective variables. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense, net of estimated forfeitures, is reflected in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;604&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;124&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,384&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;302&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,988&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;426&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock id="F_000134" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:3pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company&amp;#8217;s comprehensive loss was the same as its reported net loss. &lt;/p&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000135" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss per Share of Common Stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, convertible preferred stock, stock options and convertible preferred stock warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss for all of the periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. &lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000136" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&amp;#8217;s financial position or results of operations upon adoption. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-10&lt;font style="font-style:italic;"&gt;, Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation&lt;/font&gt;, or ASU 2014-10, which eliminates the definition of a development stage entity, the development stage presentation and disclosure requirements under ASC 915, &lt;font style="font-style:italic;"&gt;Development Stage Entities&lt;/font&gt;, and amends provisions of existing variable interest entity guidance under ASC 810, &lt;font style="font-style:italic;"&gt;Consolidation&lt;/font&gt;. As a result of the changes, the financial statements of entities which meet the former definition of a development stage entity will no longer: (1)&amp;#160;present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2)&amp;#160;label the financial statements as those of a development stage entity, (3)&amp;#160;disclose a description of the development stage activities in which the entity is engaged, and (4)&amp;#160;disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. Furthermore, ASU 2014-10 clarifies disclosures about risks and uncertainties under ASC Topic 275, &lt;font style="font-style:italic;"&gt;Risks and Uncertainties&lt;/font&gt; that apply to companies that have not commenced planned principal operations. Finally, variable interest entity rules no longer contain an exception for development stage entities and, as a result, development stage entities will have to be evaluated for consolidation in the same manner as non-development stage entities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2014, the FASB issued new guidance related to the disclosures around going concern. The new standard provides guidance around management&amp;#8217;s responsibility to evaluate whether there is substantial doubt about an entity&amp;#8217;s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The Company will apply the guidance and disclosure provisions of the new standard upon adoption.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under ASU 2014-10, entities are no longer required to apply the presentation and disclosure provisions of ASC 915 during annual periods beginning after December&amp;#160;15, 2014. In addition, the revisions to the consolidation standards are effective for annual periods beginning after December&amp;#160;15, 2015 for public companies and are effective for annual periods beginning after December&amp;#160;15, 2016 for nonpublic entities. Early adoption is permitted for any annual reporting period or interim period for which the entity&amp;#8217;s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). The Company has adopted ASU 2014-10, effective January 1, 2015, but there was no impact on its financial position, results of operations or cash flows. &lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000137" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Stock-based compensation expense, net of estimated forfeitures, is reflected in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;604&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;124&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,384&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;302&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,988&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;426&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock id="F_000138" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets (in thousands) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preclinical and clinical &lt;sup style="font-size:85%; vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,669&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,216&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;517&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,186&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,398&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;sup style="font-size:85%; vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:95.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;sup style="font-size:85%; vertical-align:top"&gt;&lt;/sup&gt;A substantial majority of these prepayments consist of advances to our contract manufacturers. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="F_000139" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accrued Liabilities (in thousands) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and related&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,143&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,737&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preclinical and clinical&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,489&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,259&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;188&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;411&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;399&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;259&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,219&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,666&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock id="F_000140" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table sets forth the Company&amp;#8217;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements at March 31, 2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160,162&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160,162&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements at December 31, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160,125&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160,125&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3.5pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="F_000141" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except per share data): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders - basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,006&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(44,985&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,810&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,788&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares used to compute basic and diluted net&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; loss per share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,810&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,788&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted net loss per common share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.79&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16.13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000142" contextRef="C_0001513818_20150101_20150331">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following potentially dilutive securities outstanding at the end of the periods presented have been excluded from the computation of diluted shares outstanding: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,761,967&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,188,896&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;185,514&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:13.3%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:100%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:4pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <dei:EntityIncorporationDateOfIncorporation id="F_000143" contextRef="C_0001513818_20150101_20150331">2008-12-10</dei:EntityIncorporationDateOfIncorporation>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000144" contextRef="C_0001513818_us-gaapSubsidiarySaleOfStockAxis_vsarSecondaryOfferingMember_20150101_20150131" decimals="INF" unitRef="U_shares">4999999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000145" contextRef="C_0001513818_us-gaapSubsidiarySaleOfStockAxis_vsarSecondaryOfferingMember_20150101_20150131" decimals="-5" unitRef="U_iso4217USD">80200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <vsar:WorkingCapital id="F_000146" contextRef="C_0001513818_20150331" decimals="-5" unitRef="U_iso4217USD">226600000</vsar:WorkingCapital>
  <us-gaap:NumberOfOperatingSegments id="F_000147" contextRef="C_0001513818_20150101_20150331" decimals="INF" unitRef="U_vsarSegment">1</us-gaap:NumberOfOperatingSegments>
  <vsar:CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod id="F_000148" contextRef="C_0001513818_20150101_20150331">Three months or less</vsar:CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000149" contextRef="C_0001513818_us-gaapRangeAxis_us-gaapMinimumMember_20150101_20150331">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000150" contextRef="C_0001513818_us-gaapRangeAxis_us-gaapMaximumMember_20150101_20150331">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="F_000151" contextRef="C_0001513818_20150101_20150331" decimals="0" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="F_000152" contextRef="C_0001513818_20140101_20141231" decimals="0" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements id="F_000153" contextRef="C_0001513818_us-gaapRangeAxis_us-gaapMaximumMember_20150101_20150331" decimals="2" unitRef="U_pure">0.50</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000154" contextRef="C_0001513818_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">604000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000155" contextRef="C_0001513818_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">124000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000156" contextRef="C_0001513818_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">1384000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000157" contextRef="C_0001513818_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">302000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000158" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_iso4217USD">1988000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000159" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_iso4217USD">426000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:PrepaidExpenseCurrent id="F_000160" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">3669000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent id="F_000161" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">2216000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:OtherPrepaidExpenseCurrent id="F_000162" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">517000</us-gaap:OtherPrepaidExpenseCurrent>
  <us-gaap:OtherPrepaidExpenseCurrent id="F_000163" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">182000</us-gaap:OtherPrepaidExpenseCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000164" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">1143000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000165" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">1737000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <vsar:PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent id="F_000166" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">5489000</vsar:PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent>
  <vsar:PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent id="F_000167" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">3259000</vsar:PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000168" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">188000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000169" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">411000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000170" contextRef="C_0001513818_20150331" decimals="-3" unitRef="U_iso4217USD">399000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000171" contextRef="C_0001513818_20141231" decimals="-3" unitRef="U_iso4217USD">259000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:AssetsFairValueDisclosure id="F_000172" contextRef="C_0001513818_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20150331" decimals="-3" unitRef="U_iso4217USD">160162000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000173" contextRef="C_0001513818_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20150331" decimals="-3" unitRef="U_iso4217USD">160162000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000174" contextRef="C_0001513818_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20141231" decimals="-3" unitRef="U_iso4217USD">160125000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000175" contextRef="C_0001513818_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20141231" decimals="-3" unitRef="U_iso4217USD">160125000</us-gaap:AssetsFairValueDisclosure>
  <vsar:AreaOfFacilityLease id="F_000176" contextRef="C_0001513818_us-gaapStatementGeographicalAxis_vsarMenloParkCaliforniaMember_20140301_20140331" decimals="0" unitRef="U_utrsqft">12943</vsar:AreaOfFacilityLease>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract id="F_000177" contextRef="C_0001513818_us-gaapStatementGeographicalAxis_vsarMenloParkCaliforniaMember_20140301_20140331">P39M</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
  <vsar:OperatingLeaseObligationNet id="F_000178" contextRef="C_0001513818_us-gaapStatementGeographicalAxis_vsarMenloParkCaliforniaMember_20150331" decimals="-5" unitRef="U_iso4217USD">1900000</vsar:OperatingLeaseObligationNet>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000179" contextRef="C_0001513818_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_vsarTwoThousandNineStockOptionPlanMember_20140321" decimals="INF" unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000180" contextRef="C_0001513818_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_vsarStockOptionPlanTwoThousandFourteenMember_20150331" decimals="INF" unitRef="U_shares">2031000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum id="F_000181" contextRef="C_0001513818_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_vsarStockOptionPlanTwoThousandFourteenMember_20150101_20150331" decimals="INF" unitRef="U_pure">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000182" contextRef="C_0001513818_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_vsarStockOptionPlanTwoThousandFourteenMember_20150331" decimals="INF" unitRef="U_shares">2947000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum id="F_000183" contextRef="C_0001513818_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_vsarEmployeeStockPurchasePlanMember_20150101_20150331" decimals="INF" unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000184" contextRef="C_0001513818_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_vsarEmployeeStockPurchasePlanMember_20150331" decimals="INF" unitRef="U_shares">392000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized id="F_000185" contextRef="C_0001513818_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_vsarEmployeeStockPurchasePlanMember_20150101_20150331" decimals="INF" unitRef="U_shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding id="F_000186" contextRef="C_0001513818_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_vsarEmployeeStockPurchasePlanMember_20150331" decimals="INF" unitRef="U_shares">9000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesIssuedBasic id="F_000187" contextRef="C_0001513818_20150101_20150331" decimals="-3" unitRef="U_shares">27810000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
  <us-gaap:WeightedAverageNumberOfSharesIssuedBasic id="F_000188" contextRef="C_0001513818_20140101_20140331" decimals="-3" unitRef="U_shares">2788000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000189" contextRef="C_0001513818_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_vsarOptionsToPurchaseCommonStockMember_20150101_20150331" decimals="INF" unitRef="U_shares">2761967</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000190" contextRef="C_0001513818_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_vsarOptionsToPurchaseCommonStockMember_20140101_20140331" decimals="INF" unitRef="U_shares">2188896</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000191" contextRef="C_0001513818_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20150101_20150331" decimals="INF" unitRef="U_shares">185514</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>vsar-20150331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- RRD ActiveDisclosure(SM) XBRL Schema Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2015-05-06T18:23:29.7602757+00:00 -->
<!-- Version            : 2.0.5.0 -->
<!-- Package ID         : 5D450A663E0E1D6253DC3DA711642366-0001513818-001504 -->
<!-- Copyright (c) 2015 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:vsar="http://www.versartis.com/20150331" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.versartis.com/20150331" xmlns="http://www.w3.org/2001/XMLSchema">
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd" namespace="http://fasb.org/us-types/2014-01-31" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" namespace="http://fasb.org/us-gaap/2014-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2014-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" namespace="http://xbrl.sec.gov/country/2013-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2014-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2014-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2013-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2011-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2011-01-31" />
  <annotation>
    <appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.versartis.com/20150331/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vsar-20150331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vsar-20150331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vsar-20150331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vsar-20150331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" id="Role_StatementCondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" id="Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
        <link:definition>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>100040 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureFormationAndBusinessOfCompany" id="Role_DisclosureFormationAndBusinessOfCompany">
        <link:definition>100050 - Disclosure - Formation and Business of the Company</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100060 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponents" id="Role_DisclosureBalanceSheetComponents">
        <link:definition>100070 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100080 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100090 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureEquityIncentivePlans" id="Role_DisclosureEquityIncentivePlans">
        <link:definition>100100 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStock" id="Role_DisclosureNetLossPerShareOfCommonStock">
        <link:definition>100110 - Disclosure - Net Loss per Share of Common Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100120 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100130 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponentsTables" id="Role_DisclosureBalanceSheetComponentsTables">
        <link:definition>100140 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100150 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStockTables" id="Role_DisclosureNetLossPerShareOfCommonStockTables">
        <link:definition>100160 - Disclosure - Net Loss per Share of Common Stock (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetail" id="Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetail">
        <link:definition>100170 - Disclosure - Formation and Business of the Company - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100180 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedStockBasedCompensationExpenseDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedStockBasedCompensationExpenseDetail">
        <link:definition>100190 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetail" id="Role_DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>100200 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetail" id="Role_DisclosureBalanceSheetComponentsAccruedLiabilitiesDetail">
        <link:definition>100210 - Disclosure - Balance Sheet Components - Accrued Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" id="Role_DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>100220 - Disclosure - Fair Value Measurements - Financial Instruments Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>100230 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" id="Role_DisclosureEquityIncentivePlansAdditionalInformationDetail">
        <link:definition>100240 - Disclosure - Equity Incentive Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStockSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail" id="Role_DisclosureNetLossPerShareOfCommonStockSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail">
        <link:definition>100250 - Disclosure - Net Loss per Share of Common Stock - Summary of Computation of Basic and Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStockSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesOutstandingDetail" id="Role_DisclosureNetLossPerShareOfCommonStockSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesOutstandingDetail">
        <link:definition>100260 - Disclosure - Net Loss per Share of Common Stock - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Shares Outstanding (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </appinfo>
  </annotation>
  <element id="vsar_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="vsar_RemeasurementOfCallOptionAndPreferredStockLiability" name="RemeasurementOfCallOptionAndPreferredStockLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="vsar_InitialPublicOfferingCosts" name="InitialPublicOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="vsar_ConvertiblePreferredStockCallOptionLiabilityMember" name="ConvertiblePreferredStockCallOptionLiabilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="vsar_ConvertiblePreferredStockWarrantLiabilityMember" name="ConvertiblePreferredStockWarrantLiabilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="vsar_ConvertiblePreferredStockToCommonStockMember" name="ConvertiblePreferredStockToCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="vsar_FormationAndBusinessOfCompanyTextBlock" name="FormationAndBusinessOfCompanyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="vsar_BasisOfPresentationAndUseOfEstimatesTextBlock" name="BasisOfPresentationAndUseOfEstimatesTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="vsar_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" name="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="vsar_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" name="PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="vsar_PublicOfferingLineItems" name="PublicOfferingLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="vsar_PublicOfferingTable" name="PublicOfferingTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="vsar_SecondaryOfferingMember" name="SecondaryOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="vsar_WorkingCapital" name="WorkingCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="vsar_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="vsar_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="vsar_CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod" name="CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent" name="PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="vsar_AreaOfFacilityLease" name="AreaOfFacilityLease" type="num:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="vsar_OperatingLeaseObligationNet" name="OperatingLeaseObligationNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="vsar_MenloParkCaliforniaMember" name="MenloParkCaliforniaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="vsar_TwoThousandNineStockOptionPlanMember" name="TwoThousandNineStockOptionPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="vsar_StockOptionPlanTwoThousandFourteenMember" name="StockOptionPlanTwoThousandFourteenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="vsar_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="vsar_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>vsar-20150331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2015-05-06T18:23:29.7602757+00:00 -->
<!-- Version            : 2.0.5.0 -->
<!-- Package ID         : 5D450A663E0E1D6253DC3DA711642366-0001513818-001504 -->
<!-- Copyright (c) 2015 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="vsar-20150331.xsd#TemplateLink" roleURI="http://www.versartis.com/20150331/role/TemplateLink" />
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:href="vsar-20150331.xsd#Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="vsar-20150331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:type="locator" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10090.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="vsar-20150331.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <loc xlink:href="vsar-20150331.xsd#vsar_RemeasurementOfCallOptionAndPreferredStockLiability" xlink:type="locator" xlink:label="vsar_RemeasurementOfCallOptionAndPreferredStockLiability" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="vsar_RemeasurementOfCallOptionAndPreferredStockLiability" order="10140.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10170.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10180.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureBalanceSheetComponentsAccruedLiabilitiesDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <loc xlink:href="vsar-20150331.xsd#vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStockSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureNetLossPerShareOfCommonStockSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStockSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10010.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>vsar-20150331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2015-05-06T18:23:29.7602757+00:00 -->
<!-- Version            : 2.0.5.0 -->
<!-- Package ID         : 5D450A663E0E1D6253DC3DA711642366-0001513818-001504 -->
<!-- Copyright (c) 2015 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <roleRef xlink:type="simple" xlink:href="vsar-20150331.xsd#TemplateLink" roleURI="http://www.versartis.com/20150331/role/TemplateLink" />
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="vsar-20150331.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <loc xlink:href="vsar-20150331.xsd#vsar_InitialPublicOfferingCosts" xlink:type="locator" xlink:label="vsar_InitialPublicOfferingCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <loc xlink:href="vsar-20150331.xsd#vsar_RemeasurementOfCallOptionAndPreferredStockLiability" xlink:type="locator" xlink:label="vsar_RemeasurementOfCallOptionAndPreferredStockLiability" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="vsar-20150331.xsd#vsar_ConvertiblePreferredStockToCommonStockMember" xlink:type="locator" xlink:label="vsar_ConvertiblePreferredStockToCommonStockMember" />
    <loc xlink:href="vsar-20150331.xsd#vsar_ConvertiblePreferredStockWarrantLiabilityMember" xlink:type="locator" xlink:label="vsar_ConvertiblePreferredStockWarrantLiabilityMember" />
    <loc xlink:href="vsar-20150331.xsd#vsar_ConvertiblePreferredStockCallOptionLiabilityMember" xlink:type="locator" xlink:label="vsar_ConvertiblePreferredStockCallOptionLiabilityMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10190.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="vsar_ConvertiblePreferredStockCallOptionLiabilityMember" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="vsar_ConvertiblePreferredStockWarrantLiabilityMember" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="vsar_ConvertiblePreferredStockToCommonStockMember" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10610.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vsar_RemeasurementOfCallOptionAndPreferredStockLiability" order="10690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10970.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="11130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="11210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="11370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="11410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="11750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="11890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="11970.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="12170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3" order="12250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="12370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="vsar_InitialPublicOfferingCosts" order="12430.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <loc xlink:href="vsar-20150331.xsd#vsar_SecondaryOfferingMember" xlink:type="locator" xlink:label="vsar_SecondaryOfferingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="vsar-20150331.xsd#vsar_PublicOfferingTable" xlink:type="locator" xlink:label="vsar_PublicOfferingTable" />
    <loc xlink:href="vsar-20150331.xsd#vsar_PublicOfferingLineItems" xlink:type="locator" xlink:label="vsar_PublicOfferingLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="vsar_PublicOfferingLineItems" xlink:to="vsar_PublicOfferingTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vsar_PublicOfferingTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vsar_SecondaryOfferingMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vsar_PublicOfferingLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vsar_PublicOfferingLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vsar_PublicOfferingLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10240.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <loc xlink:href="vsar-20150331.xsd#vsar_CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod" xlink:type="locator" xlink:label="vsar_CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <loc xlink:href="vsar-20150331.xsd#vsar_WorkingCapital" xlink:type="locator" xlink:label="vsar_WorkingCapital" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="vsar-20150331.xsd#vsar_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="vsar_SignificantAccountingPoliciesTable" />
    <loc xlink:href="vsar-20150331.xsd#vsar_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="vsar_SignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="vsar_SignificantAccountingPoliciesLineItems" xlink:to="vsar_SignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vsar_SignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vsar_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vsar_SignificantAccountingPoliciesLineItems" xlink:to="vsar_WorkingCapital" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vsar_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vsar_SignificantAccountingPoliciesLineItems" xlink:to="vsar_CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vsar_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vsar_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10520.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vsar_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" order="10630.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedStockBasedCompensationExpenseDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedStockBasedCompensationExpenseDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10330.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <loc xlink:href="vsar-20150331.xsd#vsar_OperatingLeaseObligationNet" xlink:type="locator" xlink:label="vsar_OperatingLeaseObligationNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <loc xlink:href="vsar-20150331.xsd#vsar_AreaOfFacilityLease" xlink:type="locator" xlink:label="vsar_AreaOfFacilityLease" />
    <loc xlink:href="vsar-20150331.xsd#vsar_MenloParkCaliforniaMember" xlink:type="locator" xlink:label="vsar_MenloParkCaliforniaMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:type="locator" xlink:label="us-gaap_SegmentGeographicalDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:type="locator" xlink:label="us-gaap_SegmentGeographicalDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:type="locator" xlink:label="us-gaap_StatementGeographicalAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="vsar_MenloParkCaliforniaMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vsar_AreaOfFacilityLease" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vsar_OperatingLeaseObligationNet" order="10230.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <loc xlink:href="vsar-20150331.xsd#vsar_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="vsar_EmployeeStockPurchasePlanMember" />
    <loc xlink:href="vsar-20150331.xsd#vsar_StockOptionPlanTwoThousandFourteenMember" xlink:type="locator" xlink:label="vsar_StockOptionPlanTwoThousandFourteenMember" />
    <loc xlink:href="vsar-20150331.xsd#vsar_TwoThousandNineStockOptionPlanMember" xlink:type="locator" xlink:label="vsar_TwoThousandNineStockOptionPlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="vsar_TwoThousandNineStockOptionPlanMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="vsar_StockOptionPlanTwoThousandFourteenMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="vsar_EmployeeStockPurchasePlanMember" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10500.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="10710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10770.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStockSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesOutstandingDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureNetLossPerShareOfCommonStockSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesOutstandingDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStockSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesOutstandingDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <loc xlink:href="vsar-20150331.xsd#vsar_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="vsar_OptionsToPurchaseCommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vsar_OptionsToPurchaseCommonStockMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10130.00" priority="2" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>vsar-20150331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2015-05-06T18:23:29.7602757+00:00 -->
<!-- Version            : 2.0.5.0 -->
<!-- Package ID         : 5D450A663E0E1D6253DC3DA711642366-0001513818-001504 -->
<!-- Copyright (c) 2015 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <loc xlink:href="vsar-20150331.xsd#vsar_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="vsar_DocumentAndEntityInformationAbstract" />
    <label xml:lang="en-US" xlink:label="vsar_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Document and entity information.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_DocumentAndEntityInformationAbstract" xlink:to="vsar_DocumentAndEntityInformationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="vsar_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Abstract]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</label>
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, convertible preferred stock and stockholders&apos; equity (deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 6)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value; 5,000,000 shares authorized at March 31, 2015 and December 31, 2014, respectively; zero shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value, 50,000,000 shares authorized at March 31, 2015 and December 31, 2014; 29,257,836 and 24,245,437 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&apos; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss and comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:type="locator" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deemed dividend related to beneficial conversion feature of convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Preferred Stock Dividends And Adjustments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per basic and diluted share attributable to common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares used to compute basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</label>
    <loc xlink:href="vsar-20150331.xsd#vsar_RemeasurementOfCallOptionAndPreferredStockLiability" xlink:type="locator" xlink:label="vsar_RemeasurementOfCallOptionAndPreferredStockLiability" />
    <label xml:lang="en-US" xlink:label="vsar_RemeasurementOfCallOptionAndPreferredStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Remeasurement of call option and preferred stock liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_RemeasurementOfCallOptionAndPreferredStockLiability" xlink:to="vsar_RemeasurementOfCallOptionAndPreferredStockLiability_lbl" />
    <loc xlink:href="vsar-20150331.xsd#vsar_InitialPublicOfferingCosts" xlink:type="locator" xlink:label="vsar_InitialPublicOfferingCosts" />
    <label xml:lang="en-US" xlink:label="vsar_InitialPublicOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_InitialPublicOfferingCosts" xlink:to="vsar_InitialPublicOfferingCosts_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Liability Class [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]</label>
    <loc xlink:href="vsar-20150331.xsd#vsar_ConvertiblePreferredStockCallOptionLiabilityMember" xlink:type="locator" xlink:label="vsar_ConvertiblePreferredStockCallOptionLiabilityMember" />
    <label xml:lang="en-US" xlink:label="vsar_ConvertiblePreferredStockCallOptionLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock call option liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_ConvertiblePreferredStockCallOptionLiabilityMember" xlink:to="vsar_ConvertiblePreferredStockCallOptionLiabilityMember_lbl" />
    <label xml:lang="en-US" xlink:label="vsar_ConvertiblePreferredStockCallOptionLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock call option liability [Member]</label>
    <label xml:lang="en-US" xlink:label="vsar_ConvertiblePreferredStockCallOptionLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Call Option Liability [Member]</label>
    <loc xlink:href="vsar-20150331.xsd#vsar_ConvertiblePreferredStockWarrantLiabilityMember" xlink:type="locator" xlink:label="vsar_ConvertiblePreferredStockWarrantLiabilityMember" />
    <label xml:lang="en-US" xlink:label="vsar_ConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock warrant liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_ConvertiblePreferredStockWarrantLiabilityMember" xlink:to="vsar_ConvertiblePreferredStockWarrantLiabilityMember_lbl" />
    <label xml:lang="en-US" xlink:label="vsar_ConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock warrant liability [Member]</label>
    <label xml:lang="en-US" xlink:label="vsar_ConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Warrant Liability [Member]</label>
    <loc xlink:href="vsar-20150331.xsd#vsar_ConvertiblePreferredStockToCommonStockMember" xlink:type="locator" xlink:label="vsar_ConvertiblePreferredStockToCommonStockMember" />
    <label xml:lang="en-US" xlink:label="vsar_ConvertiblePreferredStockToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock to common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_ConvertiblePreferredStockToCommonStockMember" xlink:to="vsar_ConvertiblePreferredStockToCommonStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="vsar_ConvertiblePreferredStockToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock to common stock [Member]</label>
    <label xml:lang="en-US" xlink:label="vsar_ConvertiblePreferredStockToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock To Common Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</label>
    <label xml:lang="en-US" xlink:label="vsar_RemeasurementOfCallOptionAndPreferredStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Remeasurement of convertible preferred stock call option liability</label>
    <label xml:lang="en-US" xlink:label="vsar_RemeasurementOfCallOptionAndPreferredStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Remeasurement Of Call Option And Preferred Stock Liability</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remeasurement of convertible preferred stock warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment Of Warrants</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit for facility lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Security Deposits</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock in initial public offering, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in follow-on offering, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible preferred stock, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Preferred Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of convertible preferred stock warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Warrant Exercises</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of common stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of noncash items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of liability to additional paid in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Instruments Classified In Shareholders Equity Transfers Out Of Level3</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion to common stock and additional paid in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Amount Converted1</label>
    <label xml:lang="en-US" xlink:label="vsar_InitialPublicOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering issuance costs</label>
    <label xml:lang="en-US" xlink:label="vsar_InitialPublicOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering Costs</label>
    <loc xlink:href="vsar-20150331.xsd#vsar_FormationAndBusinessOfCompanyTextBlock" xlink:type="locator" xlink:label="vsar_FormationAndBusinessOfCompanyTextBlock" />
    <label xml:lang="en-US" xlink:label="vsar_FormationAndBusinessOfCompanyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Formation and business of company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_FormationAndBusinessOfCompanyTextBlock" xlink:to="vsar_FormationAndBusinessOfCompanyTextBlock_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="vsar_FormationAndBusinessOfCompanyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Formation and Business of the Company</label>
    <label xml:lang="en-US" xlink:label="vsar_FormationAndBusinessOfCompanyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Formation And Business Of Company [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders Equity And Share Based Payments [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</label>
    <loc xlink:href="vsar-20150331.xsd#vsar_BasisOfPresentationAndUseOfEstimatesTextBlock" xlink:type="locator" xlink:label="vsar_BasisOfPresentationAndUseOfEstimatesTextBlock" />
    <label xml:lang="en-US" xlink:label="vsar_BasisOfPresentationAndUseOfEstimatesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and use of estimates.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_BasisOfPresentationAndUseOfEstimatesTextBlock" xlink:to="vsar_BasisOfPresentationAndUseOfEstimatesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="vsar_BasisOfPresentationAndUseOfEstimatesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Use of Estimates</label>
    <label xml:lang="en-US" xlink:label="vsar_BasisOfPresentationAndUseOfEstimatesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Use Of Estimates [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</label>
    <loc xlink:href="vsar-20150331.xsd#vsar_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:type="locator" xlink:label="vsar_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="vsar_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant risks and uncertainties policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:to="vsar_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="vsar_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk and Uncertainties</label>
    <label xml:lang="en-US" xlink:label="vsar_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Risks And Uncertainties Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</label>
    <loc xlink:href="vsar-20150331.xsd#vsar_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" xlink:type="locator" xlink:label="vsar_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="vsar_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preclinical study and clinical trial accruals.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" xlink:to="vsar_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="vsar_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preclinical and Clinical Trial Accruals</label>
    <label xml:lang="en-US" xlink:label="vsar_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preclinical Study And Clinical Trial Accruals Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments Measured at Fair Value on Recurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Computation of Basic and Diluted Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</label>
    <loc xlink:href="vsar-20150331.xsd#vsar_PublicOfferingLineItems" xlink:type="locator" xlink:label="vsar_PublicOfferingLineItems" />
    <label xml:lang="en-US" xlink:label="vsar_PublicOfferingLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_PublicOfferingLineItems" xlink:to="vsar_PublicOfferingLineItems_lbl" />
    <loc xlink:href="vsar-20150331.xsd#vsar_PublicOfferingTable" xlink:type="locator" xlink:label="vsar_PublicOfferingTable" />
    <label xml:lang="en-US" xlink:label="vsar_PublicOfferingTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_PublicOfferingTable" xlink:to="vsar_PublicOfferingTable_lbl" />
    <label xml:lang="en-US" xlink:label="vsar_PublicOfferingTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering [Table]</label>
    <label xml:lang="en-US" xlink:label="vsar_PublicOfferingTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</label>
    <loc xlink:href="vsar-20150331.xsd#vsar_SecondaryOfferingMember" xlink:type="locator" xlink:label="vsar_SecondaryOfferingMember" />
    <label xml:lang="en-US" xlink:label="vsar_SecondaryOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Secondary offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_SecondaryOfferingMember" xlink:to="vsar_SecondaryOfferingMember_lbl" />
    <label xml:lang="en-US" xlink:label="vsar_SecondaryOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secondary Offering [Member]</label>
    <label xml:lang="en-US" xlink:label="vsar_SecondaryOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Secondary Offering [Member]</label>
    <label xml:lang="en-US" xlink:label="vsar_PublicOfferingLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering [Line Items]</label>
    <label xml:lang="en-US" xlink:label="vsar_PublicOfferingLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Line Items]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business incorporated date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation Date Of Incorporation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secondary public offering shares of common stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock in secondary offering, net of issuance costs</label>
    <loc xlink:href="vsar-20150331.xsd#vsar_WorkingCapital" xlink:type="locator" xlink:label="vsar_WorkingCapital" />
    <label xml:lang="en-US" xlink:label="vsar_WorkingCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Working capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_WorkingCapital" xlink:to="vsar_WorkingCapital_lbl" />
    <loc xlink:href="vsar-20150331.xsd#vsar_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="vsar_SignificantAccountingPoliciesLineItems" />
    <label xml:lang="en-US" xlink:label="vsar_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_SignificantAccountingPoliciesLineItems" xlink:to="vsar_SignificantAccountingPoliciesLineItems_lbl" />
    <loc xlink:href="vsar-20150331.xsd#vsar_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="vsar_SignificantAccountingPoliciesTable" />
    <label xml:lang="en-US" xlink:label="vsar_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_SignificantAccountingPoliciesTable" xlink:to="vsar_SignificantAccountingPoliciesTable_lbl" />
    <label xml:lang="en-US" xlink:label="vsar_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Table]</label>
    <label xml:lang="en-US" xlink:label="vsar_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</label>
    <label xml:lang="en-US" xlink:label="vsar_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Line Items]</label>
    <label xml:lang="en-US" xlink:label="vsar_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Line Items]</label>
    <label xml:lang="en-US" xlink:label="vsar_WorkingCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Working capital</label>
    <label xml:lang="en-US" xlink:label="vsar_WorkingCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Working Capital</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</label>
    <loc xlink:href="vsar-20150331.xsd#vsar_CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod" xlink:type="locator" xlink:label="vsar_CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod" />
    <label xml:lang="en-US" xlink:label="vsar_CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents maximum investments maturity period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod" xlink:to="vsar_CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="vsar_CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents maturity period</label>
    <label xml:lang="en-US" xlink:label="vsar_CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Maximum Investments Maturity Period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairments of long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets Held For Use</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" />
    <label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage for the amount of benefit realized upon ultimate settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Settlements</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preclinical and clinical</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense Current</label>
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</label>
    <loc xlink:href="vsar-20150331.xsd#vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preclinical and clinical trials accrued liabilities current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent" xlink:to="vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and related</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</label>
    <label xml:lang="en-US" xlink:label="vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preclinical and clinical</label>
    <label xml:lang="en-US" xlink:label="vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preclinical And Clinical Trials Accrued Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</label>
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Hierarchy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurement Frequency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets, fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</label>
    <loc xlink:href="vsar-20150331.xsd#vsar_AreaOfFacilityLease" xlink:type="locator" xlink:label="vsar_AreaOfFacilityLease" />
    <label xml:lang="en-US" xlink:label="vsar_AreaOfFacilityLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of facility lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_AreaOfFacilityLease" xlink:to="vsar_AreaOfFacilityLease_lbl" />
    <loc xlink:href="vsar-20150331.xsd#vsar_OperatingLeaseObligationNet" xlink:type="locator" xlink:label="vsar_OperatingLeaseObligationNet" />
    <label xml:lang="en-US" xlink:label="vsar_OperatingLeaseObligationNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease obligation net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_OperatingLeaseObligationNet" xlink:to="vsar_OperatingLeaseObligationNet_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:type="locator" xlink:label="us-gaap_StatementGeographicalAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:type="locator" xlink:label="us-gaap_SegmentGeographicalDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_SegmentGeographicalDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</label>
    <loc xlink:href="vsar-20150331.xsd#vsar_MenloParkCaliforniaMember" xlink:type="locator" xlink:label="vsar_MenloParkCaliforniaMember" />
    <label xml:lang="en-US" xlink:label="vsar_MenloParkCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Menlo park California.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_MenloParkCaliforniaMember" xlink:to="vsar_MenloParkCaliforniaMember_lbl" />
    <label xml:lang="en-US" xlink:label="vsar_MenloParkCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Menlo Park, California [Member]</label>
    <label xml:lang="en-US" xlink:label="vsar_MenloParkCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Menlo Park California [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</label>
    <label xml:lang="en-US" xlink:label="vsar_AreaOfFacilityLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating facility lease area</label>
    <label xml:lang="en-US" xlink:label="vsar_AreaOfFacilityLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Facility Lease</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating facility lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leasing Arrangements Operating Leases Term Of Contract</label>
    <label xml:lang="en-US" xlink:label="vsar_OperatingLeaseObligationNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total obligation under lease</label>
    <label xml:lang="en-US" xlink:label="vsar_OperatingLeaseObligationNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Obligation Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Ownership Plan (ESOP) Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Ownership Plan E S O P Disclosures By Plan [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Ownership Plan (ESOP), Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Ownership Plan E S O P Plan [Domain]</label>
    <loc xlink:href="vsar-20150331.xsd#vsar_TwoThousandNineStockOptionPlanMember" xlink:type="locator" xlink:label="vsar_TwoThousandNineStockOptionPlanMember" />
    <label xml:lang="en-US" xlink:label="vsar_TwoThousandNineStockOptionPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nine stock option plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_TwoThousandNineStockOptionPlanMember" xlink:to="vsar_TwoThousandNineStockOptionPlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="vsar_TwoThousandNineStockOptionPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2009 Plan [Member]</label>
    <label xml:lang="en-US" xlink:label="vsar_TwoThousandNineStockOptionPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nine Stock Option Plan [Member]</label>
    <loc xlink:href="vsar-20150331.xsd#vsar_StockOptionPlanTwoThousandFourteenMember" xlink:type="locator" xlink:label="vsar_StockOptionPlanTwoThousandFourteenMember" />
    <label xml:lang="en-US" xlink:label="vsar_StockOptionPlanTwoThousandFourteenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock option plan two thousand fourteen.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_StockOptionPlanTwoThousandFourteenMember" xlink:to="vsar_StockOptionPlanTwoThousandFourteenMember_lbl" />
    <label xml:lang="en-US" xlink:label="vsar_StockOptionPlanTwoThousandFourteenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Plan [Member]</label>
    <label xml:lang="en-US" xlink:label="vsar_StockOptionPlanTwoThousandFourteenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option Plan Two Thousand Fourteen [Member]</label>
    <loc xlink:href="vsar-20150331.xsd#vsar_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="vsar_EmployeeStockPurchasePlanMember" />
    <label xml:lang="en-US" xlink:label="vsar_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_EmployeeStockPurchasePlanMember" xlink:to="vsar_EmployeeStockPurchasePlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="vsar_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan [Member]</label>
    <label xml:lang="en-US" xlink:label="vsar_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common stock issued and outstanding increase annually</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock shares subject to outstanding awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares reserved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</label>
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common stockholders - basic and diluted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted-average shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Issued Basic</label>
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares used to compute basic and diluted net loss per share</label>
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted net loss per common share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</label>
    <loc xlink:href="vsar-20150331.xsd#vsar_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="vsar_OptionsToPurchaseCommonStockMember" />
    <label xml:lang="en-US" xlink:label="vsar_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vsar_OptionsToPurchaseCommonStockMember" xlink:to="vsar_OptionsToPurchaseCommonStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="vsar_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase common stock [Member]</label>
    <label xml:lang="en-US" xlink:label="vsar_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially dilutive securities excluded from computation of diluted shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>vsar-20150331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2015-05-06T18:23:29.7602757+00:00 -->
<!-- Version            : 2.0.5.0 -->
<!-- Package ID         : 5D450A663E0E1D6253DC3DA711642366-0001513818-001504 -->
<!-- Copyright (c) 2015 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.versartis.com/20150331/role/TemplateLink" xlink:href="vsar-20150331.xsd#TemplateLink" xlink:type="simple" />
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="vsar-20150331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DocumentDocumentAndEntityInformation">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <loc xlink:href="vsar-20150331.xsd#vsar_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="vsar_DocumentAndEntityInformationAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:href="vsar-20150331.xsd#Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="vsar-20150331.xsd#Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="vsar-20150331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:type="locator" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_InterestExpense" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="vsar-20150331.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <loc xlink:href="vsar-20150331.xsd#vsar_InitialPublicOfferingCosts" xlink:type="locator" xlink:label="vsar_InitialPublicOfferingCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <loc xlink:href="vsar-20150331.xsd#vsar_RemeasurementOfCallOptionAndPreferredStockLiability" xlink:type="locator" xlink:label="vsar_RemeasurementOfCallOptionAndPreferredStockLiability" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="vsar-20150331.xsd#vsar_ConvertiblePreferredStockToCommonStockMember" xlink:type="locator" xlink:label="vsar_ConvertiblePreferredStockToCommonStockMember" />
    <loc xlink:href="vsar-20150331.xsd#vsar_ConvertiblePreferredStockWarrantLiabilityMember" xlink:type="locator" xlink:label="vsar_ConvertiblePreferredStockWarrantLiabilityMember" />
    <loc xlink:href="vsar-20150331.xsd#vsar_ConvertiblePreferredStockCallOptionLiabilityMember" xlink:type="locator" xlink:label="vsar_ConvertiblePreferredStockCallOptionLiabilityMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="vsar_ConvertiblePreferredStockCallOptionLiabilityMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="vsar_ConvertiblePreferredStockWarrantLiabilityMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="vsar_ConvertiblePreferredStockToCommonStockMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vsar_RemeasurementOfCallOptionAndPreferredStockLiability" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_li0l2" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3" order="12240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="vsar_InitialPublicOfferingCosts" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureFormationAndBusinessOfCompany" xlink:href="vsar-20150331.xsd#Role_DisclosureFormationAndBusinessOfCompany" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureFormationAndBusinessOfCompany">
    <loc xlink:href="vsar-20150331.xsd#vsar_FormationAndBusinessOfCompanyTextBlock" xlink:type="locator" xlink:label="vsar_FormationAndBusinessOfCompanyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vsar_FormationAndBusinessOfCompanyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="vsar-20150331.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponents" xlink:href="vsar-20150331.xsd#Role_DisclosureBalanceSheetComponents" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponents">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="vsar-20150331.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureFairValueMeasurements">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="vsar-20150331.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureEquityIncentivePlans" xlink:href="vsar-20150331.xsd#Role_DisclosureEquityIncentivePlans" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureEquityIncentivePlans">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStock" xlink:href="vsar-20150331.xsd#Role_DisclosureNetLossPerShareOfCommonStock" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStock">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="vsar-20150331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <loc xlink:href="vsar-20150331.xsd#vsar_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" xlink:type="locator" xlink:label="vsar_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <loc xlink:href="vsar-20150331.xsd#vsar_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:type="locator" xlink:label="vsar_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <loc xlink:href="vsar-20150331.xsd#vsar_BasisOfPresentationAndUseOfEstimatesTextBlock" xlink:type="locator" xlink:label="vsar_BasisOfPresentationAndUseOfEstimatesTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vsar_BasisOfPresentationAndUseOfEstimatesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vsar_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vsar_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="vsar-20150331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:href="vsar-20150331.xsd#Role_DisclosureBalanceSheetComponentsTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponentsTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="vsar-20150331.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStockTables" xlink:href="vsar-20150331.xsd#Role_DisclosureNetLossPerShareOfCommonStockTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStockTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <loc xlink:href="vsar-20150331.xsd#vsar_PublicOfferingLineItems" xlink:type="locator" xlink:label="vsar_PublicOfferingLineItems" />
    <loc xlink:href="vsar-20150331.xsd#vsar_SecondaryOfferingMember" xlink:type="locator" xlink:label="vsar_SecondaryOfferingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="vsar-20150331.xsd#vsar_PublicOfferingTable" xlink:type="locator" xlink:label="vsar_PublicOfferingTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="vsar_PublicOfferingTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_PublicOfferingTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vsar_SecondaryOfferingMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_PublicOfferingTable" xlink:to="vsar_PublicOfferingLineItems" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_PublicOfferingLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_PublicOfferingLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_PublicOfferingLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <loc xlink:href="vsar-20150331.xsd#vsar_CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod" xlink:type="locator" xlink:label="vsar_CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <loc xlink:href="vsar-20150331.xsd#vsar_WorkingCapital" xlink:type="locator" xlink:label="vsar_WorkingCapital" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="vsar-20150331.xsd#vsar_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="vsar_SignificantAccountingPoliciesLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="vsar-20150331.xsd#vsar_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="vsar_SignificantAccountingPoliciesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vsar_SignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_SignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_SignificantAccountingPoliciesTable" xlink:to="vsar_SignificantAccountingPoliciesLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_SignificantAccountingPoliciesLineItems" xlink:to="vsar_WorkingCapital" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_SignificantAccountingPoliciesLineItems" xlink:to="vsar_CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vsar_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedStockBasedCompensationExpenseDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedStockBasedCompensationExpenseDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureBalanceSheetComponentsAccruedLiabilitiesDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <loc xlink:href="vsar-20150331.xsd#vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <loc xlink:href="vsar-20150331.xsd#vsar_OperatingLeaseObligationNet" xlink:type="locator" xlink:label="vsar_OperatingLeaseObligationNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <loc xlink:href="vsar-20150331.xsd#vsar_AreaOfFacilityLease" xlink:type="locator" xlink:label="vsar_AreaOfFacilityLease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <loc xlink:href="vsar-20150331.xsd#vsar_MenloParkCaliforniaMember" xlink:type="locator" xlink:label="vsar_MenloParkCaliforniaMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:type="locator" xlink:label="us-gaap_SegmentGeographicalDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:type="locator" xlink:label="us-gaap_StatementGeographicalAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LossContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="vsar_MenloParkCaliforniaMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vsar_AreaOfFacilityLease" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vsar_OperatingLeaseObligationNet" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="vsar-20150331.xsd#vsar_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="vsar_EmployeeStockPurchasePlanMember" />
    <loc xlink:href="vsar-20150331.xsd#vsar_StockOptionPlanTwoThousandFourteenMember" xlink:type="locator" xlink:label="vsar_StockOptionPlanTwoThousandFourteenMember" />
    <loc xlink:href="vsar-20150331.xsd#vsar_TwoThousandNineStockOptionPlanMember" xlink:type="locator" xlink:label="vsar_TwoThousandNineStockOptionPlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="vsar_TwoThousandNineStockOptionPlanMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="vsar_StockOptionPlanTwoThousandFourteenMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="vsar_EmployeeStockPurchasePlanMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStockSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureNetLossPerShareOfCommonStockSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStockSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStockSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesOutstandingDetail" xlink:href="vsar-20150331.xsd#Role_DisclosureNetLossPerShareOfCommonStockSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesOutstandingDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStockSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesOutstandingDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <loc xlink:href="vsar-20150331.xsd#vsar_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="vsar_OptionsToPurchaseCommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vsar_OptionsToPurchaseCommonStockMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0`&SU:ATP$``/(2```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F-%NVC`4AN\G[1TBWT[$
MV-LZ-A&X8-UEA[3N`3S[0"(<V[(-A;?O26A153$0*E+/#1'$/O^')3Z1?SS=
MMK;80$R-=Q43Y9`5X+0WC5M6[._]K\&(%2DK9Y3U#BJV@\2FDX\?QO>[`*G`
MW2Y5K,XY_.`\Z1I:E4H?P.&=A8^MRO@V+GE0>J66P.5P>,.U=QE<'N1N!IN,
M?\)"K6TN;K?X\9XD@DVLF.T7=ED54R'81JN,I'SCS*N4P5-"B3O[-:EN0OJ$
M&(P?3>CN_#_@:=]O/)K8&"CF*N8[U2(&WUK^X./JG_>K\O20(Y1^L6@T&*_7
M+9Y`F4($95(-D%M;]M>R58U[YCZ1WR].O+^(*X-TWZ\??"&'),+QF0C'%R(<
M7XEPW!#A^$:$8T2$XSL1#C&D`D+%J(**4@45IPHJ4A54K"JH:%50\:J@(E9!
MQ:R2BEDE%;-**F:55,PJJ9A54C&KI&)6^5YFS?A$#[Q_??L/MQ]SYI$RY9V%
M=.6_@?NAYY)K%<'\R1&[CZL#O)Q]AD,KJV<UE@!7/H3#W%/YV$S,HP\).YH(
MEP,\ES#=[D'`01!S`X<:YEB=<4C$?N?RP%=]"G0-D@%S))OWC=7D$0``__\#
M`%!+`P04``8`"````"$`M54P(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($
M`BB@``(`````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(
MNR%4'L`D[A^UC:,D0/?VA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[
MUVIXK9]6#Z!B(F=I%,<:CAQA5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+
M\>QRI9$P4<IA:-&3&:AEW)3E/8:_'E`M/-7!:@@'>P>J/OH\^;*W-$UO>"_F
M?6*73HQ`GA,[RW;E0V8+J<_;J)I"RTF#%?.<TQ')^R)C`YXFVEQ/]/^V.'$B
M2XG02.#S/-^*<T#KZX$NGVBI^+W./.*GA.%-9/AAP<4/5%\```#__P,`4$L#
M!!0`!@`(````(0#-42++O`$``+D1```:``@!>&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;',@H@0!**```0``````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``"\6,MN@S`0O%?J/R#?&[.;=Q620ZM*N;;I!UC@``H89+N/_'VM-(5$BK87
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MW6YT>EZZT'F:8$E-TWA0K4E5E3X5JC0]G"Y$H>!6&%)@N`M$U@>XJ0&2&V0W
M>*3#0VXSCJ09'P\J-:Y05F=OWH:_+9?.ZC+\-U3RZH?+^@<``/__`P!02P,$
M%``&``@````A`!_YA#T$`P``9PD```\```!X;"]W;W)K8F]O:RYX;6R45EU/
MI#`4?=]D_P/A?>73\2/.&-UULB:[QF1<?6PJW!D:H67;XCC_W@LX>`<<HD]0
M2@_GGG-NR]GY2Y$[SZ"-4'+J!@>^ZX!,5"KD:NK^NYO_.'8=8[E,>:XD3-T-
M&/=\]OW;V5KIIT>EGAP$D&;J9M:6IYYGD@P*;@Y4"1)GEDH7W.)0KSQ3:N"I
MR0!LD7NA[T^\@@OIM@BG^C,8:KD4"?Q2256`M"V(AIQ;I&\R41IW=K84.=RW
M%3F\+&]X@;Q?<M?)N;%7J;"03MU#'*HU[#S057E9B1QG3R(_<KU95^2M=E)8
M\BJW=UC>%AWU"N,PG-1OUE+<"UB;]T7UT'EY$#)5Z_I5E';3C2(DL&ZF'D1J
M,YSW?;][]AO$*K/;APCO$?Q&0?Q.<W5D4]Y6$89.L2MIA=VP:]FJ+Q1:6*M^
MC94%KJ-/!=[HZS2HB5.4GTJF(`VD#.^,RD7*42QVR7,N$R`H(::B@PF_!H,,
M.C81@6D$_P2;A452!643$Y3XDV3>4"@95+^KZ;`/,V^"C"EK%+ZLC)!@#%-+
M9C-@I*3PA,`TT:`U+:JBX'I3KUN(E1289BXMNT@254E+8"),2\?FJ,_FS1&V
MJ&U%LXH2FU-:0P&HT\=]@#D7FMWSO`+V%[BI-"K:6Q\2`B?]]?C)0MAF32,(
MYL7BEH%;A\`-@AA,'0[\/LS5_ZI-:H)?%\_`;C%I.^NIM\$@L#=8_1^%/I2@
M40RNH5:V)H=&+2@/:FXP2.RX+30DT83($@PR.PZ$DKY'_X@"#6*[SV%VQQ]S
M&OZ(MF(PS.W'1K<P.TK3W`:#X(XK316*:7*#073'&XD"!3N5#2(\+C7FKI,Z
MIJT0#+(\#H0![(#J+;QK2ASTML^]GMUJ*#G!B6EOA8-4[\7!;4)7%`>K?.<S
M2/6>)F=S(7$_ISBTR\)!J$>;G>Y],>VR<)#IC[N=7:1X)N\<4N$.SB#3XUFD
M389G,Q'HBZ&F$0IIM^*@/I*;6.`YG/`\P1^$^M*<L/'AI/74V_XCS5X!``#_
M_P,`4$L#!!0`!@`(````(0"QT,ZJJ0,``+0+```8````>&PO=V]R:W-H965T
M<R]S:&5E=#0N>&ULE%9=;^(X%'T?:?]#E/<2')(0$#`:J+HSTJRT6NW'LTD,
M1$WBR#:E_?=S[9LO&]JE+RVQCX_/O??DYJZ^OE:E]\*$+'B]]LEDZGNLSGA>
MU,>U_\_?3P^I[TE%ZYR6O&9K_XU)_^OFMR^K"Q?/\L28\H"AEFO_I%2S#`*9
MG5A%Y80WK(:=`Q<55?`HCH%L!*.Y.52503B=)D%%B]I'AJ6XAX,?#D7&'GEV
MKEBMD$2PDBK0+T]%(SNV*KN'KJ+B^=P\9+QJ@&)?E(5Z,Z2^5V7+'\>:"[HO
M(>Y7$M&LXS8/5_15D0DN^4%-@"Y`H=<Q+X)%`$R;55Y`!#KMGF"'M?^-+'<D
M\H/-RB3HWX)=Y.BW)T_\\KLH\I]%S2#;4"==@3WGSQKZ(]=+<#BX.OUD*O"G
M\')VH.=2_<4OWUEQ/"DH=PP1Z<"6^=LCDQED%&@F8:R9,EZ"`/CK586V!F2$
MOIK_ER)7I[4_2R;Q?#HC`/?V3*JG0E/Z7G:6BE?_(8BT5$@2MB0S4-_NA_>2
M!"C(Q/=(%=VL!+]X8!JX4C946Y`L@;@+#&7TH;X7*82H2;YI%L,%04@HS\LF
MCE?!"V0T:R%;A,Q]KX<0&['K$+H0H*Z7"'&[$F=0P=NY[Q3I0XZBQ+YO>PT)
M;<3N&A'/>XBE$5(WUOBQ-@T&!XQ2$:<]K4GH%B'&T69A-UJP+HX^<[$&KWV(
MJJ]!O'`N1DAJ:DCF9#JU]W?C_2A-AN.6*C#U_>G08%M5XMRZ14B"SB*IZYSQ
M=C@G4:_9$I5\1I0&.Z*<6[<(05%A&%ZI&N_/XW1V6Q6\$?>G2H,=58YGMPA!
M50^W9%F`]W7I3]>H,7SL:`UV=`WAHJ,1$ID21H-MT-W=IOOJ+SXC0H,=$8,3
M4`1"4$08.@UAA[MMZ@A)HR$&RT@$NL_]N3%H1]=5<]2,:[^O&GS=>[=@AEJ6
M3MPB&JFWQ=WHZ!&\(!\7D&#S';>&Q)&P;3&CIM2N=++C>-1.;%&ZDX[<I#\S
M_]_#"?9?2]30?[&B+08;%OC]1N:0I45$T2(=LF^+U#WV\R*Q,ULBW6Y.$+,P
MYG^83N:N_VT`22;D/>LY_5XG\H[J7C?^4>=N$XD8K&4X3XG3@_5\-7@4`$.0
MF$4<GG"XJ)@XLATK2^EE_*P'(P*Q]ZLXM&WUT&;&KGX#9J:&'MD?5!R+6GHE
M.\!1R!?X5^#4A0^*-^;CON<*IB7S\P33,8-99#H!\(%SU3WHGM+/VYM?````
M__\#`%!+`P04``8`"````"$`5?N=?=@"``#E!P``&0```'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6R455UOFS`4?9^T_V#YO1`(A`2%5`U5MTF;-$W[>':,
M`:N`D>TT[;_?-0X42#>E+R$VYYY[[KG79GO[7%?HB4G%19-@SUE@Q!HJ,MX4
M"?[U\^%FC9'2I,E()1J6X!>F\.WNXX?M2<A'53*F$3`T*L&EUFWLNHJ6K";*
M$2UKX$TN9$TT+&7AJE8RDG5!=>7ZB\7*K0EOL&6(Y34<(L\Y9?>"'FO6:$LB
M644TZ%<E;U7/5M-KZ&HB'X_M#15U"Q0'7G']TI%B5-/X2]$(20X5U/WL!83V
MW-WB@K[F5`HE<NT`G6N%7M:\<3<N,.VV&8<*C.U(LCS!=UZ<KK&[VW;^_.;L
MI$;_D2K%Z9/DV5?>,#`;VF0:<!#BT4"_9&8+@MV+Z(>N`=\EREA.CI7^(4Z?
M&2]*#=T.H2!35YR]W#-%P5"@<?S0,%%1@0#X134WDP&&D.?N>>*9+A.\7#EA
MM%AZ`$<'IO0#-Y08T:/2HOYC0=Z9RI+X9Q)XGDF\T`G\,%J_AV5Y9H%GS^)?
M*\6U974NW1--=ELI3@@F#X2KEI@Y]F(@-O8$_[0'?#$Q=R:H"P6T@I8^[?S(
MV[I/T`=ZQNS?P"S74TS:8TP#0<\@"GP:BWJ[5[T8`YZ+\:>)]I>8,)I"4@N)
M,'JM:4!,Q(%+UXLS8"/.#):Q;M]OC-)$RR%1ATDM)NKF>FQ+\)[,!IQ@J.JU
MGBB8)MI;3#"H2T<;DYIA(JZOV8#AF$PRA[/,%C/*/-J89%Z])[,!SVM>S3);
MS*J;6L_?!'/S[?M.V40(3,;U%ACP7,ALX/86`XZ/&C0_(#UF?D#,QVET:O]_
M0`QX+F8S<\5B1OVP&QMKD_,*MY[8Z]9>)#63!4M952E$Q=%<I1Y$#;OVED_]
M&,;:E#&\@%NV)07[1F3!&X4JED/HPHE@$J2]I^U"B[8[W@>AX7[M_I;P.65P
MFA8.@',A=+\P"88/].XO````__\#`%!+`P04``8`"````"$`B`V\%\<"``"8
M!P``&0```'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6R45=MNHS`0?5]I_\'R
M>[DE(2D*J5JJ[E;:2JO57IX=,&`58V0[3?OW.[83"J3;=%]"/)PYG#DS#.NK
M9]Z@)RH5$VV*0R_`B+:Y*%A;I?C7S[N+%49*D[8@C6AIBE^HPE>;SY_6>R$?
M54VI1L#0JA376G>)[ZN\IIPH3W2TA3NED)QH.,K*5YVDI+!)O/&C((A]3EB+
M'4,B/\(ARI+E]%;D.TY;[4@D;8@&_:IFG3JR\?PC=)S(QUUWD0O>`<66-4R_
M6%*,>)[<5ZV09-M`W<_AG.1';GLXH><LET*)4GM`YSNAIS5?^I<^,&W6!8,*
MC.U(TC+%UV&2+;&_65M_?C.Z5X/_2-5B_T6RXAMK*9@-;3(-V`KQ:*#WA0E!
MLG^2?6<;\%VB@I9DU^@?8O^5LJK6T.T%%&3J2HJ76ZIR,!1HO&AAF'+1@`#X
M19R9R0!#R+.][EFAZQ3/8F^Q#&8AP-&6*GW'#"5&^4YIP?\X4'B@<B31@02N
M!Y(P^F^2V8$$KJ\DT6H1+N+S4GQ7EG7IEFBR64NQ1S!Y(%QUQ,QQF`"SL6?Y
M3WO`%Y-S;9)L*J`5M/1I$\7+M?\$?<@/F!N'66+TBADCLC<0LQ[B@[Y>)/@V
M%3F#27B[AT>1)FDB,NKI;1TW#F*GSP:R06`D`)R9"IB?=<DDP;@,'8A7$P4.
M,[?38JS-!H&1@OE8P?NE&W"*H9A7[^/+R9,=9F6[%\9!&$_,R::`:-$SC)2!
M#T-OWE=FP!-ERZ#G=5UQF($G@\#HR?'XR69VSW?%))WKBL,,%`P"(P4PWA^O
MW8`GM9]TQ6'>Z<H4<-(5MPG=.\ZIK&A&FT:A7.S,EHN@WWW4+>";,($7`3;?
M))[!8K9QO[\!B[$C%7T@LF*M0@TM@3+PS,*0;K6Z@Q:=??.V0L-*M']K^`)2
M&/#``W`IA#X>S/+NOZF;OP```/__`P!02P,$%``&``@````A`*1)MQGT`@``
M2@@``!D```!X;"]W;W)K<VAE971S+W-H965T,C(N>&ULE%9=;YLP%'V?M/]@
M^;TAA@!)%%(UJ;I56J5IVL>S`P:L`D:VT[3_?M=V2H!V7?(2P/?X^-QS[>NL
MKI_K"CTQJ;AH$DPF4XQ8DXJ,-T6"?_V\NYICI#1M,EJ)AB7XA2E\O?[\:740
M\E&5C&D$#(U*<*EUN_0\E9:LIFHB6M9`)!>RIAH^9>&I5C*:V4EUY?G3:>35
ME#?8,2SE.1PBSWG*;D6ZKUFC'8ED%=6@7Y6\5:]L=7H.74WEX[Z]2D7=`L6.
M5UR_6%*,ZG1Y7S1"TET%>3^3&4U?N>W'&_J:IU(HD>L)T'E.Z-N<%]["`Z;U
M*N.0@;$=298G^(8LMW/LK5?6G]^<'53O':E2'+Y(GGWC#0.SH4RF`#LA'@WT
M/C-#,-E[,_O.%N"[1!G+Z;[2/\3A*^-%J:':(21D\EIF+[=,I6`HT$S\T#"E
MH@(!\(MJ;G8&&$*?[?/`,UTF.(@F83P-",#1CBE]QPTE1NE>:5'_<2!RI'(D
M_I$$GD<2XE],$AQ)X'DB\><A":/_2_%<6M:E6ZKI>B7%`<'.`^&JI68?DR4P
M&WL",/E]>\`7,^?&3+)3`:V@I$]K/PI7WA/4(3UB-@X38W3"#!';=Q!!!_%`
M7R<2?+M<I)DT$NEW]#:/C8/$ME8FL6UO8"``G.D+^-@=`P87^YE'T6AEAYF=
M5NX-#%:>7;*R`2<8DN@\)_%X98>9VZH1,CLY;BW9#L)Q$'>Z!ZI@ZY_OAP&/
M59UX724<)K*JPME\T2WK5/7#@1^>P@-5T26J#'BL:CY<=N,P,^?5?!3=]J,S
M0KJY`TUP`,YWRH#'FD8%VCB,TQ0L3DXXH_K1?_IDKK;>F?]X-QOP2%,XKI[#
MN#T5^V0LJA\.H]Y9<$ZYWNVZ4LUDP;:LJA1*Q=[T91_<[T;=E;$A2SBZT*M'
MXUNX2NRXUP6@E;>T8`]4%KQ1J&(Y4$XG,6PHZ2X#]Z%%:WO%3FAHXO:UA#N;
M05.83@"<"Z%?/\QUT_T+6/\%``#__P,`4$L#!!0`!@`(````(0"\J=_%PP(`
M`"@'```9````>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;)1576^;,!1]G[3_
M8/F]$#Z3H)"JH>HV:9.F:1_/#ABP"AC93M/^^UW;2?AHU[4O@.US#^>>>[EL
MKA_;!CU0(1GO4NPY"XQHE_."=56*?_V\NUIA)!7I"M+PCJ;XB4I\O?WX87/D
MXE[6E"H$#)U,<:U4G[BNS&O:$NGPGG9P4G+1$@5+4;FR%Y04)JAM7'^QB-V6
ML`Y;AD2\A8.7)<OI+<\/+>V4)1&T(0KTRYKU\LS6YF^A:XFX/_17.6][H-BS
MAJDG0XI1FR=?JHX+LF\@[T<O)/F9VRR>T;<L%USR4CE`YUJASW->NVL7F+:;
M@D$&VG8D:)GB&R_)8NQN-\:?WXP>Y>@9R9H?/PE6?&4=!;.A3+H`>\[O-?1+
MH;<@V'T6?6<*\%V@@I;DT*@?_/B9LJI64.T($M)Y)<73+94Y&`HTCA]IIIPW
M(`"NJ&6Z,\`0\FCN1U:H.L5![$3+1>`!'.VI5'=,4V*4'Z3B[1\+\DY4EL0_
MD<#]1.+Y[R8)3B1P'TC\5>1%\?^EN#8MX](M462[$?R(H/-`N.R)[F,O`69M
M3_A/>\`7'7.C@TPHH"64]&'KQ\'&?8`ZY"?,SF*6&`V8*2)[`3&0N*#O(A)\
MFXL,H!->KN%9I`Z:B?2G"G86LC2UTHEEHXV)`'#F_0)T$+3+V($XG"FPF'!0
M,-J8*`BG"EY/78-3#,E<O/>6R]F;+69EJA?$\7IZG(V/?=^++\<35=`I8U]>
M5Z7!<U5#P4UG[2PF-*HB;Z8Y&Y]ZJZ&:$TWQ>S1I\$Q3-'OKSF*L4Z&W&JPP
MDF%X:0I[[`?KU<PI.YGL-]=24=&,-HU$.3_HJ>-#II==.Q!W7@*-"9-HMI_!
MH#3[[N4`!E5/*OJ-B(IU$C6T!,J%LP2?A!UU=J%X;[Z$/5<PHLQC#7\D"BV_
M<`!<<J[."SU,+_^X[5\```#__P,`4$L#!!0`!@`(````(0"UK:G`DP,``'T+
M```8````>&PO=V]R:W-H965T<R]S:&5E=#$N>&ULE%9;;YLP%'Z?M/^`_)Z`
MR:5-%%(U5-TF;=*TZ[,#)K$*F-E.T_[[G8.!@E-5](6+^?R=S^?&V=P\%;GW
MR)46LHP(G0;$XV4B4U$>(O+[U_WDFGC:L#)EN2QY1)ZY)C?;CQ\V9ZD>])%S
MXP%#J2-R-*9:^[Y.CKQ@>BHK7L*73*J"&7A5!U]7BK.TWE3D?A@$2[]@HB26
M8:W&<,@L$PF_D\FIX*6Q)(KGS(!^?125;MF*9`Q=P=3#J9HDLJB`8B]R89YK
M4N(5R?K+H92*[7,X]Q.=LZ3EKE\NZ`N1**EE9J9`YUNAEV=>^2L?F+:;5,`)
MT.V>XEE$;NDZIG/B;S>U@_X(?M:]9T\?Y?F3$NE747+P-L3)L/U/GO/$\!0B
M1SR,R%[*!]SZ!98",*)K`!K1_UHSMR%:\3LS_>?6Y'T=MN_*2WG&3KGY(<^?
MN3@<#5A:@!O0&^OT^8[K!,(`MJ;A`ED3F0,%7+U"8#Z!&]F352=2<XS(;#E=
M7`4S"G!OS[6Y%TA)O.2DC2S^6A!MJ"Q)V)#`_=Q\7T[I/%B^@V/6<,"]Y0A'
M<OCV3+6[[IAAVXV29P^2%53KBF'JTS7PONX3<`9B;Q$<D2N(6D0T!.9Q&VS\
M1W!]TB!V%@'7#D&'B+A%8/1`0R<$'#->"()1"`8+E>WL0M]NZ-B]1,PZQ$`(
M>*$O!+-E!HGZMF=P$^!ZYYYW[%:A1=2U42_$O86!_?G0_MMV$1P1.%OG[X5C
MUR+@VB&60T3<(MR(0'+W'?&V$`0/A5P-S>PLP@K9OY8\<8MPA2S?(P3!0R'7
MCA"+6-02YF&P<B(5V^]UI`:!@;P?[P\$#V6L'!D6,:]EA`%UXA:WGUUGX*]L
M=,$B>*B"NA5K(?W\H&[)MA!7RNH]4A#L2'%*=&<A`RDO-6J+IH6X4BA4Z'BW
MU&A'C),%NP8S4./&J,-<R,$N-SI*U/;$?A53ITAW#<:F"UW0V35U\CKN(!=J
ML/>-5V,[Y4"-6\O48E!-MIU,:#B90=)D^$>84"?1XPY\H0M;X'A=MF$.=#DN
MV-&VJ;YTNTLY+>9"#L2Z+V=<YX=QQTWLT*VQ!M-K_LW*TE;_*EP&X>PEY+;M
MV.'&_JT+K@X\YGFNO42><%BAL+5;[::O9BSJ/L`<4[$#_\;4093:RWD&6X/I
M%;1:92<A^V)D5<\">VE@@JD?CS#F<OBW!E,`9U*:]@7]U@W.V_\```#__P,`
M4$L#!!0`!@`(````(0`]@<8-100``"L/```9````>&PO=V]R:W-H965T<R]S
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M;[)]"?-^\\,L[[V[+R/[JL@;+OBQ=<#.)=#QG!,W<<%ILSH4,`-,N]6PX]I^
M])>I']ON9M4EZ-^"787RV1)G?OVU*0Z_%S6#;$.=L`)[SI]1^OV`(1CLCD8_
M=17XL[$.[)B]E.U?_/H;*T[G%LH=P8QP8LO#>\I$#AD%&R>(T"GG)0#`JU45
MN#0@(]E;]WXM#NUY;<_F3K3P9C[(K3T3[5.!EK:5OXB65_^1R)=69!)($WB7
M)G[DA$&TB+_B,I,N\-Z[!$X01WXT_P)+*%W@_>8R<4(N):?+=9JUV6;5\*L%
M"QBF+RX9;@=_"<9]DBDE0]I_E'5(-YH\HLO:7M@6)%3`4GG=!+&W<E^AO+G4
M;$D#KX/&UQ6[7H&U1-M4";C`.T!#-53H^RNB9T,QLO6N6PJH(($!<D<QTR7I
M'4E\FX]&"U57:3'%X0_7<4^-@V#%*MD*8@-S2YIPF-G.#*1*0$."2JM('R<0
MQ6L;)CP4+@KU;&Q),J?*)[@]9G-=LM,D81!&X6RA2U*2=//1:"%9TVE1K-,&
ML5&\+6F4Q)F!5`EH*',=95HM<=!GM22-@F0&4B6@(<&N4[.#2#-HMA_7%`>9
M63*+2AH%R0RD?0`W_&V[:W1X&BO]Y6,J%)M4D;Y(MJ11J,Q`J@0TE$1'F58[
M'/19[4BC()F!5`EH2#X42DW/M.)UH\P\F=63(KDGX=3SO%N)NO:ZDY(;>*I&
M=%!LQ4H=)X)2`U=;1Q`;C6'KDRCQNNX1.F&B_<6_/!A];R='J-SDT45T;NS3
M7^>F[JYS&]UJZY.H;WKAXDZ"2:*"*A$=%%OUUT&IP>N@L;%C?.44D(4W(ZFJ
MT;FP*1M<GY]>/K5R^)GAS!@?7U)TR\YN%$G5B,Z%'=K@^KSMX?/CJ,.,%B2)
MY(+T'.]VKLOT*:>#?%!1(CHF=FT%\^/^YU./U\N9F.4D$:V[60*WDM&^5HX*
MR:=$=#YLX=/YJ.%K?(GQZUN?1)(/Z,9\_;G1/Y*E<LR=_8O-?#H?M7Z5;_2H
M`E<67`*$E]R!4XX/F3PE0LFC.PL]1U>L.;$=*TMAY?P%[R,^-+(A.MR5'@-\
M3G.'?\!5Y9*=V!]9<RIJ897L"$,]9P$KJ:'+#GUI^:5[2M_S%BXIW<<S7$H9
M/!][#HB/G+?]%_R!X9J[^1\``/__`P!02P,$%``&``@````A`('MRG'7`@``
MG0<``!D```!X;"]W;W)K<VAE971S+W-H965T,C8N>&ULC%7+;MLP$+P7Z#\0
MO$<O/V58#F(%:0,T0%'T<:8I2B(BB@))Q\G?=TG:@B4WJ2^VJ)T=S<ZN5NO;
M5]&@%Z8TEVV&XR#"B+54%KRM,OSKY\/-$B-M2%N01K8LPV],X]O-YT_K@U3/
MNF;,(&!H=89K8[I5&&I:,T%T(#O60J242A`#1U6%NE.,%"Y)-&$21?-0$-YB
MS[!2UW#(LN24W4NZ%ZPUGD2QAAC0KVO>Z1.;H-?0":*>]]T-E:(#BAUON'ES
MI!@)NGJL6JG(KH&Z7^,IH2=N=[B@%YPJJ65I`J`+O=#+FM,P#8%ILRXX5&!M
M1XJ5&;Z+5_D"AYNU\^<W9P=]=HUT+0]?%"^^\9:!V=`FVX"=E,\6^EC86Y`<
M7F0_N`9\5ZA@)=DWYH<\?&6\J@UT>P8%V;I6Q=L]TQ0,!9H@F5DF*AL0`+](
M<#L98`AY=?\'7I@ZPY-Y,%M$DQC@:,>T>>"6$B.ZUT:*/QX4'ZD\27(DF8#Z
M8SRYEB3T@EQ]]\20S5K)`X*9@4?JCM@)C%=`?"K,R^A+?:]2*-&2W%D6QP5%
M:.C.RR9)XW7X`I;2(V;K,0N,>LP(D9\0MA,@K]<(A8\U3J"%_S;_),DF#27-
MYB-%EY!DB,@O$;-%#QEH!._.-7ZLS8)A!,ZL2*))S^LLW7K,U$V`]3@_NS%X
M\G3X9-O!_[MCDS(,Y?7-2**Q/1ZS=.V\2>S"&4K,!X#I-%W.>L!`(8SX]=Y8
M\$A9'/6\WAN/F?M!6RS'\7P47_;I`UGSH2QKW!0R/VZ=31K)2T=3L_68]^6-
MXN_(@S?EW+7K^FJ31O+B\61Y3.K[&@6+M+?'N0M[U'(<X_$\."/P_ODUZ=>(
M8*IB.6L:C:C<VQ48`W%_UV_G+6QGM\O"/@#;L2,5>R*JXJU&#2LA%<1``Y3?
MK_Y@9.?>XITTL!?=90V?009O1!0`N)32G`YV;_0?ULU?````__\#`%!+`P04
M``8`"````"$`[&Y]N^$"``#>!P``&0```'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6R4E5UOFS`4AN\G[3]8OB\$$O*ED*I)U6W2)DW3/JX=8\`J8&0[3?OO
M=PY.")`N[6X2,.]Y_9QSS&%U^UP6Y$EH(U45T\`;42(JKA)993']]?/A9DZ)
ML:Q*6*$J$=,78>CM^N.'U4'I1Y,+80DX5":FN;7UTO<-ST7)C*=J4<&35.F2
M6;C5F6]J+5C2!)6%'XY&4[]DLJ+.8:G?XZ'25')QK_B^%)5U)EH4S`*_R65M
M3FXE?X]=R?3COK[AJJS!8B<+:5\:4TI*OOR254JS70%Y/P<3QD_>S<V%?2FY
M5D:EU@,[WX%>YKSP%SXXK5>)A`RP[$2+-*9WP7([I_YZU=3GMQ0'T[DF)E>'
M3UHF7V4EH-C0)FS`3JE'E'Y)<`F"_8OHAZ8!WS5)1,KVA?VA#I^%S'(+W8X@
M(<QKF;S<"\.AH&#CA1$Z<54``/R24N+)@(*PY^;_(!.;QW0\]:+9:!R`G.R$
ML0\2+2GA>V-5^<>)@J.5,PF/)F.@/SX/WVOB.Z`FOWMFV7JEU8'`F8$M3<WP
M!`9+,,;$)H#D,-I4_Y4II(@F=^@2TQDE$&Z@.T_K<#%>^4]04G[4;"XU05^Q
M/2FP$X#7,D+B7<;7BWY"03&B8!.0;>,6P/O,-MCW4A'-6DF/!"K4)<%JC>$P
M72?"H)C")F>`Q:3U=Y!.,VFIMYV%'L'DD@#[=9T`@X"T1Q`-")RF0]!9Z!'`
M;L,:O$V`0<,:3`<$3C-UQV<V#1;3<Q>:*FU[BF`^GR_.'CW&:9_Q>G50/&0;
M[+QQFDYU.@N]G>$=^/_J8-!;_7&:#D%GH4>`GYQ7WNCK-<"@80W.M75GU&E<
M?X)Y%`6#0PP#&$T:1$?DYJF;-Z70F=B*HC"$JSW.RA`ZW:ZV8_PNQ)=@L+Z!
M\=X,0[]]`..U9IGXQG0F*T,*D8+ER)O!&=%N0+L;J^IFRNV4A<':7.;P'14P
M&D8>B%.E[.D&!T_[95[_!0``__\#`%!+`P04``8`"````"$`3]Y?KWT$``"U
M$```&````'AL+W=O<FMS:&5E=',O<VAE970R+GAM;)Q878_B-A1]K]3_$.5]
M2.R$A"!@M60T[4JM5%7=[7,(!J))8I1DAIE_WVM?@S_X6.@+$/OX^/C>Z^.8
MV9>/IO;>6==7O)W[9!3Z'FM+OJ[:[=S__L_+T\3W^J%HUT7-6S;W/UGO?UG\
M^LOLP+O7?L?8X`%#V\_]W3#LIT'0ESO6%/V([UD+/1O>-<4`C]TVZ/<=*]9R
M4%,'-`R3H"FJUD>&:7</!]]LJI(]\_*M8>V`)!VKBP'T][MJWQ_9FO(>NJ;H
M7M_V3R5O]D"QJNIJ^)2DOM>4TV_;EG?%JH9U?Y"X*(_<\N&,OJG*CO=\,XR`
M+D"AYVO.@BP`IL5L7<$*1-B]CFWF_E<RS2GU@\5,!NA'Q0Z]\=OK=_SP6U>M
M_ZA:!M&&/(D,K#A_%=!O:]$$@X.ST2\R`W]UWIIMBK=Z^)L??F?5=C=`NL>P
M(K&PZ?KSF?4E1!1H1G0LF$I>@P#X])I*E`9$I/B0WX=J/>SF?I2,QFD8$8![
M*]8/+Y6@]+WRK1]X\R^"B*)"$JI(X%N1$/HP2:1(X%N3T,F8C).?2PEP63)*
MS\50+&8=/WA0>B"\WQ>BD,D4F$5X(@CRY?!`7,28KV*0'`KH'G+ZOJ!D%KQ#
M&DH%62(D]3T-L1'Y!41T@@0@[Z01PO:X1C'(T4A/]'(92X2D,E5B7;G18`F`
MP)@";@='@"&(YLIC9V*$Q'IBH\&:.'YD8@&>^[`&'?*Q,S%")IBR**2)D[;<
M!)`T'"?)B<$2!K5O1N2^LA&#'(&:'E."D$0*C,G$Z<[-;AIED\OB$EO<[70)
ML",J/=&B*(2@*!K%<>P`<A-`4IHE.N%6U&`[F%&[+4R`'6%ZO2@,(3&F<Z(G
ME;VYV9L0'4I+DCCGC/U_6Y(`.Y(R)U8(04F)$0>49/:F1`NV)&6/2!)@6U(4
M.I(0<DS?.,J<79&;`)+&-+LBC(`QWA\LB;:-('*VVU)A#"<P6ZRH$,>I;V=*
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M2QQ]R.8EVG;:6*\:RU]A4-P3B2)JF):$Y`Z$7#=<^M!!(-&./"=C2X5!>92F
MX]0QF-Q"D"2-$EV[=NR<T^"^%T.X`+H6$KOFJS#'=]<+Q[B%N'B.XRT1[S\-
MZ[8L9W7=>R5_$S=`"N]1IU:\G2[)="DOITY[+FZMXO4].'7`I7%?;-F?1;>M
MVMZKV08HPU$*SM?AM1,?!KZ7UY(5'^"Z*'_NX.\!!O>/<`3@#>?#\4%,</K#
M8?$?````__\#`%!+`P04``8`"````"$`F00>3>T"``!1"0``&````'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;)26R6[;,!"&[P7Z#@+OT2YOL!Q$2M,6:(&B
MZ'*F)<HB(HD"2<?)VW=(>J.\-/;!6OCSYS<S7#2_?VT;YX5P05F7HL#UD4.Z
M@I6T6Z7H]Z^GNPERA,1=B1O6D12]$8'N%Q\_S#>,/XN:$.F`0R=25$O9SSQ/
M%#5IL7!93SIHJ1AOL81'OO)$SPDN=:>V\4+?'WDMIATR#C/^'@]65;0@CZQ8
MMZ23QH23!DO@%S7MQ<ZM+=YCUV+^O.[O"M;V8+&D#95OVA0Y;3'[NNH8Q\L&
MXGX-8ESLO/7#B7U+"\X$JZ0+=IX!/8UYZDT]<%K,2PH1J+0[G%0I>@AF>>`C
M;S'7"?I#R48<W3NB9IO/G);?:$<@VU`G58$E8\]*^K54KZ"S=]+[25?@!W=*
M4N%U(W^RS1="5[6$<B<0D0IL5KX]$E%`1L'&#1/E5+`&`.#?::F:&I`1_*JO
M&UK*.D71R$W&?A2`W%D2(9^HLD1.L1:2M7^-*-A:&9-P:P+7K4D0WFP2;4W@
M>C`))TF0C/Z/XIFP=)8>L<2+.6<;!Z8>@(L>JXD<S,!9I2>^F![(B^KSH#KI
MKJ`64-.719S,O1<H0[&59*>2T%;D9Q317N(!WIX1TC9DC&`BG"_ACE%U@F(A
MY\`XVMOK,#(CB76I5%SYT0L+`%R.`:X/K,0I`JO#P./!P$8RU9D+/MW%=G-^
ML=F"BF^!4N(!U,0>-3.2D89*?/VS%?DUA84&$^C]^5+B`=K4'C@SDEBC^79;
M?K[-PAG=@J/$-DXR&#(SDO,XY]LLG/$M.$H\P`GL#&1&<G$V76RVH-1Y=[0/
M7)_B2CR`&JSNS$BLV31(8WY58L%-;X%3X@'<85\Q"]](#%PX#9/Q)!KL#;DE
MB<,XB:/#*K;@X/2Z(75:/<`;K/]LJ[G*9VO.`YI#T6SW/5Z1[YBO:"><AE2P
M-_GN&-8.-T>B>9"LU]OZDDDXRO1M#9\N!/9&WP5QQ9C</:A#=_\QM/@'``#_
M_P,`4$L#!!0`!@`(````(0`?BHO[!"T``+2/```4````>&PO<VAA<F5D4W1R
M:6YG<RYX;6S4G=MN'4>6IN\'F'=("!XT#9"TSK:J;#4H2JIFMV6Q1<F%06$N
MDGLGR;3W@=ZYMPYU51C,(\S-`-V`T=?S%)XW\9/,]Z\5$9D9F9ND7&77#%`'
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M3"85O_/KE$[Y*Q\Q]'*XG,^7B^)DO9Q\OUN<7)2KJBE>;M8F3Q`L?^UPR1(6
M#;WR5[.<U5,;XDDY*Q>3B@X0GZ;8>;,H-].:P3_E[Y.GQ2>?YAT=+8K7%\M-
M@[Q`N\UB5C5-L5Q?5*MW=5,5S64UJ<_JH6P\K29)-N[GG48R'C0-TQC\6C87
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M'_^QA?5^@?8\1B.#%*IUC7G<JDU/UJS0C/'+,_3]`F5<0YSC96-TNL+N#Z0A
M24%.RD'+@6C<]`UG_YNV7K82DK_2Y_6M,^\WNW;:H\W'YSS:],H)CYK/M'V8
MP+/B)3:@%'N[-F2,RU5U@25"DQ1?+[&3'VU?J_>3ZG)=@)G<QA>8[?)CS&X7
MD@[,;I@P\"I:S'RC7E4-P`Z=*94WK="(2S-M>;L_5`O6/K-FY71>+PQ[287F
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M&=O:V^%%"71LD.4`LHT"L?D(%#[>CO;'X77"SI<WQLXV!_<@KIB)..6C-SMG
MR1IET9A*W,X@QQMT,3LN/7(YZG/DNSZ8VDV&R:=VYL#D2FG!!9I4U;0I3+YD
M=<VQ-#YKE95V%^.PEGJ\W)S.T$K+,U0@EL#TLA:6WITLFS$?[Z;CG"UG"/P>
MHO0W'$(:?51W_Z+I5^^KU41N\S7B&(1G8(?Z1._WUB&Z"_+@[<0;L)(,V;0X
M_5#<9*_U(F:5N!M3-PR/+C;+>8V#;HPUUE`NU"D1F\5"F$#<;>&GG)NO?%^&
M>.N;)YO+RYFI/CAO2LP*LQX,\@+UK7D3]I@/:/0R<.<U7(G)@C$4Z+0I],WZ
MN#8M_O3"',]!1*_?5U0['V15R[[_Y+0?]9_ZG60XHQ@HXQM.)N_'#7V"(C?I
M)7]%W'#S93VWP&\TCT\V3;VP^--9@:M%:&M^62X&=BKH?7'6,9$O"TYL#ZC>
MV2>.J?#R1X[R;3^B6.QH1C__Y=_"I'[^R[]_"MUEWR;+U>720WSP2PQ`_/3C
M'0L.W_Y"VZJ7#?"(GYX"+]FR:I_06UHE'(G,$5&?+B?HSVKO3-%7"7&]O`2,
MS<M)M3'OT^`!=*%?T[RS#Q'*BR3$WL_W9'+X6UAF?BIMORXN-G.Z/U\MWZTO
M"F(H[')5$!BWJ:V1?8-`FE[6QMUU@D`?!O,-'H2&FJXVYPC&8FJ1R(9>40$U
MPT(B]LACE69+#N9$[]]'[XI7CPC8%CN0UG\190<!W`ZA?O[+_VJ*"W($/VR(
M^+)+;M3=`S%G#6`.R5]4B]F2N-J*@.IA.:M9ZZ(N]XL3=DP-XK;!%[M==K,I
MGU;5`I-<S\M5#7WIG-?Q@T33<1>J@SQWU?N,P"O-<;=X?S)CKQ17!Y^7LV87
MM<R3<Z(F:Z(*18DRXV?S-7>+Y>FZI+F-=:Z8"7%E-4&KV[L7M>RKYM0L%XMJ
MMFL$6)4UTJ,],`4B]=*@)`&<]C,H4J()'Z+C6T22$7JE'$H*&K,ST+>>=R(9
M@UP*;^@_Q_S/Z6>D5?ZLT!W9H=NW^-=D.7,&FY,.NJ,GJ^?$%+W)ZWH.//RF
M>E>\6L*:^O6LG(O:WH,>?&8=6_;H=\TE$O#5+7164ZW>5K<>%VY.&+F3T1&C
ME`1537.('L$`0ONZS0,!2<7I6?P0"=S$@+GS^B2%V?FK#;.W?38QX&.*@#U'
M8$W<Z0L\*^IC/&:$'PM!\++C:^RH2_QJ37*Y8-E,:"%-->.5"?%M_=!YX5.7
M*4B%FV:@WSI0B!7W9(+>+.&3*-%G9;V2/]K`7Z[[Z)[=I^]F,R/`RS];3SR]
M5H<==WO=H&JP@ZQ)O!,Z:!<OZGA<*_P4=*.LOX8BN&%02'_'CD]#AL(2?$[D
M."--/3:+XZ,E(<HZ+5#L43.JA(4H3+:FN'C67//B!X2OH%/I2@?]_>Y]^!ZW
M:$FNJT3<E%=IU]S9<-$D1@K:!ETN:\BLS-#@HGIIC$&OWVT6:&<LQ;L:32S:
MA!Q-AU6S47S?T`3L!-1`;'BRJA#QN&);*K:#!JT!BB%P*"9U%%DSF1S3I.5B
ML3&6,V9E6L_AP8),X[](2?$.CTQ.?OKQH2<[VXF_V3]!GXI9S>,V+GGV'I<&
MST_6>P[VUTJEW$^>'8YJ=EZ'YF+=B,URE'BT*/ZY9)(T42)VMWAG40KPG^A1
M%DWJ(7-!Q!YH@H1G=O%15G)D8,]E\>ZB)A!&7QY2+.[O/GKT2/^-D?/!V_Y&
M(&83FX77NUUKOS9LQNH=A$$^(30AN=8WX'>D4Z*UAU98!LMK[GE0YL@S_,UN
M`\U1_.Z*,2$S`^\Q2VN2&<4G7]S>OUN@,V=FQ,HS!FL'EOX0-+8$TZY1PO?#
M+::\4_4CP3XSERV%#3.KL'Y\LIEC"4U%G=3G"S*"F/IU,8+$\LV["X/\XI>?
M$.<R377<5622NS?N9#T+:QC@_-<2JZX9^!C!OB`6AM`:`B`#*?V'3E=WJZEY
MP2:Y^O?&$F0""H2,8,BF(%NFR"F;P^_$>OU=,<0;T!K_,A1HBR)SOX*.)ATF
M27\X.#@V&3%<>*EXB`>@HY[[Q2L:F7X:$=U$AA,"%QW3@GS,R^^K(C*)LPQQ
MF,W<V#0`O!+.P;1I>6[M6&`Y]XRFN-6RLZ86HM]#X,?15M]I8WMD"`T,C;XT
M9E,^8D]=K+;-,X;+BRF:#*EIV^E?;HOVX?:U:THWH.P^NGU:2W@\2D)J$K9,
M)!M(T>N_ABEE"5EPQR8%[!Y@L#P'J)]!&LG*B&U(V5';FZ#1W!8Y5QN#?HOJ
MZA15>%N@PSOR<[,/>\MW"P9L-J=-/:W1#KM%>@'`_4'NQC^1`H:$373E=D4=
MHMXUYM^$"H5^'\H"C<PT!]QFLH9L.=>IZJ,19&7U@/,HF]6L!I!+@;D=-X:>
M,C.,/EI#>W@63"WV38!*/HQ93$$QV%--`F3Y!T&=#G%;:.2S<_BP1?Y:X]^Q
MV]$R7[$]]Z-A=ORGZ02E,D;^7+,F/P8M8^J_LQSS8=A6+=J-B-(>B+CX85&=
M.WJR,,DPB@X=6'3(KO_T8RR`RITD@4+--\_KBK*?W+EW;__>3S\&TV3#OENN
MOI<X10=%S>[>?;C_,#7S?0P[8L9H`@N@BEP[;"Q78JNRN#S+,8?2XHKH'\='
M-!<APBL)^LJ`C&6^;&K]%!>+BCF$A*_833JH+&%SME'N1WR!P&_.+[IZ4^ZN
M68YF@_IOFK.-.+O(G3,>:9*794-5R9RX*-/'1UX;NLW0#@TE^A`;'+D@:(02
M1B+P8<W'[N[Z.Y"`6G4&-R4!'A<&7A#0A1T"N[(5L7WYMJQGMK8P,5^BZ=QJ
M-8=MS);%=%5GR(&..ZG.Y9N,&N2XLRY<;!^C*0K1^#O[**_DVVS$K?HQRW(`
MALXH,+!Z&J_/F2YI"2I6-RNQ-H@.MCF-P20)HBD7E2FXE8(-7:PM6#(SI!5M
M%;16O:%<<%=16NTVVSU8_B'!1Y;?FFVBJOA(Q:INOL\%^'FJ#Z@7E+9MC&Z^
MJ9>`?`RBX0@4['?1R$8*PN2E6'SK6*;-<"XEC";F$GS[HU-O%51;3Q&:3[#U
MC4)6Z*+"[L%29_+`6MVG1=1K0E12T\::'3QQBK8FW0PGT0%SNB#K6`3:H"$I
MCB*Z=+(!D$_QFJF6$!K!HLB35)P`PT'J7,P+"SN^8CS$4*51%"TU@YUX!<5-
MN-]`I96V<RPI^)K-#42UE0?&1]A'G&1R+<L9:RZ+Q<9JC%B(-M;5*K:F'8>@
M(UIDB6MNE'"LT$%+(V.V&<4XNN\9DB"-U(4>;/];P7'!=P644!NF"85C)N[N
MIWC$+I*`^$-VR8@1"Z*MEZHZB!,V8!]'%<?TPU5&1CS8R87T-SH=(XYHLBF#
M+@;QJLS.&I$3=^=1PT&'.!W?XP$%]<-\1[M;+:<;+(6Y.)=4Z)AW;001.#&F
M5&[>6]EBP`CGH+:)A8D,DN)$.O83T6F[AI!:+7^"[JNUR,VSBP4AK7,84[6H
ME'R2\#+#(Z:_J"^=$V!A@3&;[J+XOO*0!2D9]M!;@.)0>TO2?U+6BOX!M08L
M?!RG'.*L[-LILVA9EK$-NK-A&#?9A&`236?).7^^I.A72WJJ^.Q!IY0CN.7/
MGQY8*!LEV0F1`*M8D>G+=D=C(2#TD%7QL@4YM;1KJ.`$-2!.,-J5MBKM@QD?
MF3VI$4VX#6*UR]DOCGKJR4+ND):*U';1;'Q<?_A]5GZ@@=F^)-_V$_&]4',1
ME7S[+F%;\KZ&Z@UEEEWY*J=OV2),"X%%/!ZHU]F'P<Y!AZA6NCC&L8LQ)>ZS
MZ-8*?0!H$38NJO>R:`Q**R%X9QPCFNRXZ.^!XFZZI37M,JTK5*7:S4KD-&3T
M"(?XEE%#"6,0VG8FTZ;%V+WF$&(=#DS8(84S6U:XY"VBM-=N.$#D(IJ(4;RA
MD0)HD:K/P4:?W:\D,]80/X0]LD"K[`M:<<8Q`0J(/4GN]I4XC>7<IQ[&`E91
M3TJF$C*C3M$!E/VB`M<7JPHDX*<#F*7514/+4[%WTRM;;L%R=*L>N,C!V[U2
MU"[+7&-GWTF.S-"RD69H>^8UP+0^+)&81U<N65%:*M,C6V&J%)=H*@_.8U\,
MLEF@^$E+3!2<`+VR1H4WIBM25/`G\:2F&A`>S817/"R0)I.<HYSQIF:0S%MB
M4$D=4$7S9]ZH!$IFF(P`G/OB4K8J4]K#+@D1@KN1;F3#*!H=;KU1"7`+T)D'
M)1%U7+?;"<R<5NMW"N[X%FM4([`)V7[QM;+@*D"5J,/E%FJ'J2`5D0V5[TBS
MX/F8"6AGI9HL!HV3$K\P/^,D!?O2U,ZP82'I!K='>X;^@LP`8"%5E8U*.!5>
MIJY6+,WH<"U&RP0_Q"NT7=')\P#'8,K!V=*D]XL_4KP8Z&$]$D$F[F-ZTG2_
M5?P3EP&`Z>F9>WQI;_J^7M@GS$3H:\[:(:5*_$3W7J#?%B-MXR!#^WK.4D4)
MZ3WYZR%-0A=Z#G>9"3(?0=UY$(968$4M)F>S(_1RO;*T"#3_6DG0KV&#:7%@
MX:2\>5=!KZJW=47=&;L]PM3F`DKKA][?042IY8+_482")7C`VZ8ZJ5<XQ#"V
MV>*0J>AX:A/*ICYH^1XET_:C@8Q'D5!<-##:J8)IEGB1K=HO7L5_Z`P!6`)H
M[)5?"0X8C@&)LA?.<.BH_CA(M:B(\(>`L+;*_%@+,9M*\TA`<BH[#I'C2EZA
M&P]PKID7EMGT>Z=A5,+>E(4XX:JILU*'C*Y*M4["R1*ID64%&F$$7%]I!?G"
MPGK#'-Q)$.C&,U$&#"-%V&"GWF>^4_(%RN%J<A<K\]R#Z@A`3VX6/UY+(K8\
MQ8,(OABB<*5D6B>.HU[;27R*F'B&-HF(33K:T#:PA8]O=&VI9=V.^*KV/(OX
M,;EA!F@@+L]%G&^-.%"P]42/6D]T3&02]9VN@?A=9V:KZTCRQ;39#8[SH,MB
M%#*4]KG^&)Z%Z>9#.K0FCFNQ(K$!.;C5>D\[7X!J\1B#B`C+J4)H'Z"VM0H,
M=E.HT`)LF)5NV`%61PN,UHZ!-+/B2-),TN`\%G"5[YR8<WQKG+[(A*HOQ+&R
MS*P&!O?L&B`<&V'"^JY-,H:LD0!<4BO^=_4><.LOZ:B&)!FCNFC.T&1E9VD!
M6=!2&0U'`!:@`@"#64D]<U@L@0GZUJR,D4V9)Q+1CT$K$!DXS(926`T-%<UO
M`"27BC!K*%.F#JN[,1\ED?>-53V69TZ83G^2K`_%R:%YAZC%?`.@F)=DRE`N
M-D<::^>7IYCEMR:R]8*29H?5JG#/6VX6@[:#O7K=US,7N'$*,JH@1]M&YXP-
MD-R;82TX/(O`^2K:EMJK?BZDY8VHZ!VYP@)>`]G\+I?-K]7]3S\>Y<\IY;"*
M`QCHAPT^K5Q;^,9,E;8#S\NW05T3)L.S\A*CH$]Y%KD>+_GW>?=QV,&X1TY:
MUY(PZ6(P?$A("VK"*M91<>3\++#3DEXQ@>V+B+,W0="+"PRHKVQ7#!E]6MOI
MU*CMW<PWTSM%.I>KU?(T%')A<SJ-`JO"BJ71J>/!B;G%!!OTA"F9H!-C.'J<
MD-)G6XDYH.:;(2>VE`I%/FPM<P8@K(DLL'",2)BU44/`03NLN5XYM5$6I]I"
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M\<"U<NCP9TC5]%Q>=9=FEYIP8T`)?@R^@NI,#E^]I-Z"XDR3=L90;%#RACPH
MN]!VXK5X62C'_/+3ZJ*<G0UVK[,-'0H`:]*\>I/TS0F^6N3\P/>)7'@<D(C3
M1_WBE(PV:;T?39)M5.C.NEE3JZ@-[I*XI8YE4YPBQ1%F7=PF;!O60$@^YO0#
MCW:((QE7`#_Z;^8?.YI/)(@!H$0*FXAIAZ@6MK!O4FV)OU`^BE.GG'V('M)0
M\7-FHHD'%1W&,V>;1VD^04TFG>1,K(B[B)30>Y0!=VWBTFTQ;J],P079-$2[
M4BY\1J*#P]YNTN?E-`#5>H5P"`HQ!%Z:AS:`+(8DO=[/K;9@&,@OK,&DC1.%
MZ9\NSVDM,HFT42C0,"3;;O`O<>4&@P]AV*;L'<UAQ,]^%853S-(Y06@AG*`C
MVT!%QX]':\18A5S:+=E85T0ABK4]=8%;(#UFC,(V-E8'ZUJ&O.$N$4\SY"J<
M#>%U'B)3RNJ(`VP8Y90PV1[FWC*?1"<M%U]@*5.(\@?ZJP29D'&J]-7Y8+J,
MMP5`',F8G_[RZ`RY,;\%0#X'9V$$PLN)1_!3;D$,X,XQB-6"(4GX<Y*;;)O?
M*-1C"1K>:'M2P3$G%9NZDRT-S5F++=T@8`@$,)Y9D+!F\Q&VCNT;I6!(NZVY
MV3JR8YS%NGP_O/B@JTN1$2\9DC&!H)S]])=:20@NAB@0`6FHB4;:]\G/NL18
M$$'1P5TA<+]=@.'];5=P\753>$A']-:A7#*=$@<O[+$D3O18]+@%$JG6P]45
MH^A]L[8!]'5G:W)M`4W">Q9FT+R40S*Q1L<0?$@0S4IVT&5MW*.=C@N9-LF[
M@8="%5;Y/O@UHF#79Q+COO.0E!0"FHN&7H-C.]AF7N`\I'Z#@AFC7\!@L<*K
M.P<`]-;87&^O588B,LFQCOG+PE*^RJ&Q[]\;2T%4I<TB+]`YOONB*V_JH`L0
M4RZR[4W-;2#1VI,HR0<@+Z@.8G+=ZBJ8F4<0+:8WXU(2\`*P&L1<R?L55TI]
MA%LHI*P)_MN*[/$"AIUX$EA-TT1P+\@P!)PC+@HG-Q+SN5,8[5*X+<"@2+-A
ML\A.=$38F-R.?J*2F!/]63X3'-U&%?W<LGZE"6]0&@&OR0'`VSFKS_`'4)RJ
M'T"@OE<Q*:.?5EI&W,?"4+HTIO8)^R#?0O31FM7<+&T_SBMO71X;>D.I<D+R
MHP0A@L"ZY'4QF',$(BMYT6IZMC3))\)`X)\E[-2?_O2CVITA2$JQF[V<65A5
MCW.2T3]V%>!ENL_C)U".P7;JV%5+./4@BQG"DMK&2$MY),8U5H6+'\!B+7P7
M7[!1U'$W@*%=;3M1H-LT?M^[^6XSM;J9_>*?PU_FG<!,=A"D,ZEM8Q!I:$<A
M24^Z)`2F!=@7'+/H5J:?LD(=OTB5/P.PZ^>1GZ#2P-UX/?$\<J[DG\L_T-GE
M$"83JR$J,D3+HII?SI8?!O@PT5>+;+N.!MS4H(EWYTRT3DQ-,Q1M(^V)YQ+D
M)*S=AM:LCK87JKQ4!@=6"*)FG289B:R.,'15F\[Q>H8B<85<(+^42"H<98KX
M``F,>VU_Y3%%1)7`Z&OCV1259@Y]PL%?B=N[Z:\GLY*CX2<3LE*R+QZ-5"!'
MTCI?3BM/Q*:7DS9I2>%ABR$Y@SMB)&0^1M"0>$-/C`W5\F^GO(>MMG+AJ/R0
MZ50HK)HL0[[XRVW=C/9]QB5<DI:@A!6-$LB6$1L60S@_NHD>8YIT8)?="G7M
MP(FSBI(DE!&6($LQ2:3D'8Z<]DB6W;1<%\,R68W=7@-BV2NX(03FT"B*:X3[
MM#X=Q.E>6U;YA6>5GS'X(`KT(EYIE,O92]0U&\N./PO78>4M/LD?V-T<^</#
MWOR_'KD-H]\BYN<Z@6A*SSP(+6\+988M@7?*MN0.&U&M+$X2*ZK+(`1V&U,`
MX>Y)*0@M/T[&WYYP?M=*BU$K5B"#B45P@"V]#(G%[HDJZF"?)]38+/;4BWKR
M#5I@7?1C!4M@GX0SI5\@*9?B*?.'/R*=U?/E/$7?(Y<10Z<^Q3T-]]!)M\H_
M]KI"E)X.;*C50)_JD+6HK4&+$]VN(:)!:Z)&?N];OE/H7LJ+8H?V'LRGYHV]
M#D>#\"<Z(<C`P)2I[B\1AVAVZ;T;7`H2RXK>Y9>!].0UC0REV[N`X@YK3*<G
M!W2(ZM)$\F4U&:Z01/7+3F'C5'>72.C;&-M^\31<:)*F+W*UZV4W[+Z3WW2U
MTE'73+Q'$2VT)8>=/U;@2VEUTRCZS1;?X1?;7E]GW%1$PIQ6#,MHFDE%:%V[
MJVE"\6W-8U;*_8>X-6ZG`6+7+'"_>%)-2KF(FKU4A`"ZRIT3ZZ/>`_,G`8/#
M6T+TY&QT_3E[Z]TH96C^*Z7!B:X#&$&J!Q+XBLAD=FAIM5S@>5*FPP^#J.MS
M*V50\$I^#_\O$_/.(CD;HB;(&14#G??->0ZGP>!/3?YY*O$]:$\+G=@=J0(S
M3Y981LM3/#\X>=))6&"!="8.TPCHUDBG7+,JN,86EU/,L@O\AB>)H])5C8JZ
MXAM*LF37Y1U;]9*IQUCCP=ERD)WK.R6:<3[9+(`9E`#-A&7$>4CAX4=(:2T(
M-7Q@G]M!O":-QZ:@VZJY\5HYTZJM%QT]/^4LT,*8!EM0Q^B:%V*+1B"R3>7L
M[_KQ$><#-]0%Z2R)+^@F9(]+'-V8-Y>&B-3CWIW;KIAUS#F<=*XYFOSKG'1^
MO%L\"^=:`DP]#/YDNZ975$BC$>"*5^Y*&/?:Q:?AT#G0C<-EX5I8F/?;@*H(
MWV*8!6>?P<`6:_P#]7$64,26OUY>(F)?Z-Z"0S2WGWYE&H/U_SIKUQW!PU/>
M)A4')V]L>]D,K(L5KZ7C/VZ,#9YXY:]AD6YH$B[&CX>Q02K.(,-?+QT"N*62
MF'5RLL%C,S*[LUD<G!P6CW06=4";7Y$WGBH<[A>VZ1@A:XK;.)C%;[M#II;$
M<%9$]98R%Z$Y]H&J`]`XG!IQ/4YHX$#?CN(\\I\Y\4978\#!BGY%NOZ_P^P6
M62F#(A0!940F!K9Q8?2/5G/"U7[7I%,Z"K1+QYS[?[V]DDM4&*@>X0;B`70#
M%Y,\5K51M?I=L7.'8$L0#C9/1UK9W+WUTMWN;DS!7!\,=F]>'L(#QZAHUBK,
M/,YC4$=EEDS.?8C=8N<N8Q&Z)_&Z=:F&O67EKY'RG7OT%608E`X!&JY5<=<Y
MT'6H!.2'^.5Q++43?`V\"N`F(HC<83?%\COWNV.$Y9]1KRD+J5.(XWTDZMJT
M6I'NJBD(H+B=W4&"9?38I5VG`M)7\6H8;;`&T.9F!?6XWT6>3D=QDOC$#'"7
M,U&&=&$2`.)42'W+,9:.MG/C</?SWUCGO4KG:][$2*+LUD`]_)8*SS='E[:`
M\NP8!&!8=+5-"QD6>3_4VC-IG`=NY581%RYQK*H"I)JMP;N59><(S^YV);G:
M*/#3\@W@74%AF!`-&T32,/>`'=SJ!>@(U[+?0;LH0S+*>VIL6L`6POIP#HA^
MJW*))0AFRW=(X"!RHN%T0D(<?]<P\N*W#Q!@7/_JEB-0R^9<<>$.D@,71Z0F
M\)W,12QB$31'+?8XFMI.I/-\*</#7!5$]3"M>D#*'%JKN)N")^*5T025_F(;
MUS*L"C"@6B4ET1@P4B-%I"5O!/4)Z>J\$=%/%7-,EYM3(+.)ES;*X(?U&(/Y
MQCL\7E"M:#O3F[*I&)J$>;)M[NB?+9?K!6YT=\TCRY.R2GZ`=NT,H6=:IDI<
M?YDMYGJ?X#"9VVYZ1?JUW]P2&!:*]DLF8HEI(0S$=CW<+Y[934<1J(L:],O1
M/+C&IQ>=1D^1N_2P=2WY^ZC+UIV0A#:YMWU7N06ZPTB&I:/]R,Q&"^E>3+!P
MD-7"\1:N#B+-4,'BC<+!_L0"$HQAD'"=2B3I-KIQ.Y@3[CYUU`ARN`C.;;P*
MTGWA@;O[`A<Y&%F&Z_J;_+'#/S"!#O>FH+""(C-`]U=W_M`Z1Q.$_N,.7,DK
M]HYB"V$I'EZ0*#M-Y2CV&=?>:#.E'4$;!4M)/\N+=5M*M!K5MA.FF4X.Q_E^
MJC&M5".E2VQ,.<GF.^UXY#&U[_.[@B31:>]S9)+/>+]-^-:(%SZX5E&T$<T?
M?70L/QYRN[#H/\?`:NX]2UTGZ)5YS^O'3[K?B["H#F>%1D(A+SME5GW?L#A`
M:H^[SM/+;CWY20L&MU_1=X_@T@TGPDC]^A5Q:HC[V@T/:%P"&Y"H'XEWO-!^
M^"7I+VXWZ/^FD,*X)\K8XX5>6\'(H_U[#_Z6]Z`]!HVGP3J7GKT4J_27L7Y\
MT+-&\_(["C@]4D]KA<E$RE"')`43"B&MSGLB,,,!PXT9>ZO24_G<1AG7S8J"
MFP$G$4:Q#U5\W7Y_XIHMH`@JU?`$VY8O81O%A^V69^3N<4PP<$VH1,P;/6^/
M/+SP\S/FT%_1[&D')F_G7C3X#;M^C6'Q1)'4F9\;,5[%/(>KP(*-S()D;85M
MP)AVG"`DF8D(=L\3^-DT6!5QT#"*FY(VI3;8BNE"P34LT$F44L<:"]?[8C-(
M8&U9J::0,E?"`P]RLNY0Q1T^19/_Y*6V@T\%^>.[XZWOY8]5A3$,X9)IRXX^
MYN_]_)?_F3^Z8HU=M6$H-7^7_>M]0N40I,XNX`8DIZ550MW&4J.]QF1"TJVV
MVYGO@4K)/F+(YR57FTL-V#''0<@;*.+;V"+PP)&"3X!<%:2A&,"S(4(+AZ$4
MO$\[Q%B4E)I80%T:Q!_=N;O[Z/Z]HM%=./"=8A/@S!>C%W2Z946!"^WUKOD\
MW=1VFY"UB`E%#Y+4G$7=`Y[&$[MN@-?V&:`EI4ZZ\(:\F><(VO2%QYPX@<`=
MI:@$@_#9#6MW]A_%"]:$T0D=&('::W$&FO"99T2/\#O8>X+PQWA_`TIW=A>#
M*2+'`@NBNC-SM;Q&\$2Y/D][I[+1[?P@''ZC\:6+PM::LK%4A);WE".A$Y75
M6.`U9"AD92W9Y!$;R^2\K4ESXP$;P53J(YW"]]H>>3;3EFU]I.<BA,'=G,=Z
M76?]W;D_OJ).US3QK@^Z&W37P51(";0PV2+[+-2G%=YUX!UYG0HBMF/:79,&
M,(\,+!;1.L8F5*7HZ.8IKDRH?(E\%>@1)@>FM:B737(2,KF6P8NW;**E0X=7
M].11!H31;[^B^H^_(U?&14OA4Z%2>Y#!,MZA%$*A.%B3:[*\$":>D<&:A`HU
MQ8-$G`1O(98=2/39*[U+C)#E0@>1R#UP:0S;AD)@D`M:!X+1V9UT4-[I[H+:
M)INWD&D+^NY2.\Y!J+DOR7=W;X/U^)14RH=IC<[V*1204F0@\/;Z\G3_)%Z;
M7X'I_C.H2<Z[K.R&OSQJV5+=59/GI8(T:,A?8;':#VH2N4;73F\I?Q>O<W<O
MBB>HO^!EL`JQQ_W]!_\E3C&?4TC_&;CNI/JW[8MQ=+2-4HVQWYH(&'?#V665
MX$UB82*60A"QAK"/&J#K)9N1+KB4W?B\^XDL6+$G.0:$.D6<W<*$($HC[#%@
MS1&[YYPQ4'PCVBG4N$6U%^Z7Z.N_9R?'QS%S=4HBG:1RJY%Z=B6%!5[#*U$A
M>9[=Q`JX%U@(6O2I=>\13-Y^*RVGE:Q?DNF6*IK:;RX33H^_I3BH1]=,'RT)
MFH8RY*A1:&;EI7?^CJ)AELU+4^_UOWZ7[>@V&=)ZNIS3YY)'5_%(QA8YO"7&
MIR`@GRN$5B=6A;0=BWR^S^W>7@VEV$VHXF$-S&UKT9.X?N`CV06R'.3U5"\*
M@"*@8+XH6K;"$`GJ:$V)Z2S\$\XS7?W%I:BS(N5ZGI#?/\9!FW8AX(AR6.&7
M5GR3$?>&D\\IOG-7,OTP?QS"`*TOL7.?^XN_&+A=@\\[117>:O6\ZVVO4/MC
MQM[)O^534'EG^CBDU<.UA,N;/+EZ_Q@N%9[EK^[<WO_\T>`AP>@[`__01TD%
M2C?9G7:K\0_"JO^.=7;1>6%:%"V.5,K]?[*F)*GRC>+N&@Q6))Y$DP*05]33
M*7'EZ!=^;.\(TB<LN!#PPYX7Q85+@C28U&'9[-6"#E8=QWO^LU>"AJ?V!;>V
M%)&*81U'YIRZXDI!.;B+:'J&V?^RFCC?O[]W,5Q?SUY3_-?;#4(]HF@%9='E
M^G.PHDZI+OE)OWH^G9MT24KJ.RKMH6(:!)]>6OK>(I/Q%J\>`^6:X!653N%B
M*V>*#240`T_\Y,;7DQ<[\7LS`_4;KCW-9T!$1U$`]\)$KD-"**3QE=4>M%68
M7OQZJ#_DQ0=9R!L>=^\I4KM+!3)W96SSIE``K,UY6/7[M,WWYNT^A@:OK3Y_
M2($)5SJ3I]8JGU'THS-#NNU<7[5#^?+W83?($8K8\XELRP,4.UN&)41L"8%8
M%&\KM7AX<1@2`N.AP9&`=3Z9;8'`;7-1(I]`'V&!HW0E0D.8JSVKU>D1G?(J
M!6EEG0:,*2AQ=<7X5JIT]E-4[Z"EUMH^#976:9CCB.ER.G1Z.^[4;UL'4N(G
M[1T)SWKBGHT=1S3@>.7GS9_K.R@6GQ#C;ODN5+''A99(DX?]CSI?=]EYRH6=
M]?;/].+NO8Z'-!*RLUE]]`=9[Q3$F-<7#:5X!$-RRN%QIZ^D#[#9L7\P+W[V
MHOC3UPI@'NE2HL%'Q!()L$CMYZ84RLJ'1#O<\,-]V+KPY8WX`8ATAB:YB7;,
M-Q^"_<X^V;'U2V%MTY!<C4-M"X5YY&$PXLUU]"]FBCMWK]S*:[Y[<>7N_;%_
M]7F^NF_2;<)M4#W<B9TW-=L@F;"D;A<P(2]^>:5;X_Q%/WD$DA:O$@B0OYNW
M.4JWW%E`9W#A6-[^A6Y-VLRW;G[/4&FN9J@Z1_5P*=)]C7GG][Q2)7_\0G<Z
M73'F@_'7T&TRQ*J9C3BZ/?(9SW=>>_`UGTQ',5[''GL%Y_=^@8$LKM-ESU+X
MR?.>P2T?,;D'?GV!T.S+,QF?>,85XN!18)]U)\%56J@')[K57=N^??@'_QJ*
M&>7LDOUMKVQ%`'LJ,[B9K;^6:%E/5L3@H,'!PA4?:K]B?B.0XOJ9^+=K&YN"
M=:`[HK<'53H(HIO%QA;^E>BC,U,L6I8U32*^VP$M<0=WBS<G3XM/!HBP,]5`
MU0,45[=`($&CEUTPI%;?+#E"'E/8AHZN9$SO'W<NG?W-134DF=-"\M^!*ML3
MMS=!&ENRF=<129%GPO<()0FW37Y0)YWIR:?;_'`V`/O7S"#OPJ`E#DJ;G[Z2
MQ.WYTSS?B]K,^][:6(Y[WO@>&5:S2_D/K_/\K4<G+56;MY4?1%H[R[I>OW%Y
M/^0C]HN81<M_=(@XIEIUWV/X*M^3#ST5')*VQ8'.KU])8<N=6IXQ,DT^OI@4
M[>W.;$BS>4ENN,(EXK;\Q38YMZWKCH'$@9MT!W)(9CJ\FUX9I)CR05M8T^LN
M./I7)FWRKEHC9X&BXVZ.9:M(M^.'(2/%\MX[7D1H.8Y"DZ<$Q`I[+)?>:66>
M+OS6P03\\K&N5T<+CRO5ORHZ>TTD]F/7]RLY@XD&^3Y=%__9R@D'*#F+,WV,
MMSJ6Z[C"0^L2(XV%BR50KI+Z?B`,B>BRAKU`B"2P7T?,<AH`P49B6B,K_ZQI
MUH__KP````#__P,`4$L#!!0`!@`(````(0#;^W5(``T``+Y\```-````>&PO
M<W1Y;&5S+GAM;-Q=>V_;R!'_OT"_`\&T10^HK1=E2S[+AU@QVP!I>KBX:(%>
M4=`29?/"ATI1B7U%OWMGEJ]9/I?42NMKC$`2)<[\YCT[?%U_]^RYVA<[W#F!
MO]!'YT-=L_U5L';\QX7^UWOS;*9KN\CRUY8;^/9"?[%W^G<WO_[5]2YZ<>U/
M3[8=:4#"WRWTIRC:7@T&N]63[5F[\V!K^_#-)@@]*X*/X>-@MPUM:[W#G3QW
M,!X.+P:>Y?AZ3.'*6XD0\:SP\WY[M@J\K14Y#X[K1"^,EJYYJZOWCWX06@\N
M0'T>&=8JI<T^E,A[SBH,=L$F.@=R@V"S<59V&>5\,!\`I9MK?^^97K335L'>
MCQ;Z.-NDQ=^\7R_T"UV+15X&:P#QNW_O@^C;W\0O;_[PYLWP7]]\^X\?[/4_
M?_Q]^;L?O]$'*1M"$VS03/-\V$@6OHXI#Q();JXW@9\+,@'03$%7G_W@JV_B
M=^`,(![^[.9Z][/VQ7)ARPCAK0(W"+4(K`SRL2V^Y=GQ+Y:6ZSR$#OYL8WF.
M^Q)O'N,&YAC)[SP'S(0;!S&'T_)Y0#2I3#.$P<DTP2U4)@]$LG!CLTS63Q4R
M<;RF[;P.T1_'BTG1+)<T7F6_*.GP$%Z9K0B?\/%AH9LFY)#1<(AJI08[$K/Y
M<@C\3L;L8GHRR2;FQ+R4*AGGBV6[(<.)*5.5+0S-MY?O3J9.^<SJI$O2\*DB
M``-.KA8="-V&^+XT\>\4?G+B@B;58IQW,,I<XF?AE^?'>\>S=]I'^ZOV0^!9
M/BJ7%C;VZ^JZ+)\T(N=<0#Z+U+LFY^7R6]",G/;%.!6C<NM2D*>WI>?H%%)]
MB+KH\7"/B/LD'4)5RNJLER.[*%5.J^KE..G\?-(:#IW5E(;:B61H%4".JMCJ
M16HPI'HJ]^B%`)8C@-$6S7+8L/ZQ24]]V;!BM(,JY;ANMOH&]XVWW%S#(""R
M0]^$K[7D_?W+%E:G/LPL4/8![MGZZ\?0>AF-F5.)[;`+7&>-*!Z7;$V<9)SE
MQ9VYO&-\"3)1%#5$37-Y>02B=[?SI7RDRSG+``.)XH]-^).,].T4_R03->'?
M4II.DZZ41;`,=6;TM,C!&=;P_'(^G\]&%[/9;&Y,1H;!E/R0>+3CK^UG&\=:
MTM141C`%!//);'XQ!B!#8\98G13!!`!<3J>SZ6@^-N`_R\+'1R!;IU-=M54)
M`D56)0@4696508FQ"L-9Q;%*$"BR*D&@R*J7LLI$DO\NE5N5(%!D58)`D579
M2E1BK,*1&L6Q2A`HLBI!H,BJTIK/)%;GRJU*$"BR*D%P:JMF@QQLK3$-ESLS
M:?UQNH2#J9')FO@NO-BJ$=:I#T&XAD/JZ7'B$:Y4XVTWUZZ]B4"$T'E\PM<H
MV*)`013!`>B;Z[5C/0:^Y<+;0;I'^MJP)QRBAZ/Q"SUZ<E:?@1FW"(]U$[,X
M%H<LZQFXFC`NC>&E,1U?Q`LV2:P]>^WLO;)T&>]*OP0UHF[;!2<Z]#,FB3OD
M1R$&:(7$?()[,%,S2PON`#Z1NH3@'C)DS(_(B<I(]A"3D>P@*"/90U1&")VJ
MX$HUN0[V<'9(T<"F.1L.V:JOL[]4$R3`*SRF=9^R/EMWJ=!HZSZB.DV5!_FE
M%!NW8_QCW7&%I"U[E.5LV:%"RI8]1&7D_:92XFQT@>FY`DE!W]S/^\$`1O&.
ME7B2[(2'9..#LL+.*R!LF7B%Q%6Z5P`'Q.E6.07562%QP<9E+?4S=`JHE3R!
M5"-UTCA`'[*R7?<3=@9_WV3-",SW;JZ?-^3L,CCE#T^_PI/7\"U,RI.W<>,1
M?P!>=3N-:W?2K.W6??FX]Q[LT&3G`3(6;"L.Z_-/MZQCRC^_=9U'W[/9A%*/
MR7P?!I&]BMAYBNPH7QV>20V>44)(!,\A_(T:_J`G87T<PA\F8)5&!+THY0_.
M)<Q?IC_`["C5!YB`.G43'ID(8,Z1(@`CJ$"`9Y`F@0WNJ0(!K!]3!."@.0*`
MT^`5A\0!G`N0L00?R%D"_V.QA!R32LFQ/**4=>D7^#=(:7+I]R`UDWP+CIZK
M&3XT`#B(95V*595BB-DATG(5P(<&%9A0=>64/)@P9'X'.L@!*%,(2;H<($@#
M31J1YY4DYP)/48W<2NQ#B%-@*E(-`>`H@4`,,5)4?T<4@Z(*3+U!40FF$+@:
MW)PEI,8$M017(15A`#Q*HB+/UR.N8IQ0#02"J@Q)O&&L*D52#*IR9&Z*L:H4
M22"HRI#4$JI2),6@*D<24ZA*D00":$1)AJ264)4B*095.3(WQ415BB005&5(
M8HG)D5/D@(Y-XR$JF9_.\;+8NM$C&"A=_A=M];QI':2.ZA9-0"O=/5X]Q2M'
ML`5;2Y&E-(*STMFI]A2$SL^PR,1K=U<P3+5#':_UCIP5W?(UM+;W]C,L1>,#
M8,^;@P1LP93SATFVKG5A+ET_!V`1L'2+(EHE9XOZUL%\P3/XX7:KA[2"P.&.
M:@RHZP2#=!>0%"(8N:K5!$52.09J*L23S)QA,]=#],IFK;Y*F4.U5L8<ES+J
MF$/,*V,N+'AMR3H@)8]DV_P`+&,R%#^Y\^,:4JH+_&(50:PP*:YJFW*0R>;0
MAU=/DI'@NK+,*,?`4E7(NF3,@_$UG2%P9#L<XI\*S/**X?+0P*2#IM5`O<_@
MI%\\P-()<VO`53DY#[G;@H*T*)/BQ$D<?FTQZQ)_M'KQ6/KJLB$@Y3-K6>Q0
MP[%S_MCY@DV^50\1DJJ(;7J)+TB[@[3INKNW+RBN6YP=^F`1M4,?VAWL(.9U
M8S*">8U5FK/&Z\U8G<(HS_Y%5\&V(5WXD^:^D!Y+S*IG("90PA%7[#-\AY=#
M.*Y''<%B-+,>G&LX?'C2@DBBC55V1!5R3G_D-(&GL/-320VO@4?7B<]Q%ZY9
M'%"X<V(O78I&1`NS5Q41]>;LJR7Y0:M@5="E06AHO(\?M'VR3`/@GI'1P>8I
MX`-6"J!5L8F*G+4`69<`YP=V4EIR4GY31I;"7.GTDN:&TTLN>V[6*:2A]HJY
M&-_(]+>Y6'=56LC_4FI)ST18K+@8^54]*%]Q>S+KD,3$UB\T?@IM,@!NRAUU
M#7%1'V)>4V+VJKRFH1H=WY`2JM&8+(8`\.'U@:^,8/+RV*_.[K"]@7]WL]?F
M,[K0.308.EE9(J*QTL*.)DP.R+[&V08]9G8J?+SC=QL>DR`LI-J>+6TQU8*7
M5I8>?I7>D]EQ2P^7%4;PZ9BEIX59]QST?S++B+-D?Z=NT2O?A];U#R?T,_E9
M/:W571IYK@7C50B!*R,.ZO*"%&;2[85GK:9E!]XV-`N\0]66W2[&&$-V5,9\
MHI(YYX9\Q0`_Z>.&<CP#F%<6M1;G59_$ZX!SNBVEH.ZX:_U>9@-\VF/*):WP
MD5Y7.HK]D)`%RI)U-X'L^B\&O*0E]<`!4F6P-OM\M76+UB2TN:.N?6AW2$U]
M2CJN1BJK2-LALMR1&J3'ZQDJJ9<<@E=L;:+H4B!QY:*..3G,`L*>H#5@]X10
M<*(VNZ8$KB(A]^3A[\B377.BX7-:X&#C\+?:F?9VA>Z:K?"PIC_L'1=N,8I'
M`["S6NUW<'>[VWAC<@5'$ZULG(NK;4H+_*`K+:`0]Q%CO$:,X((I1U=:P#ZF
MA4T3H06W*^I,"[PJH07O*"TXN:,K+M@EH<7K?BJH>Z/*CNQ:5Z(O$%D$%Z65
MVQ'S):$%(G>EE=L1#$=I@<A=:>5V!(2$E@%,NM+*[0A6H+3`W;K2RNQH8*+)
M]345U/U%I1UY7\5$+H*+TLKMR/LJ/I*Q*ZW<CKROHLA=:>5V!*I$7P9\T956
M;D<^3QB">8+J*[<CK_NIH.Z+&97W>!RLBT@74\EM!^^(CK!=$*>26XWW\HF@
ME\=8<GOQ_FT(^G=,);<4T",2&?"%N$29C2:\=@U![=Y:ZS3K\@Z#=48$!CQG
M9K5WX>FP`3Y;EEUXB:>6$('P$@DA2D_VZK.VA/OH983X>,`R*D+H[GGK6KX5
M!>&+AA=;9N1XHT\%R?TQ"#(=\12PEQ8!]"=X$B\\Y%<#O<0:XGT8+[3K0B:+
M!5X]>.>5+F1@[Q@-[W]XCXPN9&#OF`R?5+%_$B'SWM_N,POQN11+MPB)#X[_
MV5[SGL-K>`P@12A]M/=1:&7^QX<4'E`2(H)W7\QH\"DB?F1:>JO(I/_\"#=;
M3)6(%Z*2V,$>6H3G7_8142/N18C@8$Z$R+T3P=UZTR#F2"`L(1(!7`"=D2AD
M%$$:?[-"'Z.%"]V"C]9(E%].#MW_^CF_$R?3>X3/JF;WZ,S6`Z"HM;VQ]FYT
MGWVYT//W?V;WP09G2G[UO?,EB!B)A9Z__X`W&(<HAH4GI)L/.[AI-;QJ^]!9
MZ/^YN[V<O[LSQV>SX>WLS)C8T[/Y]/;=V=18WKY[9\Z'X^'ROZ`R?+#W%3P9
M^H`'9[,'?,,%Y2/C:N?"X[7#1-@$_*=\VT(G'V+X["H!@`T'I%,A!KOLP>,W
M_P,``/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL``!,```!X;"]T:&5M
M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9
MEEA3HD#227T;VN.``<.Z89<!N^TP;"O0`KMTGR9;AZT#^A7V2$JR&,M+T@8;
MUM6'1")_?/_?XR-U]=J#B*%#(B3E<=NK7:YZB,0^'],X:'MWAOU+&QZ2"L=C
MS'A,VMZ<2._:UOOO7<6;*B010;`^EINX[85*)9N5BO1A&,O+/"$QS$VXB+""
M5Q%4Q@(?`=V(5=:JU68EPC3V4(PC('M[,J$^04--TMO*B/<8O,9*Z@&?B8$F
M39P5!CN>UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B
M;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[6<G@%@WP=-K2Q%
MFO7^1JV3T2R`[.,R[6ZU4:V[^`+]]2696YU.I]%*9;%$#<@^UI?P&]5F?7O-
MP1N0Q3>6\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV%
M;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT`
M;Q)<F+%#OEP:TKR0]`5-5-O[,,&0$0MZKYY__^KY4_3J^9/CA\^.'_YT_.C1
M\<,?+2UGX2Z.@^+"E]]^]N?7'Z,_GG[S\O$7Y7A9Q/_ZPR>__/QY.1`R:"'1
MBR^?_/;LR8NO/OW]N\<E\&V!1T7XD$9$HEOD"!WP"'0SAG$E)R-QOA7#$%-G
M!0Z!=@GIG@H=X*TY9F6X#G&-=U=`\2@#7I_==V0=A&*F:`GG&V'D`/<X9QTN
M2@UP0_,J6'@XBX-RYF)6Q!U@?%C&NXMCQ[6]60)5,PM*Q_;=D#AB[C,<*QR0
MF"BDY_B4D!+M[E'JV'6/^H)+/E'H'D4=3$M-,J0C)Y`6BW9I!'Z9E^D,KG9L
MLW<7=3@KTWJ''+I(2`C,2H0?$N:8\3J>*1R5D1SBB!4-?A.KL$S(P5SX15Q/
M*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2
MAAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF)
M$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[
M#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9>$\H
M8P,U9^2F-+VWA`UHW(=!O<X<.DE^$$M">-29#`P<7""P68,$5Q]1%0Y"G$#?
M7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-5
M8,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B<R\'DN6HPF%L3
M.AL$_1!8N0G'?LT:SCN8D;&VN_51YA;CA8MTD0SQF*0^TGHO^ZAFG)3%RI(B
M6@\;#/KL>(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1
MVVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[
M8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T
M74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY
M;6TSY1;G-.F*EV(&9\<Q2T*<EEN=HEDF6[@I2+D,YJT@'NA6*KM1[ORJF)2_
M(%6*8?P_4T7O)W`%L3[6'O#A=EA@I#.E[7&A0@Y5*`FIWQ?0.)C:`=$"5[PP
M#4$%=]3FOR"'^K_-.4O#I#6<)-4!#9"@L!^I4!"R#V7)1-\IQ&KIWF5)LI20
MB:B"N#*Q8H_((6%#70.;>F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G>
M:W/@G^Y\;#*#4FX=-@U-9O]<Q+P]6.RJ=KU9GNV]147TQ*+-JF=9`<P*6T$K
M3?O7%.&<6ZVM6$L:KS4RX<"+RQK#8-X0)7"1A/0?V/^H\)G]X*$WU"$_@-J*
MX/N%)@9A`U%]R38>2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"VENPL
M_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%]</0.
M?#:8,25-,,&G*H&AAQZ8/(#DMQS-TJV_````__\#`%!+`P04``8`"````"$`
M.S&@5,<#``"D#```&0```'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6R45UUO
MHS@4?1]I_P/R>_F&-%'(J*'JSDBSTFJU'\\$G`05,,).T_[[N1<#M4VV0U]"
M,,?'Q^=>7R[;KZ]U9;W0CI>L28AGN\2B3<Z*LCDEY)^_G^[NB<5%UA19Q1J:
MD#?*R=?=;U^V5]8]\S.EP@*&AB?D+$2[<1R>GVF=<9NUM($G1];5F8#;[N3P
MMJ-9T4^J*\=WW=BIL[(ADF'3+>%@QV.9TT>67VK:"$G2T2H3H)^?RY:/;'6^
MA*[.NN=+>Y>SN@6*0UF5XJTG)5:=;[Z?&M9EAPKV_>J%63YR]S<S^KK,.\;9
M4=A`YTBA\SVOG;4#3+MM4<(.T':KH\>$/'B;U(N)L]OV!OU;TBM7_EO\S*Z_
M=V7QHVPHN`UQP@@<&'M&Z/<"AV"R,YO]U$?@S\XJZ#&[5.(O=OU&R]-90+@C
MV!%N;%.\/5*>@Z-`8_L1,N6L`@'P:]4EI@8XDKWVUVM9B'-"@MB.5F[@`=PZ
M4"Z>2J0D5G[A@M7_29`W4$D2?R"!ZT#BK>V5YZZ#U7*28""!ZT@2VZ$?K>X7
M2''DMGJ7'C.1[;8=NUJ0>B"<MQDFLK<!YM$>N9G)L/_S"XQ"D@=D2<B*6&`%
MAR"_[/PPVCHO$)A\P.PE!GXGC*<CTCG"#^,)XX#B238XJ<J^'<U1'8)1'487
MY>[E@"K%GY;I$>DXY5VL'TP030F8MEP)@C4E<D!3XINV*).TE4-]90Q=`.?C
M8R]P$N"4*/CA:MJ9M$=BPLFO5!G0%$#R+M\[@A,"QD[Q#PW7]Q)RWR?0G1<$
M?AR[KJNK2W60!\F_5D&:P/@S`A&L"_3#>WWQO<3$,L6EO)E`B>GMT\3`\5CN
M%H)-,6M#C,2$O1@S:<9G6!O5@X/O->.\_SII<)(A)C+"LI<8R)0IO'YDBAHQ
MIJBU+NKC#$:P*<9,)(F1B60(36\_TTSRX!BI+GTLJ$>;BMZKA3Q3`T@Y5.J(
MOCK6P4_'R)/5\^.3/8!4%7+:/%L]+(&?5R$+IWK*_2@T\K:G3HB>*\;K(IU`
M9K)X6`\58;\(CJR>NJ#WE\H0'`E2;5%&].!@+5167U9U/5E!@?3]=,S*[@!2
M5<AI-X)C5-Z%*N8E^$9P)$@/CO&&2+&#@D-X0YA1<1<*NU%Z([/T0I>(:Z[=
MOMZY]BQA9G57-H6RW:EI=Z(IK2INY>R"#9\//-/HU(P^!/C:,\93?Y/VX\[T
M`'K$-CO1/[+N5#;<JN@1*%T;^[E.=IGR1K"V;[(.3$!WV/\]P]<`A38$MD"L
M(V-BO,%,G[XO=C\!``#__P,`4$L#!!0`!@`(````(0#A.$;C"P,``.0(```9
M````>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;)16R6[;,!"]%^@_$+S'6FS+
M"RP'L8.T`5J@*+J<:8F2B$BB0-)Q\O<=DI9"VEG<BRUQ'A_?S!MIM+I^:FKT
M2(5DO$UQ-`HQHFW&<]:6*?[]Z^YJCI%4I,U)S5N:XF<J\?7Z\Z?5@8L'65&J
M$#"T,L654MTR"&16T8;($>]H"Y&"BX8HN!5E(#M!26XV-740AV$2-(2UV#(L
MQ24<O"A81F]YMF]HJRR)H#51H%]6K),]6Y-=0M<0\;#OKC+>=$"Q8S53SX84
MHR9;WI<M%V170]Y/T81D/;>Y.:-O6":XY(4:`5U@A9[GO`@6`3"M5SF##'39
MD:!%BF^BY38*<;!>F0+]8?0@G6LD*W[X(EC^C;44J@T^:0=VG#]HZ'VNEV!S
M<+;[SCCP0Z"<%F1?JY_\\)6RLE)@]Q0RTHDM\^=;*C.H*-",XJEFRG@-`N`7
M-4RW!E2$/)G_`\M5E>)Q,IK.PG$$<+2C4MTQ38E1MI>*-W\M*#I269+X2#(&
M]<=X?"E)8`69_&Z)(NN5X`<$30-'RH[H%HR60-PG9F4,J;Z5*:2H26XTB^&"
M)"38\[B.IXM5\`@ES8Z8C<7,,!HPD8_8]@CM!,@;-$+BIQK'8.'KQ>\EZ4TG
MDF+_O,TK$!^Q/4=,9P/$TPBU.]4X>;-!>HUZ$[2"4Y(X"0=^4]J-Q4Q,)^A:
M;YT%3\'$5_!^=30XQ9#>8,9L>G*PA<R-F]%B/O?#6S<\B9,AZFF""KA5>5^3
M!ON:XN2D1386XU3#6?!.3OR3=5]_[(?>])$?%N,H<!8\!=#IE^>NP7[N9WY8
MR,3XD823H>"F3;9N-(I?HIXD/8Z<A_U].S38EQ0GIT^0Q3C%<!:\DQ?^R9?9
MH3=]9(?%.`J<!4\!C(?_2-Z@_>S/##EBCD_(>/Y2=&N)%Q^'+[6SNNRPL2_C
MAHJ2;FE=2Y3QO1XD$?@\K-HAM]%#SHRI(0`SIB,E_4Y$R5J):EK`UG`T@Z="
MV"EE;Q3OS+MPQQ5,%W-9P=<$A?=).`)PP;GJ;_3;=_@^6?\#``#__P,`4$L#
M!!0`!@`(````(0!6-E=(60<``!,>```9````>&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;*R96X^C-A2`WROU/R#>-V!R(]%D5A/NTE:JJFW[S!"2H$E"!,S.
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M4TU%?8()P%_K7-'4`(_DWS>V!P-7N^ZXL:>+R7SI3@F(6Z]EV\4556E;Q7O;
MU>>_F1#AJIB2*5<"3ZYD-ED2=S5=@HX[_6:\'SQY/\^5@]_I"&K[6<-3#'AW
MH`67AZ<8:#8A,W=!C;PSSI+W@Z<8YR'#8'7U\X.G&.\QPU:\(SS%@&,3=%@4
M^Z0(\RY_?FKJ#PM6&L2IO>9TW9(UZ!#9P$P<\N-6>D!>4"4O5,O&!J,A\BWD
M]+=G;SI]<KY!'A9<9HMEB"X1"`F:=%1M:(+(!+$)$A.D)L@4X(`3!D]`0O\/
MGJ!:J">$#5L!%-<89@L)T24T062"V`2)"5(39`K0S(8EJ)H]O@V(.%-A6/!J
MG%TSSDQF)ET0(!(B$B$2(Y(@DB*2J42S$[8,U4Z:Z-Y\,JSFAU.=ZH'%`@\E
MUV=Z2+=,:`Z;LQ1RY[I0,`@-@4<D0B1&)$$D1213B>86<(#JEOOAI\*][6+&
M6T:6LR'?`T1"1")$8D021%)$,I5H5L&V_;A55%BWBI.5M(J1&;AQ""B9&YD?
M#D+"/1$B,2()(BDB&2->?XAJAL*6^[BA5%@WE!/%4$9FX%G%4".]PT%H,!21
M&)$$D121C)$10VGYJ9Q3]_.4"NN&,N)Y,J*,S!;LM'*)L3K#H7VPD>N0N1YS
MPLHD>F(E0Z_^#'2)X;ET:!=:,U6K%EHXC56+^PT+W-,=J^)M6T-TX"`;<<,4
M#&*',E6@>X&1J1I<SUT8VQ(3FD/**1E@"(5,:$GG,YSX[E+7%#$A#QZ*D*\+
MQ4QHZ@^121BY/X&4"1D36.FZ,R9T<P*:NPELUJ:_R7Q""]+>Y5_KZRV70TTH
M?-YKT9W.T13")=U`7'VJ`9=:R@P-!?)9BBY]LU,D5,M.L4`R2Q.A1TJE`@VJ
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M)1BE&&4:TAU$RT4E,7ZR#['B$OPM9KXE#"G1#C`*,8HPBC%*,$HQRC2DVT>K
MQ,?MH]+&D<R14O<2AGY2^$HIX:L(HQBC!*,4HXRCD?*7T#+Q<9-94:F%E->9
ML@@(>IT;^W8)+`6DM6JYVA\T,9>"DTU();+CC3)8"H@^F5`S<L;0,NYQVUG1
MI]G.D'&L&EM[0(9J4<PIY&BYXF7&@JP6QL*/<+>8([6FQ5*IH9SXOK\RCJY,
MZZ:M`<\H5^^O\5Y:7P,<&2>L44$'0DJF3<C1PNV=0OSY')VEN%<LD-QE$H&D
M[E0@./V'0YBLC%HY$U*X.(65\R]2I9<VO,*+.^7K%9?R)0HQBC"*,4HP2C'*
M-*1'G99K#R\%>-TU=SZ._`5=K+IJHY+[24+AD@TN+>AHOGR3"S`*,8HPBC%*
M,$HQHC<G<A+,/G83PCYZG\OF4`;EZ=1:1?U.;SF\):3Q@-D5S':^AD]+X""3
MD]F:UB6XY87,UR\P-FZ!\@'ZC&M;0$L?"',<C]X!]>4]:IF*VR&C)2/0!^IT
M/(.`+-?TL!EK\=<A[+NX!79PZ#/6`M=3+V.C;.GP(YJV'DQXC(,A8_YZF:U?
M1EV\!=^/N3Y8K.&#&38A`*M'C0:;QPQ+P.(Q'H!C@U''AM`2CK9$T$)?P/"L
MX"5T'8^V)-"2C+;`*RD$H]?F#%&'*[EK?BA_RYM#=6FM4[F'9';[%Z^&7>JQ
M'QW_;/%:=W`9!YL=W/'`Y6L)'ZO@@LFV]G7=B1\P76>XSGW^!P``__\#`%!+
M`P04``8`"````"$`;X)??M,"```@"```&0```'AL+W=O<FMS:&5E=',O<VAE
M970Q."YX;6R45<ENVS`0O1?H/Q"\1[L7&9:#V$':`"U0%%W.M$191"11(.DX
M^?L.25O6XB:.#[9)OGE\;V9(+F]?JA(]4R$9KQ/L.QY&M$YYQNI=@G__>KB9
M8R05J3-2\IHF^)5*?+OZ_&EYX.))%I0J!`RU3'"A5+-P79D6M"+2X0VM827G
MHB(*AF+GRD90DIF@JG0#SYNZ%6$UM@P+<0T'SW.6TGN>[BM:*TLB:$D4Z)<%
M:^2)K4JOH:N(>-HW-RFO&J#8LI*I5T.*494N'G<U%V1;@N\7/R+IB=L,1O05
M2P67/%<.T+E6Z-AS[,8N,*V6&0,'.NU(T#S!=_YB$V-WM33Y^</H07;^(UGP
MPQ?!LF^LII!L*),NP);S)PU]S/04!+NCZ`=3@!\"930G^U+]Y(>OE.T*!=6>
M@"'M:Y&]WE.90D*!Q@DFFBGE)0B`;U0QW1F0$/)B?@\L4T6"PZDSF7FA#W"T
MI5(],$V)4;J7BE=_+<@_4EF2X$@2@OKC^L2)@LEL?@6+:Q49@_=$D=52\`."
MIH$]94-T"_H+8-;.HO\Z`TLZYDX'F5!`2ZC&\RH(ITOW&5*8'C'K,<;O(S9C
M1!#.6XP+`EN5X'VH,H0J7L[_2:4.&JJ<M?S&R?H"IH_87$"$<8OIJ83\=56^
MK4Z#H0\P.N<P\EI>J\YB(M,&.O&;SD1OY^@C.VMP@L%79^=!;=86,S&U#>-9
M'/25;>RZ4=83`JW33<%U[:2#AH(&&ZXM9FX$S;W`.S>*2=7&KH\%3?N"WJZ)
M!@^%A'WG:XOIU*0ST4O%[",[:_![W6`QG9T[$[V=]:LS.-/OGQ8=-/0>#;Q;
M3$>!G9B:JD2Q^;0A/4GQ6-+[UXP.&DH:]H7%="39B7.CG,^4%60O>7L'-F1'
MOQ.Q8[5$)<WA/'C.##I)V"O>#A1OS"VRY0JN9O.W@)>8PGGT'`#GG*O30#\B
M[=N^^@<``/__`P!02P,$%``&``@````A``NCS;M%!P``51T``!@```!X;"]W
M;W)K<VAE971S+W-H965T."YX;6RL6=MNXS80?2_0?Q#TOK:IBV4;21;174`+
M%,6V?59D.1;6M@Q)V>S^?8<B*5[&R2I%7]:;H^$AY\R0/+;N/G\_GZQO==<W
M[>7>)HN5;=67JMTWE^=[^Z\OZ:>-;?5#>=F7I_92W]L_ZM[^_/#K+W>O;?>U
M/];U8`'#I;^WC\-PW2V7?76LSV6_:*_U!9X<VNY<#O!G][SLKUU=[L=!Y]/2
M6:W6RW/97&S&L.OF<+2'0U/5<5N]G.O+P$BZ^E0.L/[^V%Q[P7:NYM"=R^[K
MR_53U9ZO0/'4G)KAQTAJ6^=J5SQ?VJY\.D'>WXE75H)[_`/1GYNJ:_OV,"R`
M;LD6BG/>+K=+8'JXVS>0`97=ZNK#O?U(=H7CVLN'NU&@OYOZM5?^;_7']C7K
MFOUOS:4&M:%.M`)/;?N5AA9["L'@)1J=CA7XH[/V]:%\.0U_MJ]YW3P?!RBW
M#QG1Q';['W'=5Z`HT"P<GS)5[0D6`/]:YX:V!BA2?A\_7YO]<+RWW?7"#U8N
M@7#KJ>Z'M*&4ME6]]$-[_H<%$4[%2!Q.`I^<Q%DM/,</-A]A<3D+?/[WI7B<
M!#XYB;?8^+ZWW@3S\PDX"7R*E;R;/VRF443XY/'!(B"KK4OGQ+HM60W&DL;E
M4#[<=>VK!?L$5.ZO)=UU9+>U+5%+QC!5]ZWB0E4IR2-EN;=A[5"W'CKRVP-9
M!W?+;]!%%8\);\3H$9&(H"U#:6,32$P@-8',!'(3*!1@"2),2D`G_0]*4!:J
MA,@A%("4QC'2%A%B2&P"B0FD)I"90&X"A0)H:4/KFVE[;VYF46\Z"+:M5N^-
MGE;(8CPI1820&"$)0E*$9`C)$5*HB)8O[%(UW]N'ELB3!L/.@(]W&IL%>;`3
ME:"MKD8T!4U51DB"D!0A&4)RA!0JHN4.=9V?.PT><Q<K#AGBP3$A$PU61J)3
MD!@6(R1!2(J0#"$Y0@H5T1)=?R11&JPGRI"U,^WB""$Q0A*$I`C)$)(CI%`1
M+2LX7^>7CP;K67%D*[-BB`?](@OJ>WI!XRE(%#1AB,,N9'I0IQP9?<-X=&?3
M*(4Z(#IU/@4)ZD*EUG*GYE&YI][?MC18SYTACE)1AOB;\;9R5L37UQ9/S\7:
M$L[A3?JE'!F]%DM[&D7O0&`UQ,RGYX*U4%FUC&&;S<^8!NL9,\2%+2)K&YA7
M#PMR0'49Y*\-)5B0[XY*N>NU<;0EG$3V5<KGWDQ*97,FRK6)'(<8"RG4B32I
M"'C8^5J-T;I8''+!&T@A`E<7(N)1ONR`6$#^*(Y/#-.3"&+9>*F`)$LF6"24
M"X@1DXU1N4*PC,2Z&-3@*%N%6;H%]87#L:F^ABVD"#$WMA`M,3=TS"7!S2<:
M-20,TCO*-Q*.>)0/AYA4$K64B`I&V3RR,4J=\`!':2HQO])5@N;=R7(1Q29S
MW*WA5`IM,EU+ZIK>T?)+>WU+2_@N,XG)O)<F)H-\>6)&!$$QAA(,I1C*,)1C
MJ-`@/6]JGXR\W0W].G>K;=14F>_24F60OQUK_<FX`R+"1^@'E3PW]751:Z.L
MZT8/JXMA1DA;#/=&<)3(]@R,LS^"$?0X!:<CNC_&4(*A%$,9AG(,%1JDIPS"
M?"!E&FV<;0Q2W0S]M@Y1"A1C*,%0BJ$,0SF&"@W2\Z-V9WY)F3D"N41E0L(A
M6:R(0S\Q-C)*<"4<4JV-@.1.S>1`M8F,QLYEE*`O!-?HG'05J/&9KP*S29H*
MW#G)BR8B#'K;XL@`L<*$0X[4-Q60XG+DP#=LC@P0S(6@&9GUW*D%FI\[,TQ:
M[@S2;Z;`N%(BPIT6J"*W/KZ96!1W.X1XA@E(!(ULMY1#KGHSS9DLYP/%9(%K
MW*:%-IDN&C5#\T5CUDD3C4&&Y3$6$!$>)=LJYM!Z-9[GOK<Q_2`>DPI(ME4F
M(,F<Z\RNXQO,A39&D\/YD`,<H_53DD-&#QE.(>)1BBV).;0FHQQD8PQ)\)!4
MS*7T"X[*=6*/&.=+H0W1Q3`<X/NW)!QVYI7!(:,WC)T0\2C5#@N(N59W:Q0P
M$<2RZ*F`E-80+!+*!<2(<6<(EI%8%^,G%FZ6'88OCD@C!ND-@^PP'_@3.RRB
MF$,-'()T8Y,I?9?R,>JA(VC>M\,BBDWFK]?&05GP`#:9KN4-6TA\^=5BGAV&
M=Q-(3.X1Y24;\2C%(<<82C"48BC#4(XA^LZ$KHO-R/)F[T#8#^;GNGNNH_IT
MZJVJ?:'O-V`'/MQ-,'OY$CJN>/MB/('[>!?#+0@WHO$D@R?YS2?P*N=Q;&EC
M1`BO>$838>(.3'YCAA`6-=[?1ORC!_RW'H3>#GY&Q$L-_1W\ZG8#7^_@=RN,
M1Y#SS90AXUMXM-G!+R^8)]OLX+<3C(/5`U%OS0PN#42]]20DH!)\]\%L(8&T
MV25I"!422!Q,+(Q93H_@I=:U?*Y_+[OGYM);I_H`3;$:MT/'7HNQ/P;^+?&I
M'>!UUOB%\0BO+VOXY6RU`"M^:-M!_$$GF%Z(/OP+``#__P,`4$L#!!0`!@`(
M````(0#Z"!WC5PT``)M(```8````>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
MK)S;;B,W$H;O%]AW$'0?RWV0?(#M8*QN'H!=8+'8P[5&EL="+,N0-)GD[;?8
M))NL^GLM2\E-G/E8K&85J\F_J9;N?OYM\SKZ=;7;K[=O]^/BXG(\6KTMMT_K
MMV_WXW__2_UT/1[M#XNWI\7K]FUU/_Y]M1___/#7O]S]V.Y^V;^L5H<1>7C;
MWX]?#H?WV\EDOWQ9;1;[B^W[ZHU:GK>[S>)`_]Q]F^S?=ZO%4]=I\SHI+R]G
MD\UB_3;V'FYWG_&Q?7Y>+U?-=OE]LWH[>">[U>OB0./?OZS?]]';9OD9=YO%
M[I?O[S\MMYMW<O%U_;H^_-XY'8\VRUO[[6V[6WQ]I;A_*^K%,OKN_@'N-^OE
M;KO?/A\NR-W$#Q1COIG<3,C3P]W3FB)P:1_M5L_WXR_%K9W5X\G#79>@_ZQ7
M/_;9_X_V+]L?>K=^^MOZ;479IGER,_!UN_W%F=HGAZCS!'JK;@;^L1L]K9X7
MWU\/_]S^,*OUMY<#3?>4(G*!W3[]WJSV2\HHN;DHI\[3<OM*`Z#_CC9K5QJ4
MD<5OW=\?ZZ?#R_VXFEU,KRZK@LQ'7U?[@UH[E^/1\OO^L-W\UQL5P95W4@8G
M]'?`R0<=J]"1_L:.%]?3:3V[OJ*K?]"Q#AWI;^QX^K#I$EWLL]Y)<7-1E].K
MZR[X#RY_%7K2WWCYSXV;;KONDO0W=+Q*V?[@@C>A'_T-_8X,=>+GN2N;9G%8
M/-SMMC]&="_23.[?%^[.+F[)6ZP7?^V^@OY?`5'E."=?G)?[,85/M;&GJO_U
MH2C*N\FO5*G+8/,X8,,MYM'"E:5SVTC02J`DT!(8"6P&)I2$/A-4K7]")IP7
MEXD8PV,$*34B,?-H$;LT$K02*`FT!$8"FP$6-MUK>=C#"T6<9V=,2T(^SY<U
MG\5';U.G%,R!-$!:(`J(!F*`V)RP.&EI^'R<SICN"/KS04%[HYKNW<RHXMF8
M]T;][`)I@2@@&H@!8G/"8J>5[?.Q.^,N]CCB1T]J6AZR0,6TSWNCV*T!T@)1
M0#00`\3FA`5*2W<>J%O-IG2_G[B:.2\\`YY,:3O.,C`54]T;]1D`T@)10#00
M`\3FA&6`UN`_(0/."\^`)R(#,Y&!WJC/`)`6B`*B@1@@-B<L`T[*BAWMC!IP
M7G@&/!$9N!(9Z(WZ#`!I@2@@&H@!8G/",D`W:IZ!CY=T9\P#]43<[M<BT-ZH
M#Q1("T0!T4`,$)L3%FA!-V0>J;O?R^D%+0\GWO&=(YZ%@,1\WX@T)*L^#XA:
M1`J11F00689X-IRRR2K_XWDOO`ZB/2Z._#$@"CFB.:(&48M((=*(#"++$(_/
M29C/Q^<%#XO/(U[9Y:6<TMXJ9J$I`+6(%"*-R""R#/&0G9S)0CZ_P+TN8MGP
MB!=X6<AL]%8I&X#:`I!"I!$91)8AG@TG<+)L'"EP+X=8R$$AT8*2]O%2ZG'J
MX99$*I,4,J`6K10BC<@@L@SQD)W4R4(^4]&X(P"QR@<DIE_*UV25<N%]9:M$
MBU8*D49D$%F&>"Z<Z!&YJ*[=.<;)R[V73Y3V&-5CT2NJO#2DR$U6L6.#J$6D
M$&E$!I%EB*?#*2"1CO,V/R^E6#9Z=95G0PK>HK=*V0#4HI5"I!$91)8AG@VG
MAK)L'%D;O'9B(7O$-H<2(NZ-4L2`V@*00J01&426(1ZQDT59Q.?O#5Y?L61X
M)!8'*?>+WBIE`U"+5@J11F006898-DHA!3^>_\Z:Z[V`V/P7I=3WR:H/&5&+
M2"'2B`PBRQ`/6>B],_>&$H5@0&+ZY2-`LDJY\+[RO0&M%"*-R""R#/%<.(66
MW0Q'IM_KN;SBRU[BY2N>E/O)*H7<=XRH12N%2",RB"Q#/&2GN;*0W?3/JHMT
M4O[IT]O2JS>6CE[09>FHI%0.';/I;A"UB!0BC<@@L@SQ=#B)EJ7C2`5X0<="
M[C5>'K+4PV5O%:>[0=0B4H@T(H/(,L1#'A"'9RD`)Z&$/`R(+P&5E,K)*F4#
MY2%:*40:D4%D&>+9^-/D88GR,""1#JF6DU5*1Z\K(VK12B'2B`PBRQ!/AU-B
MG[\?O&YC]T,OY?+[02KBLK>*\36(6D0*D49D$%F&>,A.=WT^9*_26,@>T7%A
M#&9>`FH0M8@4(HW((+(,\?B<N,KB2XKOR&+G11F+-""Z6=.3<"7E;AFL9GT^
MFHAXQZ0,V8"KDT199\U%643YATG.)UE=IS$Q*SZ``8ET?=,],GZ<L@I%440\
M<BD0HU4^O."+=TQJBH_X)"%3H9")*$]9L,K'%%!GQ0<P("O"4_:1E*&*J`+B
MD4M1%:WRX0UUK)/\X",^:>>O<.</B"_NM=SYDU5<'!I$+2*%2",RB"Q#/&3*
M:+X2')D99RUN+(]$R')[KWJK%#*@%JT4(HW((+(,\9#%]GXD9-S"*X_X`UXM
MM_!DE4+N.T;4HI5"I!$91)8A'K+8PM-Z?^+'&Q7N[@&)`I"[>[**H3>(6D0*
MD49D$%F&>#;$[G[FXVZ%VWY`(A=R,TQ6*1=!'*0/3%JT4H@T(H/(,L1S(93`
MD9L!]__*(W8S3&%A[HU2Q(#:Y"I:*40:D4%D&6(1UT)*N-D_[_"W\\17PX!$
M`211T[V--$]6,=`&48M((=*(#"++$$^'$#8?%T"-:B8@5@!%+=5,LDHA>U_4
M,:(6K10BC<@@L@SQD(4R^@,5@*JI]DA40-)HH0)ZJQA[DSI&U")2B#0B@\@R
MQ-,QH-/.._ZI4;@%)-(AUX=D%6-O$+6(%"*-R""R#/%TG"0":Q2!`?$;8IHD
M9Z@`WS&K_B9UC%EH$2E$&I%!9!GB(3LI)AX'SWC3I?:*+G\Z#(A/_U0*XF05
M`V\0M8@4(HW((+(,\5R<I`YK5(<!B9"E($Y6*63OBSI&U**50J01&426(1ZR
M4(='M@"4@/2*IGLLF);]R.>(&D0M(H5((S*(+$,\/J'WCL2'LLZ]F>D>>]).
M-0_(W5/IV&,JG@&:9)6FU/NBCA$IM-*(#"(;$'V80;YXR$Y=97?TD9"]%F,W
M;D!YR$&QT5V>A2R$?N.6/<H5W6`QOA:10J01&40VH(&0W0WW^9`[:Z[=`J+/
M2>+(YP'1K>/>1"\O"R'EFV00^[3133;!$:6<Z-0Q>!9Y-,D@>K;13>>93;=;
MK$^('45<YX!>>:,E*)M;$>T\6J43H2:B=.321I1*1P5$QVLQ&!VMDB\34?)E
M(^I\\9"%B/NXPFEID@<7`;ECMCYD>'")1M2]-RJF0L\WT:KJRF0F7V1O8WNJ
M+!51JA(=T8?7,M'*7ZLH1=W8V-Y=BV=,Z+PC&4,M-_7(G:STR9A)71.-LI/>
MB*[\]SFJ:S'F-AC0B7`L#Q7[I%K0$27/)J*;SG-U*799RQSS9)RD\J:H\@)R
M#U9],HJI?.R)5GF1#=1/T(*E3]#-M7A<:(,;.I%-"?)]Z&0O(OVIBYEHY0NH
M+D4Q6W8MGC,A$X\4$*K!J4>TCL4QSQ$UB%I$"I%&9!!9AGA\)TF_*4J_@-P>
ME=6$F,QYLHI9:!"UB!0BC<@@L@SQD(7T._M@<(JJ,""W:V79D(]^R2IE(\C)
M5"8M6BE$&I%!9!GBV3A)*$Y1*`;$"P"7R"`!TW+7I(XQ"RTBA4@C,H@L0SQD
M)]<RH>@*X+R'_ZD7?KF(#(A7P$P^_26K&'N#J$6D$&E$!I%EB*5C=I*([*RY
MB`Q(5(#8E^;)J@\948M((=*(#"++$`]9:,?S3\-FJ"L#$A4@'I/FR2JEP_O*
MMHH6K10BC<@@L@SQ=`A=Z=)1%/4Y;T/-4'0&)/(A]-`\6:5\>%\L'X`4=M2(
M#"++$,^'4(U_H#Q04<X\$NF0CQW)*J6C[QA1BU8*D49D$%F&>#J$;CQ_O:0O
M[\M'DH!$.H1`FR>K&'N#J$6D$&E$!I'[G0$W5%]\/AW^=P/\%\`WJ]VWU7SU
M^KH?+;??W6\"T&KS<-=C_X,%CS/WBP7=406TE-32:5MHJ:BE<G(16NKX^P>R
M93J]=2)OH,]T1BW=XP/TN:*6[E$46JZII7L*@98;:NGV<-DRNZ2Q=>I%MM04
M*9W$#XRMIDCI4'JHA2+UQT7@C2+U!RW00I'2J<60-XJ4CLH&6DIJH5>BAEHH
M!_0RT4!+16/SCR!R!!6-C9X4A_K0V.BCZJ$6&@%];#O04E+M^#,?>9V2,NJ/
M;*"%,DIO>0YYHU'3RY!#+31J>C%PJ(5&3<<C`RT%]:'OF@RU4!_ZVL50"T5*
M7T$8:J%<^U>29#P%U9L_@I0M)=4;O=T]X(VZ#%9H03WH^W\#/0K*-'US;JB%
M,DU?,!MJH4S3EZV&6BC37A&*,=//EWP9]D4=ACRY:1[B=.FA*W^I;[_0LC4P
M)'<W#7&:Q<%)I#D<G$*:P<$)I/D;NE7FU>7MG`Z;<$3SJJ26H2#HE/G6G?L.
M]*EOJ&5H:NG,\M8=2V(?.G.\=<>*V/)8T:#I'8&A%JH@^BQ]H*6F$J+3CZ$6
M*B'Z])5:)OVLTT_#O"^^K?Z^V'U;O^U'KZMGVB8N.U6U\S\NX_]QV+Z3WJ(?
MB-D>Z$=ANO]]H1\!6M&/>%RZK^,^;[>'^`]W@?YGA1[^!P``__\#`%!+`P04
M``8`"````"$`&+0GT-$"```,"```&````'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;)1576^;,!1]G[3_8/F]&)-O%%*EJ[I-VJ1IVL>S8PQ8!8QLIVG__:YQ
M0J%A;?I"PN7<<^X]OES6UX]5B1Z$-E+5":9!B)&HN4IEG2?X]Z^[JR5&QK(Z
M9:6J18*?A,'7FX\?U@>E[TTAA$7`4)L$%]8V,2&&%Z)B)E"-J.%)IG3%+-SJ
MG)A&"Y:V255)HC"<DXK)&GN&6%_"H;),<G&K^+X2M?4D6I3,0OVFD(TYL57\
M$KJ*Z?M]<\55U0#%3I;2/K6D&%4\_IK72K-="7T_TBGC)^[VYHR^DEPKHS(;
M`!WQA9[WO"(K`DR;=2JA`V<[TB)+\);&-Y1BLEFW!OV1XF!Z_Y$IU.&SENDW
M60MP&\[)G<!.J7L'_9JZ$"23L^R[]@1^:)2*C.U+^U,=O@B9%Q:.>P8=N<;B
M].E6&`Z.`DT0S1P35R44`%=423<:X`A[3'`$PC*U18(G\V"V""<4X&@GC+V3
MCA(COC=657\]J.V(>*ZVM%MFV6:MU0'!>0/:-,Q-#XV!>+P6*,)AMPZ<X`5&
M(&/`P(<-#2=K\@!-\R/FQF/@^HSI$`1$.V50NUS9@9VR<\65<N,#?9EH7&;R
M'AD'!EO[Q8?3CM<K>\RT/>I^/]/W"#DP6`X_SS:=67D$P:#U0+.NG(&;,`%]
M-]O9BI9ND-XX4Y?85M)9>XSTO:7A?%QV/B)+9\&;JBYOJ'J,#%47XZHP@?UF
M7Q]:!QY*'2,P0CU?E^-2;OGVW@_G:S1?OMV@RQNJ'B/#!E?CJJNAZNL-.O!0
MZA@9-$C#<2D*X_6R0WK)$;:)0]U3:-`CI?\1!E1?^/4F83&_[/(4FCR_BG[W
M^@57"9V+3Z(L#>)J[_9J!"NKBW8[?QNY_)?Q:;SUWP+2/8%=W+!<?&<ZE[5!
MI<B`,PP6,.S:;W-_8U4#ML!&5A:V</NW@*^N@+45NL')E+*G&U`FW7=\\P\`
M`/__`P!02P,$%``&``@````A`.>+$!+<!0``\!@``!@```!X;"]W;W)K<VAE
M971S+W-H965T-2YX;6R<F=MNVS@0AN\7V'<0=!]+I"Q;"N(4E8KN%M@"B\4>
MKA69MH5:EB$I3?OV.^30(H=,XL--&U,_AQ]GAK\<YN'#CW8??!?]T'2'5<AF
M<1B(0]VMF\-V%?[S]^>[+`R&L3JLJWUW$*OPIQC"#X^__O+PTO7?AIT08P`1
M#L,JW(WC\3Z*AGHGVFJ8=4=Q@">;KF^K$3[VVV@X]J):JTGM/N)QO(C:JCF$
M&.&^OR1&M]DTM?C4U<^M.(P8I!?[:@3^8=<<AU.TMKXD7%OUWYZ/=W77'B'$
M4[-OQI\J:!BT]?V7[:'KJZ<][/L'FU?U*;;ZX(5OF[KOAFXSSB!<A*#^GO,H
MCR#2X\.Z@1W(M`>]V*S"C^R^3+(P>GQ0"?JW$2^#]7,P[+J7W_IF_4=S$)!M
MJ).LP%/7?9/2+VLY!),C;_9G58$_^V`M-M7S?ORK>_E=--O=".5.84=R8_?K
MGY_$4$-&(<R,IS)2W>T!`/X-VD:V!F2D^J'^?VG6XVX5)HM9NHP3!O+@20SC
MYT:&#(/Z>1B[]C\4,1T*@W`=)`%Z_9Q?&B1"(+6_3]58/3[TW4L`30-+#L=*
MMB"[A\"GC2'&M-6W=@I;E$$^RB@J%FQB@/)\?US&#]%WR&BM)05*EF$P21A5
ME">%+`3038BP;Q<Q@0J^GOL3D9Q$B3BGZQ6O2*BB]!7I<I(01DB=S?@^FQ1#
M!UBI6#JY*%`R5_67&2ZM`;+P_)J%I7@5PJZF&BS=I*`D4S6\X])FI@VK4I=$
MP/(Y-P("!GUM9T0VUOFJR4E.9A*Z?H$2*S/6``%84(#W2R+%3F;FSL(HF:O,
MI,[#DCR<)A(>:'T[(>_S2+'#DTYA52$*E"P4#\NSC#XN\3'BOEDD^7YR3O_Y
M(LE)#IOI`61#B54D'$#8/%T8<R`IRF_!D9,<''-($0<E%@X.(`[GRWS*'<%A
MX#)V>MXOF5([S>L4I=`:B\0>H8L[SGQF<31/<K3-KC`+##6XZSLV3YVJE5J`
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M'FPD+5`]3ID<T[[L6P_WS3MSS5MKK&.E1Y!R,5_FYB12)FF>EBU>R(26:]MC
M;OQ-YPDU-M-I1/X*`+_?O/Y>Y8Y17TCD&W;N&K:*+,U'KL^<CB_)4V,=-%N.
M65_(YIMV[IHV1\W459YG$P'+EVEJC(0R2D.]OJ)HPZ2BIF5T15&#C&F^R`V!
M[GQ;P'*VC$VC4D;'VR_,H^_QN2F49D0-,@)`NO#J3!0)MPXX972<_D)&W_'=
M-!4<-<C(DY@OG$XMJ2*>Y[FQ1@KI&/^%D/X+('?25'#O!6"/4`CG!?"^\7/?
M^*W=Z2IZQJ]GZ;KRM^Q,_GYR??.K6=3V<_/^1R2ML>S,'B'Y2&[R>36+_H;@
M%45K;`A\.Z@1"B'-]FH;2-"BB0V8,ZPS@1H;`D>P.'F:F7:F2#<Y>^([.XO-
MNT,SH<AFLD8HQ4T>GJ`_0]#I.Y-?'=38$-8(A;C)I)-73-JK#FIL"-N5^3(U
MKQZ*=),G)[XGL]C47U<'13:3-4(I;G+=!!WU_>J@QH:P1BC$3:X*5\SN70.+
M3;)U*CQ;U=/P4HUQSJUO4DB%%\]X,=N*?BM*L=\/0=T]RTME!E]GIE&\\"[@
MPEO=#D?3`[AO/E9;\;7JM\UA"/9B`U/CV1)ZH\<;:_PP=D=U,?K4C7#3K'[<
MP5\6!-PRQC,0;[IN/'V05['3WRH>_P<``/__`P!02P,$%``&``@````A`#SB
M-SQW`@``YP4``!D```!X;"]W;W)K<VAE971S+W-H965T,3`N>&ULC%1=;]HP
M%'V?M/]@^;UQ$CXZ(D)%5[%56J5IVL>S<9S$(HXCVT#[[W=M0PBE0KP$[!R?
M<\^YOID_O,H&[;@V0K4Y3J(8(]XR58BVRO&?WZN[+Q@92]N"-JKE.7[C!C\L
M/G^:[Y7>F)ISBX"A-3FNK>TR0@RKN:0F4AUOX4VIM*06EKHBIM.<%OZ0;$@:
MQU,BJ6AQ8,CT+1RJ+`7C3XIM)6]M(-&\H1;J-[7HS)%-LEOH)-6;;7?'E.R`
M8BT:8=\\*4:29<]5JS1=-^#[-1E3=N3VBPMZ*9A61I4V`CH2"KWT/",S`DR+
M>2'`@8L=:5[F>)EDCU-,%G.?SU_!]V;P'YE:[;]I4?P0+8>PH4VN`6NE-@[Z
M7+@M.$PN3J]\`WYJ5/"2;AO[2^V_<U'5%KH]`4/.5U:\/7'#(%"@B=*)8V*J
M@0+@B:1P-P,"H:\Y3D%8%+;.\6@:3>[C40)PM.;&KH2CQ(AMC57R7P`EOJC`
MY4M[HI8NYEKM$;0;T*:C[O(D&1!_7`L4X;!+!\[Q/48@8R"_W2*9I7.R`]/L
M@'D,&'B>,#V"@&BO#&JW*SNP4W:IN%(>P\90YE3(F<SH7,:%/H+673?J#@%N
M:&(VZFV$"@)F[-,=^AJ?"UX7<F"('GY.<5U$>@!!U0/0N"_GS"[<A-M3=6"O
MWL=ZV(%T!U*3CZ6FYU+^.L=I=`\<UTV[@^>RAYUA.Y/9])UL&*QP>R77%?_*
MF\8@IK9N:%*XC_UN/\_+U/7G_?XX6_HY)_T+F+..5OR%ZDJT!C6\!,K8>]%A
M4L/"J@XJAVE3%B;,_ZWA@\KA2L81&"^5LL<%")/^$[WX#P``__\#`%!+`P04
M``8`"````"$`Q%I%A2D(```,)0``&````'AL+W=O<FMS:&5E=',O<VAE970Y
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M^\,^_UF(-AO'C>F\G=+S^N5`]_W#Z*\W0KOX`/+'_>:<9NEKWB*Y-N\HWO.D
M/6F3TM/#=D]WP,+>.">OC\UGPXR-<;/]]%`$Z'_[Y#.K_=_(=NGG\KS?KO:G
MA*)->6(9>$G3;\S4V3)$SFWPMHH,1.?&-GE=?QSR_Z2?=K)_V^64[@'=$;LQ
M<_MSGF0;BBC)M+H#IK1)#]0!^MLX[MG0H(BL?Q37S_TVWSTV>YV6T>\,R;KQ
MDF2YM6>*S<;F(\O3X]_<QBB5N$:WU*!KJ=$U6B.C,^F-2.2*8Z]TI*MP;'7'
M`V-0M'[%L5\ZTK5T'-_F2/TI;G=8.1I&:S#J]`QVOU=:')6.=+VOJS31BA;I
M>E]7)Z6CP<9$&?;;^FI42:5_[NNM(7+)_BE=>S?ETA#)-&12;HPM&Z]\$-(_
M=_:7$LE=949O[*_(J"%3>KV_;3YUBIDX7^?KIX=S^MF@Y8VBG+VOV6)IF$Q-
MS$$^G*I9^:M)2;.1J3PSF<<F^=.$RV@E^?YDC"8/[>\T^S>ES?2"C6HQ$Q9L
MJC/9N0X6.K!TL-2!K0-'!ZX./!VL=.#K(-!!J(-(!W$-M"D;54IH]/X;*6$R
M+"4BF%,!9(ZZ6OR%A7"9ZV"A`TL'2QW8.G!TX.K`T\%*![X.`AV$.HAT$->`
M$G]:#)3X7WX<B9'/K.G!4Q_YXXX:URFWZ<M<S(#,@2R`6$"60&P@#A`7B`=D
M!<0'$@`)@41`XCI1`D^+[QV!9]:T:M'ERIK#C?KT`)-&8T--SZPRJL8]D`40
M"\@2B`W$`>("\8"L@/A``B`AD`A(7"=*,NAQ=D<RF'61#!'"*2<#*@!JD=<7
MG,I(N,V!+(!80)9`;"`.$!>(!V0%Q`<2``F!1$#B.E$B3]7`'9%GUFKD.1GU
MJY5_!F0.9`'$`K($8@-Q@+A`/"`K(#Z0`$@()`(2UXD29BI6[@@SLU;#S,FP
M)\/,29^F5&W(]]3%9EX9B2&_`&(!60*Q@3A`7"`>D!40'T@`)`02`8DYZ1;[
M+27R;/]>KSFO/V"9M1IY3NJ1YZ1/4ZH6^;X6^<JHBCP0"\@2B`W$`>("\8"L
M@/A``B`AD`A(S,F%R-.^[([(,VLU\IP,:TL+)WV:93+R@Y$6^<JHBCPG72ED
ME83O\UGQOZR\:M+C@2IM5T9"V@%I%Z2]RJLN/52E5Y61D/9!.@#IL/*J2VL!
MB2HC(1W7I97)PK;0=^2L,%>35J*NDJ/Q6+W;66DUE`F8"S2LEKB%T)I4R"I1
MKSCK*;9M2^$HM6R!I):#6BYJ><)1:JT$DEH^:@6H%0I'J14))+5B14O-!=NR
MU5<NOEMNL:.B?+???)NF-`O(Z,**UJ-=<;E7YAL_JEQ%]J?LU(.F6H\N<AJ-
MM0WTK+0:TL(JK0;:L)T+JS'?A@\[QE`KNQ:BN6[5`TMXR<0N!;K:G"VL?MV<
M@\VYPDLVYPETM;E5:352ZLJ)MN'RL<5`./+C/[;`A#>U&`G'JRW&2HOJH&'[
MS&N#YJ_T_5>#A@[VJE'#MZO*J.&(1HT82#-V]$4#:20S.Q=(%BJ+$O6DE56B
MH4S(4CA**UL@J>6@EHM:GG"46BN!I):/6H&PDO<8"B2U(H&D5JQHJ0EA&]!Z
M0B[,UGK@^7Y5"3Q']0J$'2%2X-429*+M-.?22F1L@<A"M$1D(W(0N8@\1"M$
M/J(`48@H0A27Z$)!0E&]*Q=\NZKD@J-Z35*(4BZ4!QX4)=)*YH)KU<N2THK&
M@[!:2L?:,@R%B;02CH[0D@N_*Y"4]Z1C75Y;Y5?22LC[0DO*!P))^5`ZUN7U
M`D5:"?E8:!7RZH1B6]D[)A3?^9*>T)ZR4W2:/5^5*-Q**5%*)!_?"Z$E5S*K
M1$J)`EIV:3646@YJN:CE"4<9Y95`4LM'K0"U0N$HM2*!I%:L:*FY8/O=>B[^
MOQ*%J6A5)$=?E2C<ZJL2I;22-4-7J^L71MF<7.2M$BF/J%N:LX7CKYMSL#E7
M>,EQY`GT18G"._55B0(W&)3RH_JS[I8;C(3C%R5*O45UT-`-71TT-Y8H3$8;
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M,Z4)NS0;F736>(&/33H)N\`GYKQ8PK6.+B<F'1ZAO3<QZ>0'>3@QZ=B&>+L2
MHG=1WM=OB;\^O^U/6>.0O-)0Z12G`6?^-@O_D)<;O)<TI]=0BKW>CMXZ2F@/
MVFE1'?*:IKGXP!JHWF-Z^@<``/__`P!02P,$%``&``@````A`,CQS_7Y!P``
M+"(``!D```!X;"]W;W)K<VAE971S+W-H965T,3(N>&ULK)I;;Z-&%,??*_4[
M6'Y?F\$&8Y2DBKE+K515V_:9V#A&:QL+R&;WV_?,C;D<DA"I+\OZ-V<.\S]S
M9N8`N?OMQ^4\^UZU7=U<[^=DX<QGU77?'.KK\_W\[Z_IEV`^Z_KR>BC/S;6Z
MG_^LNOEO#[_^<O?:M-^Z4U7U,_!P[>[GI[Z_A<MEMS]5E[);-+?J"BW'IKV4
M/?QLGY?=K:W*`^MT.2]=Q_&7E[*^SKF'L)WBHSD>ZWT5-_N72W7MN9.V.I<]
MC+\[U;=.>KOLI[B[E.VWE]N7?7.Y@8NG^ESW/YG3^>RR#XOG:].63V?0_8.L
MR[WTS7X@]Y=ZWS9=<^P7X&[)!XHU;Y?;)7AZN#O4H("&?=96Q_OY(PD+=S-?
M/MRQ`/U35Z^=]O]9=VI>L[8^_%Y?*X@VS!.=@:>F^49-BP-%T'F)>J=L!OYL
M9X?J6+Z<^[^:U[RJGT\]3+<'BJBP\/`SKKH]1!3<+%R/>MHW9Q@`_#N[U#0U
M("+E#W9]K0_]Z7Z^6L]G3U77IS5U-9_M7[J^N?S+&XEPP3N[HC-<96=_X6V<
M%8%[376R$D[@*ISXB\#SUGZP`2?OW!W&R88.5WEW$!EXQ//I[=_I":VL)UQ%
M3V_:+7W1$:[REMYB[7J;@"E^YY8;T1.NGU,)"Y6-%:[REA-5;D5/N$Y2N>2I
MP3(M+OORX:YM7F>P?"$)NEM)-P,2@C.98ESMD'1OY1PD&W7R2+W<ST$_I%4'
M"^7[`_&=N^5W2.Z]L-F-V)@6D;2@F4S=QC9(;)#:(+-!;H-"`TL(PA`)2/3_
M(1+4"XV$U+"30(7&M61+"]DEMD%B@]0&F0UR&Q0:,&3#TM1EC^\M<IZI,>PB
MVCR[SLJ4L^,V:Q6"")$8D021%)$,D1R10B>&3MA)INNDQK`BX/).0G,CC^WA
M+%\C1&)$$D121#)$<D0*G1A"8>.;+I0:,Z$R^7:<K&%+&J2[SMJ<XV@PDMUB
M1!)$4D0R1')$"IT80F&CGBZ4&IM".8'ITX5ZEM#!:!"*2()(BDB&2(Y(H1-#
M*.RKTX528U,H)YOUL"=%B,2()(BDB&2(Y(@4.C%4T2I5.WG>WWBHL:E*D*U2
MQ<D:%L:0N<2S=J=X,)(3FB"2(I(ADB-2<.*R*LH0"L?J=*'4V!0JB":4DS4L
M#$VHM43CP6@0BDB*2(9(CDC!R8A0`FMINE)F;4H5R'75I`JT]EE5X3K$6J&Q
M,AB$2C<JXU.)>)E,BXM,=:3U"GBV(I@K`^FYD&Z89V.2"2TKM'2FA10\&\SZ
M4[W_MFO@%QB,Y/@*=(D:BA<F<.C(V^V84SAO]9EV'=_:HX25!_N'E@^652RL
M-G1,LDASG8WI*Q%6+LRQ9A685JD<5S`,-9LTB'Q\$%O3??'1(,S`T\+&"CSQ
M%O3Y@L7^:W-[*_;P)#$$GY='1O`Y6L&TJ%`0JZJ-B*BK5,K&$@4\9>'YP>J4
M"(N5ZI1*I&8_DWZ452[1X-J:F4*Z87W,.-'*R(J3Z],'Q[&TU$/#2RHC-!R9
M>4F(.8T1X5:!*I!BB=RW0R,ZJ3BDLI.^=I'K7%H-KE%H=,]F:&@MI85F9)GJ
M\>"5EQ$/CJQXV'4^]*![>\"?L_D#CD"K82$ETDH/@+#2`X!\Y;*C\E5(Q'R9
MDF':=<G\N4^MFFD[%G5B[>`<68O&.H0C^A(#.OKZ7@1/]F;^Q,)J8U1H]BZ=
M""M82]HR=:S)3Z65BFHV:1#Y^""L0ZB0[M\:A!E[6NAIZ6;'?N*.Q<M%F&)U
M7'"D5WH$H1BC!*,4HPRC'*/"0*9N6@I:NCW873_[KH&ZL;*.([.6)U8^162P
MDA&+,4HP2C'*,,HQ*@QDQH)6BUHL/MAR>&UIS#5'EF3K.(_(8*4D(Y1@JQ2C
M#*,<H\)`IF1:-TZ7S*M,0S)'1GHC%!.$$HQ2C#*,<HP*`QGZW$]5O\S:S&*)
MM$I?H`]*?64E9SG!*,4HPRC'J!!HI.`'](DI9=:69%[SZ@6_L'J[X%<&2JUP
MH_;"5%C!N2VM,M7QC8)?&<@^A72#3U`8\V>T\S)13V?FP"[NB75P1<(*"G(Y
MIEB@S58443[9^M;"3W"W5-Y/*]JQ56XY)T$0;*V-M#"ZF6N`UEB3U[C+*S(C
M*!Q9]8/U@!")CEK]'`OD.RPH!#XRH$H!]THE4HF32:15W1+!V(8G`;*UBOI"
M6N'2VZ7%VO2H\-+.B(JH]K1WJLPG%),*Q1@E&*4891CE&!4&,F?=*B;?/\SH
M$X=U?@L4^#3)3==6K?2!:UP3N1P%*NLCC&*,$HQ2C#*,<HP*`YGZK)KH`WVX
M]*'O&"":@=H?(HQBC!*,4HPRC'*,Z$=0-0BNCW_4Y)^:+E7[7$75^=S-]LT+
M_6"YHLMTP/QKZHYL0WJ\0@K8+>X:/K2R-8I:?&AA:8-:-O+CK-WBA?!.>>0N
MX&K4$SABJ\SV0Z`#5+LCG@AT@=IOK"6`%I:+EK>"K*!E3&/D.B$]EK&WR"5A
M#"<4;H&S#OJ,M<`WZT>V0UGWW\&W[#'[G0MA'+G##H;+GC0M/X]K\#\J'>9P
M5%X0PLM4+"':AO#N<803)Z0O_7`+O-$+Z4L[W`*O(L)H-+CP1@*\C8TK@1;Z
M,(Z]P0N),!UMR:`E&VV!UQ,P-N9M.40,OM7?RN?JC[)]KJ_=[%P=86DX["&\
MY5_[^8]>O,)Z:GKX6@\5%'RGA;_*J.`MIK.`W?38-+W\`<-=#G_G\?`?````
M__\#`%!+`P04``8`"````"$`#311LZ4'``#6(0``&0```'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6RLFEEOXD@0Q]]7VN^`>!_`W%A)1N$POH_5[.ZS`R98
M`8QL9S+S[;?:[78?10A(^Q+#CZI_VU5]5+?S\/W7\=#ZF>1%FIT>VUJGUVXE
MITVV34^OC^V_?QC?INU64<:G;7S(3LEC^W=2M+\__?G'PT>6OQ7[)"E;H'`J
M'MO[LCSKW6ZQV2?'N.ADY^0$O^RR_!B7\#5_[1;G/(FWE=/QT.WW>N/N,4Y/
M;:J@Y[=H9+M=NDF6V>;]F)Q**I(GA[B$^R_VZ;E@:L?-+7+'.'][/W_;9,<S
M2+RDA[3\78FV6\>-;KV>LCQ^.<!S_]*&\89I5U^0_#'=Y%F1[<H.R'7IC>)G
MGG5G75!Z>MBF\`0D[*T\V3VVGS4]TL;M[M-#%:!_TN2C$#ZWBGWVL<[3K9N>
M$H@VY(EDX"7+WHBIM24(G+O(VZ@R$.:M;;*+WP_E7]F'F:2O^Q+2/8(G(@^F
M;W\ODV(#$0693G]$E#;9`6X`_K:.*>D:$)'X5W7]2+?E_K$]&'=&D]Y``_/6
M2U*41DHDVZW->U%FQW^ID59+49%^+0+76J2O=29:;S:8@,@5QT'M"%?FV.E/
M1]IH3%J_XCBL'>%:.TYO<P39ZGG'C:.F\>>]TN*D=H3K?;<*(ZUJ$:[WW>JL
M=M1(IZC#?MN]:DU6X<-]=ZNQ7)(/M>O@IEQJ+)D:3\J-L24=EO9"^'#G_4(B
MJ2O/Z(WWRS*J\91>O]\N'3O54%S&9?STD&<?+9C?(,K%.2:SI:83-38(:7=J
MAN5GHQ*&(U%Y)C*/;?"'`5?`5/+SJ3_0'KH_8?AO:ILYME$L%LR"C'4BNU3!
M2@6&"M8J,%5@J<!6@:,"5P6>"GP5!"H(51`)H`O9:%("O??_2`F1(2EAP9PS
M(.1(SM""63"7I0I6*C!4L%:!J0)+!;8*'!6X*O!4X*L@4$&H@D@`4OQA,I#B
M?WD]8CV?6,/*(_1\;=J3XSJG-D.>BP4B2T16B!B(K!$Q$;$0L1%Q$'$1\1#Q
M$0D0"1&)1"(%'B;?.P)/K&'6@HLPY_25R%.C$2Q#C9$V58P6C5'3[Q%9(6(@
MLD;$1,1"Q$;$0<1%Q$/$1R1`)$0D$HF4#%C.[D@&L:Z2P4(XIV0R;.:?!2)+
M1%:(&(BL$3$1L1"Q$7$0<1'Q$/$1"1`)$8E$(H49EOX[PDRLY3!3,A[P,%,R
MA,0*77X@CXME8\3RM4+$0&2-B(F(A8B-B(.(BXB'B(](@$B(2$1)OZKZI<A#
ML7)'Y(FU''E*Q,A3,H1<"Y$?*I%OC)K((V(@LD;$1,1"Q$;$0<1%Q$/$1R1`
M)$0DHN1"Y,D&7JPYKR^PQ%J./"5C86JA9`BYYI$?393(-T9-Y"GI<R&C)G2[
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M=(L*-3:;(>;D?`8Z$O0:AA8UFO#,+AGB9<F*.7(KHT9CGI`U<^16)D-<R\):
M-M9RF"/7<AGB6A[6\ID5?\:`(:X5,L2U(DE+3@C9;(H)N3!:Q<#3O:D4>(K$
M>H.<<T$NY()CIARJ++D5R]@*(P.C-48F1A9&-D8.1BY&'D8^1@%&(491C2Z4
M'^2T[YY<T/VJE`N*Q`JD$H5<2"L<*D&X%<\%U1*+D-H*^@.S6G-'81I&90BW
M8HX6T^)#V&:(RSO<49179GF76S%YCVEQ>9\A+A]P1U%>+4>X%9./F%8E+P\H
MLG&]8T#1?:Z41(J^J$G`@XPQL2AA2*A*:M3G,YE1([$N88X\,B9#7,O"6C;6
M<I@CUW(9XEH>UO*Q5L`<N5;($->*)"TY%V1W*^9"76UN*U'H'AF:8>F?D\-U
MNMB(_0:5*-3JJQ*EMN(U0U^IXE>L.3[)&S62EJA;FC.9X^?-6;@YFWGQ?N0P
M]$6)0F_JJQ*%6@WX`_JU_$1<ZVYYP)`Y?E&BB"W*G89LS*]UFAM+%"*C%+84
M08',.M("7F,2*P$M,5IA9&"TQLC$R,+(QLC!R,7(P\C'*,`HQ(B\T.61H`FA
M+VCI6Z%CDK\FB^1P*%J;[)V\?-5F4`XVF+X9G@_UJ!JF*A_I415UE6MC]BI9
M^66A]76R>D.FT"\#?0GS/_X%%D/=O/@+K&,Z6:6P#RQ!T,ZE7^`M]_.E]N?D
M[?<%I7E?CR[:#_3HHOY0?X:@XUM:C'4XKKK`)SH<IES@4WTYO<#74QW.'["]
M,]7A\`#S8*K#SA]XMXDXO%4_QZ^)%^>OZ:EH'9(=)+Y7;3%S^EZ>?BGK7<-+
M5L+[]&H#L8?_GTA@8]/KP$C?95G)OI`&FO_(>/H/``#__P,`4$L#!!0`!@`(
M````(0#@J#\3&`<``'<<```9````>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM
M;*Q9VV[C-A!]+]!_$/2^EJF+91M.%K'N0`L4Q;9]5F0Y%F);AJ1L=O^^PYMX
M4Q*EZ,MZ<S0\Y)P9DL?6[NN/R]GZ7G=]TU[O;+18VE9]K=I#<WVZL__ZEGY9
MVU8_E-=#>6ZO]9W]L^[MK_>__K)[;;OG_E37@P4,U_[./@W#;>LX?76J+V6_
M:&_U%9X<V^Y2#O!G]^3TMZXN#V30Y>RXR^7*N93-U:8,VVX.1WL\-E4=M]7+
MI;X.E*2KS^4`Z^]/S:WG;)=J#MVE[)Y?;E^J]G(#BL?FW`P_":EM7:IM\71M
MN_+Q#'G_0'Y9<6[RAT%_::JN[=OCL``ZAR[4S'GC;!Q@NM\=&L@`RVYU]?'.
M?D#;PG5MYWY'!/J[J5][Z?]6?VI?LZXY_-9<:U`;ZH0K\-BVSSBT.&`(!CO&
MZ)14X(_..M3'\N4\_-F^YG7S=!J@W`%DA!/;'G[&=5^!HD"S<`/,5+5G6`#\
M:UT:W!J@2/F#?+XVA^%T9WNK11`N/03AUF/=#VF#*6VK>NF']O(/#4*,BI*X
MC`0^&8F[7/AN$*X_P^(Q%OC\[TOQ&0E\,A)_L0X"?[4.Y^<3,A+XY"MY-W_8
M3$1$^&3QX2)$RXV'YS1U<V@-2$GC<BCO=UW[:L$^`97[6XEW'=IN;(O7DC*,
MU7VKN%!53/*`6>YL6#O4K8>._'[ONNN=\QVZJ&(Q>S,&J1$1C\`M@VEC'4AT
M(-6!3`=R'2@DP`$11B6@D_X')3`+5H+GL.>`)(V6-H_@0V(=2'0@U8%,!W(=
M*"1`21M:7T_;?W,S\WKC0;!MI7JCE5YO&N,+*2(#B0TD,9#40#(#R0VDD!$E
M7]BE<K[3AQ;/$P?#SH`/J;$W:OWV-,B'W3,&H7"I!D5CT%AE`TD,)#60S$!R
M`RED1,D=ZCH_=QQ,<N<KWE-D1:X6LD$C`XD-)#&0U$`R`\D-I)`1):O59[+"
MP6I6#-F,6S:BB`\RBH(&OEK0>`SB\B04<>D]A<^OE"'D.B6"9>,HB3K4SL%\
M#.+4A4RMY`Y'[OR*XF`U=XI0LT`K2I%@30_Q)0JTM,?G?&T)X_!'_5*&>".2
MC:/(U;!$FICY^)RS%C*KDC%VD=*%]?[^Q<%JQA3QH)E$;4-733*B02ZL000%
M*S4HID&!1Y3R5BOM6$@8B>BKE,V]%KK,F2A7)G)=I"VDD"=2I((3:;Y4.%B5
MBB(>W)="A=!358AH4""J'S,D(+H$*%0')(Q5'"(I0P1%9I#F"BE::P4K9%)%
M`@3N5M:`^IL%-DG#J:F>]RWD!AE.M!$N+-D3#X1$U89!:A\%6JX1BPI@^PH)
MC4;B42%1S$=KK<`)"W"E5N+S2[W$:=Z=+.=1=#+7VVC7=J%,IFJ)G9.T]70M
MO[6WM[0$8S^*2?T7W*E\K^\1A0)Q3D8F%)M08D*I"64FE)M0H4!JWM@Z:7E[
M:_S=9JIMY%2IYU)2I5"P(;7^HIW\$6(CU.-)G);JNK#'D=8UT</R8J@C4KV,
MI]F4/6*^"3:4Z-A0NP0B$<5K&)M08D*I"64FE)M0H4"J"MCMS%>!>B.E)!22
M;0T6"0Y#"8I-*#&AU(0R$\I-J%`@-3_HA4_DAZ.UHXI!XO2(\+=UB/K`X8@H
M7N6$0;+'X9#8O)D8*#>1UNNYB.+T!><B%DI5`3N@^56F?@E$Y=1[1"'9ZC#H
M;:\C`CA-PFD$<\HAR>Z(@6_X'1'`F0M.0YC5W+$7FI\[=4Y*[A12+ZM0NV4B
M1*,^<#TLBMD>A'S-$"2<1K1;RB!/OJSF3)9KDX6>=L$6RF2J:-@5S1>->BA%
M-`II]D=;0(18E+`S,8-62W+$!_Y:-X;FF)1#HJTR#@GF7&7VW$!C+I0QJAS8
M(<V7@_HI10YFL>#DD"X&S3Q$B$9)3B5FT`H1.=!:&Y*80U(&*?UB$.<JL8^T
M\Z50B!4Q7,T4OG]QDFCU2&60UAO:3HA8E.R-.43-L;?1"IAP8E'TE$-2:W`6
M`>4<HL1F9W`60JR*\8&KF^60X4+0KQT&J8>.X9!9U`<.F4=1TQJZR-"-SB_U
M7<KGEPX=3O.^0^91=+)@M=(.RH(%T,E4+2><(@K$MXUY#AGN*$-,9AO%)1NQ
M*,DTQR:4F%!J0ID)Y2:$WRG@==$9:=[T'0']0?E2=T]U5)_/O56U+_CW?VBZ
M^]T(\Y<3WO8!F.#>TYZ`]]QBGS?UQ(<GI-OU,:[+WW5H3R*TVL9PIYIL&3S)
M)Y_`BY.'Z97!]!-,>SSY%`Z)3.7QX&\?P.&;2]I#?I/I!5OXV6LB'L$K'OC"
M8CZ)(.O)I"'G*3P*MS'YA5:3+PNW\*/,!#\*0-:I-8'K`UG)$V<D@]<^M_*I
M_KWLGIIK;YWK([3%DFR(CKXXHG\,[*OC8SO`"Q_R+?($+_AJ^!%MN8`KY]BV
M`_\#%N6,KPSO_P4``/__`P!02P,$%``&``@````A`#X5>I"/`@``9P8``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,3$N>&ULC%5=;]HP%'V?M/]@^;UQ$J"4
MB%#!$%NE39JF?3P;QTDLXCBR#;3_?M<V34E!;5]"[)Q[SKW']YKY_:-LT(%K
M(U2;XR2*,>(M4X5HJQS_^;VYN</(6-H6M%$MS_$3-_A^\?G3_*CTSM2<6P0,
MK<EQ;6V7$6)8S24UD>IX"U]*I26UL-05,9WFM/!!LB%I'-\2246+`T.F/\*A
MRE(POE9L+WEK`XGF#;60OZE%9Y[9)/L(G:1ZM^]NF)(=4&Q%(^R3)\5(LNRA
M:I6FVP;J?DS&E#US^\4%O11,*Z-*&P$="8E>UCPC,P),BWDAH`)G.]*\S/$R
MR5933!9S[\]?P8_F[!V96AV_:E%\%RT'L^&8W`%LE=HYZ$/AMB"87$1O_`'\
MU*C@)=TW]I<Z?N.BJBV<]@0*<G5EQ=.:&P:&`DV43AP34PTD`$\DA>L,,(0^
MYC@%85'8.L>CVV@RC4<)P-&6&[L1CA(CMC=6R7\!E/BD`I=/;4TM7<RU.B(X
M;D";CKKF23(@OIX+).&P2P?.\10CD#'@WV&1S*9S<H"BV0FS"AAXOF!Z!`'1
M7AG4/J[LP$[9N>)2686-<YGTNLQH*.-,'\'1O5VH"P+<>1&SNYX_9!`P8^_N
M>5WCH>#;0@X,UL//BUT7EIY`D/49:-:G,W`5.N'<5=]CTYEKJ'=*=H$^D][B
MT\[`XSB^+GM[*9O&XVCZKJP+',J>=H:RR759:,77U:9C.)BW37=10\W3SE#S
M=4.%P0[3([FN^!?>-`8QM7=#F\(\]+O]?;),77^\WA]G2]_*I/\`<][1BO^@
MNA*M00TO@3+V_NEP4X2%51UD#M.N+$RX?ZWA0N<P$G$$9I=*V><%")/^+V+Q
M'P``__\#`%!+`P04``8`"````"$`G']&AQP%``"2$@``&0```'AL+W=O<FMS
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M02Z78B(>%X'C`Y$GB3Y/A"-/#";>(G3#&;GZD\2`)\*1)[KN)/#"^8+>]Y-,
MT*6&9T.F-S)SSC/A^-]N%IXU>DDX\L3%.)=+G@A'GO@O]^JPT:7-DI1]N5FU
M^&;!$PCCUUU+\CR[$:B)+F%U&OKFG]H&^H6(O!"5M0W^H2,ZZ/6/C>?-5LX'
M]&?%8[9FC*M&Q"*"-".1372PTT&J@TP'N0X*"3A0A*$2T*/_0R6("JF$\+`5
M0"J-9EM$B)1$!SL=I#K(=)#KH)"`8AN>,-GVX^E!C#,)AHE`&F=W&JAVMBPF
MN)<@-DABD)U!4H-D!LD-4LA$\0D3@NR3-+H73H;)9'2K$QUX6.`@]?I<JP$+
M"F'2'H+<T%.#XB%H&'B#[`R2&B0S2&Z00B9*6:``<EF>#S\)IM[%'6\9";VA
MWV.#)`;9&20U2&:0W""%3!17,(>/=T6"55><+.^N&`F@C-*`^NJ`)D.0*,_.
M(*E!,H/D!BD8\>CBJAB%*7>\41*L&N5$,LI(`)65C&J/>#($#48-DAHD,TAN
MD(*1!T;)ME1:IY[W*0E6C3+B27W*2#!CJ]74#;7!',X/'KE&,'1%R@G;/I$5
M*QNRZ!HX=;7*Y<-YH5K(JLK0PFH\WC$)5ATSXD'G2`.IF8QYT'VN3CA9#"9W
MG-Q[)&7$I_M/NE!GADYNZ!2RCF+4A6ERO%,:K5KER(>5??`:+M7QC$40K(-#
M$&PGU:A$1/FT+6;ZXK83Y^^-E`IT[XM,H*?7RD44NY;K:;U2B//T6FK%R!YF
M]-/@LAT/+%FBZ;8<^?)C/INJM8A%T&S(2P2:T_*X_D*[YQT/\*1N$3GWELH$
MNBOG`BVILC_5%LM"$5:+078VXXO!]D%*,1@*U-5:6])CET?)3?:@?WB4QPJT
M7"S4HNZXC"\W$,OQ[^.3C;I8+J)8`P7ZCKM0KJ76C&R3QM>,;:J4FC$$.QS1
M4S&\S)(Y2$*)B78F2DV4F2@W$7E]OE^1^6.OP^P-IT'M$<7H?.ZL"K^35UTH
MR&8U8/8>O@TCV$>`"YV[OGA!U\[$LPB6:#,CGD>PHCW@BRBAS:_I9(L(U@,S
M'KX,O-#VT.*WY(O!@_BM%\'NWM39@@'Z@4'3>0FB%RC=@X0@@HTB<&?(@"\"
MU_*(?BG;8WWIK#,Z0!FGDSE,'"W[IL!^]/@*Y87O`KB';P'TWQ-\^T&P)D[)
M)ON`<2]^D`L,7Y,V?P,``/__`P!02P,$%``&``@````A`$X;`Y"5#0``!TD`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,3,N>&ULK)Q;;^,X$H7?%]C_$.1]
MXTBRG,3H],"6Q`NP"RP6>WEV)TYB3!('MGMZYM]O421%51U.$AO],I[^6"R1
M1R7JB)']Y9??7Y[/?EOO]IOMZ^UY<7%Y?K9^O=O>;UX?;\__\V_UM^OSL_UA
M]7J_>MZ^KF_/_UCOSW_Y^M>_?/FQW?VZ?UJO#V>4X75_>_YT.+S-)Y/]W=/Z
M9;6_V+ZM7ZGE8;M[61WHG[O'R?YMMU[=]YU>GB?EY>5L\K+:O)[[#//=9W)L
M'QXV=^MV>_?]9?UZ\$EVZ^?5@<:_?]J\[6.VE[O/I'M9[7[]_O:WN^W+&Z7X
MMGG>'/[HDYZ?O=S-[>/K=K?Z]DSS_KV8KNYB[OX?D/YE<[?;[K</APM*-_$#
MQ3G?3&XFE.GKE_L-S<#)?K9;/]R>+XJYG97GDZ]?>H'^NUG_V(_^_VS_M/VA
M=YO[OV]>UZ0VG2=W!KYMM[^Z4'OO$'6>0&_5GX%_[L[NUP^K[\^'?VU_F/7F
M\>E`I[NF&;F)S>__:-?[.U*4TER4M<MTMWVF`=!_SUXVKC1(D=7O_>>/S?WA
MZ?:\FEW45Y=50>%GW];[@]JXE.=G=]_WA^W+_WQ0$5+Y)&5(0I^9).]TK$)'
M^HP=+Z[K>CJ[OJ*CO]-Q&CK29^QX_+#I$/W<9T.2XN9B6M97U_WDWSG\5>A)
MG_'PGQLW77;](>DS=+Q*:K]SP)O0CSY#OP^&.O'GN2^;=G58??VRV_XXHVN1
MSN3^;>6N[&).V6*]^&,/%?1G!425XY(L7);;<YH^U<:>JOZWKV5Y^67R&U7J
M78A98DS!(YH8X<K2I6TEZ"10$F@)C`1V!"8DPJ`$5>M/4,)E<4K$.2PC&$DC
MIATC8I=6@DX")8&6P$A@1X!-FZZU\;3S"T4\SRZ8EH31>2XNIWPZ2Q\S31(T
M0%H@'1`%1`,Q0.R8L'G2TO#Y>;I@NB+H8RCHHI`3]4%3NFK^/*@9@H:S"Z0#
MHH!H(`:('1,V=UK9QG-W%WE-E\&1%[G+THL2I[+TI*:[U$B!FM=#,P3%;BV0
M#H@"HH$8('9,F`*TIO\$!5P6KH`G0H&94&`(&A0`T@%10#00`\2."5.`%N>?
MH(#+PA7P1"AP)108@@8%@'1`%!`-Q`"Q8\(4<!YW=*M[?Z5SP6(%*$MQPUKZ
M(+$"7(NY#T'#W(%T0!00#<0`L6/"YDZ+U'CN;@4HZPNZ7(Y<`UP>?OX]$>?_
M1F@P!`T:`.F`*"`:B`%BQX1I4-`Z-1;A_0+HHZ$"2CZQ98CB)2"M3Y.BAODC
MZA`I1!J10609XBHX_S.Z#$XNA<(;*;I)QDDM`^+%(*^:)D7%CBVB#I%"I!$9
M1)8AKH:S12,U/J@);Z*X+RBA)GR4J`D1U11#5%(!4(=1"I%&9!!9AK@*SC6-
M5#C1(!3>?+&*\$A41,6OHB9TI*BDQ=`QH@ZC%"*-R""R#'$MG(L26E37[FGY
MV+72E8E8+`,2<@ACV:2H./<648=((=*(#"++$)?#62HAQTEW#K<+(=7P2*@A
M_6/HR(ICZ!@%ZC!*(=*(#"++$%?#V:N1&A\L%]Z,.7$'?UR6HOB7A8]BRT4)
M(@Q!<<9MZA=1AT@ATH@,(LL0%\$YK)$(I]]!O%4C?>(,EL7@WI)D12D-=8J*
M'5M$'2*%2",RB"Q#7`WGN49J?%`2WJ&)DA`+P+(8?-Q8!6FJ4U128>@848=1
M"I%&9!!9AK@*SG6-5#CU#N+-&ZN(P<^-M9`FNQBBXL1;1!TBA4@C,H@L0TR+
M\BB?V4<+GUF4PD`O0Q1;)""J25&#"H@Z1`J11F0068:X"AF?.:LNTD;NIS<7
M2S2:`?$[1R5V')L4E>3PN48WDPZC%"*-R""R#'$YG+<;72#O+Q.E=X)LF2@J
M^?@9HGA1R*@F1245T&ABE$*D$1E$EB&N0L9HGN0F2K2:`8F:D+8[124UT&IB
ME$*D$1E$EB&NQD^SFB5:S8"$',)\-"DJR>%SL4L$D,*.&I%!9!GB<@BK^<$E
M@G[2>72RF&+*XN;:I*@TY:%C1!U&*40:D4%D&>)3/LI/EH.?C,-<!D2[N1$U
MB%I$'2*%2",RB"Q#?'Y_:A4_.+GH#,N`Z%0-9KJHI$^.4;-!CS8BWC%92C[@
MH]Q<.;BYJ/XRHM&?/R*Z'HTI=.RC^``R1NKZIG_\_$`RM$YE0'SFTD;&J/'P
MLAV3YV(CKHZR.WTTWT&,:"191*,Q182251FG$9[8WY>L[RC&$KP&ETRXL29V
M'`\OUW&:'`F7["@S4`UF8*BR@/A*-Q7^H$E1L6.+J$.D$&E$!I%EB$]9W/D_
M.#-X>Z^&N_3H^I_*VWN*2E,>.D;4891"I!$91)8A/F5Q>_]@RL,M?#P_<;]>
M5CZ*6[ZIB&I25)QRBZA#I!!I1`:198BK0)?2V/B>O%M0N43B:O5(7`;RAA\Z
MC@Q-BZA#I!!I1`:198BK(6[X)SXG5^@$`A):R/MCBDJ5X7.-Y.DP2B'2B`PB
MRQ#70IB##ZZ/P1*DZZ.4^V3+RD>QZZ.&Y7L(2B(`ZE*J&*40:40&D66(BR`,
MARN(T[:;*S0C`8F:2-:G?\NF25%QHBVB#I%"I!$91)8A+H>P/Q_4Q.!Y4DT4
M4V%PEI6/8C4!44V*2BH,'2/J,$HATH@,(LL04V$J+-7I1=%GXHMF0*(HDKGS
M19&BXMQ;1!TBA4@C,H@L0UR.C,$[;2MI&ES::,<Y("&'7#)25)+#YQJOFQBE
M$&E$!I%EB,MQE'N<#NYQ=(W4R9CVIWL9HO@U(J.:%)54\.FI8T0=1BE$&I%!
M9!GB*@A#>>*==(I.,R!>$;4TURDJ3KQ%U"%2B#0B@\@RQ+4XRFE.!Z<91[X,
M2$Q9FNL4%3NVB#I$"I%&9!!9AOB4A:U\_T8Q1>\84-V_C!W6O&`G$VHQJD.D
M$&E$!I%EB,]/&,4/YH=^<!I0NC";@)RH:0NE%@\/;8J*9[E#I!!I1`:1#8AV
MRBD]G[+S8)_>(J<73.7C0$3C*0=?1V=V-&7QA-"&CG0VTI2'CA$IC-*(#"(;
M4&[*POU]<);1X4T]HAWW.,PF(-*Y?P_[LA#/`&T*B'VZF";=%U5$21.=.H;,
M0D>3`F)F&]/TF?GI/LKJN3N3>/H+R.T^CLZMF&T3H]+N4AM1VK[I(DJEHP*B
M?:<X&1VC4BX34<IE(^ISL2F[]?7S%=Y'<^\6D-M_&J8,CS<QB.[,0U!1"]??
MQJBJ+Y.9?(V[B^VILE1$J4IT1.\>R\0H?ZRB%'5C8WM_+*Z8L'[O7R#NI691
M)`&Y)_)!C)EP/TT,&NT:1W35RU-4UV+,70B@W=-8'BKV2;6@(TJ9340W?>;J
M4MQE+4O,Q7!>Z],+)-W90`R/G-,>Q"AJ\;S4A([.@(ZBH'Y"KM(+=',MGB"Z
MD(:V!)-`O@]M%D6D/W4P$Z-\`4WE"R&6'8MK)FSB!P6$;K#VB$HTCKE!U"+J
M$"E$&I%!9!GB\SO*^M6#]1N?6G'FEB'*K6.C`A!138J*PK2(.D0*D49D$%F&
MN`K.N8VN#/<P<-+?E6MO`<<OH`3DUJB1&O(!,44E-7RN4>5T&*40:40&D66(
MJW&4=ZP'[SB:GUPBER&*UX2,:E)44L&GIXX1=1BE$&E$!I%EB*L@[*2KB=-V
M#6JTF@'QHIC)9\04%>?>(NH0*40:D4%D&>)R'&4UZ\%JCHM"W*J6(4H4A8AJ
M4E12P:=G10%(84>-R""R#'$5A.D\?6>M1D,:D"@*\7S5I*@DA\_%5@I`"CMJ
M1`:198C),1.&U,E!7W0[Y2VM/A5WJP$)/821:E+4H`>B#I%"I!$91)8AKH>P
MFZ>7QPRM:$!"#OF\DJ*2'#[7N#PP2B'2B`PBRQ"7P_DU<5L];0FE[[Q+,QJ0
MD$/8S"9%)3E\+B8'((4=-2*#R'T]WPW5I_=R^*_;^^]-OZQWC^MF_?R\/[O;
M?G=?I;]R%GC`X7O^]?5\09EHT**%%LVY6Z!R+3?4TM\G99_9)?UL0.]`H<7]
MH$"_EP(M9?RI`=&RJ*?S!;F'W`BF-(+>G8L^R[JFEER?13VC;/T3,?2949_^
MR0=:KJ@EUV=1W<P7].21&1NUN#^99%JFI`X]T^1:2)ULML6TI%%7V3ZD&VT[
MY[)5U)+O0[K1MEJN#^GF]Y5``\J6'<&BHO-#?S;-9*,6]Z?V7`L=AQYR<RUT
M%K+9%M45'2=;B=3B_F:9RT;5F^VS*$E1>ADBTX=:W#NAN1;2@-Z/S+703.E5
MP5P+S93>J,NUT$QI-RC34M$(_(.H/`L5C2`[ZD5!5S"]Y)W)1BWN5?A<"]5H
MML^BO)PO_`:@'`&UN->H,]E*JMYLGT5!6M.W5#)]J,5]T2O70C.EKSWE6DAK
M_\0CQU:0UMGC+`JZZNE+$;EL=!;HRR.Y%JJJ;)\%29U5FH3.ZDPRY^(7!:E,
M7_;+'9M4IB]%YEI(Y6P?^JV615Y)ZI#+Y,H\QUV)9?B"+O.L@FXQR<0OZ61D
MSSD)GM6;Y,[E;\KK>>/WK<3Y;JK+N7NY#56BOQW,W6Y^KN6*6K+'F5[/W68S
M]J&=9.K3MTR&(=#/T+RM'M?_6.T>-Z_[L^?U`]U;+WLKNO,_9./_<=B^D<VD
M'Z/9'N@':/K_?:(?'%K3#X9<NF\T/VRWA_@/.O1D^`FCK_\'``#__P,`4$L#
M!!0`!@`(````(0!7O$QO,@$``$`"```1``@!9&]C4')O<',O8V]R92YX;6P@
MH@0!**```0``````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````"<D4%+PS`8
MAN^"_Z'DWJ9IJ8S09J"RDP/!B;);3+YMP28-2;3;OS?KNCK1D\?POGGR?%_J
M^5ZWR2<XKSK3()+E*`$C.JG,MD'/JT4Z0XD/W$C>=@8:=`"/YNSZJA:6BL[!
MH^LLN*#`)Y%D/!6V0;L0+,78BQUH[K/8,#'<=$[S$(]NBRT7[WP+N,CS&ZPA
M<,D#QT=@:B<B&I%23$C[X=H!(`6&%C28X#')"/[N!G#:_WEA2"Z:6H6#C3.-
MNI=L*4[AU-Y[-17[OL_Z<M"(_@2_+A^>AE%398Z[$H#8<3\M]V$95[E1(&\/
M;/_FVL3[78U_9[44@QT5#G@`F<3WZ,GNG+R4=_>K!6)%3JHTKU)"5D5.RXI6
MLW6-SZWQ/IN`>A3X-_$,8(/WSS]G7P```/__`P!02P,$%``&``@````A`-/T
MYX.<`@``.@@``!``"`%D;V-0<F]P<R]A<'`N>&UL(*($`2B@``$`````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````G%9=3]LP%'V?M/\0Y1U2"AI3Y0;Q
M53$)MDHI[-$RS@VU<.S,OJGH?CTW"2WIYD:"-\?WZ_C<<^VPLY=21RMP7EDS
MC8\.1W$$1MI<F:=I?+^8'7R/(X_"Y$);`]-X#3X^2[]^87-G*W"HP$>4POAI
MO$2L)DGBY1)*X0_);,A26%<*I$_WE-BB4!*NK*Q+,)B,1Z-O";P@F!SR@VJ;
M,.XR3E;XV:2YE0T^_[!85P0X9>=5I9442*=,[Y1TUML"H^L7"9HE?2,C=!G(
MVBE<IR.6]#]9)H6&2TJ<%D)[8,G[!KL!T9`V%\KYE*UPL@*)UD5>_27:QG'T
M*#PT<*;Q2C@E#!*LQJW[:->Z\NC2W]8]^R4`>I:00[?9+ON^_;4Z2<>GK0>M
M=CV;#!T2,NQB7"C4X'\5<^$P!/FTC[E%T2'N`&VZR$D;_-H@\<5_F*[;RO:1
M;\]P::G1QD/.:>6M5KE`^K@06AA);&X=&UZZ*L,A1Q^)R9"JE1\J\Q82+C-K
MA4V":AFXJ+TRX#VW!<<E\""RK"Y+X=:-3Z:>C*)I(!WP<REM;3`8\D8.SQI!
M$&]E16-H=J6Q96M&XN,/0M?`[T#XVM%Y]_E2JE)A:V\/0$PCZ9>&GT8Z".7Z
M3]TU65)2M0(^I[Z%77\2UEM+;-`50="%@^;,34FB*PMF'^8FW(+AF'&PSCY"
M^4(\ZK`Z]M#:17R&@/!IA@45CAEFX#C(P'#,23!F+VMS!Y7X6`C)W=7!D'U$
MSY2A&R(8,BCC\!2&=<S/\US1^Q"L,JSGL-"&8W9:LW-)_W,MWRKS[.^KA;VB
MZVOS[NQNLG;"<KJ1-_;W#79#3X[339++I:#YSC<^_QN:5_*A^Q5(CTX.1\<C
M>@![>RQY?_335P```/__`P!02P,$%``&``@````A`&11S\>6````J@```!``
M``!X;"]C86QC0VAA:6XN>&UL/([!"@(A%$7W0?\@;]\X,XN(4`<*^H+Z`'%>
MHZ!/\4G4WV>;-A<.%\Z]:GFG*%Y8.632,`TC""27UT";AL?]=CB!X&9IM3$3
M:O@@PV+V.^5L=%=O`XEN(-;@6RMG*=EY3):'7)!Z\\PUV=:Q;I)+1;NR1VPI
MRGD<CS)U`1CE1-5PF680H9\`$7\IC9+_%?,%``#__P,`4$L!`BT`%``&``@`
M```A``;/5J'3`0``\A(``!,``````````````````````%M#;VYT96YT7U1Y
M<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P(_4```!,`@``"P``````````
M```````,!```7W)E;',O+G)E;'-02P$"+0`4``8`"````"$`S5$BR[P!``"Y
M$0``&@`````````````````R!P``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"+0`4``8`"````"$`'_F$/00#``!G"0``#P`````````````````N
M"@``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@````A`+'0SJJI`P``M`L`
M`!@`````````````````7PT``'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+
M`0(M`!0`!@`(````(0!5^YU]V`(``.4'```9`````````````````#X1``!X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L!`BT`%``&``@````A`(@-O!?'
M`@``F`<``!D`````````````````310``'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"+0`4``8`"````"$`I$FW&?0"``!*"```&0``````````````
M``!+%P``>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+`0(M`!0`!@`(````
M(0"\J=_%PP(``"@'```9`````````````````'8:``!X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L!`BT`%``&``@````A`+6MJ<"3`P``?0L``!@`````
M````````````<!T``'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+`0(M`!0`
M!@`(````(0`]@<8-100``"L/```9`````````````````#DA``!X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L!`BT`%``&``@````A`('MRG'7`@``G0<`
M`!D`````````````````M24``'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"+0`4``8`"````"$`[&Y]N^$"``#>!P``&0````````````````##*```
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+`0(M`!0`!@`(````(0!/WE^O
M?00``+40```8`````````````````-LK``!X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"+0`4``8`"````"$`F00>3>T"``!1"0``&```````````````
M``".,```>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!`BT`%``&``@````A
M`!^*B_L$+0``M(\``!0`````````````````L3,``'AL+W-H87)E9%-T<FEN
M9W,N>&UL4$L!`BT`%``&``@````A`-O[=4@`#0``OGP```T`````````````
M````YV```'AL+W-T>6QE<RYX;6Q02P$"+0`4``8`"````"$`^V*E;90&``"G
M&P``$P`````````````````2;@``>&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M
M`!0`!@`(````(0`[,:!4QP,``*0,```9`````````````````-=T``!X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L!`BT`%``&``@````A`.$X1N,+`P``
MY`@``!D`````````````````U7@``'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"+0`4``8`"````"$`5C972%D'```3'@``&0`````````````````7
M?```>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+`0(M`!0`!@`(````(0!O
M@E]^TP(``"`(```9`````````````````*>#``!X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L!`BT`%``&``@````A``NCS;M%!P``51T``!@`````````
M````````L88``'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+`0(M`!0`!@`(
M````(0#Z"!WC5PT``)M(```8`````````````````"R.``!X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"+0`4``8`"````"$`&+0GT-$"```,"```&```
M``````````````"YFP``>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!`BT`
M%``&``@````A`.>+$!+<!0``\!@``!@`````````````````P)X``'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+`0(M`!0`!@`(````(0`\XC<\=P(``.<%
M```9`````````````````-*D``!X;"]W;W)K<VAE971S+W-H965T,3`N>&UL
M4$L!`BT`%``&``@````A`,1:184I"```#"4``!@`````````````````@*<`
M`'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+`0(M`!0`!@`(````(0#(\<_U
M^0<``"PB```9`````````````````-^O``!X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L!`BT`%``&``@````A``TT4;.E!P``UB$``!D`````````````
M````#[@``'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"+0`4``8`"```
M`"$`X*@_$Q@'``!W'```&0````````````````#KOP``>&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+`0(M`!0`!@`(````(0`^%7J0CP(``&<&```9````
M`````````````#K'``!X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L!`BT`
M%``&``@````A`)Q_1H<<!0``DA(``!D``````````````````,H``'AL+W=O
M<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"+0`4``8`"````"$`3AL#D)4-```'
M20``&0````````````````!3SP``>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM
M;%!+`0(M`!0`!@`(````(0!7O$QO,@$``$`"```1`````````````````!_=
M``!D;V-0<F]P<R]C;W)E+GAM;%!+`0(M`!0`!@`(````(0#3].>#G`(``#H(
M```0`````````````````(C?``!D;V-0<F]P<R]A<'`N>&UL4$L!`BT`%``&
M``@````A`&11S\>6````J@```!``````````````````6N,``'AL+V-A;&-#
>:&%I;BYX;6Q02P4&`````"4`)0#L"0``'N0`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EECAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity Incentive Plans - Additional Information (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 21, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">29,257,836</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">24,245,437</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=vsar_TwoThousandNineStockOptionPlanMember', window );">2009 Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for future issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant[us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=vsar_TwoThousandNineStockOptionPlanMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant<br>/ us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis<br>= vsar_TwoThousandNineStockOptionPlanMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=vsar_StockOptionPlanTwoThousandFourteenMember', window );">2014 Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for future issuance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant[us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=vsar_StockOptionPlanTwoThousandFourteenMember]" onclick="toggleNextSibling(this);">2,031,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant<br>/ us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis<br>= vsar_StockOptionPlanTwoThousandFourteenMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of common stock issued and outstanding increase annually</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum[us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=vsar_StockOptionPlanTwoThousandFourteenMember]" onclick="toggleNextSibling(this);">4.50%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum<br>/ us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis<br>= vsar_StockOptionPlanTwoThousandFourteenMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of common stock shares subject to outstanding awards</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=vsar_StockOptionPlanTwoThousandFourteenMember]" onclick="toggleNextSibling(this);">2,947,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis<br>= vsar_StockOptionPlanTwoThousandFourteenMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=vsar_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of common stock issued and outstanding increase annually</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum[us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=vsar_EmployeeStockPurchasePlanMember]" onclick="toggleNextSibling(this);">1.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum<br>/ us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis<br>= vsar_EmployeeStockPurchasePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved</a></td>
        <td class="nump"><a title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance[us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=vsar_EmployeeStockPurchasePlanMember]" onclick="toggleNextSibling(this);">392,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance<br>/ us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis<br>= vsar_EmployeeStockPurchasePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares issued</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized[us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=vsar_EmployeeStockPurchasePlanMember]" onclick="toggleNextSibling(this);">300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized<br>/ us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis<br>= vsar_EmployeeStockPurchasePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding[us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=vsar_EmployeeStockPurchasePlanMember]" onclick="toggleNextSibling(this);">9,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding<br>/ us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis<br>= vsar_EmployeeStockPurchasePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of common shares reserved for future issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=vsar_EmployeeStockPurchasePlanMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=vsar_EmployeeStockPurchasePlanMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=vsar_StockOptionPlanTwoThousandFourteenMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=vsar_StockOptionPlanTwoThousandFourteenMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=vsar_TwoThousandNineStockOptionPlanMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=vsar_TwoThousandNineStockOptionPlanMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table sets forth the Company&#8217;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at March 31, 2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,162</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,162</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,125</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,125</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]E-&4V864X9%\P.39B7S1A,#5?86$T9%]B
M.3@U.&)E.#8X9&,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO931E
M-F%E.&1?,#DV8E\T83`U7V%A-&1?8CDX-3AB93@V.&1C+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O
M;G-O;&ED871E9%]"86QA;F-E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O;G-O;&ED871E9%]"86QA;F-E,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E
M9%]#;VYS;VQI9&%T961?4W1A=&5M93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M
M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y&;W)M
M871I;VY?86YD7T)U<VEN97-S7V]F7W1H95\\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#8N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C
M8V]U;G0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,#<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"
M86QA;F-E7U-H965T7T-O;7!O;F5N=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#@N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y&86ER7U9A;'5E7TUE87-U<F5M96YT<SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;6UI=&UE;G1S
M7V%N9%]#;VYT:6YG96YC:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^17%U:71Y7TEN8V5N=&EV95]0;&%N<SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970Q,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYE=%],;W-S7W!E<E]3:&%R
M95]O9E]#;VUM;VY?4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,BYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C;W5N=#$\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,3,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I
M9VYI9FEC86YT7T%C8V]U;G0R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0F%L86YC95]3:&5E=%]#;VUP;VYE;G1S7U1A8FQE/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#$U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1F%I<E]686QU
M95]-96%S=7)E;65N='-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^3F5T7TQO<W-?<&5R7U-H87)E7V]F7T-O;6UO;E]3
M,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D9O<FUA
M=&EO;E]A;F1?0G5S:6YE<W-?;V9?=&AE7S$\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3@N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C
M8V]U;G0S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#$Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT-#PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R
M,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D)A;&%N8V5?4VAE971?0V]M<&]N
M96YT<U]0<F5P83PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D)A;&%N8V5?4VAE971?0V]M<&]N96YT<U]!8V-R=3PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970R,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D9A:7)?5F%L=65?365A<W5R
M96UE;G1S7T9I;F%N8SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,RYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S7SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970R-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D5Q=6ET>5]);F-E;G1I
M=F5?4&QA;G-?061D:71I;SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-2YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/DYE=%],;W-S7W!E<E]3:&%R95]O9E]#;VUM;VY?4S(\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,C8N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.971?3&]S<U]P
M97)?4VAA<F5?;V9?0V]M;6]N7U,S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(W+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@/"]X.D5X8V5L5V]R:W-H965T
M<SX-"B`@/'@Z4W1Y;&5S:&5E="!(4F5F/3-$(E=O<FMS:&5E=',O<F5P;W)T
M+F-S<R(O/@T*("`\>#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*
M("`\>#I0<F]T96-T4W1R=6-T=7)E/D9A;'-E/"]X.E!R;W1E8W13=')U8W1U
M<F4^#0H@(#QX.E!R;W1E8W17:6YD;W=S/D9A;'-E/"]X.E!R;W1E8W17:6YD
M;W=S/@T*(#PO>#I%>&-E;%=O<FMB;V]K/@T*/"]X;6P^/"%;96YD:69=+2T^
M#0H\+VAE860^#0H@(#QB;V1Y/@T*("`@/'`^5&AI<R!P86=E('-H;W5L9"!B
M92!O<&5N960@=VET:"!-:6-R;W-O9G0@17AC96P@6%`@;W(@;F5W97(N/"]P
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?931E
M-F%E.&1?,#DV8E\T83`U7V%A-&1?8CDX-3AB93@V.&1C#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V4T939A93AD7S`Y-F)?-&$P-5]A831D7V(Y
M.#4X8F4X-CAD8R]7;W)K<VAE971S+U-H965T,#$N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4Q
M0T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1O8W5M96YT(&%N9"!%;G1I
M='D@26YF;W)M871I;VX\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y!<'(N(#,P+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D1O8W5M96YT($%N9"!%;G1I='D@26YF;W)M871I
M;VX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$;V-U;65N="!4>7!E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XQ,"U1/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!;65N9&UE;G0@1FQA9SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^9F%L<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%!E<FEO9"!%;F0@
M1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^36%R(#,Q+`T*
M"0DR,#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@665A<B!&;V-U<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^,C`Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%!E
M<FEO9"!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^43$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1R861I;F<@4WEM8F]L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#Y64T%2/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%;G1I='D@4F5G:7-T<F%N="!.86UE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#Y697)S87)T:7,L($EN8RX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT
M<F%L($EN9&5X($ME>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,#`P,34Q,S@Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A<B!%;F0@1&%T93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^+2TQ,BTS,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I
M;&5R($-A=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y!
M8V-E;&5R871E9"!&:6QE<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S
M($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M.2PR-C`L,C,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]E-&4V864X9%\P.39B7S1A,#5?86$T9%]B.3@U.&)E.#8X9&,-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO931E-F%E.&1?,#DV8E\T83`U
M7V%A-&1?8CDX-3AB93@V.&1C+U=O<FMS:&5E=',O4VAE970P,BYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P15!5044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V]N9&5N<V5D
M($-O;G-O;&ED871E9"!"86QA;F-E(%-H965T<R`H56YA=61I=&5D*2`H55-$
M("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I
M960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0W5R<F5N="!!<W-E=',\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L
M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,S`L,C8Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q-S`L-38V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V5S(&%N9"!O=&AE<B!C=7)R96YT
M(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PQ.#8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#,Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1O=&%L(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,S0L-#0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3<R+#DV-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@87-S971S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.#0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,38\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y
M(&%N9"!E<75I<&UE;G0L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,S4L,SDU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3<T+#(Y-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT
M(&QI86)I;&ET:65S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8V]U;G1S(%!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L,C4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&QI86)I;&ET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#(Q.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-C8V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@0W5R<F5N="!,:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-RPX,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV+#DR-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($QI86)I;&ET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#@R,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L.3(U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM:71M
M96YT<R!A;F0@8V]N=&EN9V5N8VEE<R`H3F]T92`V*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-T;V-K:&]L9&5R<R<@97%U:71Y/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@)#`N
M,#`P,2!P87(@=F%L=64[(#4L,#`P+#`P,"!S:&%R97,@875T:&]R:7IE9"!A
M="!-87)C:"`S,2P@,C`Q-2!A;F0@1&5C96UB97(@,S$L(#(P,30L(')E<W!E
M8W1I=F5L>3L@>F5R;R!S:&%R97,@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!A
M="!-87)C:"`S,2P@,C`Q-2!A;F0@1&5C96UB97(@,S$L(#(P,30L(')E<W!E
M8W1I=F5L>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL("0P+C`P,#$@<&%R
M('9A;'5E+"`U,"PP,#`L,#`P('-H87)E<R!A=71H;W)I>F5D(&%T($UA<F-H
M(#,Q+"`R,#$U(&%N9"!$96-E;6)E<B`S,2P@,C`Q-#L@,CDL,C4W+#@S-B!A
M;F0@,C0L,C0U+#0S-R!S:&%R97,@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!A
M="!-87)C:"`S,2P@,C`Q-2!A;F0@1&5C96UB97(@,S$L(#(P,30L(')E<W!E
M8W1I=F5L>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D
M9&ET:6]N86P@<&%I9"UI;B!C87!I=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS-C`L.#,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C<X+#8R-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@9&5F:6-I
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3,S+#(V-BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,3$L
M,C4Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1O=&%L('-T;V-K:&]L9&5R<R<@97%U:71Y/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,C<L-3<U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38W+#,V.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QI
M86)I;&ET:65S(&%N9"!S=&]C:VAO;&1E<G/B@)D@97%U:71Y/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(S-2PS.34\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$W-"PR.30\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4T939A93AD
M7S`Y-F)?-&$P-5]A831D7V(Y.#4X8F4X-CAD8PT*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]E-&4V864X9%\P.39B7S1A,#5?86$T9%]B.3@U.&)E
M.#8X9&,O5V]R:W-H965T<R]3:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-DY!0SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYD96YS960@0V]N<V]L:61A=&5D
M($)A;&%N8V4@4VAE971S("A5;F%U9&ET960I("A087)E;G1H971I8V%L*2`H
M55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3=&%T96UE;G0@3V8@1FEN86YC:6%L(%!O
M<VET:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!P87(@=F%L=64\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#`Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E
M9F5R<F5D('-T;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@;W5T
M<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VLL('!A<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C`P,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R
M97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&ES
M<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDL,C4W+#@S
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(T+#(T-2PT,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.2PR-3<L.#,V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0L
M,C0U+#0S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?931E-F%E.&1?,#DV8E\T83`U7V%A-&1?8CDX-3AB93@V.&1C#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4T939A93AD7S`Y-F)?-&$P-5]A
M831D7V(Y.#4X8F4X-CAD8R]7;W)K<VAE971S+U-H965T,#0N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$4T14%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;F1E;G-E9"!#
M;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!/<&5R871I;VYS(&%N9"!#;VUP
M<F5H96YS:79E($QO<W,@*%5N875D:71E9"D@*%531"`D*3QB<CY);B!4:&]U
M<V%N9',L(&5X8V5P="!097(@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES
M92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^3W!E<F%T:6YG(&5X<&5N<V5S/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E
M;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-RPQ
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#0L.#8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PQ.#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#<Q-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&]P
M97)A=&EN9R!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C(L,C@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-RPU.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&9R;VT@;W!E<F%T:6]N<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C(L,C@Q*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<L-3@S*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E
M<W0@:6YC;VUE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W1H97(@:6YC;VUE("AE>'!E;G-E*2P@;F5T/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q,2PX-#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@86YD(&-O;7!R
M96AE;G-I=F4@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,C(L,#`V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$Y+#0R-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1E96UE9"!D:79I9&5N9"!R96QA=&5D('1O(&)E
M;F5F:6-I86P@8V]N=F5R<VEO;B!F96%T=7)E(&]F(&-O;G9E<G1I8FQE('!R
M969E<G)E9"!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,C4L-34Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE="!L;W-S(&%T=')I8G5T86)L92!T;R!C;VUM;VX@<W1O
M8VMH;VQD97)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(R
M+#`P-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#0T+#DX-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S('!E<B!B87-I8R!A;F0@9&EL=71E
M9"!S:&%R92!A='1R:6)U=&%B;&4@=&\@8V]M;6]N('-T;V-K:&]L9&5R<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C<Y*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,38N,3,I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y796EG:'1E9"UA=F5R86=E(&-O;6UO;B!S:&%R97,@=7-E9"!T;R!C;VUP
M=71E(&)A<VEC(&%N9"!D:6QU=&5D(&YE="!L;W-S('!E<B!S:&%R93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L.#$P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPW.#@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4T939A93AD7S`Y
M-F)?-&$P-5]A831D7V(Y.#4X8F4X-CAD8PT*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]E-&4V864X9%\P.39B7S1A,#5?86$T9%]B.3@U.&)E.#8X
M9&,O5V]R:W-H965T<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%0S-!1SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYD96YS960@0V]N<V]L:61A=&5D(%-T
M871E;65N=',@;V8@0V%S:"!&;&]W<R`H56YA=61I=&5D*2`H55-$("0I/&)R
M/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S
M:"!F;&]W<R!F<F]M(&]P97)A=&EN9R!A8W1I=FET:65S/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(R+#`P-BD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$Y+#0R-BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^061J=7-T;65N=',@=&\@<F5C;VYC:6QE(&YE="!L;W-S('1O
M(&YE="!C87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I97,\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T
M:6]N(&%N9"!A;6]R=&EZ871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3@X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296UE
M87-U<F5M96YT(&]F(&-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:R!C86QL
M(&]P=&EO;B!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDL-38P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y296UE87-U<F5M96YT(&]F(&-O;G9E<G1I8FQE('!R969E
M<G)E9"!S=&]C:R!W87)R86YT(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPR-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VAA;F=E<R!I;B!A<W-E
M=',@86YD(&QI86)I;&ET:65S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&%S
M<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PT-38I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(W
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06-C;W5N=',@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-C4W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06-C<G5E9"!L:6%B:6QI=&EE<R!A;F0@;W1H97(@
M;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-34S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C`L-3(T*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4L.#`X
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@:6YV97-T:6YG(&%C=&EV:71I
M97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4'5R8VAA<V4@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@S."D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!U<V5D(&EN
M(&EN=F5S=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#,X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@9FEN86YC
M:6YG(&%C=&EV:71I97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@
M<W1O8VL@:6X@:6YI=&EA;"!P=6)L:6,@;V9F97)I;F<L(&YE="!O9B!I<W-U
M86YC92!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,R
M+#$X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@
M:6X@9F]L;&]W+6]N(&]F9F5R:6YG+"!N970@;V8@:7-S=6%N8V4@8V]S=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@P+#(P.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E
M9',@9G)O;2!I<W-U86YC92!O9B!C;VYV97)T:6)L92!P<F5F97)R960@<W1O
M8VLL(&YE="!O9B!I<W-U86YC92!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-C0L-SDS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&5X97)C:7-E(&]F
M(&-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:R!W87)R86YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3<P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&5X
M97)C:7-E(&]F(&-O;6UO;B!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!P<F]V:61E9"!B>2!F
M:6YA;F-I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.#`L,C(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3DW+#4U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I;F-R96%S92!I;B!C87-H(&%N
M9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU.2PV.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ.3$L-S`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S
M(&%T(&)E9VEN;FEN9R!O9B!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$W,"PU-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,RPR.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A
M;&5N=',@870@96YD(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C,P+#(V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(P-"PY.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE;65N=&%L
M(&1I<V-L;W-U<F4@;V8@;F]N8V%S:"!I=&5M<SPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/9F9E<FEN9R!I<W-U86YC92!C
M;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR.3,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;G9E<G-I;VX@;V8@<')E9F5R<F5D('-T;V-K(&-A;&P@;W!T:6]N(&QI86)I
M;&ET>2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E-U<'!L96UE;G1A;"!D:7-C;&]S=7)E(&]F(&YO;F-A<V@@
M:71E;7,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]N=F5R<VEO;B!O9B!L:6%B:6QI='D@=&\@861D:71I;VYA;"!P86ED
M(&EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL
M-3@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VYV97)S:6]N(&]F('!R969E<G)E9"!S=&]C:R!W87)R86YT(&QI
M86)I;&ET>2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-U<'!L96UE;G1A;"!D:7-C;&]S=7)E(&]F(&YO;F-A
M<V@@:71E;7,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]N=F5R<VEO;B!O9B!L:6%B:6QI='D@=&\@861D:71I;VYA;"!P
M86ED(&EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L-S4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VYV97)S:6]N(&]F('!R969E<G)E9"!S=&]C:R!T;R!C;VUM
M;VX@<W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3=7!P;&5M96YT86P@9&ES8VQO<W5R92!O9B!N;VYC
M87-H(&ET96US/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;G9E<G-I;VX@=&\@8V]M;6]N('-T;V-K(&%N9"!A9&1I=&EO
M;F%L('!A:60@:6X@8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q,C(L,CDP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%]E-&4V864X9%\P.39B7S1A,#5?86$T9%]B.3@U.&)E.#8X
M9&,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO931E-F%E.&1?,#DV
M8E\T83`U7V%A-&1?8CDX-3AB93@V.&1C+U=O<FMS:&5E=',O4VAE970P-BYH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D9O<FUA
M=&EO;B!A;F0@0G5S:6YE<W,@;V8@=&AE($-O;7!A;GD\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG
M(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1F]R;6%T:6]N(&%N9"!"=7-I;F5S<R!O9B!T
M:&4@0V]M<&%N>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I
M=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXQ+B!&;W)M871I;VX@86YD($)U<VEN97-S(&]F('1H92!#;VUP86YY
M(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z-'!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/E9E<G-A<G1I<RP@26YC+B`H=&AE("8C.#(R,#M#;VUP
M86YY)B,X,C(Q.RD@=V%S(&EN8V]R<&]R871E9"!O;B!$96-E;6)E<B8C,38P
M.S$P+"`R,#`X(&EN('1H92!3=&%T92!O9B!$96QA=V%R92X@5&AE($-O;7!A
M;GD@:7,@86X@96YD;V-R:6YE+69O8W5S960@8FEO<&AA<FUA8V5U=&EC86P@
M8V]M<&%N>2!I;FET:6%L;'D@9&5V96QO<&EN9R!L;VYG+6%C=&EN9R!R96-O
M;6)I;F%N="!H=6UA;B!G<F]W=&@@:&]R;6]N92!F;W(@=&AE('1R96%T;65N
M="!O9B!G<F]W=&@@:&]R;6]N92!D969I8VEE;F-Y+B!4:&4@0V]M<&%N>2!I
M<R!D979E;&]P:6YG(&1R=6<@8V%N9&ED871E<R!T:&%T(&ET(&AA<R!L:6-E
M;G-E9"!F<F]M($%M=6YI>"!/<&5R871I;F<@26YC+B`H)B,X,C(P.T%M=6YI
M>"8C.#(R,3LI+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
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M,'!T.VUA<F=I;BUT;W`Z,3-P=#MM87)G:6XM;&5F=#HT+C4T)3MT97AT+6EN
M9&5N=#HP)3MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^56YA=61I
M=&5D($EN=&5R:6T@1FEN86YC:6%L($EN9F]R;6%T:6]N/&9O;G0@<W1Y;&4]
M,T1F;VYT+7-T>6QE.FYO<FUA;#L^(#PO9F]N=#X\+W`^#0H\<"!S='EL93TS
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M:"`S,2P@,C`Q-2!I<R!U;F%U9&ET960N(%1H92!C;VYD96YS960@8V]N<V]L
M:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN8VQU9&5D(&EN('1H:7,@
M<F5P;W)T(')E9FQE8W0@86QL(&%D:G5S=&UE;G1S("AC;VYS:7-T:6YG(&]N
M;'D@;V8@;F]R;6%L(')E8W5R<FEN9R!A9&IU<W1M96YT<RD@=&AA="!M86YA
M9V5M96YT(&-O;G-I9&5R<R!N96-E<W-A<GD@9F]R('1H92!F86ER('!R97-E
M;G1A=&EO;B!O9B!T:&4@<F5S=6QT<R!O9B!O<&5R871I;VYS(&9O<B!T:&4@
M:6YT97)I;2!P97)I;V1S(&-O=F5R960@86YD(&]F('1H92!F:6YA;F-I86P@
M8V]N9&ET:6]N(&]F('1H92!#;VUP86YY(&%T('1H92!D871E(&]F('1H92!I
M;G1E<FEM(&)A;&%N8V4@<VAE970N(%1H92!R97-U;'1S(&9O<B!I;G1E<FEM
M('!E<FEO9',@87)E(&YO="!N96-E<W-A<FEL>2!I;F1I8V%T:79E(&]F('1H
M92!R97-U;'1S(&9O<B!T:&4@96YT:7)E('EE87(@;W(@86YY(&]T:&5R(&EN
M=&5R:6T@<&5R:6]D+B!4:&4@86-C;VUP86YY:6YG(&-O;F1E;G-E9"!C;VYS
M;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@86YD(')E;&%T960@9FEN
M86YC:6%L(&EN9F]R;6%T:6]N('-H;W5L9"!B92!R96%D(&EN(&-O;FIU;F-T
M:6]N('=I=&@@=&AE(&%U9&ET960@9FEN86YC:6%L('-T871E;65N=',@86YD
M('1H92!R96QA=&5D(&YO=&5S('1H97)E=&\@9F]R('1H92!Y96%R(&5N9&5D
M($1E8V5M8F5R)B,Q-C`[,S$L(#(P,30@:6YC;'5D960@:6X@=&AE($-O;7!A
M;GDF(S@R,3<[<R!A;FYU86P@<F5P;W)T(&]N($9O<FT@,3`M2R!F:6QE9"!O
M;B!-87)C:"8C,38P.S8L(#(P,34@=VET:"!T:&4@52Y3+B!396-U<FET:65S
M(&%N9"!%>&-H86YG92!#;VUM:7-S:6]N("@F(S@R,C`[4T5#)B,X,C(Q.RDN
M(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,3-P=#MM87)G:6XM;&5F=#HT+C4T)3MT97AT+6EN9&5N=#HP)3MF;VYT
M+7=E:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^4V5C;VYD87)Y($]F9F5R:6YG
M(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z-'!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/DEN($IA;G5A<GD@,C`Q-2P@=V4@8V]M<&QE=&5D(&$@
M<V5C;VYD87)Y('!U8FQI8R!O9F9E<FEN9R!O9B!C;VUM;VX@<W1O8VLL('!U
M<G-U86YT('1O('=H:6-H('=E(&ES<W5E9"`T+#DY.2PY.3D@<VAA<F5S(&]F
M(&-O;6UO;B!S=&]C:RP@=VAI8V@@:6YC;'5D97,@<VAA<F5S(&ES<W5E9"!P
M=7)S=6%N="!T;R!T:&4@=6YD97)W<FET97)S)B,X,C$W.R!E>&5R8VES92!O
M9B!T:&5I<B!O=F5R+6%L;&]T;65N="!O<'1I;VXL(&%N9"!R96-E:79E9"!N
M970@<')O8V5E9',@;V8@87!P<F]X:6UA=&5L>2`D.#`N,B!M:6QL:6]N+"!A
M9G1E<B!U;F1E<G=R:71I;F<@9&ES8V]U;G1S+"!C;VUM:7-S:6]N<R!A;F0@
M97-T:6UA=&5D(&]F9F5R:6YG(&5X<&5N<V5S+B`\+W`^#0H\<"!S='EL93TS
M1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT
M.C`E.V9O;G0M<VEZ93HS+C5P=#L^)FYB<W`[/"]P/CPO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?931E-F%E.&1?,#DV
M8E\T83`U7V%A-&1?8CDX-3AB93@V.&1C#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V4T939A93AD7S`Y-F)?-&$P-5]A831D7V(Y.#4X8F4X-CAD
M8R]7;W)K<VAE971S+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U
M;G1I;F<@4&]L:6-I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E
M;G0Z,"4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(N(%-U;6UA
M<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`\+W`^#0H\
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M;VTZ,'!T.VUA<F=I;BUT;W`Z-'!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M
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M9"!3=&%T97,@;V8@06UE<FEC82`H)B,X,C(P.U4N4RX@1T%!4"8C.#(R,3LI
M+B!4:&4@<')E<&%R871I;VX@;V8@=&AE(&%C8V]M<&%N>6EN9R!C;VYD96YS
M960@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN(&%C8V]R
M9&%N8V4@=VET:"!5+E,N($=!05`@<F5Q=6ER97,@;6%N86=E;65N="!T;R!M
M86ME(&5S=&EM871E<R!A;F0@87-S=6UP=&EO;G,@=&AA="!A9F9E8W0@=&AE
M(')E<&]R=&5D(&%M;W5N=',@;V8@87-S971S(&%N9"!L:6%B:6QI=&EE<RP@
M=&AE(&1I<V-L;W-U<F4@;V8@8V]N=&EN9V5N="!A<W-E=',@86YD(&QI86)I
M;&ET:65S(&%T('1H92!D871E(&]F('1H92!C;VYD96YS960@8V]N<V]L:61A
M=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+"!A;F0@=&AE(')E<&]R=&5D(&%M
M;W5N=',@;V8@97AP96YS97,@9'5R:6YG('1H92!R97!O<G1I;F<@<&5R:6]D
M+B!!8W1U86P@<F5S=6QT<R!C;W5L9"!D:69F97(@9G)O;2!T:&]S92!E<W1I
M;6%T97,N/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M($UA<F-H(#,Q+"`R,#$T(&EN8VQU9&4@;VYL>2!T:&4@86-C;W5N=',@;V8@
M5F5R<V%R=&ES+"!);F,N/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
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M=F4@8V%S:"!F;&]W<R!F<F]M(&]P97)A=&EO;G,N($%T($UA<F-H)B,Q-C`[
M,S$L(#(P,34L('1H92!#;VUP86YY(&AA9"!A;B!A8V-U;75L871E9"!D969I
M8VET(&]F("0Q,S,N,R8C,38P.VUI;&QI;VX@86YD('=O<FMI;F<@8V%P:71A
M;"!O9B`D,C(V+C8F(S$V,#MM:6QL:6]N+B!4:&4@0V]M<&%N>2!E>'!E8W1S
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M(&UO<W0@<F5C96YT;'D@:6X@2F%N=6%R>2`R,#$U+"!T:&5R92!C86X@8F4@
M;F\@87-S=7)A;F-E('1H870@=&AE($-O;7!A;GD@=VEL;"!B92!S=6-C97-S
M9G5L(&]R('1H870@86YY(&YE961E9"!F:6YA;F-I;F<@=VEL;"!B92!A=F%I
M;&%B;&4@:6X@=&AE(&9U='5R92!A="!T97)M<R!A8V-E<'1A8FQE('1O('1H
M92!#;VUP86YY+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
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M;W`Z-'!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M9F%M:6QY.E1I;65S($YE
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M;BUT;W`Z,3-P=#MM87)G:6XM;&5F=#HT+C4T)3MT97AT+6EN9&5N=#HP)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M;F)S<#L\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HT+C4T)3MT97AT+6EN9&5N=#HP)3MF
M;VYT+7=E:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^0V]N8V5N=')A=&EO;B!O
M9B`\9F]N="!S='EL93TS1'1E>'0M=')A;G-F;W)M.G5P<&5R8V%S93L^8SPO
M9F]N=#YR961I="`\9F]N="!S='EL93TS1'1E>'0M=')A;G-F;W)M.G5P<&5R
M8V%S93L^<CPO9F]N=#YI<VL@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M(&QI;6ET<RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HQ,W!T.VUA<F=I;BUL969T.C0N-30E.W1E>'0M:6YD96YT
M.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II=&%L:6,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY2:7-K(&%N9"!5
M;F-E<G1A:6YT:65S(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z-'!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M9F%M
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M92!S;W5R8V4@<W5P<&QI97)S+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM
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M=&AE(%4N4RX@1F]O9"!A;F0@1')U9R!!9&UI;FES=')A=&EO;B`H)B,X,C(P
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M(&]N('1H92!#;VUP86YY+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
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M,'!T.VUA<F=I;BUT;W`Z,3-P=#MM87)G:6XM;&5F=#HT+C4T)3MT97AT+6EN
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M87-E.SYE/"]F;VYT/G%U:79A;&5N=',@/"]P/@T*/'`@<W1Y;&4],T0G;6%R
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M(#,Q+"`R,#$U(&%N9"!$96-E;6)E<B`S,2P@,C`Q-"!T:&4@0V]M<&%N>28C
M.#(Q-SMS(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@=V5R92!H96QD(&EN
M(&9I=F4@:6YS=&ET=71I;VYS(&EN('1H92!5;FET960@4W1A=&5S(&%N9"!I
M;F-L=61E(&1E<&]S:71S(&EN(&UO;F5Y(&UA<FME="!F=6YD<R!W:&EC:"!W
M97)E('5N<F5S=')I8W1E9"!A<R!T;R!W:71H9')A=V%L(&]R('5S92X\+W`^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$S
M<'0[;6%R9VEN+6QE9G0Z-"XU-"4[=&5X="UI;F1E;G0Z,"4[9F]N="UW96EG
M:'0Z8F]L9#MF;VYT+7-T>6QE.FET86QI8SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E!R;W!E<G1Y(&%N9"`\9F]N="!S='EL
M93TS1'1E>'0M=')A;G-F;W)M.G5P<&5R8V%S93L^93PO9F]N=#YQ=6EP;65N
M="P@3F5T(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z-'!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M9F%M:6QY.E1I
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M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3-P=#MM87)G
M:6XM;&5F=#HT+C4T)3MT97AT+6EN9&5N=#HP)3MF;VYT+7=E:6=H=#IB;VQD
M.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^26UP86ER;65N="!O9B!,;VYG+4QI=F5D($%S<V5T
M<R`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
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M,C`Q-"X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
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M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-'!T.W1E>'0M:6YD96YT.C0N-30E
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M8V%R<FEE9"!A="!F86ER('9A;'5E+B`\+W`^#0H\<"!S='EL93TS1"=M87)G
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M<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M92!O9B!F86ER('9A;'5E(&UE87-U<F5M96YT<R!A<R!F;VQL;W=S.B`\+W`^
M#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HT+C5P=#L^)FYB<W`[/"]P/@T*
M/&1I=CX-"CQT86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O
M;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HY,24[)SX-"CQT<CX-"CQT9"!V86QI
M9VX],T1T;W`@<W1Y;&4],T1W:61T:#HX)3L^#0H\<"!S='EL93TS1"=M87)G
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M=&]M('-T>6QE/3-$=VED=&@Z,"XY-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V9O;G0M<VEZ93HX<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$
M=VED=&@Z.3(N,#8E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY5;F%D:G5S
M=&5D('%U;W1E9"!P<FEC97,@:6X@86-T:79E(&UA<FME=',@9F]R(&ED96YT
M:6-A;"!A<W-E=',@;W(@;&EA8FEL:71I97,[/"]P/CPO=&0^#0H\+W1R/@T*
M/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C@E.SX-"CQP
M('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M<VEZ93HT+C5P
M=#L^)FYB<W`[/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HQ<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DQE=F5L)B,Q
M-C`[24D\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HP+CDT)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W
M:61T:#HY,BXP-B4[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[9F]N="US:7IE.C0N-7!T.SXF;F)S<#L\+W`^#0H\<"!S='EL93TS1"=M
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M<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HX)3L^
M#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7-I>F4Z
M-"XU<'0[/B9N8G-P.SPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,7!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY,979E
M;"8C,38P.TE)23PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C`N.30E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T
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M+C`V)3L^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
M+7-I>F4Z-"XU<'0[/B9N8G-P.SPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,7!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M;BUT;W`Z.7!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M9F%M:6QY.E1I;65S
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M="X@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M(&UO;F5Y(&UA<FME="!F=6YD+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$S<'0[;6%R9VEN+6QE9G0Z-"XU-"4[
M=&5X="UI;F1E;G0Z,"4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-T>6QE.FET
M86QI8SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/E!R96-L:6YI8V%L(&%N9"!#;&EN:6-A;"!4<FEA;"!!8V-R=6%L<R`\+W`^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C1P
M=#MT97AT+6EN9&5N=#HT+C4T)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SY4:&4@0V]M<&%N>28C.#(Q-SMS(&-L:6YI8V%L('1R:6%L(&%C
M8W)U86QS(&%R92!B87-E9"!O;B!E<W1I;6%T97,@;V8@<&%T:65N="!E;G)O
M;&QM96YT(&%N9"!R96QA=&5D(&-O<W1S(&%T(&-L:6YI8V%L(&EN=F5S=&EG
M871O<B!S:71E<R!A<R!W96QL(&%S(&5S=&EM871E<R!F;W(@=&AE('-E<G9I
M8V5S(')E8V5I=F5D(&%N9"!E9F9O<G1S(&5X<&5N9&5D('!U<G-U86YT('1O
M(&-O;G1R86-T<R!W:71H(&UU;'1I<&QE(')E<V5A<F-H(&EN<W1I='5T:6]N
M<R!A;F0@8VQI;FEC86P@<F5S96%R8V@@;W)G86YI>F%T:6]N<R`H)B,X,C(P
M.T-23W,F(S@R,C$[*2!T:&%T(&-O;F1U8W0@86YD(&UA;F%G92!C;&EN:6-A
M;"!T<FEA;',@;VX@=&AE($-O;7!A;GDF(S@R,3<[<R!B96AA;&8N(#PO<#X-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z.7!T
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M9"!E>'!E;G-E<R!U;G1I;"!T:&4@<V5R=FEC97,@87)E(')E;F1E<F5D+B`\
M+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C$S<'0[;6%R9VEN+6QE9G0Z-"XU-"4[=&5X="UI;F1E;G0Z,"4[9F]N="UW
M96EG:'0Z8F]L9#MF;VYT+7-T>6QE.FET86QI8SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E)E<V5A<F-H(&%N9"`\9F]N="!S
M='EL93TS1'1E>'0M=')A;G-F;W)M.G5P<&5R8V%S93L^9#PO9F]N=#YE=F5L
M;W!M96YT(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z-'!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M9F%M:6QY.E1I
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M;W-T<R!W:&5N(&EN8W5R<F5D+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$S<'0[;6%R9VEN+6QE9G0Z-"XU-"4[
M=&5X="UI;F1E;G0Z,"4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-T>6QE.FET
M86QI8SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/DEN8V]M92`\9F]N="!S='EL93TS1'1E>'0M=')A;G-F;W)M.G5P<&5R8V%S
M93L^=#PO9F]N=#YA>&5S(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z-'!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M
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M.VUA<F=I;BUT;W`Z.7!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M9F%M:6QY
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M($-O;7!A;GD@=VEL;"!D971E<FUI;F4@=VAE=&AE<B`H:2DF(S$V,#MT:&4@
M9F%C=&]R<R!U;F1E<FQY:6YG('1H92!S=7-T86EN86)I;&ET>2!A<W-E<G1I
M;VX@:&%V92!C:&%N9V5D(&%N9"`H:6DI)B,Q-C`[=&AE(&%M;W5N="!O9B!T
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M:6]N(&)E8V]M97,@879A:6QA8FQE+B`\+W`^#0H\<"!S='EL93TS1"=M87)G
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M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-'!T.W1E>'0M:6YD
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M=F4@=F%R:6%B;&5S+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
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M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT
M.C`E.V9O;G0M<VEZ93HY<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P
M/@T*/&1I=CX-"CQT86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R
M+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HQ,#`E.R<^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HT.24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4P
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@8V]L<W!A;CTS1#8@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HT.24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C4P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HR,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/C(P,34\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C,E.R!B;W)D97(M=&]P.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z
M(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS
M1#(@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR,B4[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD
M.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(P,30\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF
M;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU,"4[/@T*/'`@
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C(P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,R4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
M96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,C`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z-3`E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
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M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^-C`T/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,R4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
M96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B-&1C`P,#`[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C(P)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L
M;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXQ,C0\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z-3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HR,"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HS)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC1D8P,#`P.V9O;G0M9F%M:6QY
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C(P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^,S`R/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z-3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3,N-W!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^5&]T86P\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,C`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,R4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E
M<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(T9&,#`P,#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,C`E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\+W1R/@T*/"]T86)L93X\+V1I=CX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B9N8G-P.SPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,W!T.VUA<F=I;BUL969T.C0N-30E.W1E>'0M:6YD96YT.C`E
M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II=&%L:6,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY#;VUP<F5H96YS:79E
M($QO<W,@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3-P=#MM87)G
M:6XM;&5F=#HT+C4T)3MT97AT+6EN9&5N=#HP)3MF;VYT+7=E:6=H=#IB;VQD
M.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^3F5T($QO<W,@<&5R(%-H87)E(&]F($-O;6UO;B!3
M=&]C:R`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
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M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3-P
M=#MM87)G:6XM;&5F=#HT+C4T)3MT97AT+6EN9&5N=#HP)3MF;VYT+7=E:6=H
M=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^4F5C96YT($%C8V]U;G1I;F<@4')O;F]U
M;F-E;65N=',@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M;W!E<F%T:6]N<R!U<&]N(&%D;W!T:6]N+B`\+W`^#0H\<"!S='EL93TS1"=M
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M<F0@:7-S=65D($%C8V]U;G1I;F<@4W1A;F1A<F1S(%5P9&%T92`R,#$T+3$P
M/&9O;G0@<W1Y;&4],T1F;VYT+7-T>6QE.FET86QI8SL^+"!%;&EM:6YA=&EO
M;B!O9B!#97)T86EN($9I;F%N8VEA;"!297!O<G1I;F<@4F5Q=6ER96UE;G1S
M+"!);F-L=61I;F<@86X@06UE;F1M96YT('1O(%9A<FEA8FQE($EN=&5R97-T
M($5N=&ET:65S($=U:61A;F-E(&EN(%1O<&EC(#@Q,"P@0V]N<V]L:61A=&EO
M;CPO9F]N=#XL(&]R($%352`R,#$T+3$P+"!W:&EC:"!E;&EM:6YA=&5S('1H
M92!D969I;FET:6]N(&]F(&$@9&5V96QO<&UE;G0@<W1A9V4@96YT:71Y+"!T
M:&4@9&5V96QO<&UE;G0@<W1A9V4@<')E<V5N=&%T:6]N(&%N9"!D:7-C;&]S
M=7)E(')E<75I<F5M96YT<R!U;F1E<B!!4T,@.3$U+"`\9F]N="!S='EL93TS
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M:6YC;VUE+"!C87-H(&9L;W=S+"!A;F0@<VAA<F5H;VQD97(@97%U:71Y+"`H
M,BDF(S$V,#ML86)E;"!T:&4@9FEN86YC:6%L('-T871E;65N=',@87,@=&AO
M<V4@;V8@82!D979E;&]P;65N="!S=&%G92!E;G1I='DL("@S*28C,38P.V1I
M<V-L;W-E(&$@9&5S8W)I<'1I;VX@;V8@=&AE(&1E=F5L;W!M96YT('-T86=E
M(&%C=&EV:71I97,@:6X@=VAI8V@@=&AE(&5N=&ET>2!I<R!E;F=A9V5D+"!A
M;F0@*#0I)B,Q-C`[9&ES8VQO<V4@:6X@=&AE(&9I<G-T('EE87(@:6X@=VAI
M8V@@=&AE(&5N=&ET>2!I<R!N;R!L;VYG97(@82!D979E;&]P;65N="!S=&%G
M92!E;G1I='D@=&AA="!I;B!P<FEO<B!Y96%R<R!I="!H860@8F5E;B!I;B!T
M:&4@9&5V96QO<&UE;G0@<W1A9V4N($9U<G1H97)M;W)E+"!!4U4@,C`Q-"TQ
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M92!E;G1I=&EE<RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M:6YG(&%F=&5R($1E8V5M8F5R(#$U+"`R,#$V+B!%87)L>2!A9&]P=&EO;B!I
M<R!P97)M:71T960N(%1H92!#;VUP86YY('=I;&P@87!P;'D@=&AE(&=U:61A
M;F-E(&%N9"!D:7-C;&]S=7)E('!R;W9I<VEO;G,@;V8@=&AE(&YE=R!S=&%N
M9&%R9"!U<&]N(&%D;W!T:6]N+CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z.7!T.W1E>'0M:6YD96YT.C0N-30E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E5N9&5R($%352`R,#$T
M+3$P+"!E;G1I=&EE<R!A<F4@;F\@;&]N9V5R(')E<75I<F5D('1O(&%P<&QY
M('1H92!P<F5S96YT871I;VX@86YD(&1I<V-L;W-U<F4@<')O=FES:6]N<R!O
M9B!!4T,@.3$U(&1U<FEN9R!A;FYU86P@<&5R:6]D<R!B96=I;FYI;F<@869T
M97(@1&5C96UB97(F(S$V,#LQ-2P@,C`Q-"X@26X@861D:71I;VXL('1H92!R
M979I<VEO;G,@=&\@=&AE(&-O;G-O;&ED871I;VX@<W1A;F1A<F1S(&%R92!E
M9F9E8W1I=F4@9F]R(&%N;G5A;"!P97)I;V1S(&)E9VEN;FEN9R!A9G1E<B!$
M96-E;6)E<B8C,38P.S$U+"`R,#$U(&9O<B!P=6)L:6,@8V]M<&%N:65S(&%N
M9"!A<F4@969F96-T:79E(&9O<B!A;FYU86P@<&5R:6]D<R!B96=I;FYI;F<@
M869T97(@1&5C96UB97(F(S$V,#LQ-2P@,C`Q-B!F;W(@;F]N<'5B;&EC(&5N
M=&ET:65S+B!%87)L>2!A9&]P=&EO;B!I<R!P97)M:71T960@9F]R(&%N>2!A
M;FYU86P@<F5P;W)T:6YG('!E<FEO9"!O<B!I;G1E<FEM('!E<FEO9"!F;W(@
M=VAI8V@@=&AE(&5N=&ET>28C.#(Q-SMS(&9I;F%N8VEA;"!S=&%T96UE;G1S
M(&AA=F4@;F]T('EE="!B965N(&ES<W5E9"`H<'5B;&EC(&)U<VEN97-S(&5N
M=&ET:65S*2!O<B!M861E(&%V86EL86)L92!F;W(@:7-S=6%N8V4@*&]T:&5R
M(&5N=&ET:65S*2X@5&AE($-O;7!A;GD@:&%S(&%D;W!T960@05-5(#(P,30M
M,3`L(&5F9F5C=&EV92!*86YU87)Y(#$L(#(P,34L(&)U="!T:&5R92!W87,@
M;F\@:6UP86-T(&]N(&ET<R!F:6YA;F-I86P@<&]S:71I;VXL(')E<W5L=',@
M;V8@;W!E<F%T:6]N<R!O<B!C87-H(&9L;W=S+B`\+W`^/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-&4V864X9%\P
M.39B7S1A,#5?86$T9%]B.3@U.&)E.#8X9&,-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO931E-F%E.&1?,#DV8E\T83`U7V%A-&1?8CDX-3AB93@V
M.&1C+U=O<FMS:&5E=',O4VAE970P."YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D)A;&%N8V4@4VAE970@0V]M<&]N96YT<SQB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D]R9V%N:7IA=&EO;B!#;VYS;VQI9&%T:6]N($%N9"!0<F5S96YT871I;VX@
M3V8@1FEN86YC:6%L(%-T871E;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E(%-H965T
M($-O;7!O;F5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD
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M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-'!T.VUA<F=I
M;BUL969T.C0N-30E.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[
M9F]N="US='EL93II=&%L:6,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SY0<F5P86ED(&5X<&5N<V5S(&%N9"!O=&AE<B!C=7)R
M96YT(&%S<V5T<R`H:6X@=&AO=7-A;F1S*2`\+W`^#0H\<"!S='EL93TS1&UA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E
M.V9O;G0M=V5I9VAT.F)O;&0[.V9O;G0M<VEZ93HY<'0[/B9N8G-P.SPO<#X-
M"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC
M;VQL87!S93IC;VQL87!S93L@=VED=&@Z,3`P)3LG/@T*/'1R/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HW,"4[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="US:7IE
M.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,3,E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT
M.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ,R4[/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C<P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ,R4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[
M9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/C(P,34\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z
M.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ,R4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[
M9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/C(P,30\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z
M.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HW,"4[/@T*/'`@<W1Y;&4],T0G
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M=7`@<W1Y;&4],T0G9F]N="US:7IE.C@U)3L@=F5R=&EC86PM86QI9VXZ=&]P
M)SXH,2D\+W-U<#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC1D8P
M,#`P.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C<P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
M;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,3$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXU,3<\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B-&1C`P,#`[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,3$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXQ.#(\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HW,"4[(&)O<F1E<BUB
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O
M=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC1D8P,#`P
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:7IE.C$P<'0[)SXF;F)S<#L\+W`^#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT
M86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HQ
M,#`E.R<^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z
M-"XU-"4[=VAI=&4M<W!A8V4Z;F]W<F%P/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="US:7IE.C@N-7!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/CQS=7`@<W1Y;&4],T0G9F]N="US:7IE.C@U)3L@
M=F5R=&EC86PM86QI9VXZ=&]P)SXH,2D\+W-U<#X\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HY-2XT-B4[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^/'-U<"!S='EL93TS1"=F;VYT+7-I
M>F4Z.#4E.R!V97)T:6-A;"UA;&EG;CIT;W`G/CPO<W5P/D$@<W5B<W1A;G1I
M86P@;6%J;W)I='D@;V8@=&AE<V4@<')E<&%Y;65N=',@8V]N<VES="!O9B!A
M9'9A;F-E<R!T;R!O=7(@8V]N=')A8W0@;6%N=69A8W1U<F5R<RX@/"]P/CPO
M=&0^/"]T<CX\+W1A8FQE/CPO9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HQ,W!T.VUA<F=I;BUL969T.C0N-30E.W1E
M>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II=&%L
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M<W`[/"]P/@T*/&1I=CX-"CQT86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HQ,#`E.R<^#0H\='(^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C<P)3L^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ,R4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([
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M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I
M>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
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M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY$96-E;6)E<B`S
M,2P\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[
M9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z-S`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1T
M;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$S)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
M96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`Q-3PO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1T
M;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$S)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
M96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`Q-#PO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$Q)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,2PQ-#,\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E
M<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(T9&,#`P,#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXQ+#<S-SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HW,"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,3$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B-&1C`P,#`[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,3$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
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M86P@<V5R=FEC97,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[=VAI=&4M
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M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
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M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B-&1C`P,#`[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A
M<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,3$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$Q)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
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M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC1D8P,#`P
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$Q)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E
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M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-S`E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^5&]T86P\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R
M+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U
M8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(T9&,#`P
M,#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
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M)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\+W1A8FQE/CPO9&EV/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+71O<#HS<'0[;6%R9VEN+6)O='1O;3HP<'0[=&5X
M="UI;F1E;G0Z,"4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?931E-F%E.&1?,#DV8E\T83`U7V%A
M-&1?8CDX-3AB93@V.&1C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V4T939A93AD7S`Y-F)?-&$P-5]A831D7V(Y.#4X8F4X-CAD8R]7;W)K<VAE
M971S+U-H965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY&86ER(%9A;'5E($UE87-U<F5M96YT<SQB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64@
M1&ES8VQO<W5R97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E($UE87-U<F5M96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD
M96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXT+B!&86ER
M(%9A;'5E($UE87-U<F5M96YT<R`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM
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M86ER('9A;'5E(&AI97)A<F-H>2`H:6X@=&AO=7-A;F1S*3H@/"]P/@T*/'`@
M<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT
M+6EN9&5N=#HP)3MF;VYT+7-I>F4Z.7!T.SXF;F)S<#L\+W`^#0H\9&EV/@T*
M/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z
M8V]L;&%P<V4[('=I9'1H.C$P,"4[)SX-"CQT<CX-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-#,E.SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@8V]L<W!A;CTS1#$T('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HU-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT
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M36%R8V@@,S$L(#(P,34\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-#,E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!C;VQS<&%N/3-$,30@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HU-B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[
M9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z-#,E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT
M97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="US:7IE.CAP
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS
M<&%N/3-$,B!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT
M.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^5&]T86P\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L
M;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
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M<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$=&]P(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[
M)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE
M.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/DQE=F5L(#$\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C(E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
M96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L
M<W!A;CTS1#(@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H
M=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DQE=F5L(#(\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US
M:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/DQE=F5L(#,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C(E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C(E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT
M97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3`E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C(E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MW:61T:#HT,R4[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T
M('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SY-;VYE>2!M87)K970@9G5N9',\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C
M,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXQ-C`L,38R/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L
M92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;F<M5&]P.C`N-S5P=#MW:61T:#HR)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@
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M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$P)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@
M,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,B4[(&)O<F1E<BUB;W1T
M;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,"4[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C(E.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
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M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B
M;W)D97(M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ,"4[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#ID;W5B
M;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3`E.R!B;W)D
M97(M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR)3L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$P)3L@8F]R9&5R+71O<#ID;W5B;&4@
M,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,B4[/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L@8F]R9&5R+71O<#ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,3`E.R!B;W)D97(M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z-#,E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,30@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU-B4[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
M+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D9A:7(@5F%L=64@
M365A<W5R96UE;G1S(&%T($1E8V5M8F5R(#,Q+"`R,#$T/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD
M.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-
M"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-#,E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^5&]T86P\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT
M.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I
M>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[
M9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/DQE=F5L(#$\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I
M>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C(E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I
M9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DQE=F5L(#(\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I
M9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W=I9'1H.C(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT
M+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R
M.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/DQE=F5L(#,\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT
M+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MW:61T:#HT,R4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C(E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C(E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3`E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C(E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL
M93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HT,R4[(&)O<F1E<BUB;W1T;VTZ9&]U
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M.B!N;W)M86P[)SY-;VYE>2!M87)K970@9G5N9',\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L
M92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3`E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R
M+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L
M;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXQ-C`L,3(U
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HR)3L@8F]R9&5R+6)O='1O
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M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O
M='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$P)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,B4[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&
M1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C(E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
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M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^
M#0H\+W1A8FQE/CPO9&EV/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,RXU
M<'0[/B9N8G-P.SPO<#X-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.C5P=#L^
M)FYB<W`[/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?931E-F%E.&1?,#DV8E\T83`U7V%A-&1?8CDX-3AB93@V
M.&1C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4T939A93AD7S`Y
M-F)?-&$P-5]A831D7V(Y.#4X8F4X-CAD8R]7;W)K<VAE971S+U-H965T,3`N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM
M:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S($%N9"!#
M;VYT:6YG96YC:65S($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM:71M96YT<R!A
M;F0@0V]N=&EN9V5N8VEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXU+B!#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R`\
M+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C1P=#MM87)G:6XM;&5F=#HT+C4T)3MT97AT+6EN9&5N=#HP)3MF;VYT+7=E
M:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^1F%C:6QI='D@3&5A<V5S(#PO<#X-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-'!T
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M;WAI;6%T96QY("0Q+CD@;6EL;&EO;B!A<R!O9B!-87)C:"8C,38P.S,Q+"`R
M,#$U+B`\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%]E-&4V864X9%\P.39B7S1A,#5?86$T9%]B.3@U.&)E.#8X
M9&,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO931E-F%E.&1?,#DV
M8E\T83`U7V%A-&1?8CDX-3AB93@V.&1C+U=O<FMS:&5E=',O4VAE970Q,2YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D5Q=6ET
M>2!);F-E;G1I=F4@4&QA;G,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY$:7-C;&]S=7)E($]F($-O;7!E;G-A=&EO
M;B!296QA=&5D($-O<W1S(%-H87)E8F%S960@4&%Y;65N=',@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M<75I='D@26YC96YT:79E(%!L86YS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UW96EG:'0Z8F]L
M9#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/C8N($5Q=6ET>2!);F-E;G1I=F4@4&QA;G,@/"]P
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HT
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M26X@36%R8V@@,C`Q-"P@=&AE('-T;V-K:&]L9&5R<R!A<'!R;W9E9"!T:&4@
M,C`Q-"!%<75I='D@26YC96YT:79E(%!L86XL(&]R('1H92`R,#$T(%!L86XN
M($%S(&]F($UA<F-H)B,Q-C`[,C$L(#(P,30L('1H92!E9F9E8W1I=F4@9&%T
M92!O9B!T:&4@,C`Q-"!0;&%N+"!T:&4@0V]M<&%N>2!S=7-P96YD960@=&AE
M(#(P,#D@4&QA;B!A;F0@;F\@861D:71I;VYA;"!A=V%R9',@;6%Y(&)E(&=R
M86YT960@=6YD97(@=&AE(#(P,#D@4&QA;BX@06YY('-H87)E<R!O9B!C;VUM
M;VX@<W1O8VL@8V]V97)E9"!B>2!A=V%R9',@9W)A;G1E9"!U;F1E<B!T:&4@
M,C`P.2!0;&%N('1H870@=&5R;6EN871E(&%F=&5R($UA<F-H)B,Q-C`[,C$L
M(#(P,30@8GD@97AP:7)A=&EO;BP@9F]R9F5I='5R92P@8V%N8V5L;&%T:6]N
M(&]R(&]T:&5R(&UE86YS('=I=&AO=70@=&AE(&ES<W5A;F-E(&]F('-U8V@@
M<VAA<F5S+"!W:6QL(&)E(&%D9&5D('1O('1H92`R,#$T(%!L86X@<F5S97)V
M92X@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M9F]R(&ES<W5A;F-E('5N9&5R('1H92`R,#$T(%!L86X@=V%S(&%P<')O>&EM
M871E;'D@,BPP,S$L,#`P+B`@56YL97-S('1H92!";V%R9"!P<F]V:61E<R!O
M=&AE<G=I<V4L(&)E9VEN;FEN9R!O;B!*86YU87)Y)B,Q-C`[,2P@,C`Q-2P@
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M871E;'D@,BPY-#<L,#`P('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=V5R92!S
M=6)J96-T('1O(&]U='-T86YD:6YG(&%W87)D<R!U;F1E<B!T:&4@,C`Q-"!0
M;&%N+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.CEP=#MT97AT+6EN9&5N=#HT+C4T)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SY);B!-87)C:"`R,#$T+"!T:&4@0F]A<F0@86YD
M('-T;V-K:&]L9&5R<R!A<'!R;W9E9"!T:&4@,C`Q-"!%;7!L;WEE92!3=&]C
M:R!0=7)C:&%S92!0;&%N+"!O<B!T:&4@15-04"P@=VAI8V@@8F5C86UE(&5F
M9F5C=&EV92!A<R!O9B!-87)C:"8C,38P.S4L(#(P,30N(%1H92!#;VUP86YY
M(&AA<R!R97-E<G9E9"!A('1O=&%L(&]F(&%P<')O>&EM871E;'D@,SDR+#`P
M,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&9O<B!I<W-U86YC92!U;F1E<B!T
M:&4@15-04"X@56YL97-S('1H92!";V%R9"!P<F]V:61E<R!O=&AE<G=I<V4L
M(&)E9VEN;FEN9R!O;B!*86YU87)Y)B,Q-C`[,2P@,C`Q-2P@86YD(&-O;G1I
M;G5I;F<@=6YT:6P@=&AE(&5X<&ER871I;VX@;V8@=&AE($534%`L('1H92!T
M;W1A;"!N=6UB97(@;V8@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A=F%I;&%B
M;&4@9F]R(&ES<W5A;F-E('5N9&5R('1H92!%4U!0('=I;&P@875T;VUA=&EC
M86QL>2!I;F-R96%S92!A;FYU86QL>2!O;B!*86YU87)Y)B,Q-C`[,2!B>2!T
M:&4@;&5S<V5R(&]F("AI*28C,38P.S$E(&]F('1H92!T;W1A;"!N=6UB97(@
M;V8@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!S:&%R97,@;V8@8V]M;6]N('-T
M;V-K(&%S(&]F($1E8V5M8F5R)B,Q-C`[,S$@;V8@=&AE(&EM;65D:6%T96QY
M('!R96-E9&EN9R!Y96%R+"!O<B`H:6DI)B,Q-C`[,S`P+#`P,"!S:&%R97,@
M;V8@8V]M;6]N('-T;V-K+B!!<R!O9B!-87)C:"`S,2P@,C`Q-2P@=&AE($-O
M;7!A;GD@:&%S(&%P<')O>&EM871E;'D@.2PP,#`@<VAA<F5S(&]F(&-O;6UO
M;B!S=&]C:R!U;F1E<B!T:&4@15-04"X@/"]P/CPO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?931E-F%E.&1?,#DV8E\T
M83`U7V%A-&1?8CDX-3AB93@V.&1C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V4T939A93AD7S`Y-F)?-&$P-5]A831D7V(Y.#4X8F4X-CAD8R]7
M;W)K<VAE971S+U-H965T,3(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY.970@3&]S<R!P97(@4VAA<F4@;V8@0V]M;6]N(%-T
M;V-K/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^16%R;FEN9W,@4&5R(%-H87)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($QO<W,@<&5R
M(%-H87)E(&]F($-O;6UO;B!3=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E
M>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXW
M+B!.970@;&]S<R!P97(@<VAA<F4@;V8@0V]M;6]N(%-T;V-K(#PO<#X-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-'!T.W1E
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M<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.CEP=#L^)FYB<W`[/"]P
M/@T*/&1I=CX-"CQT86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R
M+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HQ,#`E.R<^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HS,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C8X
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@8V]L<W!A;CTS1#8@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HS,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C8X)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ-"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/C(P,34\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C(E.R!B;W)D97(M=&]P.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z
M(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS
M1#(@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-"4[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD
M.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(P,30\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF
M;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MW:61T:#HV."4[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N
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M9&5R<R`M(&)A<VEC(&%N9"!D:6QU=&5D/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@
M(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*#(R+#`P-CPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID
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M9RU4;W`Z,"XW-7!T.W=I9'1H.C(E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R
M+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
M96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B-&1C`P,#`[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID
M;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HV."4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.R!B;W)D97(M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C(E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC1D8P,#`P.V9O
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$R)3L@8F]R9&5R+71O<#ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,BPW.#@\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z-C@E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HR)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M1D8P,#`P.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^,BPW.#@\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MW:61T:#HV."4[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R
M9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^*#`N-SD\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HR)3L@
M8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC1D8P,#`P.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[
M=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXD/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B@Q-BXQ,SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@
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M+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.CEP=#L^)FYB<W`[
M/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M;VTZ,'!T.VUA<F=I;BUT;W`Z.7!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M
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M=#L^)FYB<W`[/"]P/@T*/&1I=CX-"CQT86)L92!B;W)D97(],T0P(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(@<W1Y
M;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HQ,#`E.R<^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C8X)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS
M1#8@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HS,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W
M<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N
M="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C8X)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M<VEZ
M93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M8V]L<W!A;CTS1#(@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M-"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E
M:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(P,34\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ-"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US
M:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/C(P,30\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HV."4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
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M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,B4[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B-&1C`P,#`[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.W=H
M:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HV."4[/@T*/'`@<W1Y;&4],T0G;6%R
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
M;W1T;VTZ,'!T.W=I9'1H.C$R)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXQ
M.#4L-3$T/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,B4[/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B-&1C`P,#`[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.W=H:71E+7-P86-E
M.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M:78@86QI9VX],T1L969T/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P
M<V4Z8V]L;&%P<V4[('=I9'1H.C$S+C,E.R<^#0H\='(^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P,"4[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7-I>F4Z,W!T
M.SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\+W1A8FQE/CPO9&EV/@T*/'`@
M<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HT+C4T)3MT97AT+6EN9&5N=#HM-"XU-"4[9F]N="US:7IE.C1P
M=#L^)FYB<W`[/"]P/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z-G!T.SXF
M;F)S<#L\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%]E-&4V864X9%\P.39B7S1A,#5?86$T9%]B.3@U.&)E.#8X
M9&,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO931E-F%E.&1?,#DV
M8E\T83`U7V%A-&1?8CDX-3AB93@V.&1C+U=O<FMS:&5E=',O4VAE970Q,RYH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14%"044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5M
M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A0;VQI
M8VEE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S
M,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:7,@;V8@
M4')E<V5N=&%T:6]N(&%N9"!5<V4@;V8@17-T:6UA=&5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HT<'0[;6%R9VEN+6QE9G0Z-"XU-"4[
M=&5X="UI;F1E;G0Z,"4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-T>6QE.FET
M86QI8SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/D)A<VES(&]F(%!R97-E;G1A=&EO;B!A;F0@57-E(&]F($5S=&EM871E<R`\
M+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
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M8V$@*"8C.#(R,#M5+E,N($=!05`F(S@R,C$[*2X@5&AE('!R97!A<F%T:6]N
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M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z.7!T.W1E>'0M
M:6YD96YT.C0N-30E.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^5&AE(&%C8V]M<&%N>6EN9R!C;VYD96YS960@8V]N<V]L:61A
M=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%R92!C;VYS;VQI9&%T960@9F]R
M('1H92!Q=6%R=&5R(&5N9&5D($UA<F-H(#,Q+"`R,#$U(&%N9"!Y96%R(&5N
M9&5D($1E8V5M8F5R(#,Q+"`R,#$T(&%N9"!I;F-L=61E('1H92!A8V-O=6YT
M<R!O9B!697)S87)T:7,L($EN8RX@86YD(&ET<R!W:&]L;'DM;W=N960@<W5B
M<VED:6%R>2P@5F5R<V%R=&ES($-A>6UA;B!(;VQD:6YG<R!#;VUP86YY+"!E
M<W1A8FQI<VAE9"!I;B`R,#$T+B!!;&P@:6YT97)C;VUP86YY(&%C8V]U;G1S
M(&%N9"!T<F%N<V%C=&EO;G,@:&%V92!B965N(&5L:6UI;F%T960N(%1H92!5
M+E,N(&1O;&QA<B!I<R!T:&4@9G5N8W1I;VYA;"!C=7)R96YC>2!F;W(@86QL
M(&]F('1H92!#;VUP86YY)W,@8V]N<V]L:61A=&5D(&]P97)A=&EO;G,N($%L
M;"!O=&AE<B!A8V-O;7!A;GEI;F<@8V]N9&5N<V5D(&9I;F%N8VEA;"!S=&%T
M96UE;G1S(&9O<B!T:&4@<75A<G1E<B!E;F1E9"!-87)C:"`S,2P@,C`Q-"!I
M;F-L=61E(&]N;'D@=&AE(&%C8V]U;G1S(&]F(%9E<G-A<G1I<RP@26YC+CPO
M<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M;2!O<&5R871I;VYS+B!!="!-87)C:"8C,38P.S,Q+"`R,#$U+"!T:&4@0V]M
M<&%N>2!H860@86X@86-C=6UU;&%T960@9&5F:6-I="!O9B`D,3,S+C,F(S$V
M,#MM:6QL:6]N(&%N9"!W;W)K:6YG(&-A<&ET86P@;V8@)#(R-BXV)B,Q-C`[
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M($IA;G5A<GD@,C`Q-2P@=&AE<F4@8V%N(&)E(&YO(&%S<W5R86YC92!T:&%T
M('1H92!#;VUP86YY('=I;&P@8F4@<W5C8V5S<V9U;"!O<B!T:&%T(&%N>2!N
M965D960@9FEN86YC:6YG('=I;&P@8F4@879A:6QA8FQE(&EN('1H92!F=71U
M<F4@870@=&5R;7,@86-C97!T86)L92!T;R!T:&4@0V]M<&%N>2X@/"]P/CPO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4V5G;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,3-P=#MM87)G:6XM;&5F=#HT+C4T)3MT97AT+6EN9&5N=#HP)3MF;VYT
M+7=E:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^4V5G;65N=',@/"]P/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HT<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.W1E>'0M:6YD96YT.C0N-30E
M.R<^5&AE($-O;7!A;GD@;W!E<F%T97,@:6X@;VYE('-E9VUE;G0N($UA;F%G
M96UE;G0@=7-E<R!O;F4@;65A<W5R96UE;G0@;V8@<')O9FET86)I;&ET>2!A
M;F0@9&]E<R!N;W0@<V5G<F5G871E(&ET<R!B=7-I;F5S<R!F;W(@:6YT97)N
M86P@<F5P;W)T:6YG+B!!;&P@;&]N9RUL:79E9"!A<W-E=',@87)E(&UA:6YT
M86EN960@:6X@=&AE(%5N:71E9"!3=&%T97,@;V8@06UE<FEC82X@/"]P/CPO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]N8V5N=')A=&EO;B!O9B!#<F5D:70@4FES:SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C0N-30E
M.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II
M=&%L:6,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SY#;VYC96YT<F%T:6]N(&]F(#QF;VYT('-T>6QE/3-$=&5X="UT<F%N<V9O
M<FTZ=7!P97)C87-E.SYC/"]F;VYT/G)E9&ET(#QF;VYT('-T>6QE/3-$=&5X
M="UT<F%N<V9O<FTZ=7!P97)C87-E.SYR/"]F;VYT/FES:R`\+W`^#0H\<"!S
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M9F5D97)A;&QY(&EN<W5R960@;&EM:71S+B`\+W`^/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2:7-K(&%N
M9"!5;F-E<G1A:6YT:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HQ,W!T.VUA<F=I;BUL969T.C0N-30E.W1E>'0M:6YD96YT.C`E.V9O
M;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II=&%L:6,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY2:7-K(&%N9"!5;F-E<G1A
M:6YT:65S(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z-'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
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M8V4@<W5P<&QI97)S+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
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M4RX@1F]O9"!A;F0@1')U9R!!9&UI;FES=')A=&EO;B`H)B,X,C(P.T9$028C
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M92!#;VUP86YY+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
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M;7!A;GDN(#PO<#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD($-A<V@@17%U:79A;&5N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\<"!S='EL
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M<V9O<FTZ=7!P97)C87-E.SYC/"]F;VYT/F%S:"`\9F]N="!S='EL93TS1'1E
M>'0M=')A;G-F;W)M.G5P<&5R8V%S93L^93PO9F]N=#YQ=6EV86QE;G1S(#PO
M<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M=6EV86QE;G1S+B!!="!-87)C:"`S,2P@,C`Q-2!A;F0@1&5C96UB97(@,S$L
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M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD($5Q=6EP
M;65N="P@3F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ
M,W!T.VUA<F=I;BUL969T.C0N-30E.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I
M9VAT.F)O;&0[9F]N="US='EL93II=&%L:6,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SY0<F]P97)T>2!A;F0@/&9O;G0@<W1Y
M;&4],T1T97AT+71R86YS9F]R;3IU<'!E<F-A<V4[/F4\+V9O;G0^<75I<&UE
M;G0L($YE="`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
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M;W!E<F%T:6]N<R!I;B!T:&4@<&5R:6]D(')E86QI>F5D+B`\+W`^/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y);7!A:7)M96YT(&]F($QO;F<M3&EV960@07-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,W!T.VUA<F=I;BUL969T.C0N-30E
M.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II
M=&%L:6,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SY);7!A:7)M96YT(&]F($QO;F<M3&EV960@07-S971S(#PO<#X-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-'!T.V9O;G0M
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M:"`S,2P@,C`Q-2!O<B!$96-E;6)E<B8C,38P.S,Q+"`R,#$T+CPO<#X\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D9A:7(@5F%L=64@;V8@1FEN86YC:6%L($EN<W1R=6UE;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,W!T.VUA<F=I;BUL969T
M.C0N-30E.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US
M='EL93II=&%L:6,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SY&86ER(%9A;'5E(&]F($9I;F%N8VEA;"!);G-T<G5M96YT<R`\
M+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
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M/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M;F]B<V5R=F%B;&4@:6YP=71S+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM
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M;65N=',@87,@9F]L;&]W<SH@/"]P/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I
M>F4Z-"XU<'0[/B9N8G-P.SPO<#X-"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$
M,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z
M.3$E.R<^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z
M."4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DQE=F5L)B,Q-C`[23PO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`N.30E
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7-I
M>F4Z.'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.CDR+C`V)3L^#0H\<"!S='EL
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M:65S.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@
M<W1Y;&4],T1W:61T:#HX)3L^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7-I>F4Z-"XU<'0[/B9N8G-P.SPO<#X-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,7!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SY,979E;"8C,38P.TE)/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,"XY-"4[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M<VEZ93HX<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z.3(N,#8E.SX-"CQP('-T>6QE
M/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M<VEZ93HT+C5P=#L^)FYB
M<W`[/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HQ<'0[;6%R9VEN
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M:65S.R!A;F0\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M=&]P('-T>6QE/3-$=VED=&@Z."4[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[9F]N="US:7IE.C0N-7!T.SXF;F)S<#L\+W`^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C%P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^3&5V96PF(S$V,#M)24D\+W`^/"]T9#X-"CQT
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M87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@<W1Y;&4],T1W:61T:#HY,BXP-B4[/@T*/'`@<W1Y;&4],T1M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[9F]N="US:7IE.C0N-7!T.SXF;F)S<#L\+W`^
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z.7!T.W1E>'0M:6YD96YT.C0N
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M/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')E8VQI;FEC86P@86YD($-L:6YI8V%L(%1R:6%L($%C8W)U
M86QS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,W!T.VUA
M<F=I;BUL969T.C0N-30E.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O
M;&0[9F]N="US='EL93II=&%L:6,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SY0<F5C;&EN:6-A;"!A;F0@0VQI;FEC86P@5')I
M86P@06-C<G5A;',@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HT<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.W1E>'0M:6YD96YT.C0N-30E.R<^5&AE($-O;7!A;GDF(S@R,3<[<R!C
M;&EN:6-A;"!T<FEA;"!A8V-R=6%L<R!A<F4@8F%S960@;VX@97-T:6UA=&5S
M(&]F('!A=&EE;G0@96YR;VQL;65N="!A;F0@<F5L871E9"!C;W-T<R!A="!C
M;&EN:6-A;"!I;G9E<W1I9V%T;W(@<VET97,@87,@=V5L;"!A<R!E<W1I;6%T
M97,@9F]R('1H92!S97)V:6-E<R!R96-E:79E9"!A;F0@969F;W)T<R!E>'!E
M;F1E9"!P=7)S=6%N="!T;R!C;VYT<F%C=',@=VET:"!M=6QT:7!L92!R97-E
M87)C:"!I;G-T:71U=&EO;G,@86YD(&-L:6YI8V%L(')E<V5A<F-H(&]R9V%N
M:7IA=&EO;G,@*"8C.#(R,#M#4D]S)B,X,C(Q.RD@=&AA="!C;VYD=6-T(&%N
M9"!M86YA9V4@8VQI;FEC86P@=')I86QS(&]N('1H92!#;VUP86YY)B,X,C$W
M.W,@8F5H86QF+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
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M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD($1E=F5L
M;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,W!T
M.VUA<F=I;BUL969T.C0N-30E.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT
M.F)O;&0[9F]N="US='EL93II=&%L:6,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SY297-E87)C:"!A;F0@/&9O;G0@<W1Y;&4]
M,T1T97AT+71R86YS9F]R;3IU<'!E<F-A<V4[/F0\+V9O;G0^979E;&]P;65N
M="`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
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M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE('1A>&5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,W!T.VUA<F=I;BUL969T
M.C0N-30E.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US
M='EL93II=&%L:6,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SY);F-O;64@/&9O;G0@<W1Y;&4],T1T97AT+71R86YS9F]R;3IU
M<'!E<F-A<V4[/G0\+V9O;G0^87AE<R`\+W`^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C1P=#MT97AT+6EN9&5N=#HT+C4T
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY4:&4@0V]M<&%N
M>2!A8V-O=6YT<R!F;W(@:6YC;VUE('1A>&5S('5N9&5R('1H92!A<W-E="!A
M;F0@;&EA8FEL:71Y(&%P<')O86-H+B!5;F1E<B!T:&ES(&UE=&AO9"P@9&5F
M97)R960@=&%X(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@87)E(&1E=&5R;6EN
M960@8F%S960@;VX@=&AE(&1I9F9E<F5N8V4@8F5T=V5E;B!T:&4@9FEN86YC
M:6%L('-T871E;65N="!A;F0@=&%X(&)A<V5S(&]F(&%S<V5T<R!A;F0@;&EA
M8FEL:71I97,@=7-I;F<@96YA8W1E9"!T87@@<F%T97,@:6X@969F96-T(&9O
M<B!T:&4@>65A<B!I;B!W:&EC:"!T:&4@9&EF9F5R96YC97,@87)E(&5X<&5C
M=&5D('1O(&%F9F5C="!T87AA8FQE(&EN8V]M92X@5F%L=6%T:6]N(&%L;&]W
M86YC97,@87)E(&5S=&%B;&ES:&5D('=H96X@;F5C97-S87)Y('1O(')E9'5C
M92!D969E<G)E9"!T87@@87-S971S('1O('1H92!A;6]U;G1S(&5X<&5C=&5D
M('1O(&)E(')E86QI>F5D+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
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M-C`[=&AE(&9A8W1O<G,@=6YD97)L>6EN9R!T:&4@<W5S=&%I;F%B:6QI='D@
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M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O
M8VLM0F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HQ,W!T.VUA<F=I;BUL969T.C0N-30E.W1E>'0M:6YD96YT
M.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II=&%L:6,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY3=&]C:RU"87-E
M9"`\9F]N="!S='EL93TS1'1E>'0M=')A;G-F;W)M.G5P<&5R8V%S93L^8SPO
M9F]N=#YO;7!E;G-A=&EO;B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
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M/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HY<'0[=&5X="UI;F1E;G0Z-"XU-"4[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4L
M(&YE="!O9B!E<W1I;6%T960@9F]R9F5I='5R97,L(&ES(')E9FQE8W1E9"!I
M;B!T:&4@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!S=&%T96UE;G1S(&]F(&]P
M97)A=&EO;G,@86YD(&-O;7!R96AE;G-I=F4@;&]S<R!A<R!F;VQL;W=S("AI
M;B!T:&]U<V%N9',I.B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z
M.7!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X-"CQD:78^#0H\=&%B
M;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL
M87!S93L@=VED=&@Z,3`P)3LG/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HU,"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-#DE.SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O
M;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R
M/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&
M1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HU,"4[(&)O<F1E<BUB;W1T
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-#DE.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[
M9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY-87)C:"`S
M,2P\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R
M/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HU,"4[(&)O
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,C(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T
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M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HS)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,C(E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z-3`E.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SY/<&5R871I;F<@17AP96YS97,\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR
M,"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C,E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C(P)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M:"!A;F0@9&5V96QO<&UE;G0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,C`E.W=H:71E
M+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C,E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC1D8P,#`P.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR,"4[
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C4P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,C`E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,R4[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(T9&,#`P,#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR,"4[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M
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M)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C4P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$S+C=P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C(P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^,2PY.#@\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C,E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B-&1C`P,#`[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C(P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
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M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUP<F5H96YS:79E($QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQD:78^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C-P=#MM87)G:6XM;&5F=#HT+C4T)3MT97AT+6EN9&5N
M=#HP)3MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^0V]M<')E:&5N
M<VEV92!,;W-S(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z-'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
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M87,@=&AE('-A;64@87,@:71S(')E<&]R=&5D(&YE="!L;W-S+B`\+W`^/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@3&]S<R!P97(@4VAA<F4@;V8@0V]M;6]N(%-T;V-K/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,W!T.VUA<F=I;BUL969T
M.C0N-30E.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US
M='EL93II=&%L:6,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SY.970@3&]S<R!P97(@4VAA<F4@;V8@0V]M;6]N(%-T;V-K(#PO
M<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5C96YT($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\<"!S='EL93TS1"=M87)G:6XM
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M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#MT97AT+6EN9&5N=#HT+C4T)3LG
M/D9R;VT@=&EM92!T;R!T:6UE+"!N97<@86-C;W5N=&EN9R!P<F]N;W5N8V5M
M96YT<R!A<F4@:7-S=65D(&)Y('1H92!&:6YA;F-I86P@06-C;W5N=&EN9R!3
M=&%N9&%R9',@0F]A<F0L(&]R($9!4T(L(&]R(&]T:&5R('-T86YD87)D('-E
M='1I;F<@8F]D:65S(&%N9"!A9&]P=&5D(&)Y('5S(&%S(&]F('1H92!S<&5C
M:69I960@969F96-T:79E(&1A=&4N(%5N;&5S<R!O=&AE<G=I<V4@9&ES8W5S
M<V5D+"!T:&4@:6UP86-T(&]F(')E8V5N=&QY(&ES<W5E9"!S=&%N9&%R9',@
M=&AA="!A<F4@;F]T('EE="!E9F9E8W1I=F4@=VEL;"!N;W0@:&%V92!A(&UA
M=&5R:6%L(&EM<&%C="!O;B!T:&4@0V]M<&%N>28C.#(Q-SMS(&9I;F%N8VEA
M;"!P;W-I=&EO;B!O<B!R97-U;'1S(&]F(&]P97)A=&EO;G,@=7!O;B!A9&]P
M=&EO;BX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HY<'0[=&5X="UI;F1E;G0Z-"XU-"4[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^26X@2G5N92`R,#$T+"!T:&4@1FEN86YC:6%L
M($%C8V]U;G1I;F<@4W1A;F1A<F1S($)O87)D(&ES<W5E9"!!8V-O=6YT:6YG
M(%-T86YD87)D<R!5<&1A=&4@,C`Q-"TQ,#QF;VYT('-T>6QE/3-$9F]N="US
M='EL93II=&%L:6,[/BP@16QI;6EN871I;VX@;V8@0V5R=&%I;B!&:6YA;F-I
M86P@4F5P;W)T:6YG(%)E<75I<F5M96YT<RP@26YC;'5D:6YG(&%N($%M96YD
M;65N="!T;R!687)I86)L92!);G1E<F5S="!%;G1I=&EE<R!'=6ED86YC92!I
M;B!4;W!I8R`X,3`L($-O;G-O;&ED871I;VX\+V9O;G0^+"!O<B!!4U4@,C`Q
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M:71Y(&=U:61A;F-E('5N9&5R($%30R`X,3`L(#QF;VYT('-T>6QE/3-$9F]N
M="US='EL93II=&%L:6,[/D-O;G-O;&ED871I;VX\+V9O;G0^+B!!<R!A(')E
M<W5L="!O9B!T:&4@8VAA;F=E<RP@=&AE(&9I;F%N8VEA;"!S=&%T96UE;G1S
M(&]F(&5N=&ET:65S('=H:6-H(&UE970@=&AE(&9O<FUE<B!D969I;FET:6]N
M(&]F(&$@9&5V96QO<&UE;G0@<W1A9V4@96YT:71Y('=I;&P@;F\@;&]N9V5R
M.B`H,2DF(S$V,#MP<F5S96YT(&EN8V5P=&EO;BUT;RUD871E(&EN9F]R;6%T
M:6]N(&EN('1H92!S=&%T96UE;G1S(&]F(&EN8V]M92P@8V%S:"!F;&]W<RP@
M86YD('-H87)E:&]L9&5R(&5Q=6ET>2P@*#(I)B,Q-C`[;&%B96P@=&AE(&9I
M;F%N8VEA;"!S=&%T96UE;G1S(&%S('1H;W-E(&]F(&$@9&5V96QO<&UE;G0@
M<W1A9V4@96YT:71Y+"`H,RDF(S$V,#MD:7-C;&]S92!A(&1E<V-R:7!T:6]N
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M+B!&=7)T:&5R;6]R92P@05-5(#(P,30M,3`@8VQA<FEF:65S(&1I<V-L;W-U
M<F5S(&%B;W5T(')I<VMS(&%N9"!U;F-E<G1A:6YT:65S('5N9&5R($%30R!4
M;W!I8R`R-S4L(#QF;VYT('-T>6QE/3-$9F]N="US='EL93II=&%L:6,[/E)I
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M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z.7!T.W1E
M>'0M:6YD96YT.C0N-30E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/DEN($%U9W5S="`R,#$T+"!T:&4@1D%30B!I<W-U960@;F5W(&=U:61A
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M:&]S92!F:7-C86P@>65A<G,L(&)E9VEN;FEN9R!A9G1E<B!$96-E;6)E<B`Q
M-2P@,C`Q-BX@16%R;'D@861O<'1I;VX@:7,@<&5R;6ET=&5D+B!4:&4@0V]M
M<&%N>2!W:6QL(&%P<&QY('1H92!G=6ED86YC92!A;F0@9&ES8VQO<W5R92!P
M<F]V:7-I;VYS(&]F('1H92!N97<@<W1A;F1A<F0@=7!O;B!A9&]P=&EO;BX\
M+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.CEP=#MT97AT+6EN9&5N=#HT+C4T)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SY5;F1E<B!!4U4@,C`Q-"TQ,"P@96YT:71I97,@87)E(&YO
M(&QO;F=E<B!R97%U:7)E9"!T;R!A<'!L>2!T:&4@<')E<V5N=&%T:6]N(&%N
M9"!D:7-C;&]S=7)E('!R;W9I<VEO;G,@;V8@05-#(#DQ-2!D=7)I;F<@86YN
M=6%L('!E<FEO9',@8F5G:6YN:6YG(&%F=&5R($1E8V5M8F5R)B,Q-C`[,34L
M(#(P,30N($EN(&%D9&ET:6]N+"!T:&4@<F5V:7-I;VYS('1O('1H92!C;VYS
M;VQI9&%T:6]N('-T86YD87)D<R!A<F4@969F96-T:79E(&9O<B!A;FYU86P@
M<&5R:6]D<R!B96=I;FYI;F<@869T97(@1&5C96UB97(F(S$V,#LQ-2P@,C`Q
M-2!F;W(@<'5B;&EC(&-O;7!A;FEE<R!A;F0@87)E(&5F9F5C=&EV92!F;W(@
M86YN=6%L('!E<FEO9',@8F5G:6YN:6YG(&%F=&5R($1E8V5M8F5R)B,Q-C`[
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M86YY(&AA<R!A9&]P=&5D($%352`R,#$T+3$P+"!E9F9E8W1I=F4@2F%N=6%R
M>2`Q+"`R,#$U+"!B=70@=&AE<F4@=V%S(&YO(&EM<&%C="!O;B!I=',@9FEN
M86YC:6%L('!O<VET:6]N+"!R97-U;'1S(&]F(&]P97)A=&EO;G,@;W(@8V%S
M:"!F;&]W<RX@/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?931E-F%E.&1?,#DV8E\T83`U7V%A-&1?8CDX-3AB
M93@V.&1C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4T939A93AD
M7S`Y-F)?-&$P-5]A831D7V(Y.#4X8F4X-CAD8R]7;W)K<VAE971S+U-H965T
M,30N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*%1A
M8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S
M,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@
M;V8@17-T:6UA=&5D(%-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B!%>'!E;G-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y
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M.B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z.7!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B8C,38P.SPO<#X-"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$
M,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z
M,3`P)3LG/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HU,"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z-#DE.SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H
M=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E1H<F5E($UO;G1H<R!%;F1E
M9#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&
M1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF
M;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MW:61T:#HU,"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-#DE.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z
M8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY-87)C:"`S,2P\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O
M;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R
M/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T9&1D9&1B!S
M='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HU,"4[(&)O<F1E<BUB;W1T;VTZ
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,C(E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N
M="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!B
M9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HS
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,C(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z-3`E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY/
M<&5R871I;F<@17AP96YS97,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR,"4[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C,E.SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C(P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M<&UE;G0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,C`E.W=H:71E+7-P86-E.FYO=W)A
M<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C,E.SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC1D8P,#`P.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
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M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
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M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4P)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,C`E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,R4[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(T9&,#`P,#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HR,"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4P)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C(P)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
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M,2PY.#@\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E
M.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C,E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B-&1C`P,#`[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C(P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^-#(V/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-&4V864X9%\P.39B
M7S1A,#5?86$T9%]B.3@U.&)E.#8X9&,-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO931E-F%E.&1?,#DV8E\T83`U7V%A-&1?8CDX-3AB93@V.&1C
M+U=O<FMS:&5E=',O4VAE970Q-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)&/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D)A;&%N8V4@4VAE970@0V]M<&]N96YT<R`H5&%B
M;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D]R9V%N:7IA=&EO;B!#;VYS;VQI9&%T:6]N($%N9"!0<F5S96YT
M871I;VX@3V8@1FEN86YC:6%L(%-T871E;65N=',@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED
M($5X<&5N<V5S(&%N9"!/=&AE<B!#=7)R96YT($%S<V5T<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-'!T.VUA<F=I;BUL969T.C0N-30E
M.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II
M=&%L:6,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SY0<F5P86ED(&5X<&5N<V5S(&%N9"!O=&AE<B!C=7)R96YT(&%S<V5T<R`H
M:6X@=&AO=7-A;F1S*2`\+W`^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT
M.F)O;&0[.V9O;G0M<VEZ93HY<'0[/B9N8G-P.SPO<#X-"CQD:78^#0H\=&%B
M;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL
M87!S93L@=VED=&@Z,3`P)3LG/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HW,"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3,E.SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z
M(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ,R4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
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M+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C<P)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ,R4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/C(P,34\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT
M.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ,R4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/C(P,30\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HW,"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^4')E8VQI;FEC86P@86YD(&-L:6YI8V%L(#QS=7`@<W1Y;&4],T0G
M9F]N="US:7IE.C@U)3L@=F5R=&EC86PM86QI9VXZ=&]P)SXH,2D\+W-U<#X\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,3$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC1D8P,#`P.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P
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M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C<P)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,3$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXU,3<\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R
M86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B-&1C`P,#`[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,3$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXQ.#(\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I
M;F<M5&]P.C`N-S5P=#MW:61T:#HW,"4[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC1D8P,#`P.V9O;G0M9F%M:6QY
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
M(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M;F)S<#L\+W`^#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!B;W)D97(]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G
M8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HQ,#`E.R<^#0H\='(^
M#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z-"XU-"4[=VAI=&4M
M<W!A8V4Z;F]W<F%P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[9F]N="US:7IE.C@N-7!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/CQS=7`@<W1Y;&4],T0G9F]N="US:7IE.C@U)3L@=F5R=&EC86PM86QI
M9VXZ=&]P)SXH,2D\+W-U<#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M<W1Y;&4],T1W:61T:#HY-2XT-B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<^/'-U<"!S='EL93TS1"=F;VYT+7-I>F4Z.#4E.R!V97)T
M:6-A;"UA;&EG;CIT;W`G/CPO<W5P/D$@<W5B<W1A;G1I86P@;6%J;W)I='D@
M;V8@=&AE<V4@<')E<&%Y;65N=',@8V]N<VES="!O9B!A9'9A;F-E<R!T;R!O
M=7(@8V]N=')A8W0@;6%N=69A8W1U<F5R<RX@/"]P/CPO=&0^/"]T<CX\+W1A
M8FQE/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!,:6%B:6QI=&EE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3-P=#MM87)G:6XM;&5F=#HT
M+C4T)3MT97AT+6EN9&5N=#HP)3MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<W1Y
M;&4Z:71A;&EC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^06-C<G5E9"!,:6%B:6QI=&EE<R`H:6X@=&AO=7-A;F1S*2`\+W`^
M#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[.V9O;G0M<VEZ93HY
M<'0[/B9N8G-P.SPO<#X-"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T
M>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z,3`P)3LG
M/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&
M1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HW,"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,3,E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,R4[/@T*/'`@
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M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C<P)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,R4[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H
M=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(P,34\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L
M;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT
M+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,R4[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H
M=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(P,30\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L
M;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D
M9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HW,"4[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E
M.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B-&1C`P,#`[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$Q)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^,2PW,S<\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D:6YG
M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z-S`E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$Q)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
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M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M1D8P,#`P.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&
M1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$Q)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HW,"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3$E
M.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$X.#PO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC1D8P,#`P.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$Q)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXT,3$\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z-S`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M3W1H97(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(T9&,#`P,#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C<P)3L@
M8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID
M;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$Q)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
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M,3D\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B-&1C`P,#`[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$Q)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R
M9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^-2PV-C8\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/"]T86)L93X\+V1I
M=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,W!T.VUA<F=I;BUB;W1T;VTZ
M,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4T939A93AD7S`Y-F)?
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^1F%I<B!686QU92!-96%S=7)E;65N=',@*%1A8FQE
M<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY&86ER(%9A;'5E($1I<V-L;W-U<F5S(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1FEN86YC:6%L
M($EN<W1R=6UE;G1S($UE87-U<F5D(&%T($9A:7(@5F%L=64@;VX@4F5C=7)R
M:6YG($)A<VES/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HT
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M=#L^)FYB<W`[/"]P/@T*/&1I=CX-"CQT86)L92!B;W)D97(],T0P(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(@<W1Y
M;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HQ,#`E.R<^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-38E.SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D9A:7(@
M5F%L=64@365A<W5R96UE;G1S(&%T($UA<F-H(#,Q+"`R,#$U/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H
M:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C0S)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#$T
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-38E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W
M<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N
M="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2
M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C0S)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$=&]P(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[
M)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HR)3L@8F]R9&5R+71O<#IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N
M=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z
M8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY,979E;"`Q/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HR)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P
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M86P[)SY,979E;"`R/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HR)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG
M:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY,979E;"`S/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-#,E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HR)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$P)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HR)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MW:61T:#HR)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-#,E.R!B;W)D
M97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$P
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O
M='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,B4[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M
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M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/C$V,"PQ-C(\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W=I9'1H.C(E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P
M,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R
M+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P
M861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M
M5&]P.C`N-S5P=#MW:61T:#HR)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU
M<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N
M=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
M(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,"4[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&
M1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HT,R4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#ID;W5B;&4@,BXU<'0@
M(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3`E.R!B;W)D97(M=&]P.F1O
M=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HR)3L^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M
M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
M;VTZ,'!T.W=I9'1H.C$P)3L@8F]R9&5R+71O<#ID;W5B;&4@,BXU<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M
M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M,"4[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A
M8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C(E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$P)3L@8F]R9&5R+71O
M<#ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-
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M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C0S)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC
M.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@8V]L<W!A;CTS1#$T('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z-38E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G
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M<B`S,2P@,C`Q-#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M
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M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C0S)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
M)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HR)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H
M=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T9&1D9&
M1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N
M="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY,979E;"`Q/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M5&]P.C`N-S5P=#MW:61T:#HR)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
M;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC
M.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SY,979E;"`R/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HR)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,3(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[
M9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY,979E;"`S
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-#,E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$P)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
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M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HR)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP
M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HR)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
M)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[
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M;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP
M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN
M9RU";W1T;VTZ,'!T.W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M5&]P.C`N-S5P=#MW:61T:#HR)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N
M=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$P)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
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M861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z
M-#,E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
M.W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
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M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
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M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,B4[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R
M96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D
M:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P
M,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
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M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[
M=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$V,"PQ,C4\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C(E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R
M+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HR)3L@8F]R9&5R+6)O='1O;3ID
M;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN
M9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,"4[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/"]T86)L93X\+V1I=CX-"CQP('-T
M>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI
M;F1E;G0Z,"4[9F]N="US:7IE.C,N-7!T.SXF;F)S<#L\+W`^/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-&4V864X
M9%\P.39B7S1A,#5?86$T9%]B.3@U.&)E.#8X9&,-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO931E-F%E.&1?,#DV8E\T83`U7V%A-&1?8CDX-3AB
M93@V.&1C+U=O<FMS:&5E=',O4VAE970Q-RYH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)&/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYE="!,;W-S('!E<B!3:&%R92!O9B!#
M;VUM;VX@4W1O8VL@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%87)N:6YG<R!097(@4VAA<F4@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=6UM87)Y(&]F($-O;7!U=&%T:6]N(&]F($)A<VEC(&%N9"!$:6QU
M=&5D($YE="!,;W-S(%!E<B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z-'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
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M:7IE.CEP=#L^)FYB<W`[/"]P/@T*/&1I=CX-"CQT86)L92!B;W)D97(],T0P
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HQ
M,#`E.R<^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT
M.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HS,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M1D9&('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
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M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W=I9'1H.C8X)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#8@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HS,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L
M9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C8X)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-"4[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N
M=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O
M;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/C(P,34\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R
M96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT
M+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G
M8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C(E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M
M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C
M1D9&1D9&('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H
M=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ-"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(P,30\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-&1D9&1D8@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I
M9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HV."4[(&)O<F1E
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M=&\@8V]M;6]N('-T;V-K:&]L9&5R<R`M(&)A<VEC(&%N9"!D:6QU=&5D/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U
M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O
M='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[
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M;6%L.R<^*#(R+#`P-CPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A
M9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ
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M:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C(E.R!B;W)D
M97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V-O;&]R.B-&1C`P,#`[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
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M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HV."4[/@T*/'`@
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M:&%R97,@;W5T<W1A;F1I;F<\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.F1O=6)L92`R
M+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT
M;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C(E.SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMC;VQO<CHC1D8P,#`P.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I
M;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R9&5R+71O<#ID;W5B
M;&4@,BXU<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
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M.#@\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z-C@E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.R9N8G-P.R!L;W-S('!E<B!S:&%R93PO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
M:#HR)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
M)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC1D8P,#`P.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=P861D:6YG+6QE9G0Z
M,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[
M<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,BPW.#@\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP
M861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HV."4[(&)O<F1E
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@
M(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P
M,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*#`N-SD\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&1D9&1D8@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
M(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M.C`N-S5P=#MW:61T:#HR)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@
M=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC1D8P,#`P.V9O;G0M9F%M
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M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U
M8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
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M;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z
M,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,B4[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
M(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B@Q-BXQ
M,SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T9&
M1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HQ)3L@8F]R9&5R+6)O
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M="US:7IE.CEP=#L^)FYB<W`[/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O9B!0;W1E
M;G1I86QL>2!$:6QU=&EV92!396-U<FET:65S($5X8VQU9&5D(&9R;VT@0V]M
M<'5T871I;VX@;V8@1&EL=71E9"!3:&%R97,@3W5T<W1A;F1I;F<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\<"!S='EL93TS1"=M
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M960@<VAA<F5S(&]U='-T86YD:6YG.B`\+W`^#0H\<"!S='EL93TS1&UA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O
M;G0M<VEZ93HY<'0[/B9N8G-P.SPO<#X-"CQD:78^#0H\=&%B;&4@8F]R9&5R
M/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=VED
M=&@Z,3`P)3LG/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T:#HV."4[(&)O
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z,S$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^
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M)SY-87)C:"`S,2P\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-&1D9&1D8@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I>F4Z.'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O
M<"!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T
M.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MW:61T
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M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,30E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M;F<M5&]P.C`N-S5P=#MW:61T:#HR)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,30E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E
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M<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N
M-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-C@E.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P
M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3(E.W=H:71E+7-P
M86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C(E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC1D8P,#`P.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I
M9'1H.C$R)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXR+#$X."PX.38\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T
M.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-C@E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E)E<W1R:6-T960@<W1O8VL@=6YI
M=',\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-&
M1D9&1D8@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z
M,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[
M=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
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M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C(E.SX-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC1D8P,#`P.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T9&1D9&1B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[
M<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I
M;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C1D9&1D9&('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$R)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
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M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
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M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\+W1A8FQE/CPO9&EV/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI
M;F1E;G0Z,"4[9F]N="US:7IE.C)P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V
M,#L\+W`^#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!B;W)D97(],T0P
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G8F]R
M9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HQ,RXS)3LG/@T*/'1R/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,#`E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N
M="US:7IE.C-P=#L^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/"]T86)L93X\
M+V1I=CX-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z-"XU-"4[=&5X="UI;F1E;G0Z+30N-30E.V9O
M;G0M<VEZ93HT<'0[/B9N8G-P.SPO<#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4T939A93AD7S`Y-F)?-&$P-5]A
M831D7V(Y.#4X8F4X-CAD8PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]E-&4V864X9%\P.39B7S1A,#5?86$T9%]B.3@U.&)E.#8X9&,O5V]R:W-H
M965T<R]3:&5E=#$X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%45!!0SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY&;W)M871I;VX@86YD($)U<VEN97-S(&]F('1H92!#;VUP
M86YY("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I
M/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%-H87)E(&1A=&$L('5N;&5S<R!O
M=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIA;BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4'5B;&EC($]F9F5R:6YG
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y"=7-I;F5S<R!I;F-O<G!O<F%T960@9&%T93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^1&5C(#$P+`T*"0DR,#`X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C
M965D<R!F<F]M(&ES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!I;B!S96-O;F1A
M<GD@;V9F97)I;F<L(&YE="!O9B!I<W-U86YC92!C;W-T<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X,"PR,#@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E8V]N9&%R>2!/9F9E
M<FEN9R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E!U8FQI8R!/9F9E<FEN9R!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5C;VYD87)Y
M('!U8FQI8R!O9F9E<FEN9R!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&ES<W5E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PY.3DL.3DY/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F]C965D<R!F<F]M(&ES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!I;B!S96-O
M;F1A<GD@;V9F97)I;F<L(&YE="!O9B!I<W-U86YC92!C;W-T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X,"PR,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4T939A93AD7S`Y-F)?-&$P
M-5]A831D7V(Y.#4X8F4X-CAD8PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]E-&4V864X9%\P.39B7S1A,#5?86$T9%]B.3@U.&)E.#8X9&,O5V]R
M:W-H965T<R]3:&5E=#$Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-DQ!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I
M;F<@4&]L:6-I97,@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CY396=M96YT/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VEG;FEF:6-A
M;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@
M9&5F:6-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q,S,L
M,C8V+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#$Q,2PR-3DL,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V]R:VEN9R!C87!I=&%L/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,C8L-C`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R
M(&]F(&]P97)A=&EN9R!S96=M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S(&UA='5R:71Y
M('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^5&AR964@
M;6]N=&AS(&]R(&QE<W,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DEM<&%I<FUE;G1S(&]F(&QO;F<M;&EV960@87-S
M971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI
M;FEM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT(&5S=&EM871E9"!U<V5F
M=6P@;&EV97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C,@>65A
M<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DUA>&EM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC
M:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT(&5S=&EM871E
M9"!U<V5F=6P@;&EV97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/C4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!E<F-E;G1A9V4@9F]R('1H92!A;6]U;G0@;V8@8F5N969I
M="!R96%L:7IE9"!U<&]N('5L=&EM871E('-E='1L96UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?931E-F%E.&1?,#DV8E\T83`U7V%A
M-&1?8CDX-3AB93@V.&1C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V4T939A93AD7S`Y-F)?-&$P-5]A831D7V(Y.#4X8F4X-CAD8R]7;W)K<VAE
M971S+U-H965T,C`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R0D%%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0
M;VQI8VEE<R`M(%-C:&5D=6QE(&]F($5S=&EM871E9"!3=&]C:RU"87-E9"!#
M;VUP96YS871I;VX@17AP96YS92`H1&5T86EL*2`H55-$("0I/&)R/DEN(%1H
M;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^16UP;&]Y964@
M4V5R=FEC92!3:&%R92!"87-E9"!#;VUP96YS871I;VX@06QL;V-A=&EO;B!/
M9B!296-O9VYI>F5D(%!E<FEO9"!#;W-T<R!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S
M960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,2PY.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#0R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M
M96YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^16UP;&]Y964@4V5R=FEC92!3:&%R92!"87-E9"!#;VUP96YS
M871I;VX@06QL;V-A=&EO;B!/9B!296-O9VYI>F5D(%!E<FEO9"!#;W-T<R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A;"!A
M;F0@861M:6YI<W1R871I=F4@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%;7!L;WEE92!397)V:6-E(%-H87)E
M($)A<V5D($-O;7!E;G-A=&EO;B!!;&QO8V%T:6]N($]F(%)E8V]G;FEZ960@
M4&5R:6]D($-O<W1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I
M;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M+#,X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,S`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]E-&4V864X9%\P.39B7S1A,#5?86$T9%]B.3@U.&)E.#8X9&,-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO931E-F%E.&1?,#DV8E\T83`U
M7V%A-&1?8CDX-3AB93@V.&1C+U=O<FMS:&5E=',O4VAE970R,2YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P139#04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0F%L86YC92!3
M:&5E="!#;VUP;VYE;G1S("T@4')E<&%I9"!%>'!E;G-E<R!A;F0@3W1H97(@
M0W5R<F5N="!!<W-E=',@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N
M9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R97!A
M:60@17AP96YS92!!;F0@3W1H97(@07-S971S(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E8VQI;FEC
M86P@86YD(&-L:6YI8V%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#,L-C8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`R+#(Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W1H97(\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#0L,3@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R+#,Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?931E-F%E.&1?,#DV8E\T83`U7V%A-&1?
M8CDX-3AB93@V.&1C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4T
M939A93AD7S`Y-F)?-&$P-5]A831D7V(Y.#4X8F4X-CAD8R]7;W)K<VAE971S
M+U-H965T,C(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$4V1T%#/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\
M<W1R;VYG/D)A;&%N8V4@4VAE970@0V]M<&]N96YT<R`M($%C8W)U960@3&EA
M8FEL:71I97,@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N
M;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!A>6%B;&5S($%N
M9"!!8V-R=6%L<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!A>7)O;&P@86YD(')E;&%T960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PQ-#,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-S,W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5C
M;&EN:6-A;"!A;F0@8VQI;FEC86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4L-#@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPR-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V9E<W-I;VYA;"!S97)V:6-E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDY/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RPR,3D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L-C8V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-&4V864X
M9%\P.39B7S1A,#5?86$T9%]B.3@U.&)E.#8X9&,-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO931E-F%E.&1?,#DV8E\T83`U7V%A-&1?8CDX-3AB
M93@V.&1C+U=O<FMS:&5E=',O4VAE970R,RYH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13-*04,^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
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M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY&86ER(%9A;'5E($%S<V5T<R!!;F0@3&EA8FEL:71I97,@365A
M<W5R960@3VX@4F5C=7)R:6YG($%N9"!.;VYR96-U<G)I;F<@0F%S:7,@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%S<V5T<RP@9F%I<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q-C`L,38R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-C`L,3(U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,979E;"`Q(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1F%I<B!686QU92!!<W-E=',@06YD($QI86)I;&ET:65S($UE87-U<F5D($]N
M(%)E8W5R<FEN9R!!;F0@3F]N<F5C=7)R:6YG($)A<VES(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M<W-E=',L(&9A:7(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,38P+#$V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,38P+#$R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?931E-F%E.&1?,#DV8E\T83`U7V%A-&1?8CDX
M-3AB93@V.&1C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4T939A
M93AD7S`Y-F)?-&$P-5]A831D7V(Y.#4X8F4X-CAD8R]7;W)K<VAE971S+U-H
M965T,C0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5-2D%#/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S("T@061D:71I;VYA
M;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H365N;&\@4&%R:RP@0V%L:69O<FYI
M82!;365M8F5R72P@55-$("0I/&)R/DEN($UI;&QI;VYS+"!U;FQE<W,@;W1H
M97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,30\8G(^<W%F=#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y-96YL;R!087)K+"!#86QI9F]R;FEA(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&]S
M<R!#;VYT:6YG96YC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<&5R871I;F<@9F%C:6QI='D@
M;&5A<V4@87)E83PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L
M.30S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/<&5R871I;F<@9F%C:6QI='D@;&5A<V4@=&5R;3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^,SD@;6]N=&AS/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O8FQI9V%T
M:6]N('5N9&5R(&QE87-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$N.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?931E-F%E.&1?,#DV8E\T83`U7V%A-&1?8CDX-3AB93@V.&1C#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4T939A93AD7S`Y-F)?-&$P-5]A
M831D7V(Y.#4X8F4X-CAD8R]7;W)K<VAE971S+U-H965T,C4N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5%0T%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D5Q=6ET>2!);F-E
M;G1I=F4@4&QA;G,@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#(Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-H87)E($)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!">2!3:&%R
M92!"87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL
M('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,CDL,C4W+#@S-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(T+#(T-2PT,S<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,#D@4&QA;B!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H
M87)E($)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!">2!3:&%R92!"
M87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@<F5S
M97)V960@9F]R(&9U='5R92!I<W-U86YC93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^,C`Q-"!0;&%N(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4@0F%S960@0V]M
M<&5N<V%T:6]N($%R<F%N9V5M96YT($)Y(%-H87)E($)A<V5D(%!A>6UE;G0@
M07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!R97-E<G9E9"!F;W(@9G5T
M=7)E(&ES<W5A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#`S,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@8V]M;6]N('-T;V-K(&ES<W5E9"!A
M;F0@;W5T<W1A;F1I;F<@:6YC<F5A<V4@86YN=6%L;'D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0N-3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@8V]M;6]N('-T
M;V-K('-H87)E<R!S=6)J96-T('1O(&]U='-T86YD:6YG(&%W87)D<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY-#<L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;7!L;WEE
M92!3=&]C:R!0=7)C:&%S92!0;&%N(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4@0F%S960@0V]M<&5N
M<V%T:6]N($%R<F%N9V5M96YT($)Y(%-H87)E($)A<V5D(%!A>6UE;G0@07=A
M<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@8V]M;6]N('-T;V-K(&ES<W5E
M9"!A;F0@;W5T<W1A;F1I;F<@:6YC<F5A<V4@86YN=6%L;'D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,#`E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<VAA<F5S
M(')E<V5R=F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.3(L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!9&1I=&EO;F%L('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S
M(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M931E-F%E.&1?,#DV8E\T83`U7V%A-&1?8CDX-3AB93@V.&1C#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4T939A93AD7S`Y-F)?-&$P-5]A831D
M7V(Y.#4X8F4X-CAD8R]7;W)K<VAE971S+U-H965T,C8N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$4R1T%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYE="!,;W-S('!E<B!3
M:&%R92!O9B!#;VUM;VX@4W1O8VL@+2!3=6UM87)Y(&]F($-O;7!U=&%T:6]N
M(&]F($)A<VEC(&%N9"!$:6QU=&5D($YE="!,;W-S(%!E<B!3:&%R92`H1&5T
M86EL*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%!E<B!3:&%R
M92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%87)N:6YG<R!0
M97(@4VAA<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<R!A='1R:6)U=&%B;&4@=&\@8V]M
M;6]N('-T;V-K:&]L9&5R<R`M(&)A<VEC(&%N9"!D:6QU=&5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(R+#`P-BD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#0T+#DX-2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M96EG:'1E9"UA=F5R86=E('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L.#$P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPW.#@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D+6%V
M97)A9V4@<VAA<F5S('5S960@=&\@8V]M<'5T92!B87-I8R!A;F0@9&EL=71E
M9"!N970@;&]S<R!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(W+#@Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L-S@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I8R!A;F0@9&EL=71E9"!N970@;&]S
M<R!P97(@8V]M;6]N('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#`N-SDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@Q-BXQ,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V4T939A93AD7S`Y-F)?-&$P-5]A831D7V(Y.#4X
M8F4X-CAD8PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E-&4V864X
M9%\P.39B7S1A,#5?86$T9%]B.3@U.&)E.#8X9&,O5V]R:W-H965T<R]3:&5E
M=#(W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%,TY!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY.970@3&]S<R!P97(@4VAA<F4@;V8@0V]M;6]N(%-T;V-K("T@4W5M;6%R
M>2!O9B!0;W1E;G1I86QL>2!$:6QU=&EV92!396-U<FET:65S($5X8VQU9&5D
M(&9R;VT@0V]M<'5T871I;VX@;V8@1&EL=71E9"!3:&%R97,@3W5T<W1A;F1I
M;F<@*$1E=&%I;"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y/<'1I;VYS('1O('!U<F-H87-E(&-O;6UO;B!S=&]C:R!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D%N=&ED:6QU=&EV92!396-U<FET:65S($5X8VQU9&5D(&9R;VT@0V]M<'5T
M871I;VX@;V8@16%R;FEN9W,@4&5R(%-H87)E(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0;W1E;G1I
M86QL>2!D:6QU=&EV92!S96-U<FET:65S(&5X8VQU9&5D(&9R;VT@8V]M<'5T
M871I;VX@;V8@9&EL=71E9"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S8Q+#DV-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,3@X+#@Y-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S
M=')I8W1E9"!S=&]C:R!U;FET<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%N=&ED:6QU=&EV92!396-U<FET
M:65S($5X8VQU9&5D(&9R;VT@0V]M<'5T871I;VX@;V8@16%R;FEN9W,@4&5R
M(%-H87)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0;W1E;G1I86QL>2!D:6QU=&EV92!S96-U<FET
M:65S(&5X8VQU9&5D(&9R;VT@8V]M<'5T871I;VX@;V8@9&EL=71E9"!S:&%R
M97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$X-2PU,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V4T939A93AD7S`Y-F)?-&$P-5]A831D7V(Y.#4X8F4X-CAD8PT*0V]N
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M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`R+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970P,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`U+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P-BYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#`X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P.2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3`N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#$Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970Q,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3,N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$T+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970Q-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,38N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$W+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q."YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,3DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#(P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,2YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C(N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#(S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970R-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C4N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(V+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970R-RYH=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?
M3F5X=%!A<G1?931E-F%E.&1?,#DV8E\T83`U7V%A-&1?8CDX-3AB93@V.&1C
$+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001564590-15-003914-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-15-003914-xbrl.zip
M4$L#!!0````(`#6"JT9]%RT2X'```(FB!@`1`!P`=G-A<BTR,#$U,#,S,2YX
M;6Q55`D``V4.455E#E%5=7@+``$$)0X```0Y`0``[%WK<]LVMO^^,_L_<+V[
MG7:N]2"II^-T1_&CZ]LD]MI.=^^G#DQ"$C84J1*D;?6OO^<`I`A2E$A*5",[
MR;23B'C]SL%Y`B!X^H_GF:,]4I\SSWU[I#?;1QIU+<]F[N3M4<@;A%N,'6D\
M(*Y-',^E;X\6E!_]X\<__^GT+XV&=GM[KHVL@#W2<\8MQ^.A3[^_^_"#]I]W
MM^^U*Q<;6E0[]ZQP1MU`:VC3()B?M%I/3T_-,7.AE!&GZ?MVT_)F+:W1B'L^
M\RD)`)5V3@*JB3\GFM'6NXTV_->[UP<GAGEB#)O]7MOH=_O_TVZ?M-M*![](
MJC3E#W30;#>[3;7:#;$^DPG5KLZ5:MWS3K<]ZO7,B_:%?MXSNN;YF7D^ZNMZ
MKV.8O5ZCW08DNCG0!PW\5[NC(O?F"Y]-IH'VO?6#@*S=-O&_<\]UJ>/0A?:=
M=N>Y'&K.YL1=-+61XVBWV(1KMY13_Y':S:C'YP??T6"67'X2!O[;(X5_6-3T
M_$G+:+>'+2@]BBHR[G4,O;^VLMF*:D0--E6,IC#N^I&3-`@4'N('C(L)1&K;
MIJG'U;$S9T/W#G,_/Q"^[/X9'Z3J/YFBMCX<#ENB-*[J`C?#67[?=N"W@L6<
MMJ!2`VI1GUG+=L6-T@VP@ATLVZ@$=%NR,*X*&H,])`P=$_X@*L<ER*%.HZTW
M$AY!T820>6X;+,AI8E.6QL.IU9QXCRTHR*EN>:$;^(O\)E$A-C,SS4+?!VNP
MKEU4FC,>?;:F^8VP)*<!<Q\I#_*;R+(<>#R8^_E-L`0;Z)D&S%I3GUDYU5W"
M+)[?0!2I34!3-4WHJG/"K2F=D5LZUH2\GN"\OSWB;#9W4,[%,^);ON?0<IHA
M6DQ].GY[A.K7B)6L^<SM+12GO$ZV)%FARP*-V6^//OW*I\0'^R^>0\F,$K3X
M/\K'IZWXMVC6PG8K/426Y]/=^4HO4=$)E%7L*HO+9H_,IM&OJ-%'U&H2>/[R
M<9FA1:U6?GO1[3EUO1DXLC4=YW$FZ7.U\6E+P;Z&;A2".SI!A[K"0RP[B0I+
M,7$.Y2N]X,-2K<'I\-_&JS#@^0D6K._$\MR`/LM^SGY-_.FO0KKUMO[KTI?$
MG0-)+%@D+`0VP9,QH[XF="ZM3K&NGEW]?/1CTO]I*VFVY'FJY],Y6'_/3L8!
M#^@'&(;\*.,/5/K35O)T69&ZME+-!,.`7=M*I=.6TOEI*V)"&8YTS/879X0,
M!H*(OD[#;)^VXF>[TG<($YVF3\Y?/?1U=..PZ.LT=*-.^F*-[1S$1*8TME-.
M8SOU:JQY:#-NUCWCAS#1*8FN3V.CR/N2,/\7XH3TW>(](P_,`21G#N%\],RX
M<,-G'D2GD/T\./0&`C0*(;%]%WC6YS/B.-=S3&"7+3_0V0/UOX"VH$+(B$"-
M4.CSW&$6"R0LS69002X#1-2?;"0_FSJJ,61/ID7L2(8CU9D$TYY"IX1-:4H.
MW1#L+DC_)KX/TOQ-BBIRZ)L(+1ET[YUYLYGGBA_?Y*<$>UZ;\-R%#YS9C/B+
M.^+0Z[$@=2DX=Q3:VU!X/0:V,'>2R(B2B>D'+"-KZ:L@'VNXL!]1*)]%ZC6+
MPBUQ)U1,??3@`W/9+)SESODAVX4E(>7F.&Z6(O=+3V[=>KXZN>3YJYI<E=Q7
M,[DI7WT0:>5V;BW*/^L3]RO7\F;T+H#><#K?>Y;8,E05`+?3B&]-1S`H?:2.
M-\>:%\]SD#CZXM1B`\'5%*4$6UZ-^M0N+"\D<'[YPO+E`N82PO(3=:E/'&#*
MR)Y!4,$#G^!!B*_>MI1BS%=H74H+S-=F7[Z@P!S$>LZ(<QHD:SEQZ.ZY=/&!
M^)]I<!FZ-H_D8[7Y![G#BBRX].EO(1[*4#M:5E4J\EN*YS<RN?XA2]M:?E7,
M$'*YNE:XJD);-Q?50):9L=KT84^;GK6+^?*?_P1APG!D\1Z#D5Q)OW+G8<!%
MN?Y-;UZ`WFR8W"U59U4$OBGYX2MY73KYQRR3O&Z=?-EB7N<!EZ_'EWW3FV^^
M[.M6\F4^^Q/U)CZ93YE%G.56Z0?J.MX-B,X9<=C8\UU&U+S=?`EY^UH**VR6
MKN7#WM)T\POMG&\O#H>=%[P,*=AOW'HQFSO>@E)Q7.#ZR:4^G[+YC4/<B[OK
MF^2--OYN@0^7TW[_Y-U/O9`3U_[(W*BY.,>&U5(&P3A<"=B"^@JR489'^W$)
M(";&08A)AF:%(Y=>Z`>4NB_%6.Q75,KRZ95;E6KB\B+VE%Z9W!S(7M.V`I9J
M=Q-"9D(X37NL;W(%<E7`IV_B5$&<ODG1OJ5HO\YL!&/;S`EQ/_8.$WH6,,HO
MGBTGM*E]Z7LSO,0@#,36[_7X@D`2X$[X#?7O\,W7=XO\#I9"),TWO_=B#N4>
M57\A9FF/S*H@>,4L?6T6[#"$](4<V_BZA?3+'?C8IY`FYQ<#GUE!]&++)Y<%
M_/;NTS<[6E5$E9./ZQGZTJRH3=E)?!'3_6).A:1>HJ3"GR,MJGN+UXP47<B@
MMQO_.FUE.TR&&<$C6^PI.&2BCJ-7&V=,'$[E0*DN5PFZ$61?2&:H(QK51E19
MN[;_U>$O(5@DSO]1XE_"$ZX",*L#2`^=Z7O=X!+ARO"=:L/_2\\;7.D[&?[>
M)WA/V-UB]N`YZI#=:D/^<C>ZE8.F>DP&NA#:<TLGXF2@&WPDL]04]RJ.%]]8
M=:Q=N593#ITW1A;!&?##)\Z5:]/GG^E"A="O!D&UFFO[3X8_$U<M*8*0(^>#
M:@@:\<[9IOZS#+AD#O7/H&#B^2GRA]4&'UD6=?`R'6IKHD^5"ZE!5J8@B1*$
MJ>?782`NIP.Q40#IA?8,KU/1;&JQ&9B8MT=7'R^/-+R<1E1/[CDRAD:O;9B]
MU#1MP"#QQN[CC'`\-(]_7?P6LD?BX+[H*#@COK^`VF++5(5=:![%U6H)[(:9
M0JW>K628;:.G0_O35B4X.U)08&[E^8)R%.C]=K?7VY6"&Y_.";.CL\30^#J8
M4E\<'^"1W*OX"ZUU^1GHZ(,T^A)0=L)>8.JK\-XPAX/=L*]%6>@=JLAXI]/I
MIW!N@ZC`?U2366/8ZY1%I/#PH^=:J\@*W4H%7@W2L'+'K@BOP.=485Q/[U6%
M=^-[$.P&8FTN`(E$BR#>3/I(4R@+G5-Y)O8R<[L)PE9@C0+'586E?7U;L)+O
M*JQ:'5/7''9S5*0(0ZVNI6,,\]0T@\$2EV/R&[(@#PY=-1U&C>ZBUTY[Z_S!
MJP*LT2?H1G>X#4(_I'9\<P=DX3D@:W0)?4-?`9D/8`N<-3H*B&QZV^#<#+!&
M?]$?&.T4P-V0U>DJAD9W6V0JI!K]PB9FE<%BUFCV-[$G$]Q#(L,"<583@VH8
M'T)HZEH9;'@A+F<G+G/>'@4@HZ78E@\NOH&6L]2*8G15+?!0;_WGP_L[<8%N
M([EZNK45;J,2[HC%^\2=OG8HFSJ9YJ'QN0!OY]#XJR3F*V!K=#%F.B7-#%H>
M4HW>Q*@`:63;#-?-B7,#"=V5>T;F+"#J`IY9HQLQ>^V!F4XEUP"HC+)&EV+T
M!SVC5QWE+0T(<ZD=[T"`$P]GH8,+6^=TC%L#*N`:'4Y#-TTC$T$4@]D!?*=&
M#]70]958LBIX(=U3S[&ISS&1"=3UR$Z=Z0I^7"+M4%?'KH*MSC2FUS=[PTK8
ME&``?.=FI#4F-SE)7Q&2[7'7F?.L)HK5<*=]Z`WQKWUQ\MX6ECG>L5315_54
MV:7KG%OQVTWL([685P+4KH14]6]?A!"Y@C\*@ZGGL]^IK1)0U0VNVT1`N<^L
MQ&R"L"W<JO[P#X-[Q7F8AEK5$ZZ#6@!2#KP%P&Y5;[=G@/F[7-VJ;FY+E&OW
MMRI`K>KUZH:JQ,0E;%>WJNO;PG:50+03"56]X!],P@9+UMW5!68L67YJM-F.
ME42ZJX_;!])5:U:7(S.&1K<_P-WP@L$K(ZS+=QD=H]/MF/U=$:ZQ8G7YK1*,
M+&/)-F'MU>7"2K!T+=:--P>J8*N="RL;N^L9G=H(9TOD18XM?2BXY,F!02^;
M'9<&7G"9F@J]VLFTDOL:^B"]C56`9VOP1>YM&[X;V2W32N"OYWBD"70@*E47
MHWO5SL2579HP,LQ>@5`!89$KVX:A_>[`W`J@O%OPO<=3$*N=LBNY&+6!BPF*
M2C"+G-DVG&RL9^4ZE%?BPXEH*&2-*X`$QEI=U>M5.[A7TGJE;=<Z&#EG33YZ
MKI>F:E7Q^]6.*I?5I)S3)VO1;(N\P,EM)Q>Z/NB86X/_2(-<&>Y7.S9=6M4P
M+E&QIL8O":W`;6W)QF''*`U-<#B=?IZ+KS:Z-A>^XK^AE/@4[KUXK&XWLY!>
M'ML&=H\>"7/P3$?JVRC1,N<[PIFE$K8/WU8D*\4(:R-O'XZQT>D,!]WZR%MY
M!0:K8+2(+\&D4JW^UD[4*%H>:+2;_6%"4`&FK0G8VKT6$Z#WFKJY)07_IO@!
M;VJ/'L'L3NC'$-\)NAZ+ADJ"M(&PNISQ,G/KB\!&D;'M,-9,YZ`H,RVK4`J=
M@]K)/*=S'P86KYC!OQTJ[K8&`SKS_(#]+K]-KQ"UCPRVF\Y&RD#:C8A])+/=
M'6F(-8_:^-(?A#`KJ/>1Q^K#C$SEPZ@*=1\Q0#9PV814O'M[2V?)-7W7X^0K
MC#`/Z<AA^<$UE88"=[^=/QQV>])4;8LP/1/+"PF3>.=Z''TH4`W*!OMP[H;1
M3\=D&]%DDS;+!]+I.95_7[G1FQ?G$=6Y;V"H%.TC2=8[W;2,;0>S;E+WD6CK
M1O\/H#1S=%HE:A\I>:/7+:(J@VA[`H9UN??TBQ?=VO%GCEO'$[A<5\D_JCO<
MRU)UMVL6TU<!\/[(WT>(D`U3ZZ4>$BM\8?#&]S`-MM\M/H%KO'*7#4=6``FR
M.#TNCA*'\"PJ]-P4[?L(-!I&NVNDX[S=`.^+^'V$+HWNH#W8&^U@"L1"Q[TW
MLGX+F4_7O@&ETKF/U8RT\2J/JPYZ]A'A9$[T;DO0FLF6*\:5A',O.P,KZS,[
M@-T7X7O9:S!+Z>16E$,G%J4VQTM<<"<>#_)?`0Q&G)OPP6%6_/5=E<B"D&B[
M.,\T]$'V'>>2V(I)@IPE6;9+2-$K7K12TGVVC78Q)2E(Y2A8\\%LE9Y][&GT
M.OVA68J>-0#74Q<E71?/U+=8:@-4+[HI9KO%CWY[+2%9+.M1*Q>=\KBZK4+?
MRPI(]O*"`CP[P-_+JL@NZ-=8O$OF@N15L,]ZQ;MP2NM[N8BQ)-Y]T;Z/R$,?
M]KO=4HYY*^+S+QB1UQ]ELQ*5U'W$']UA+_/*1!5T]="UEQ66H=YO#_=*V-H+
M:O2BJXK,*B^'F$8F@MC_#3MZT=5&E18JVYWAL+\K!7D??_DW"Z:?7.^!4_\1
MEV/D%VQN*2"W($D7JK?\/@SNP_`KEP>^N'*,B\_ZX#V",/=B,3OU?LT].$T.
MSAY/'5Z/Q4=Q3)4_FR*2"++R_9OE^G'R,2=<@5X;6B1+T<N6:V\`+3<)PV[F
M^-$!\/.@)WA3G+;[!$=165VS:_2[QF'/KN0$%S=I"@Z,9KB0&C&(VKK*^TV!
MYNZ\3QUVV)'QNF$8PW3P74BILD>6F_>=>5S=@-`+;]S:#GB4_!3@4,!>>OZ,
M1-MC[T+.7,JY2/?FQ%W<`[IW3CIM*[Z$*WUAWW=.\,9FC]]-@C=__A/^F&L\
M6#CT[=&,^!/F-AZ\(/!F)^UY\"9Z$GAS\1/':#`7KX8]:?_]S1A&;3R)_?F3
M!Q!4^6!,9LQ9G-RS&:1D'^F3=NO-B"O+./N=GNC8E?R)XYZX2+$C.P^$B,,#
M>.I26>N1^`RT^$2+*AXA=+VI+3FE$=?68EYIWE@+IE2+.*8AA:UY56H[&6H[
MS6[G[Y7IBW@3X=Z5Y,Q=E]KW2.9W9#9_\]>!8;3?1!0OG^AO?M">",BX:WG^
MW)-7-`*W(/@2ZB@K0FKX1F\?:V#9!E!5\$Z\^X.,/*<.>0(SU-3N%98R#AS7
MJ&M[%D@P;8SQ+E'H^X%Y<S!:,V+1,,!/4(%<1BVDY#L+4!MQY!T7A1S/G32(
MA:M.F@_V<?:`47Z@34/@IS;QO:=@JDV!`<`6#1@DH`40-XI-5X27J6.+E\OQ
MJW<K>)5A;3^<:!:>&K&!2@Z]DD!C,"RP"O02]_]L;0RYI3::@5H_:\OUZHCM
M"LME#97CS2T%;GB``J?P,"91[[_AVI02^[<01!$$4NB>EZ2,XL4U5Q-?$]/P
M<V+'6O)!L:9V!\)(%8F$-L<I=<59>*#4U>8^F%<?"->@<T0KQ42^.R%&M9.W
M)S2RS`N/L7<G%&_00%UH;SD@?BB-`=#H0(4Q^#$HG</T8],Y7OPLX1]KW@/>
M72#'FN"=!7@[*E2!A%2TG3*QH`F8N.>ZU#D64'S".#ZVHILM`D_CX1PH#$0Q
M?9[C7T`G9&0)U&UE13>3WPX=Q\)2RCI+<4"0S*HB7M4DYY-+8`;0WH@3XFRF
M11D\\.;*'<>&&TG&3F*J5P56]";9A(7XZ_48=-0O8D4V$L5GO&022YBD$>'3
M/@BY-W6TU'H7;5H8,UE:.X@!;&F\X%_<<X1YLY4^>?R50!ZI""[<H<&'OGPJ
MA!4B.(=:(+2.HQ'EY//WV"43&P3@04"G`)"D!"VWC&75!C](JPIL)!,QI,#$
M,)357'`_'!S98FG3QQ!E@KZ#<KCR&OC8A\.CT`D$^8J)B9NQ2+3D+>D<AH#0
M#V@2%DEVD!"/W&%JW['!`9CXTXX\GMKQ`W%P<5KC4TH#R>08$6+(CH^FS_6"
M)8%HNT#:A&UYI%F:8BKP.GEHN`!;I<$CA.3A7GBF>SE\2EJJ3+@P4M3)5%"E
MC$^]T`$?C@B)$`SH];^A:XG2)\AJ!-Q8K]>.(FF4(P$WA(.%:0&+&%,L2(7H
M`2JLAB*1@'<R(IKOB(CKAD($A?`"3`P)-;W=^!EMO(QVA-XD_?<B_5D2]*EY
M!VYI^5T!0</%LS4E[D0,.F,<LXR4V[^[.*O#YQ^^';_#M-5&75UNY;T>\WOE
M:O]+0("`.A2)8^V)BH#5H2B[1.-+XN<B8P,-CG@`JFR)Y!9HAV3L&"KXN)$5
MH.-_FC(PU-`7DV]&=XZ'PR'^K\DSSJNM98M(X'E<+6JN=HWR&@(#_2<05K"E
MBC)`C"%W/R([`Q85S6$#++D7Q<MS&6U)4V!1L$F@H30`RROW4["EB'2>(?(*
M*%BOOPW:34.#Z7%DRS$,F@`0P33C\JC6L:!)ZHI4(MQ/GLF<(^8;C5X4W%9A
MUN6@0DS,9A>*Q<P*OK@/?*X$"^)?4=X;Y>/E4NW,L6`V<1FD&7@60IY2`\)N
M//QT".6YZ7G%+QJ\CO3<`)L:SF:H/"!5"M.TA&M:S+8=;,I!6T^QNH?TWZBQ
M#>K&)ZFG%Y&*[,*!0[.J.X4I4P*!4I3^T3GQI?O'[GQ;A&+";9-$A"!+A$[`
M9'-M(M_O!K,%Y70>)*$#?NH'?HE5#3$?HQG8(XND?+J(`WX:C6[2GAW)D5A2
MD>G6%.:0LQP9S+(X<<75P!G,_HQ\IDMS*HTK`><PD]O>,M0F8&.M((J^,!Q"
M%R:61*5=E^>ML:F3G*V4J;>]_#BB=$W1%:S!FD9Y$7,%#APK4>(JSMA#:'8H
M/$92+\JZ12@\L@(9]\E0VA*1J\W0S<B5FV#J<85ES3K79"S/\?R3O[YD-<-,
M)5TK"LVC59TH.L^DG#AO.;&[M@S9L4(4Q2R5))[8[.*EJ`M%3U,/5+;A/;G0
M)0\?($EDX#6.DP;:&5G@@N`_P7KC"WQQ)G",\TL@,(/T3*@Z8@#9<!R9.L5K
MCTL40NZ0O\22BI-8&^JP&3!JF4L+E;0!&5#+N$PEHU0(<TEQ,;4E$UA,E=,I
MY7=D[O$W/,WA)'^5$&6.MV8&<R>MQ!PMLR:9I!?,P>M9J%RN*M)Y_HHBDU^=
MD/$NV#H>F5&73F1R;A$^U<:.]\2E`4E-5Y!-(F.5R`Z$:P_(\?BVTVA%6JQ5
M_TTWS::9]!%%U0+&D^=_5I</L;IA])J]E>KIA6VTEA;,+?@(:;9#BO\6U,9D
M"G(LL=D5I^51)A$U6?JU]8NKZ'!2=Z8HBYC)*HZ''5#Q!LDX#$+<-1@Y8(G#
MR51U:,L57AY:N%`R#E%A5Y90(]\])SPXUF:`7R0M;B`653*)FUAAP#5]7+YP
M/>$=?>%@A6]4)^D)^(BUE,$%?G2A4.Q"(I0H(,")ZY/X)>X8F"11.$/JSW@4
M=(@:$7^C(5_SZL!$FJ;7%;W&HB)M`!4Q&VXO11^";((U6`ISB"J&A<H[CJA+
MD$6/@?W1"Y="H3RHB<N#T,W_M_>NS6WCR/[P^ZW:[\#*GOU7IDKV6/(]<ZER
MG'A/MI*-*TYVZWDU!8F0Q0U%:GBQH_/IG^X&0(*Z2Y8MD.IY,9$E7H!N]!6-
M7R>H=B39OZ[9MBPRBE&1T8+UIXP%[92%%+`;GPR6WE#`]02TO,S1?8$EN!K'
MYD;GZX:Z3LO%=1SUJ/V?T:R3^QP3C\M'L-+``DEU>Z^RW0%6"PS(>D](*D\(
MTN\-DM`;*WM=U,TH!3Z*<4-/[3.#*_E?$Q`9@0:]+-#J59G34Q1.D$QZFX.^
M1H\`!9<^R+)^3OMO$RZ?E96>>R=)[4!"K`*#[:,9[5<F$V2Y%=%9)K,+_BG8
M8_4`>/,`"&K&#>X@ZAC,MX#I]D%QI*A7A@(<9#1.R"!PE7]@BL_K@W53,3*\
M+T>'"!W?K,$[D5^0K91R`;8GJ"ZSIV6<7).'>9OTVC^9O8461`]QB&Z<%Q&>
M!KE_0"GE%><VJ0Z]&W#VXD2O2A5K6]F&!>\N0*N*42BIR-4NN!W"@V@^H#^'
MX7JB))@<5^7A%J.FX*8%1C,K=MMH`9-3V[(&/M8.K9G[1`V`3H*+W@!'!YR#
M4!+(G,YXQ%01P"+1+S309)7)U(-A57V7F?$:T55=]-@D]O.>3K*/9*8V,HE`
M&#*3XI#%52IA`ZL6^*K"2TKUI+3'A?NT\#-<F\F>3J'%HR20&9(?OAM$<1C?
M@_(@7U_>!ST5-R`'!L$HU='!",-/&G;D?9=JH_,A\'-#7(A\P6.*\P3W3W,L
ML8#@LTG%,;>&VCI2POJG<<7<Z&P>K#T(JY#%J4E.Z03#31RKW>IWN%AL5,J)
M_<:;=U>5JBYP%:T]XDCHO(2]6$T/)6`MQC<Q;<_@#A$F%<`<I11)+HN:BB5%
M89#>-:)?REW\<GJ'WH?JWCI6GP'#`DQ*F:M:Y4?]>RC&F"!)IF[-(Q-.&5?7
M?DQ@E!&E<82M.H2/M:'@8,.S>K0QO(5XS,5%."<9H!(`I!J$4D>E*C9I`4WO
M"-X'J@'!E4+*[BGQ)7YC,(R/4S510%731<>*CS$V2L"IP.M"`4I.NS[%:H/I
M4V2MEY)=>8=CT'N?F5E<Z2R5NW2MINC[+`K:\4WFRQD1>U5RF^L-71O7]"D1
M"3YCO?MEY7[+(6ZD&V;5.F%R&)UUT$EA`//&2-T@J*:XM=\;(+:3WM9"40I@
MDB!@H,RP(&6LO()$0K0/KQZDN)!#3!>`N'7EK-@DFY6VG\[5KQ^\/$H3O8#,
M4_12B5EFIB#L'8$B-($KL5QW;'R@?A[Y:5$VD6")`V+*)D&/-H=HKD@@/Q&/
M@M)UX$!NF+UV7T0-W,(&8CHE9I2^;7G8EK@YDE8AD"Q0,C`>H-T2BJXQX6T\
M5851!]_GJ=E21"\+QW0`80'F[K(!>&)8+Z-*\HK*%5AHF"$.R3"9K5_*P+6L
M_>:NS!XQH:T$%=]*XD'6]-#[B`<=\1P/NB-@SJP].*&`\E2AFI@855=5#YA!
MH=2K0$U5]Q1#ZTOC.Z%9,Z,,\:V8JD07,2)+J6*>D0@2O0,XP!B!++S>=O6L
MK1*U3SLU9)V>QT$?>O\9R,C.2"82:QG]PC]]Q'HD/TA!\*D,J*7W'31OJCLE
M)9:@?M8P?C"5^'A;I1I3W4].-L9XR-=[0;X(.3@>E;12+:O*CE9B7^7:TEXR
M!H%Z,DU5*!^&R'*3F/Z(J>2/E$K6&&S-T0Q?*\'70R`?*72>I2THVUX2YA$6
M,OK`'OR/-DL33U6`TG+I!0DL5-6H-#4EO5:4U-/G:74A`]5;:+G`/!RE*:BN
MEBJ4T>$\]+Z8/S0D8VIV$(HPDD+W)$C+HI/)]Y05@;H*#\5%I5YPG]/:TRR&
M:@FKBA>4_"M=EDF*X,B9MBXT[HRZM"LUX5!%4+5T24;U,\[S/E+==::GI<<.
M?RF+/X>`UF!5[C(M2\4?Z!CUZ^`0QNM+U'JT"0+JE_8:M?K6N8W_JDDN)5$1
M4UMA@3(,I/G->ZA,OQC$3QYRB+XS:HH&;0*6LL(@BA5=2VK18V?L[,RJ]H?!
MS2^5;JPKA*=//75F'DABGR`I$__-TEZ%(#R86:_MI[=4N5K@E[54="""UG9/
M-W,W/DQ1'3+2T(_:+",^7[7FJZP+MF70SXO=[G0`OLP!N2"1R'0QF3KQ!!'!
M$!PAZZ@PCE&=%58UT#`+W%.AZHWBO6.=29A_UZ,ZWVW=\:C2!$D2*#^P'&N3
MTCXW)0?H;&.?])]0*E*:PPLCB*"TE7HLSW;HPF\J73)&2GV6/X),WT3K!QFK
M3YR#<UK2V#A0JO121614H"'\!QBJN)=QGA;!G?9-BQ=5GB-T]@B+E<K*K,*A
MUL\88=$2OHJ4IGJ[O=_ND^5"1:'<1\IB0[@-7*%SJ9A`5)?;:W>8IVB>85%C
MBHH,J:K*+<_NPQ#Q\#ZM0]3]DU?FT=2U35IF7ZL&=Q"`CP!F::Q7'-!%A3Q@
M/AYD2%<I!I17(ONK]:4V!TH>DMWKQR&:XC?/<3K@9/'I`/6>2MV]S@S2^OSM
M%2*UR#!,1P(SC,7?(TR*ZK_!&-Y'O[W"W669O#)#5@\XZ&$QX2B5;\R'7[S'
MP,\&;R[;?U?#TF]-K,\^$HH>"O,KGJCNNZC<MEGE!/Y=)1E^L=M%1[`6I9/S
M8>($1^;/I(^:[P2)C@XO3Q92:8(FTT1;1B6BQ,6JA%A$V/6(5-)G-?),+Y_+
MSN'164.7T+=('44%U?]G'N,_9-5T\3W5+RK+HJNN<-RT.:Q=<,M*@>^SB,0_
M5\35$=%=7=_->76[?BR?U!IU4AMSB+;X))M+@KZ/"T[!.NFP"GSL:$K5Z./+
MN',!>H<6J/=!5QJC*U1XCE@;,E]A&4U5W(C9)*7%6G8A``UGQM,IEZ7V37MQ
MDL1=#033'=L7:4\;/&E!.M':.]8'"?HY1&AVAME4D\]6FN@SL^)T?QU/*<XZ
M:4YVN/9^_7Z;#L%++:@Q>)2V`\64*748Q67Y'1UC*:%(%BJUPU45VL\4.TZ>
M.F]".@`W/NZQ<WU1/BTFBIA58M:8/:3IK+Q`D.+^)NZPCG1"!R)_[&>K4@GP
M7.*E!N=*O=0Z0:X3CK,3"4W+O\PLKYU9`F_5KAMG0ZWBP^+OU((Y2=0.4Q*H
MK5G@8[509:I$H[D[I+>)+.J#,=5W;?[XBO6$'O6KP;K69NTUS-Q5J)1)JYT`
MJNA-I)97D-;R)#H>=`+)1GF741*'87%<T.A1=?`0"S+,DU4!5'"/%7X@UE0E
MA,5%B#B56L\V&AF5._G"1>J:=G+[\#OM#8[4.5@;)@4/-B9"E:UF`V^(!0*C
M4)8''"N%2[3)8$977!(G]R+2:BZM%.->?_E<`*]0-:ZNBX^HO)%2Q71R8ZKF
M/)X/9-25`Q'V&ZJ[+*:.)B1M8KT5.U;%6JNL``T$B!O/"]B].9?G,=(>=9KE
MOH&)FL%@.M*GF?DA4@*$^WEZ#EY?&M2%:>)0"0\PRI2F4.F/VB0O2&"*6`M2
M%&@*A>&<(Y&%JU.(#)AG/`%1H"I\,-`6=#(C"X8:ZDA7RQ!4F#ZH4(PG3JHO
M5W*)9SD"N]S=3+(Z=9J,BGS-6754-QH@`]X>C@\]TX\(F.'KS<8@\=6>$&[P
M1+XJD,+J)=P-O+>`-G`_JF<AKX$"&663\6LQ%U5UA*]6FVE3^ZB(.1)6EZ2Z
M)Z+JB.8:R"_VR?#U:A+]2DVB=:B\.<;TR[QS\]KX54OM;*S4LMH."X(6/F7I
MV:>1&*.\J],]!IVT6+LM+Q24^<&R>GT>AXX31:9\CEZ#!P6+(\ASQE,I*T!X
ML9X"N`!MA<"P-OYJ0N6G9=657>2GZ@M!.^O8RE.`W'A&4_4=*P\CH9RKTB+:
MSD6P@'F#(Q5.53=('SKAA?0IGH3:N@_10F!5&.C+82[Z,,U#<;J?3JKI6JE(
M;R7/?;=B%):266QMJDI0[>W75`99]1S!CZ8>Q"SK:M2I?B)51O,M[)6NB+#!
ME?2!%UBSA]XW?1U5T&$56@MWW57Q"SQI+C93(NV2N(H?I0"2Z-!>6;$L9X'-
M**<"WH+W+\"/TA75,A*JD!#N*!`3I#HB6@']A*_+HK]R.-/UB.9\J?BA\SI(
M0;O$`_7.HRCOM9"`2`#+XVDDL>#1R9GTT[D$@T!ECT$AH3ZI.-AUQQR)H+!P
MPK`X/^?1,0WE$(OOI,P\A>%NEC'6>>=)9&MZ?("=HRE.NY9/:]&#<!,!GJ!.
MFI6)N@Q=P>+,?JQ'IHJ6J18W#"76-'6QLA>\37+]Q0]Z=0[BD6@C<D7WJ5.N
MUB#PE68@P%C@3UHBP&IP^D)N*D!OYJY*N):"QPJ/M<O4[$I776M+1W"Q+*HH
M:NW*2/:#,JMUCV#V9O^H'_0S`CO'`A*0LN]2X2QWI3*E:BFJA!G:;*K%@T6<
MA3KQ=:40U-"EK];*^^1YTZD://7MSR%,JDJBU+I7*\,OT=HJ3GNA8E#::`/J
M=?!3F2-7Z3EU:IP47C@N3EY,D`X/-:C<(%IA5;FF@IK7P>0CJ]7!5IDQJ2I-
M6TP6TFHB73I*`BH.^UK>4(`P3D"V6`])2R0^>U'_-_<U`LP_]:=4P4DD48E5
MM_`=HC+4(<JUGC,Z@Q&H`1N2N8M-$5`ZS3'&YKH3U,+EX"V9JZ><3<3C\5&J
MR-<<U^(&4V54\1IKS,=[K'O59W>&HS`>3^45"O%(%6B`H8HYZF.PZ^BY!\I1
MP%X?_D3VA=YT0&"/Y;DHNZSVJT[QRU)E)A6H3'QHH?*,Y@K'%6.+.4%U:*<0
M:I$68P6G`I;_N#P,1>*)R<,BL6*CI%L[`YBKJ!".ZF4+_Z@\$?8V%$"&N]X@
M1BQ178F,N_`$$!'[4AU"GC82ULOZADU5<AKW2^-E$D'UF['^=<:K%@*!&M5M
M0X`BH%2B#+&%Z*'`K'\H/`9E6S&VH276#3>'87;1K;FSZ#YKO;?HO`?:QW(1
MQTE?!ACGH6\R<6`LFX]J:F$R5E%5],%WB''!!4V1U'06K:QL!9N&3X[S%"Y-
M?WJ60M?+)65%ST#[69OCNRNH;1\=K5)1:PH8NO<$Z/K;J[_=T'_%>_1(RJUO
M\\47HMW1X?FI]>57Y$OUJ[<E\]3(3H^>;?^_`DJ[4GG9<ZV#%8K58+#`=N#!
MV:M=LN/D<C8[:-(TK#=JZ<TO5UFS2L)VKC;DV),B/SR>_"DF'('WN`6P7JG/
M"[*F_?=?'@=@W@]0/>!T'Q,Q>M;:F=VR9B7)6:5F[OEX5:HPK<(-S<DP>NHJ
M=8H'@=NCC%6=6ZIN$=O^=D3_[94Z+([8[EH+%BIO5<%BU;AQ.3'K1<?T8N?5
M<S-HKE+L=$J>(9EG:D36FA.-?8[:IVN40+.V=%!;OA23CI\H7\N49E-EC)5H
MPQF,J"T.R"<KT1>/QJ]O;HYNKNN98US,F9?I*UCV8G^OR]`VC=Z>G1/M%13C
MRXF5&UW+UG5/=L"VSM'V^&;9KP3'LPWSQ8QT,8?,7%F1*\<ON.?"3&%3U62V
ML:EJ""/95+FXX[GS.@[G3C3M>J>,!:CDT?\XRPPT2WMO=<Z.5LSPL;0X8VYV
MRY4=1$;@UZ"+R*QA@6'S4BOVM#ML7AQB1PUVC-RL4]H9Q_ZANC<I$`.K\^:#
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M#N+'2"9>&N=)#^$#OPZPW3HAMW813CJ*5:]W[\\<^-PGT%=AFB3.0L:+?`*M
M3"3,7[8*3$HU)NK`D.*8_0JT9;5CS?13'W4C]%0,"595X;GJ1F"(`HA7-1=*
M]5\P0UKY0$7O;B!4VVV@W3"./());)!,O!5IT"N82E/NJ9FF-',0D)X(>WEH
M>EZ"X@W0W-$**>X3698$W5PA%%)+&?4,I-8`^">3%&_&>]3XI7\`JS[![C`5
MO,WBS;#J\PQ;:-++M+3I3BHD;P@_#9>HMEV^QI`D"1C%F32=-_T@S`FTLVS=
M=>B]PR^MM4S3+N<+$I&_^&RI[<3B@5<H8G#A#6XK0MR.\F04:\!YA1`_=YZ&
MJ=1(`DCX@"C2.!U0!AKEG:;3FH!_51"=<R\'W8$]9$S7#LV:`@]^*6?>RI[`
MGA$V$.]`6.I'E),QRJ[LL#.I\V;.?W)YVYJNNT0:%-&!Q.9MS=6"7R3!J%^I
M1@RXXFZ3.(H1^5Q!MS9'!]Z0O<;&4=C-`/YM$9*X**<^JDY=K9PT5SH"%]!-
MT0/"(M@=RBHA&+^-X1_J-GQS=??6:CN<ZDL(AQ[OZ<9%=RSA@]"I5^0$@JL7
M>CJ2O:`?2%^WB$`9\@FD_5L4HI="CWXD)R5(>[F"H2>@?A"H'H'X)L3=<&RF
MD19#K;1)'H,DE"\AY'K\FAP6438\,,^=WY^M[)%1=!$`&BB7:1(%F`#Z:?+P
M9Y,@EC]$WC_S2'J(7M):>=D8%LV\XMN(4+'QB0?M(R0/OMY0:%I=T#A:WGML
M?%1"<%]K1.QR.%](W^*[OB@D;5KX+>]#V;`B\J[@2]]`:_];@V+#);`J$(W\
M/0R6S-8_\L"G;@KP"@B20<->M(]:L$X,)C2VAP@M$'H2D*N[;V9>+=WU1.IA
MZUYOY+D'91]5NY<0+&@PMFALLG%+7SWYJ[84HF@V@.("BC]/I`$05_*N>LY<
MW5U[E^W3UA2^_APRO[->>$<O-!29F"P).](2C5?\$*0D!@BU_2-(B0D&<1PH
MJ(FK9N;=&]*60R3:KCC$^2R@;AA"2ZC1/"HZTCCY,]K>J$$;MBN>#;&!!ET/
MD@!#7)5I1MN`)89W)F^\UVVKFX5F'390D:0G0.@5QK[=_T'#D%?'I]JP@-,C
MTH'71U1QQ0&R\,I[T\%?RWO=L=X9BJX,YT^=@B9T#9:LQ=?'UC/UBI-T1]I+
M@I&-_#_]$-V$,%`M@LI>0)IF`8:H]W"A[COR^F36NP+3MRA)LQE]A<IG%=1?
MQ"?5F(``^$%J55^:`&V$KV):_;:I^\%ES1.T5$,*72UQ]WHAK/<^3K*42"!P
M%]U]"+Z_*_M8-&&Q^ABB`"@5TSE?75*_%,_\9C^S(A#:,(Y&X5B[_&#DJ+%:
MI6,:NHO8D@F<^5!$F%<`NL!:&<%B*6W<(:E:\();\T4[R;&10LD"[-));0L0
MDE^O>G)(YW!&NQ$ME=A0@MQ:=#$)'$U$.>M2]9U60/\6@K\M6>@W#W&>"?5?
M`3F<_X*&F?*K_!Z[_5C&'%P[8ZS1?RQTLVF4J7ME5=9T`C;=]^[C@#H(4BL<
MU2<#GU!XAV060$&4S]0WENTM*NX6/'J$L9=N$H1-3C0SBWY#E#6B9C]Y%]^C
M.CC%>3?3@H;KC%9BY<FB?"0NR"#*I5I@E2FHID>Q&7=!@7X<9R`E%1K,F"ZJ
ML<+KQ,77A\MA>*1<E&8C:0F&1=17M$M'!5>]G-I548,AT<=F4>_`]Z48'&TY
ML._LT'LO$A!KXW/B^T?8I"3+I.Z(4NVXJI0`]G8IV%'U'JIF/)N<7]7#;8Y4
M?-,ZV'+<2E5$(8519MJ]4KWJ"G(N<LBJ)-6^6)&%C2+L>VL6PSR.E[90L_Y$
M-1GV_4`E0E1K'/,>+:]5S5=&2M0WK[),-QW&J4I;Y5VP2)9E(;]P:R\YH[N!
M@_H]I5I>L/KU&\?FK4D1%Y@>R\F$*-(=D\[$G%C0\IX*`XHAI_(;E"9]K8=K
MY^!IW#_ANZFG<='>2W6+3+&Q-<CD:Q5B%]=7)1FS2B;"KJ[8@MK_%##G9.RU
M%9-4ZUBE-Q_)VEF!+^;(IX/<UIP0%^UIX7[:=M'>V_KUYSP]N!=B].:N[*%6
M1H&WL"9[,*^O(*)OP[CW_?>__L7S?BWNP1ZU1%P1OE7=[.ZPF=V[4O,6=WJ!
M_]NKFS^.CH[:[?-7I-CAIR^R_]NK:_KVM'U\T;[X`ZEPU#YJJP_'Q^U7O^.`
MM[@7-Y7L>AE4Q.-#3]/((R+1*H%;GI;G<CJ_=SO9G!NUC=YHPM:[V,14M?BL
M]ES:<LLE>_;6A"Z7[[AR:R2[?.2<6R/-A73>17W62X)13`G2'O<"<>-0O0,<
MJ4<1XS[)"*LPI]E3I`58B[G#E'HT+SIW#!2DCD[:2_?=:"\Y!;&G;36X-Y&[
M['&J-]$:3-HG$6(56&_^<6<AI]E3`YRXG:?H=K;]=YO(7AA$04_#PA5_X'33
MO)BPM5Q.89U3+3%<IM4)RA4^#>M]D)EP8\%E%_%;N/?#%H]9/C^WMLBNYAZA
M/&Z=G5VZRT/&1W63*XP6X"QKV$2QB6J4B>JT.NV-S_FSB=J1'G0!^LVU;/W.
M./89JWU<WNIB!)MZ[NMOEW7-M6&G[?-=,]'A=*,;/')'WMS==VE6.,:6C3G'
MENUIO&Q?;(S5S9;-)7ESH>?2C(`-#RJ&TNL<[E7`]B2@;B>RC(O8N*]VK^:9
MR"VRM+GV\*35OMAYMG*>19RK3/=-$MW9REF;51SK.:I"V2BR462C.&<+[_AR
MX^X5;!1=4K)U@NJ&\9CCWTA\^SCWNJ?(MWMLG"J*]2/5C0HU8'K%;;3@K+)+
M7-3+*;KE=?1B1:#3=+P\/3PYV[#Z=KND6'L9;T(UFV17%8"GH?AOG&A<\VP@
M4\+<&8FQ`F$AO-Z4X/Z$_X!P&`2"$^<*?2Q!K!,8:-Z'#WDBDVGH$L412R-L
M1Q^X#Y=[U>LE"%?S,5`(68C?P\`9#)Q1ZS.9?.J<@3/XR+F3+-DG&6$5YC1[
M&#C#0:8P<,:^.&E\:GSWTL;`&4ZSAX$SFL,C5H%N\H^!,YQF3PV*_7:>HML=
M<(88)W&H0#-TJX1=;XOR6>+]*5;8^T*$=JM]<NPN#_DLL9M<X9H[9UG#)HI-
M5,-,U/GQQH>%V42Y4!:W?S4/SB$1\O:4.SRJPS[[ZFQIKN4Y;9U<;(P%R(*S
MGX+#P9'#K&&!<8\K;&D0=;9SRI;&(8;PII'#S+E-XKY,L5,Q=M*5R4/0TRWK
M.4/@!(/JD"EELX-813L_A,IB4R^QX?#&8=:PP+C'%;8SV2\G[;:[#&*Q<7`#
MQ\U#$HQ7OJSJ8%%-,(N9>YQC5-<5$W27.T_/.5SE[0:/W)$W=X^[-"NF8LO&
MG&/+]C1>.K#QQ):M_KM1C%?.>.6-E\.:EY(S-.L*/#YO==H[;P#,T*RUR?PS
M7GF]^,5&D8TB&\6U*^'/SKB)A^M<>EZ\<J2&!49LD6L62.\3\<KMX?SZ<YX>
MW`LQ>G.7CT:A1,1F$;X5(<(TWPVDS-X%:2^,TSR1Z5<8R]LP[GW__:]_\;Q?
MS9TW(DC^+<)<SKK4"_S?7MW\`9+>;E^\(L!G^.F+[/_VZIJ^/6T?7[0O_D"L
MJZ/V45M].#YNO_H=Q[E%E/<I".<UUM)3]N<//2201Q3R/DF!]%'`V"5+UIG?
MB1G4+F3!)JQ"RU8A^4!Z_3@,XT?0*YY"?TXE3!$>EPT0$]R[CH<C$8UI0?[M
MHM,^_P5^#2)89X@@'D1IEN2*+-E`9-ZC3*0W5-3R/?BBCT1\("+&D2>\1/;R
M),'7=44:I%YW[(7R08;>8Y`-"");VO<,`ID@*.YX`C_[S98!M!DN>Q-OXN0E
MP4WKB<W8/MDI_.SIG$8'304>FZ>S01-],N#:WNH`C4T_6>(`QVI3>76R!.=O
MEPD-5HKK*D5&;*SR\'4>B=P'O>/_M&O5Z/#>IP.,J@>6-RO+K2G+74+;=M;/
M%NZ])EUCGYO!;UU5H"_%I*<*&`.$LQ9M)(,_4E)PQ3-2K$<=%D'6HPU@(NO1
MFC)8Z=&.`R+*>I3U:&/%C/5HPQFL].B*?0%8C[HJ@BZ<"'EJ;O39V?4R%397
M*9::[+J";INUKWP0LB9ES4<OR]OF%L&ZPVR';2.S:DFDX4P@P9QBX[CWK&7C
MV#AFLW&L&:O8.+K/*3:.>\A:-HZ-8S8;QYJQBHVC^YQBX[B'K&7CV#AFLW%L
M\/&U_<2A^P0_CST8[7>9>?T\\C?>@WQ)K%7&WWD)_)WGY^@&-I+Q=V8V:CH[
M:K7/5BQL?/G#BHS`XQPP\KSH<5-8NH8)E#N,8GO(]I#M(=O#1LJB.VJ6[6%-
M&,7VD.TAV\--Q!<1"SL[EU^VB;51M=NVB;S#R$:Q)JQEH\A&D8VB8[QR>V=Q
MKL3.`P;>+^8X90?9QM6$;4?;XUO##9GCC'Q)(&?FRHI<Z2S%0V=)84O%;&-+
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M4;-L#VO"*+:';`_9'G);F\;*HSNJEGN]U853;!39*+)19*/86'E<?V?QYTP`
MZ8KK_.!A$_I4R/%W:Z+'R)+Y8]O:>Q:^Q9[9KS_GZ<&]$*,W"&](Z(;O@K07
MQHAOF'Z%Y[\-X][WW__Z%\_[U5QZ'0^'04;HAU>1?PUOA84IHUX@T_+FXEXO
M\'][=?,'*(]V^_*5UX/+X:<OLO_;JVOZ]K1]?-&^^*,#GX[:1VWUX?BX_>IW
M'.D666"?UEQW83YA%9X>>A;%/!'Y7H5FWF8+X&1"$$\.3T_^OMJ\U62"##14
M;QU*K`N8V0O"(!M['Z5(GS1->U)JFKO5*Q\B[Y-(>@/"^FQYV4`BAT<B&GOD
MK$K?"Z(L!E9[\4@F`GGM]0TY0B2')^X320BB'ERHOFIW6I<GQU[Z9P[JVNM+
MF<%CO$\R"F/O5B3?6]XU<`P&&`7"@W^\`)93!/,>2.'C3?#JU.OF0>C3"^$*
MX<'[@]CWXCX,,TBR\4$41-(;PMP&Z:'W%8:>(=J>%W?!7,%(XXANM.>4`^7Q
MFR#5`X4/8C1*XA_!4&0R''O_TSZ\](`9(=XN4GP;$4@9R_;9T2\:&15D89DB
M6D^[5#73W0`H-X!U#H1X_V<.U(9'T)=O8=S^K1C3<V?IIL[1/NJFLT-/T<G[
M$&&@%3Q([S:$FQLDK5_+I5PX;^>_I-[;6"0D&.^"1/:R.$E;'JQ\^KI%:CK-
M8(WHY>2-$OD0Q'D*RYT6_P-(.4I)Y^CHTKO#*XER](SB>_SFT)NA+RJ/GGA>
M^V0V4ZQ'PR7JT5>SA*VC88C5JV2_#]/#A_@@K4H36,^HZJ\T3T<2>.=7YT#D
MB$"C@1.*.@(4AG@$.J7>4(R]KO3N@1L9W&5T167^5_A@E$(:;`\$'-0$40#^
M>"!]V1V;!RYX$OPE0%_*9!A$.!71A\_S)H^/E#]&04)*K85:K2^##)1'R^L)
M(&P8*G4'1(WA-8DWE+CP'X-L$.<9O3E(TQPOQ6&G.3!0S:(%%X4A3AOH@:2*
MJR3UX!J9/,C##:7HTD$ILA::@;D^54M'V8\H)P1L)-1L3HL'$83H72O392AK
ML]F0[U%,&IA.ZPA>"AKYT/.^1:%,4[I%B3`*3^#C*Y&-CT$*'.Y*(&:$9A`&
M\$\1@74<EVND&#\NZQZ9F!ROS>%3J(2F6#ES!.899HUK2N2P'N"]/1'"M(.H
MERAO(8(9X#<S9X-+'=;(W\U0)\>&KX5EBI.%E9UF\`%G.V_(])7!-+=-N'E^
M,!Q*/U"<`;78D_2XL11)12%9ZV22FY<GY\C->4-X!)T``M?]+R@NE"Y[U%I-
MS*!@D\1MALE0BWW*+LTP'L-1&(^E-%8IA^?@(JK8D/=WM[>@QP8!O*,K>V)H
M&XJ9+MRITJO*:33V`AYLM!V,S?B2_0F&'U]V%K%[CFC@$`]W)>Z*/MN4='SB
M$X4<'X/44`-Y'?QD_>Z`]-/B>AW8PSH^.EK`^7GJ(IM88=75=+EH+4TNGV7A
MQKHA0S7@>"\27'7IK4SHGIF117NGD<5J*NQ9<U(["F[.#^'9F0<18XIAL%HQ
MN&"NU8)1ZK%9@4X_#L/X$062,IE@1(<P:GBKTJ`@*J,\*Q1=5Z1!CS2#'X0Y
M>MW1-,%$EB5!-U?/`V-LBYLQ0EHU&)E]':"O#L$2/!J\9?FC)T>9]4@(1,1/
M;S8D_<+,Y^7RM5R1+34KE3__[17F`"`NP`PYD+#X6^?>Z6^=U5>[DD4.7R?@
M>T!],4KE&_/A%\_LOQQ5NOF]^`F6N3M#9Q>SVPQN>Q.@-LU"SG;:>>FX_8)=
M'Z>4\PY:?0P2<%0_43K2>X^)AUWOJBW:%6<T4!?/Y:$*VS$:**NZS50=8R1/
MG*PT@="NM:##IY8=8%,].LBQ7JPALOP)(\NOS6#,G:RF,!E6WE5MR>TYFL%$
M5J(U9?#J?8M9B;HJ?R[TYICA=>XG2DZQ][!*`OU@.A>_:0CH(@`='P]YRO&0
MY^?H!EX1'P^9Q>/7':QT.-LUI_EHR!(^_>0&AQP^)@GS1(G>+9O<@7%D:\C6
MD*WANM;PY*1U>;$QH@Y;0P>LX6YW>'=>M[(SGOR'GB;]`_$@$W$OBX+'LH9S
MUYN$J]I$MG=;<65>O*TQ&[69B=+SUD7[R%TFOF29DAL<J8%H=5ZPK*]9`1P;
M*V8;&ZN-C57K_.+"71ZRK:K3/MY.J\><"\3R5!W]5F=JY.S#-).'3YI''FM!
M%Y\FCA#M.O^SS=PMM]*J25K^J85>[$)L)=[E-EI[)Y/.]YAL2&3,YI%%D<WC
MKIG]I`B;K:-+(NGH8=;]+)]]NQB;PA31/B6^9"!U1WGO,)`ZUP9MJS8(B':Y
M:SYS9=!SU<GN33N1A@23;`L=E4"VA7M@"]MGA^WC73.:C>&VRF2?N8W("B!W
MF[W%!11#%?=%ZQR>+($%@]1LQQ*D.!`^P%5.X(1K/5*#K3Y.[OV6L*IV`%JI
MRBWZ)ZC6"X?>N\GXM29S*F)OA`2N@*S*/_,`]!'U,YD_\Y;G2P76CG#NJ1ES
MAFBW>3(^4,\:RFP0*WA:_%6D!P$.)(+!X8S5SP3?;KX-"-A2]O(DR`)$8X<;
M@J@7PBL*_%[5I<*,_M![*WLBAR\GD643.8KI/:*D)37."$,]"T+^3]%KQ`DM
M2T7@6PG?'P&5X?G=ZFJ>NEQ1+$X-S=(F@5A7`4E'<8;-#`CAN%A6)1NK(-\*
M?U]&OH$6G6(&L`_N[TH9(;YHF",0?S^)A[-P3@W;IH6504A=R'`R+!7#]=41
ME.,3P_75@4T,U]=HO<A(4_421X;K<YH]#->W1TQD)5I3!C-<G]/LJ<$QG_V%
M5O@\PL10BGG2D6F.9N<W=UW-Q^?E:E=+N_=;F)W6^5F[=7EV[BZ;6'@<Y`H#
M(SC+&A88)[G"U@:M3?OBHG5QN7.@51:>6IVQV-^8YXM,LR3HT2ZX;I0;9.FN
M]ZU8?.I5P\NV)_NE?7':.ETU^<:BPZ+#<8[;K&&!<9(K;&LTG_YVT6EW'&84
MB\_.3P1T1KLIT_E;^^QH5FVKJ5!%3MH5I^L6NJY:V7I\>+Q.::M^K%46ZQ:,
M2<G8X]&"4N*76'+V8%5-N3W:`ZO,G,9[LFB\6UON9TNIHF?[Z\]Y>G`OQ.C-
M>Y%$L*K26YG<817X5WCVVQ`"X=__^A?/^_4A%<D;/'J2?N[?JA)SJAZ_BOQO
MJ?S<?Y]FP5!D,BWN\P+_MU<W?\#":'<ZK_!L`@[WB^S_]NJ:OCUM'U^T+_[`
M:J>C]E%;?3@^;K_Z70O)NB0Y6<H.0R1[[]N2\R`#.>BMHSO7/[J38KV]34$Z
MV0$TQ.\+*FY8=7^RBII[+LT_?;JB..0@>CUUI@3/+L!*@&L0'!(^D2(1F'7I
M!Y&(>H$(8:;PQ9`.SY1G&$:)Q#H)WPLB>ESBP]42]%LVH+_S**-#%$D`#QF%
M,.U[&<F$3E/`[W*4J7OQ],.W*,"_[C(B-=#]:BB3H">\U\:?Z!S]\NWP[M#[
MQ]75;?%=^Y>?#CV<CAI+<7HB>\H,9TRG>+.7X$$B/)$!S!/W=`=NR@_%=^G)
M8JW@`A)IF@_-MOU`9)[H]V5/G1(IS_`,D4PT8[A>9NK6,!#=(-1'A?!Z/TA[
M89SFB51GGHBR^.K9-YG#*#A)0XXU*-`JCC;-&J?\,<+GI)Z?)^:`E+J.N*U/
MD%WULAP>"I3*PPR/@^4A'LT"$B3FS`L>(2I(=KB9>,T^0^2&R_4D,<.35M6K
M]$&U/W,!'$GPH!%\6Y3S>ZBKB6]C*<RO[V1/TD$Y?<$)74`'SWQ9"(EA[+]E
M`B8E"X#_'Z+>H;H6?GH<@.\R/H@?\5!<FG?3P`]$,FZ5-WC78@PT]?X7M#=:
M+'->K87\!9,>I`,EZC@&6!MA"'_`)#1MRE'0ND/ZBIX2'.O$5!@,@5!`"B7Q
M))(^>E6).<'6SR.Z#2C9RY-$1KUQ<3).2X$>V/\3HSC]):U2.(:U2QHD54.,
MX89D'@=G,FT%'IT4Y(^C<+R,!]L4BMT*PUV`RA3_1RJQ-76L$7Y"GI4'%;4:
MC>2]4,<Y13KP^F'\F"H%4F%7IJA<>OA&)"9?A,<VD>+Y,`^)Z[[L![T@0^+_
M3_L8O/+R&4"JT+@#CW'RG5:`&*%/0I=W.F>'9U.7J^5IWHC:LI>EZH`KJNV<
M#KO2;,TT:3J].,WP<*<:%5RBE3;>4M@U=%)H-=%!5_D@PWA$)H@,C@\"$J19
MHNB%(O2@S(%9E_`O/$!22-//,S`GN-)!$^?W`]N@(3](Z-(<['2:]G,46"\1
M06K30-OND4BSEC>$\</X,"4(ZQI^^J>`@2?CD@NHT8#X70D+@ZQC0@:6;*/-
MI$>@(UYEO9S&CR84?HZD]$L!A.&8Z\6#"$*:FQZ8FB(90YD,4^UTF//&UBOM
M$ZQ57WQ])ULYY\:'OY/W2-$OQC[>@K;IC=7_9_KEQR_BE[>/77?,->&:YG:;
M-:Z4ER1G$Y[CI6JZAZ#&"BG,43?@CT,Z?:Z^!"4P2N(^D)^<O;'2!#%<&<49
M/B9!?2G)<'?Q!+O4Q\/)X$;DDNFUJ*Q<&&-J#12&7SB3(#-#`=<+.@:_Q$.?
M+SMKR4!5;*[C"!6)TN]?@O3[-5B&(,-/MK"<O(BP+,\I[%A6*M1"UN#<\/)*
MMKE\7#Z"U0?F5*K;>\0VO![_(D*O^82D\@1DTN92ZYKC<E,X>D$$MC576HFL
MD0T/`'[Q?TUT9X0<C(S`!5IE3D]1.$$RH?\)%IN^1O<&A9D^6'`5VAF=\%]U
MDOT<G=AY=Y(D#R0$7C#8/OH$_<ID@BRWPE/+_G?!V0;G0CT`WCP`@IIQ@V^+
M>N?0N\O!#_%!J%/4-4,!WCY:6F10"_$-)!II,-4JX(?WY>C=H1>?I<N5Q@(-
M8*6_[H+[*`#_#;B&OZ1HEN&^!%47>CY+S>TIFUM5:X.KD=)>-OF::7PKPJ-]
M1).G@,5>QA6P:!_B$%UI"W`&Y59%)KE-JD/O!ASN.-'"I/(=5L9GP;OU"\&3
M-:-0PHS@+Z*:1@&-\H`^-;J<B5(\%#RH**,8-068+;#_&4DP>@8D=Q18M*R!
MCW508>;>"R&"Z,$+,WRZ&D@B16^`HP->0C@/A$]G/.(>PZD8AB9&X)\\B(4:
MJU"<GI_D&$]$/L7@TP^&5?4=XD'MN6.XL.BQ2>SG/<Q?8<@N0;^ARB4"8=J"
M])TLKE)),UBU"N`&GD;I-@7O@H`N\#-<FP%A51HS'B6!S)#\\-T@BL/X'G0>
MQ5OR/NBIV`TY,`A&&HI(CC`%0,..O.\2U2"!(>6&N&F,P$!QGO0PWAF-0.\F
MC0+4N374UM&J0H2RK:3.J,+:@]`669R6H#B4Y+F)-=C2.UPL5U:4"T2U\\,W
M[Z[LS#!&C2J'HWU?G1NR%^L],`<5';`68TR%0@6N#25VP(JF%,TOBUR+)46A
M*`;!:&P5VA6&L+AFRND=>A_ZU8!7('E@^?GE5:WRH_X]%&-,4B53M^:1"6F-
MUVX_)C#*B%)IPE8=PG^`U0:Q`CP+U%0<S8N)Z[X(YR1D5!*&5(-0ZJA4Q28U
MH^D=P?M`-2#\6$@95B6^Q&],2.#CXB[1'O>"]4HK<Q08YN%N+5X7"E!RVF,K
M5AM,G[(;>BE9.I'&\#@(X)8@,XLKG:5REZ[5%%VV18D3?)/Y<D;6I"JY2[(F
M&_EF$V$@.+1P&_[SOG1K%[AS9^S.J8C0A`1/B03Q&>O=+ROW6X%(<\)!6Y50
M]$8XA;C#@$$2*-4P@'ECU@2$-%/!HCFQZ^N]4=0%`4P2-`1H8P23&RNW)I'2
M&\*K!RE*8HBI&]`773DK)LQF[?U,;_BL'S0^2A,U@M*BJ+$2*\Y,!]G;2D5(
M"%?"9.38.'']//)3K<GH)7F4E"7^@N:*!/(3\2@HYPL>\.'20'$5'5%5*^"3
MP++-QK<AL!?NQ?LHC;Y`LYRS9C'^'-%N`^TRI1V(YBT86=8@!5$AD#2SI#B,
M=@HI&8.;/29"`(L>T/<EWBAZMSBF`PC'I($;C1^D\D7,GCG>(7%W)"2'P)0]
M4!*W9=5:=&7VB)LY2K_@6TFJR8LY]#Y*8!#BK:(;"&Z$M?\LAIBP_3_T.L&M
MF1A55U7.F$&ALE(!,OP5).70^M+XK.A.F%&&^%;,=J-K'I&'HF+-D0@2O?L]
MP-B,/"M=<N!9VX2J1F%JR'IK"@=]Z/UG`+.VDMH)A(2)\J$I+G@,4BJM`'V%
MW_9;>L]-\Z:Z2ZCY1/N!]*QA_&#C=W9%2--(!U+J^RFXP=@:^7HOR`=4H*H!
M^F_]4/9T"4PEYV"!AV+PK2>S3`^NJM2JJO##$`F.EWU.WA$E1/BY_S&.[C_B
MEL`5$6^!6KQ@M4A27](15SC2[X`(Z"D*-C.1!JOS(9"/E'B9I?-HVZDDS".(
M(T90'OR/RAT2E/'H7NV"]8($Q"W-5`8`\R0]W,<J8NR>2!*JP5"E2%0QI:4;
MD\^4Y.JB7/90)V&X<NA],7^HK3*0.KV55B0A*/&3!&E9-C;Y'KU3#+Y+D%*=
M!@J]2MQAI8)5E5`,U5(Y*MI46DQIY$Q2_$^AF'6A\275I5VI"8>*#A]ID5']
MC/.$^`J5\XQIZ;'#7\K=FD-`:[`J8:_K:.!56("<2^]U<`CCM4"QP8A0M8`V
M0CHS]E\UR:4D*C(R5E"IS!O9+_,>?&HYB)\\Y!!]9Y0M#=J$NV6-$$2\1->2
M6O38&5N<]/V$`PV#,_[S5!W)R5(_=!--6M7%-W#_OW'"G_O%IM.'<L])W6LK
MWTM6OFJ+#I<*40ZY6F[86<1KF`(N9/G!S'KM.*^E:F8A5"T*.O$R)9ZJ?"XK
MG,FB1&TDQB2TVC]*<CE1>(JIJ!_DGMIJQ,^+DIMT`$[E`?F"D<AT1:N&O\_D
M$#S2:PLS'\;8EU06IHZ`]ZB6CTK(BO>.=2IM_EV/0"Z@K'7'H\J3)4F@'/)R
MK$W*>]Z4',#6`K)/*EPH+0\:GZPOYKY-@O"1,L7*O$A2F%0_:>RL^BQ_!)F^
MB=8/,I9&A'K=HK'Q9%7]MXKHJ4I,^`\P5'$OXSPMD@,Z2"A>5'F.T.E3K)@L
MRT.+R$8_8X25D_@JTOOJ[7;MC$_&%Q6%\N-I&R?X,P>NY*DRO/IR>^T.\Q0]
M#%C4F*,E7T`=#8B[$/$\Z(*S4:YWE-!\35Z91U/7-FF9?:WZ#(,`W!RPK&.]
MXH`N*O8$\_$@0[I*,:"\$ME?+7*W.5#RD$RW:M"0/DLCA!-L&>1B*X3+]BK'
MQ0@YLW)6[/E00G:[Z#[B6BK]M`_K'3:MD.CH\/)D(94F:#)-M)4.QEVL2HA%
MA'WZB<=%Y)E>/I>=PZ.SABZA;Y'P_PO:'53_GWF,_Y!5TR>`J(A:619=08GC
MINH('4585@I\GZT@];^DZ*ZN[^:\NET_ED]JC3JIC3E$VQP!_:4%?1\7W`?E
M&:JP"GSL:$K5Z$90N/,%>H<6J/=!'W=`5ZCP'+$X:K[",IJJN!$38DJ+M>Q*
M&!K.C*=3.DX5#O3B)(G!'Q&Z?YMUD?:TP9,6I!.MX@E]FJF?0X1FI_K-D9;9
M2A-]9E:<[J_C*<59)\W)#M?>K]]OTR%XJ06Q\E*=<^YB`4>6*748Q67]*9VE
M&Q=IBH5*;3)7_(QX%ZZF`W#OYCY.@O\KCCV(B<,'*C%KS![2=%9>(*!^E+C5
M/=()'8C\99IY*I40]Q4O%2OAXK0L.C,)Q]F)A*;E7V;6E\\\NF*=.3'.AEK%
MA\7?5HM+M3<U!#]#[9$#'ZN%3E,E/LNWJE?:Z+!.>=PFTA2FWV6Y/\9R'_WW
M5RQEO<)$M`@7[%,?'_%6B:Y.*4A)V4I#1X\(Z1E*-FR[9.;&2.6H@]K,H*K\
M1&J5`PJG1/3`<Y>@G%!ER2B)P[`X=FU,@3K`C<4]YLFJ!C"XQRI=T$Q4*(?U
M=2%F$*QG&Z."]HG<^2+[3OOI??B==FA'"D]@E"=IKA4<+NI$J-+S;.`-L=AD
M%,KRH'BE=H_V2<SHBDOBY%Y$6E.GE8+ZZR^?TTI%O3[;$E&),F6[Z=#8U+F1
M:BEYA>Y=.1!AOZ'JUV+J:$+2)M9;L>E6K+7*"AC)!%^-V_\+V+TYE^<QTAYU
M"KHVD.F,T1.#Z82Q9N:'2`D0;DGJ.7A]:=!KIHE#Y6#`*%/F1&5DJE2A(($I
M1"](4:#2%+9_CD06WEHA,N!AX"FF`IWF@X$(HM-5&2*+W%MMF_%]YK!1,9XX
MJ;Y<R26>QPKL(RMFDM6ITV14\&XP/U#=:*`A>'LX/O1NQ5B9Z*'P]7YID/AJ
M6POWJ")?%=MA)1QN:-Y;@$6XI5:>CB(%,LHF0_!B+JJ"#5^M]@.GMH(1NRFL
M+DEU3T0U*DM*_S<TV-5RB"]ZY<+-[TJDB_=JA%/%$&"UV<+324X;(F2]`EV_
M4J!KH8LTISKWRSP`%6V]JW6G5EFF57J*=64+G[+T`.9(C%%AJ2.&,DGC*)*E
M26AYH:#L&Y[MT8<"Z4QC9&I)Z35XR+J`=)@SGDIIAPA!R!32$:C;@11@7-10
MU=E3K,4NB_?LBE=5;`OF1<>WH-92=81*]-3AO>)$)"HJ5:%&6^J(&C-O<&2#
MJ'@+Z4/'3)$^Q9/0W/0A8@NL*@]].<Q%G^A[*&!>Z+BL+KF+]';^W'<K1F%%
MHL7697'+"AIIHKHV@M!)?A4_%D0F+P/$Z+[>4K1:4V-EU0-+/YYT9-TU767[
ME44!EH)R(5)E--_"*]"E,S84H#X:"()UZ'W3UU&U*%9<MK`\0U5)P9/F(@DF
MTB[_K'BK"LZ/CC>79PSD+&@TY;K!6_#^!6B'^@R$C(0JFH4["I@<J0[3FV")
M8.[@Z[+`M1S.=.VM.8DO?N@$(%+0K@5"Y?@HRGLMW#K2$N5!7E(KX#?+F?33
M22>#EVB/@<JJILOYFQ3^(!$4<EL8%B>-/3H/IL(.\9TT+IV-*)<QGLS(D\@V
M1_@`.YE7X`*43VO1@W"W"9Z@SN26&=T,'>X"E"76(U,%^E1W'H82B]^Z6,4.
M/CT%6.('O3H'\4BTI;NB^Q0>@#4(?*49"#`6^*-#,BK6C@(%;J#EI@)+:NZJ
M!,4IQ`7P6+N>T:[JUG7E!%:`]7-%`7=71K(?E.G/>UA@F=EH[`=]>!;J2TFU
MC]]E.%8W*7NOEJ+*K*)C046;L(BS4&=(KQ3>)P9.U=,M/L4W='P/\3'\.81)
M5>V<6O=J9?@EMF@E-"I4#$H;[52^#GXJ-U-4'E?A:Y#""\?%6:D)TN$Q))5$
M1E=!E3BJT/%U,/G(:B6\55)/JDK3%K/*M)I(EXZ2@*H(OY8W%)#!$SA=UD/2
M$C?67M3_S7T-^_5/_2E5>$$$_&P/:MX[1&6H0Y1K/6?T6"-0`T%$T:Q>J"AQ
M:7G@>[G/,\^%F<3K&J(3I,!Z5+!)+N("OX>![C30'58H'[PEN_J4T]H6!QKD
M`]U@YI1JN&,-I7R/E=SZ6.!P%,;CJ313(<>IPH$Q5#&G"`TD+#WW0'DTXE$D
M_D0RCMYT0!C*Y9%+NU#\J]ZTDJ5N3RH(U/C00C<;%1N.*UX!IHC5><!"^XBT
M&"MX/R"GX_*<)>D1S"47>3:3TYJHPL74585P5`%>.'+E8=.WH0`RW/4&,4)T
MZ]IZK"LAS)_8EPI78MJ:62_K&S95R6G\1`U#3035;\:*[AFO6HBO;6R,C:R-
M<(>)\A@LD";D>RA_*(@=Y01@I$A+K$NH+LWQO^XLNL]:[RTZA(6&O%S$<=*7
M`4;-Z$1-G$7-YH.%6U#'5:`LC64R2B3XRBF2FHZYEK7:8'SQR7&>PJ7I3\]2
MNGVYRN[3"W84>?$2<6H+LGI+D1=LN'-Z]#*]*E<JF'RN=;!"^24,%M@./#A[
MM4MVG%R^8&NW*>=J0XX]*41%Y(-/,2&KO,<=H?6*UYK:FLH!UM2@`V^IPA:U
M7*(98S^4*&-5YY:J6Z53UCZIP^+<^ZZU8*'R5A4L5HT;%\BS7G1,+W9>/3>#
MYG?V[90\0S+/U(BL-:L,QESD&D7]K"T=U)8OQ:3C)\K7,J795!EC)=IP!B.4
MD@/RR4KTQ:/QZYN;HYOK>N88%W-FC<S_$UCSN8`FUP5GZ:;1V[-SHKV"8N3^
MZ\ZQK7.T/;Y9]BO!\6S#?#$C7<PA,U=6Y,KQ"^ZY,%/85#69;6RJ&L)(-E4N
M[GCNO([#N?-AN]XI8P$J>?0_SC(#S=+>6YVSHQ4S?"PMSIB;W7)E!Y$1^#7H
M(C)K6&#8O-2*/>T.FQ>'V%&#'2,WZY1VQK%_J,9P"A+":J;\(%W.$JRRD<ZR
MYQSG.DNDCG-UQJRUCB\V-FS;U91.%D>XP25W)&ZJSLR9,K)F15ALVYAS;-N>
MQLOCH\ZNF<B6K?Z[4CN(X]K'A^<.,^UKG(G0Y6S(5NJC]TT4W4Y`OB1+FVL2
MVZW+BXM=\YF-8FTV:#C<JQ>_V"BR462CN":/3SIGN^8RF\2MQXE/;W*%?\Y"
M_5J-"(N'/05XN2*4Y33^98%]IB`SU?4+`#!/7@0`TWG\RPKIO(\(&U>RJ.[-
MAZZG,?$(AK%/&(P".Z-KM%8$N/XS1P1;0G7M(DJBA,O)3Z/N6YZ?)P'A'"K$
MQQ:BV^N&`*K["(X3>Y\@(A]]`^,]B!\CF7AIG"<]Q#W\.I")5-BX703LCF(/
M%-@P]?[,@<]]@M45IE_I+$B_R">TS40"162K`--48Z).(BF.V:]@<E8[+TT_
M]5&HGC"I&!)PK4+,U3WY$+X0KUH.5KNJ&%:%][T@N-WT5B9W`]#J"V3VE$%K
M:5W_"UA"H@IL]XAHN&R!_,,X\@B0LD%"_%:D0:]8A33EGIII2C,'B>Z)L)>'
MIE\NL#Q`QX*6='&?R+(DZ.8*"Y)Z.:EG(+4&P#^9I'@SWJ-F)/T#$-,$VS)5
MD$V+-X.8YAFVWZ67:?6@6QB1@D!$<KA$M?SS-5HGB>PHSJ3IVNL'84[PJ&7;
MOT/O'7YI"1]-NYPO"%K^XK.E=BF+!UZAB&D58!!R$4QXE">C6/<@4$T#YL[3
M,)4:H``)'Q!8'*<#.D8#_]-T6A-`NPH,=>[EH.RP>9/I-J-94[0(6,J9M[(G
ML->)#7D\$):^%.5DC'8N6UM-*NF9\Y]<WK9J[BZ1!D5T(+%YVW*UO40!5[4U
MZ((KU0P#;KE-XBA&\'FK<>0"]7W&ZEN?<J&6`"4=O2HA&Z2\;\@SPE9SV)D#
M_FT1*KXHISZJ3ETM^317R@U7?M&CU";8'2H9`KE^&\,_U&+]YNKNK=5K/=67
M4$\%O*<;%_WTA`_:0KTB)YQD+:'I2/:"?B!]W>X$A=^GA@/?HA#]07KT([F#
M0=K+54L%:CH!FJ!'.,\)<3<<FVFDQ5`KO>''(,+E2Z@+`WY-KJ$HFW>8Y\[O
MZ%CV>RDZ8@`-E',Z"11-S29H\O!GDU"X/T3>/_-(>@APTUIYV1@6S;SBVXB`
MT_&)!^TC)`^^WE!H6EW0.%K>>^PT5J*T7VO0]'(X7\A0X+N^*+!U6O@M[T/9
M?"7RKN!+WZ"O_UOCIL,EL"H0L/X]#);L[3_RP*?.(/"*K_$(3,-%^Z@%Z\3`
MAF.KD]#J4T`"<G7WS<RKI3OX2#ULW1V28J2@;!YM-^^"!0U>`EK);-S25T_^
MJDV<*!IGH+B`Q<H3:3#FE;RK_DE7=]?>9?NT-=6"80Z9K?Y?R#%XH:'(Q&1)
MV)&6:'7CAR`E,4`T]A]!2DPPH/1`04U<-3/OWI"V'"+1=L4ASF<!=7816D*-
MYE%QJ&ZE,*.%DQJT8;OBV1";P=#U(`DPQ%699K0-N!#PSN2-][IM=6;1K,-F
M0)+T!`B]:L-@]S+12/75\:F60N"MB73@]1%X7G&`7!/E=NHPN^6][ECO#$57
MAO.G3N$I^C1+UN+K8^N9>L5)NB/M)<'(;@XQ_1#=MC10[:[*OE::9@$F`^[A
M0MU#Y_7)K'<%I@=7DF8S>F25SRJHOXA/JG<%]6@`J54]E@*T$;[*'NBW3=T/
MOG:>H*4:4I+`$G>O%\)Z[^,D2XD$`G<Q3DF"]+NRCT5#(:OS*0J`4C&=\]4E
M]4OQS&_V,RL"H0WC:!2.=:P"1HXZ&59:%**?B^W%(`H)1809'*`+K)41+);2
MQAV2J@7WO35?M),<>VV4+$"OE#I;8-<&O>K)DY[#&>U&M%0*20ER:]'%)'`T
M$15ER`?J?*9Z05A-'FS)0H=_B/-,J)<0R.'\%S3,E%_E]]BYRC+FX-H98XW^
M8Z&;36M=W?>MLJ83L.F^=Q\'U+*3VCJI5BKXA,([)+,`"J)\IKZQ[(!2<;?@
MT2,,&G7#*^R#HYE9],ZB_!PUKLJ[^![5C2S.NYD6-%QGM!(K3Q;E(W%!!E$N
MU0*K3$$U\(K-N`L*].,X`RFIT&#&=%&-%5XG+KX^7`[#(^6B-!M)2S`LPE5,
M8ZCV(=B]IW(YM5ZC9EFBCXW/WH'O2\D#M.7`OK-##Z)+$&OC<^+[1]C')LND
M;II3[=&LE`"V_RG84?4>JF8\FYQ?U<-MCE1\TSK8<MQ*540AA5%FVKU2?1<+
M<BYRR*HDU;Y8D>^.(NR4;1;#/(Z7ME"S_D2U)??]0&5P5/<D\QXMKU7-5T9*
MU`.RLDPW'<:IRK?E7;!(EF4AOW!K+SFCNX&#^CVE6EZP^O4;Q^:M21$7F*[L
MR80HTAV3SL2<6-#RG@H#BB&G\AN4)GVMAVOO=M"X?\)W4Q?THE6=ZGP*]Y%,
MOE8A=G%]59(Q'68B[.J*+:C]3P%S3L9>6S%)]6I6>O.1K)T5^.)NQ'20VYH3
MXJ(]+=S/Y<FO=?-9U6S8'?9,!F?B<_^];H9VI]J"42*-NLK9&YI7J@4T?/K<
M_U(T'+LEYM(NY\RTV?F+I,U6:M_TPMDC[JW%O;6XMY:U#NK06&'W#6?V"=&;
M>VLYRQH^T\.JCGMK<6\MURI9'6`3]]9JM%[DMC#U$D?NK>4T>[BWUAXQD95H
M31G,O;6<9D\-D!)WD6-<S!GNK;7!^6$^D^@<V[AA24,8R1"_+G*%>VLYR!0V
M5;5D&YNJAC"2396+.YX[K^/@WEHL0'-YY#;,TMY;'>ZMY10[:H`WQ[VUG&7-
M'@H,FQ>GV<.]M9QB1PUVC-RL4^+>6AMEZ1AOME;Y'>X_PKVU6.*XM];>\XMM
M6^,XQ[:->VLUAD<UV)7BWEK<6VL?1-'M!"2W$=E.N,>]M=SGDCL;-!SNU8M?
M;!39*+)1Y-Y:C9/#QO?6>C:TNBHHWCO=;X.NN18C@@/&.Q,Y$H%_%?F?$>GO
M*DUEEKXK8"AG8M]=O`CVW<G$*G6N8X0FG<&]4ZATNDE4GJ"T>H+(.0%&MV4L
M.GOVUH0N%RU%QHR;MJOGC!DW]ZS[+AS7EZS2FQ*D/09)<J/:R`&.U".ZVR<9
M817F-'L*H'G68NXPI1ZH;N>.54O6T4E[:4"B]I+T\)[B#3%HF[OL<0JT;0TF
M[9,(L0JL-_\8<LUI]M3@`,W.4W0[V^VX360O#**@I\_+%'_@=-.\F+"U7$YA
MG5-;;;A,JQ.4*WP:=I!$9L*-!9==+&QE4)PM[C\_/[>VR*[F[BT?M\[.+MWE
M(1\<=9,K7$;E+&O81+&):I2)ZK0Z[8T+H-A$N5#KM*,S,:YEZW?&,:J9<GFK
MBTM[Z[FOOUW6-=>&G;;/=\U$A].-;O#('7ES=]^E6>$86S;F'%NVI_&R?;$Q
MB`%;-I?DS04PNAD!FQ_G6/#?.=RK@.U)"`9.9!D7L7%?[5[-,Y%;9&ES[>%)
MJWVQ\VSE/(LX5YGNFR2ZLY6S-JLXUG-4A;)19*/(1G'.%M[QY<:P/FP475*R
M]<`P*`Z.F^/?2'S[./>ZI\BW>VR<*HKU(]6-"C5@>L5MM."LLDM<U,LINN5U
M]&)%H--TO#P]/#G;L/IVNZ18>QEO0C6;9%=>FG?3#,80B-`;BO_&29"-O;CO
M90.92F^$.!!C[-J5(BY&&J09_BC\!Q'U8'A9[,5Y0I`9B>AE\(0H[\.'/)%)
M>NC-Y(BE$>;K`_MS"2CR5*2/*FY("4]RU>LEN?0_!J(;A$$6R/0K#FHF0LCE
MBR"$M(\GC(!S$"&:9IY%-`8#83"0>I\SY9/T#`;"Q^B=9,D^R0BK,*?9PV`@
M#C*%P4#VQ4GCD_"[ES8&`W&:/0P&TAP>L0ITDW\,!N(T>VI0P+CS%-WNP$#$
M.(E#!022R%!DTM_U5B^?C]Z?`HR]+ZYHM]HGQ^[RD,]'N\D5KB-TEC5LHMA$
M-<Q$G1]O?`":390+I7[[5_/@'+HB;T^YPZ,Z[+.OSI;F6I[3ULG%QOB&+#C[
M*3@<'#G,&A88][C"E@:1=#NG;&D<8@AO&CG,G-LD[LLT#>((@IQ4=9)-.4/@
M#H/JD"EELX/X2SL_6,MB4R^QX?#&8=:PP+C'%;8SV2\G[;:[#&*Q<7`#Q\U#
M$HS!OJSJ8%%-,(N9>YQCI-H5$W27.T_/.5SE[0:/W)$W=X^[-"NF8LO&G&/+
M]C1>.K#QQ):M_KM1C,'.&.R-E\.:EY(SW.P*/#YO==H[;VK,<+.UR?PS!GN]
M^,5&D8TB&\6U*^'/SK@QB>M<>EX,=J2&!49LD6L62.\3,=CMX92PSZL#-<\#
M>+X10?)O$>9204-?1?8C/DF!*-'^Y^B+[.5)`NOOK4B#^1C0)T<O@@%]8I;+
M+E:6S5R%/:T"W('T^G$8QH]`)4]A*2-%X<LD&R!JN'<=#T<B&A-[_W;1:9__
M`K\&D8AZB#$>1&F6Y`I1/!N(S'N4B?2&F@4>?-$'7J%:R:471Y[P$L,4KXM<
M\;IC+Y0/,O0>@VQ`@-/2OF<0R`0A9L<3:-1OM@Q'S>#3F]CFDY>$"JTGTF'[
M9*=@KJ=S6B$T%<8+38-'ML'3AD`I)]!$GPQ4M;<ZW&'3SVDXP+':U#&=+$'-
MVV5Z@)7BNDJ1\0^K/'R=1R+W0>_X/^U:-3J\D^@`H^J!C,W*<FO*<I=`L9WU
M<V][KTG7V#5F*%E7%>A+,>FI`L9PVZQ%&\G@CY047/'$$>M1AT60]6@#F,AZ
MM*8,5GJTXX"(LAYE/=I8,6,]VG`&*SVZ(LH^ZU%71="%\Q5/S8T^.[O6J%!Y
M`K]4\<ZNZ]&V64G*QPIK4B1\]+*\;6Y)J3O,=M@V,JN61!K.!!+,*3:.>\]:
M-HZ-8S8;QYJQBHVC^YQBX[B'K&7CV#AFLW&L&:O8.+K/*3:.>\A:-HZ-8S8;
MQP8?7]M/5+=/\//8@]%^EYG7SR-_XSW(ET0N932;ET"S>7Z.;F`C&<UF9MNC
MLZ-6^VS%PL:7/ZS(>#;.P0S/BQXW!7EKF$"YPRBVAVP/V1ZR/6RD++JC9MD>
MUH11;`_9'K(]W$1\$;&PLW/Y99M8&U6[;9O(.XQL%&O"6C:*;!39*#K&*[=W
M%N=*[#Q@X/UBCE-VD&U<3=AVM#V^-=R0.<Y([DGO(%<Z2_'065+84C';V%+M
M$2/94CG(%;94[O&$+54]V<:6JB&,9$OE(%>66RK>!F-3Q6QC4[5/C&13Y>".
M%7<GXE9N38<J7M`#\YWLR6%7)J8-YLFNU:?#YXL=X"3W>MLS;<JH\/424.[U
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MXCH_>-B$/A5R_-V:Z#&R9,G8]#M__3E/#^Z%&+VYZPVDGX?R<Q\A"`F!4!W\
MNXK\CX'H!F&0!3+5H(3^Y^B+[.5)`HOEK4B#]"O.Z"N,Z&T8][[__M>_>-ZO
MTX]^+Y(([DAO97(W@-6"M_;@!>^",,^D7WV(%_B_O;KY`_1!^Z3]RNO!_."G
M+[+_VZMK^O:T?7S1OOBC`Y^.VD=M]>'XN/WJ=YSB!E0],0MD%VO)9N?)X>F)
MQN7^.I!>/P[#^!$(Y]'"\=)\"*.&<:1>!C_WXN$HST06Q)$7][TN$M43D>_Y
MBJQ>)#,OC-/4&\G$2Y'PGLBR).CFZGE9C,\8PNUI!H0?Q"'(>8K/PL=?P^-%
M-/9>!Q'\'><I/#IM>?)'3X+DEX_T129^>N.5"VUK"_IRT7)6;ZEP6\U*J:O?
M7AW!VI$A'N?O`0F+O[6JH[^U$E5.8*$RM;X#+1.*42K?F`^_>,;<'57`T]UI
MX7AV\3(M'&N#S7BV4Z#;X_8+@NS;Y-X5LN(@D=+[!+\/4N\]C,W?M1.S*`AA
M\`47RZ!0A>T8?(%5W6:JCB%I)@K91-(;(&KWKK6@PT6B#K"I'H#=K!=K".1U
MPD!>:S,8H_G5%":C>+FJ+1D-L1E,9"5:4P:OWB:&E:BK\N<"%.(,KW,_#R7]
MRZ325TF@'TSGXC<-`5T\[\N[\4_9C7]^CF[@%?%N_"P>O^YT6D='9[OF-._$
M+^'33VYPR.&J-)@G2G0-"B;8&M91`MD:[H$U/#EI75YL?(")K:$#UG"W.[P[
MKUO9&4_^0T^3_H%XD(FXEZIT*O7B/$LS"!.!*KO>)%S5)K*]JTF9?6=[?&NN
M4>N<MR[:1^XR\27+E-S@2`U$J_."97W-"N#86#';V%AM;*Q:YQ<7[O*0;56=
M]O%V6CWF7""6I]+7VWFC/).S#]-,'CYI'GFL!5U\FCA"M.O\SS9SMXQ<7).T
M_+8ZHK(+\:1XEU&+]TXFG8?T;TADS.:119'-XZZ9_:0(FZVC2R+IZ&'6_2R?
M?;L8F\(4T3XEOF3<*D=Y[S!N%=<&;:LV"(AVN6L^<V70<]7)[@UZ8T."2;:%
MCDH@V\(]L(7ML\/V\:X9S<9P6V6RSXS:N!#DSG[C+,S&M8`5YZ$S7D590&%9
M\"#O$-V1$!_?_^B%N2_]FR0>7I=(@]/OG`G<V'D1X,9+LS2<!6X<Q1G\'H@P
M''N&QEY:$-DN`/9$1KB+$J)D#<$(L7$0^Q`C)S)%5\?W!@+N[TH9(0XC\<?K
M`X-FX4&:2'NZU)C!&EW(!#%\#\.:U1&\X!/#FM6!30QKUFB]R(@\]1)'AC5S
MFCT,:[9'3&0E6E,&,ZR9T^RIP7&(_3V"_GF$B:$4#SF,<HC@1"HKX&6[KGKB
M<T6UJSG<^ZV>3NO\K-VZ/#MWETTL/`YRA0^0.\L:%A@GN<+6!JU-^^*B=7&Y
M<T!*%IY:U:+O;\SS1:99$O1H%QQC'"^/@BS=];X5BT^]:AW9]F2_M"].6Z>K
M)M]8=%AT.,YQFS4L,$YRA6V-YM/?+CKMCL.,8O'9>>5T9[2;,IV_M<^.9M6V
MF@I5Y*1=<;INH>NJE:W'A\?KE+;JQUIEL6[!/92,/1XM*XE_YB5G#U:5=MNC
M/5!?E>,]63K>!27\VZJ^5]7]O@S>O(<G9N,/42].1G%"][T3&;RJ\I5=K7^\
M7K5^Y^CHXJ#=.6@?_?KSZB^<.'Z`\?B'-,VE_P[F'-W?4JT[S2D%&::?4GN0
M)PL&J9]ZEW=3(*9(QG<":4LON?H1I'\\I"(!ZL:1#S]^[O<EOO*3''9E,C'#
M-LS0\V4O`*%/?WOUX5]@1C!M0"_]]H>JIG_U^\DE_6=Q=*4)58EPF\0]*?T4
MN8R_BZ@'H[ZF75EZGCW_TYW,_^"T,OT@C4\Z[?-O=^]>_7YQU"$=4=)@Z7S4
M]'$P;_X3)]]A#-=B%&0BM"=ZMFPU'J\\Q$[G[$R/<<9+J\SX5X[4^-S_/)*X
M8*/[.WD_!'FO+,+SM21EP3I2#*$7O/J]79)P[B@LTEV+='`5^?C/^S_S`!0]
M7O!)_`B&^?!#]"#3;*B^R5"=C-5*M*=QL9[`?QTD4GK`Q&R0>G'BA3)--44W
M&\N4&,!LX;<0#"X\#!\TPKN^I;*?AQ^#OK0'?[E<$+Z(Z%[2PM=??`HB'-#,
M%4]3O#W^_RKK>-F`GC*#TZ--9J!(NF`&IT^9P8?A2`0)7O&Y_S&.[C^".?*O
MTE1FZ?_*T+^)$[C3GD-[4TDXFBNMEB99:3A/G,&2,VHG9@8G[<[+S.`]Z.4>
M^@%H-X?RJ_CQ!<SH%U3;O2`,R(K"EW<RRT(YJ9I.%QGQ31>5->E.9=*C/)$P
MW<-3:\;K#[\Z_:L0_!BXPS='&:6/KH^,4KKU_0_\6.'@"BZ!&LL=N$_TRH_X
M!GB8380O,I5XI@7/3<H'&<8D*/IUJY#FX'CN@C@[.JE8R-7F^%2ZK.`J;(\N
MI9RL09=V9Q=T6>19K$Z7?\@(;',(9+GRAV!7T@PM]8/<SHJ!T>R"-(L<FV<@
MS4:+YI@<SI>FS'J^THI,OKRXV,%4%GE.FS+EI'/VY)G<)A*,I:]_N\X3K)VV
M!GZVR&%:D_3'9V>7$T'+C)>O.;XESM"4![%@?)U.^VS=\7W.!C)9.LBE9_)7
M)^)I^[PRQOD#V&2@2](1ZU"S?='9:*#OAZ,P'DOP7D)<RQ\#T047!C,S,\:[
MR`U95S&T3XXK`UXZD">,>Y&;L"Z=SX_/-QDWQ9#`CUX(UJ)'EN-:?_R:!/#6
MJUXOR9=-9.V,P8*5?7)Q6>8+-AK9-F>V)-^P#HN..Z?;F5FAZ=5E$&KV99J"
M;A?AC9PYBZ4F=`T!F32<"P>QZ8"7&<HUR'[2;F\\8-)6JZR3\VT:R,O+:96Y
MXI)8?<#;M)BGFP]8!>0W$*G_6X2Y?!>DO3!.(;BUQ[K(<.H'%4]X.Z9'7H<B
M32N1=AS)\2>1?)?931[YJ7:%IV__)`6^'SWLFT3^F<NH-[8?5%QJ79A^P8V#
MR93N&D)UANY!=9G.(\P&]%LA,[$]^A4?_S>`4`3"U_%'#%YGDO!#-,JSE'YO
M[Q-#5LB;N+>@UW)'@'Z=TV>CWPKYE3U8T,_+$/)2KA(I/O=O!.8/,YBWJ,2S
MYROD<XITQ3]D?)^(T8`\'K,E]DE&87P+3+@68="/DR@0=H[B>$XX7$T`YUF2
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M:TM\T9@"UDO4>K"9L4+PY)9L7)Z<;T<VYE%G-T*Q0A"V*1\J]]UJ<(FJ?=A`
M%MJ[$`6K5DD7"2G-AGNAR8/$;?N;/(,AFO(FF\0KA%7/2N(55_CQ936R7'O.
M6S:P5[X?9)0(TU8DSP9Q$OR?M$N6+E:(N9Q8OP65)VKCGI%,<Y>PNM!:^#9!
M5PB>7%BME_/6ZM3DJF0PG7ZO5*/?JJ.BZC155R*+)!M7]TU$OH4M.;]H5U?!
MJJ-Z^ER6Y-Q7WNNUYG*QA:D\L=SY:ACG5=][A>#GB>]\.Y[]@&*Y:T/_-39+
MW5JE3U$AG?.S]N79N94RV0;QGI<?ERO$0F[P8[X$S.4'2-7%Y5F]^+%",/2<
M_"AKR?1)?.+"-SR'_^7NVU.D`UR"T_;)]IGQZ\\_N@G6AO__4$L#!!0````(
M`#6"JT9=DUAV40D``-IN```5`!P`=G-A<BTR,#$U,#,S,5]C86PN>&UL550)
M``-E#E%590Y1575X"P`!!"4.```$.0$``.U=;6_C-A+^7N#^@\X%BA8'V[*=
METV07.&-DR)`NC&<;-MO!2/1,6\IT24E)^ZO[Y"R+;](D2B9<A1<$"".0@[G
M&0UGAC,D<_'SJT>M&>:",/^RT6G9#0O[#G.)_WS9"$43"8>0QL___==W%_]N
M-JW1:&#UG8#,\(`(AS(1<OSCPZ\_67]\'MU9=\3_]H0$M@;,"3WL!U;3F@3!
M]+S=?GEY:8V)CWR'(-KBW&TYS&M;S>:2\A7'*``FK`$*L*6^SJVNW3ENVO!]
M\MCY=-[MG7?/6J<G=O?T^/0_MGUNVVL$?HM`6&M?0*!EMXY;Z\V&R/F&GK%U
M.UAK=CPX.K;[)R>]:_NZ,SCI'O<&5[U!_[33.3GJ]DY.FK8-G'1ZGSJ?FO*3
M?;3..9O..7F>!-:/SD^*96O4DM\#YON84CRW?K`>F"^@I3=%_KQE]2FU1K*+
ML$988#[#;FM!D2YE""_&%Y>--?F]/G':8ORYW;7M7GO9L!&U/'\59*/U2V_9
MMM/^X]>[!V>"/=0DO@C@)<2]))FD?IVSL[.V^BLT%>1<J/YWS%%O*0=?5FH+
M^5MSV:PI'S4[W6:OTWH5;@-D8%D7G%$\PF-+,7`>S*?XLB&(-Z62<?5LPO'X
MLC$3B#>ER.U>U/_[1PRM0(7N%.>2SM?1[0:[4ML1#XA0*KCLW)9-VYN]VYO,
M:!`+T"OSF3>/J#X$0%+.AROFN]@7V(4/@E'BPG/W,Z+RC3Q,,`[$5Q^%+H&G
M63A'0/C/,H0WA;J`ZB#JA%2]8BF"C:;X-<`PRHJ`A%:1+!1SP!YESH98%H,K
M]1HC\:1T#*S6,T)3R<!1&]-`+)](`1XU[<Y"U;Y?//YSR/$4$??Z=2KYZ?ON
M?3#!O"\$\'`5<@[,;@J-REG`^/(A14^8*FN9GUS;+*0K)"8PLOQQ_5=(9HC"
MJ*(?7"'.YV#;?T,TQ#J@<A(T#&O(V13S8#X$+0F`'<G*5"K3%ZSYBMZB8QC$
MFCI\8;ZCKV`I!`RS77@^5*OYT6CZ_)EGS'%XB-T[@IX()0'!A6293L0\^RR$
M*3]$<_1$<3'>$RD89KR<P`\@Z1$.$/&Q>XVX#Y95@-Q"3SIE[`[PF#A$"T`>
M:J95QP4O#A$%HD/PB[?^%9J2`%$MW4DC8=J/,L]C_D/`G&_Z+G.GKW'OB,<8
M=-0MQF]B=\,LJZ$FC+H0.DHG',QU.$[J78%"D,!3P8\O0]<`)A6LF,$^Z.I&
M*IGJ#&)!2U@EBR"><DJ236L%9FWUT^?.QAB(.TOZ\'%GZ;.YP%VT:(O0\Q2U
M)JQBO&7_,6>>#GL+-EC*JV`<&E\V.K#.MUNVW;"FG#`./2\;W885"F"432/;
MV;!>L,PZJ$2/74/@;TZ;6!#=#R^(I%8Q_EZM\.=#G.B=8LA''Q#R;@`1XSW^
M@'A3@[P8]LD'A)TG0H\E<%HK"23%&LF.;+6ZBJ%^JBO4[74FRUX$QZC//B;J
MM+3%"CA`KQ/PK3P3V_Y+`L!ZQ6?I`%/RCS'0>L5?Z4#?3A/'>.L5;R4G<M?C
MCGRY_AA_O8*O3/RY"C@Q^H*AV$5[J]A62;%Q]5=Q/[X'Y5:C1XLI;\KQ!#J0
M&;YC8J^5R!*COLLR91$\9C,FOV`?V*#`0M_UB$]$()F:X842ZR1,,DD9SW\+
M#/-9FJ`!GF'*E,DM`"2#D.DR7Z07_O-B0*UD6T+G*JJ2X,[9<N1;'Z9'$?W)
MHF08R*T?8(Y%$879Z6J<U1F,)I4R$M%R?#V>TVA4I=_1N-+8%=+P]>Y5Z/AF
M(FE`9@3LNRN4N?M?&(E2#XD&5<,`(2XM]C:V.E;)9G^&")5KX4>VEO!:9$T^
M(T&<PD#RD#YH*%I4$"SUS=6U&K`'2>C,PT*U@N9[DU.B%)+L:EU+`YEHT[U?
M74L#.2!O!2F%B@+UT.6,2+*N=8&W0J>DJ1PO`@K5`=[#NTY?#;'<"[:Z5@9R
M8<]<=9>N$!P^X20SBC>4O1C++:4/\.[32`FLFUY\.APC@0<X^GGK[U9IEKG/
ME087W#M4?BSC*_$$!M<+=:71;A*K',XBISU81,>)N>UR&/.-8!CX#2)<E2?B
M:/]^_#OB'&DNZC,(I<+8-6'R"7@V#Z04<AP1ND*4WBMC#?+97+(LM3[7'K?B
MM$WOZYP@CF&EAE5&'!1!&5FMO9TI%`PS/L!3CAVB!H//%"\$V?<8V/J_M6'D
MH_?_M%"R37G`3BA#')`<$Z2LA=JE9GI#-IHK[_[(^LY?(>$XM:"LM4];@ZKY
M\U@.QJZX@7A769C(\(CK5\P=(K;#K\Q#65G$*H2SL/7+P;54[VTZ%8*X%2*4
MYRG!*S`?`M:`0/2QZ1.*XLI%^D!05RG#?8!;(W8`.+<^!,"(#L,G2IS[,4@7
M(N.RL%*(FO="<I$##,FDK/MY_A7F]*U_$]T*X#^K>P6BS6%J8W<(S^+BNJ;;
M*C728001Y3*K$$3ND0XCB-4*T+@@<H]TD./:0YB7S-V.8W1@Z]$]:)*LD`C8
M_MYP70MGAN26VT34]=2-(;GE]C$U+LGMPXNS0A%*C8MZ%0AM*UJMZV&AZH25
MNFZI:V'1K.AVE[)U/99D5DXIR8NZEB_WM%QAQ3)8A<J>[Z'BO7^QY<EHUO4X
MU9Z6@CDVQM7L&-;^!9.O)%'7TUS[EU=:):JNY[_V)Z'BY<="9\?>L54OH5X9
ME>;2Y\P^C*"*;CF():@1S'],7<NQ,R66UH<(Z?<M+*U-2[$L"T;\IK;LQ9<W
MKU^X*MT;\U4:;.,$[`KEXO!K-+$&\MJ*U25N;V[@V_]P!]K.MT<@U9QT6N.F
MP.6';U$Q?Y==.=[?`]L57R5\"+.K`SCUB'W"+2CU6J05E,);\ZMT7>50OF/7
M2>[14V01?Z=^(97M*FZ:WL>]PUF4JKD[&8*[,19"*?T-+G.!<BHEW8V],'L=
M:$4<=73C:O'QD1-$$]ZZ!L-EJ!M^&]<PN]@<@QE1EY25TZP<Q#[*Q=P'N>PF
M$QS3>A=U]="YY%!FSM5U'X26@F19S[IN:M`20I8O++U)P7SD]@4'LBHRQ%PE
MMS<V#CQ(>?&Y>C8-`\7$_5B=NI?G,@D-P31L$2@4X9EEXN"1H"%X9GWA[TH=
ML=L'L.@9?PF])\SOQQ&",)#_.TK^:[`M3G4<9=$1#`<!;[$EY)X1^;^)-.\B
MR4_SH,9/&SHK_S9+AQ%)-O)B];_'X)=_`%!+`P04````"``U@JM&=WI@CHH1
M```@\0``%0`<`'9S87(M,C`Q-3`S,S%?9&5F+GAM;%54"0`#90Y1564.455U
M>`L``00E#@``!#D!``#M7?]/XSH2__VD^Q]Z/.ET3Z=^!W87+?=4*+Q#8BFB
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MPL.FKJD5OE`)$5JY=XC_VLO;VN)2NS]H#_N=5VX?`%RMUD?$+$8=?(=GK9#=
M$W\QQZ<'G+AS1X@97GMB>);+R))[0?](4/X).<Y!*R;\^>[JK<S$\[LV<;OQ
M/=WP@:X^AJ`M[(GNW;;Q#`6.K\9>QN/U,$M=1+S"O,9/ZV0U;*+M8O<!,T4^
MUQ_5R.03D&!6\(#;"39JK&82B!F6Y?:9(]86RJTWC(;?3_<8[@)E?1WJB$UF
MA%AB7D',)SQ4]LN'NR%/ZT]O,*-`S$>OU*/N(J(Z]8&DF'G.J6>#I-B&#YPZ
MQ(;K=O(MG\S.$7^Z=.@+_^RAP";P[2YY[Z"!+U4TL`YR+#H,3.(1H3`%(FMW
MXE<?0V/)\T+2FJ$)>00N'6KM0$E<^7(E)$'.;?#@$&LRFV$&]L0YY3Y?Q\`1
M<P1ERXL.>L!.1'0KB6X>.ZL#88;X0S@:P(IY1&@N<#GL8L?GRRN"\<-VKQ_/
M)S_%E[\`+K%%-)E-?6I]';DT"'&#RX!&7T8(!6*:Q;E$A/V&G`!_PDC8:^(M
M_T[\I\\>?1"V!WIP\)4W#WQ^ART*!II#PHD;_@N80/T,<<*OP'!@H5''SQW$
M.9D1;%]YTR?$\!-U;)#QXL^`^(M[ACP.KXM/`G\RN\;/V!FJ`&8$N[I[6#S"
M;H!_^'@%?8'[P/K(LR\C(QD^"S,;Q@#FJ:D]>@"ID.4K=<#2;=4`!C`C_HA7
M\HP<\=9&_CEB;`',A9U!56()@HV(=0MZC$)'M&"YP_$81W_+2Y='5[.0-]@7
MC-PR^DQ@ACI;?.9BF&5T+%!XT.L"N#8!8R0<L5*3054M:08"^+(PMODEHVZH
MYB?SL.&+5["\"-^<_+?+*D&L1G%^AV&#/'_9N-);VTZG1B&N.`_$NA>LFVCF
M)3"-W$)CF#%A_0#(1>62(MV0J*Y+O<J$6R'6@#B9!F%9L7*(&J,UBTSX1:@W
M(W!JB^B>)J1;T@S$Y@0-%JDP6\$.'>,YY41N@:1"3?=(18O0R+ZG(PNL$0:*
MCP*<_N+6`5T/=HJP4>;B%J6AJD#5Z*Y;X?A5;K$98&).:AC3TBW5/J9'EL4"
M;%\3]`"KTU#3>O;$?\(LX7GENW(C7K6M)L`0#@\.8UHLW4M+NTZL=G'`L)LC
M8H]C\^[B=2Y\:4O,1YSCLCI<KH7:!4^ZTSF:$Q\Y152;"M6ZO&(C^W\!]\5<
M,IG%2Q2E%[B#4*X8.:[3.^RF?B_ABW6<:/4''6!]4;$<U@MIGVHAVIK?0^B1
M.T.A.]H5/3W4VBHO((^"9L;!Q&+8BGR/\-G!,9`CE\(2\"]E,>3H:18J[<-@
M>RW]JQ@F8!BYU,77E,-UR<FXB(+0T[Y^2RAE3]&P67W0:(.M0DM6N455'9KK
MAX&^DWHQ/L616TGEJ4:T,I;CF211R%5QG4>W,L;3V:5RWK>0KLMJ6+&IXSB5
M/=D(0;T)6*W'J\X6"?-AA&H<9SL4L#QT,?-E\`/0BIFI"\[-]D>OI)A5FTU(
MMU&XS$:X5UTR;CY9%Z/7Q,-7\%$)Y*RG$X;3A)`1L]:((F8M"<89/I():M$S
M,T;=[3S$C=%\6"FS,3L]Z/?Z'WJ=7N^@-6>$"L?CZ0'HC(`#1S14T$@T&^8S
MG<#P\/&K?^&$A$X/.'Z,_8+Q]PX%\^#TP&=KT=EJ<<A,A=J*RWH7I-)#)(%H
M,-@-D29I,_+^LF25TQI9HNN<>5(`#TT`<&TV,1T_0]!;3Y'<"IWV^9^6L"I3
M,(]_@"D%9M[R(D7R_0\DI9#,7%XF,`Y[)L,H9UQ4Y29(01F:#$K%?AB:ZT]*
M\#CL?Y]XZ/$FIK`>F0RK5E<N5?5;)Z`=&3TVZP(M+V:1P'1L])#5#5/Q:%4*
MH,3"]-L%4#(XF:#U[H<J4PQ/)]"]-WJD%HCC;P5$+CDA!<?H45@U.&^R4Q(<
M/KS[SG!0RDE:P@36@<DP:37<2V6X)0#VC;:N2BT'E?,?$U`&1FOHBA-,5X!4
MR:)-P3):8^L#2R:7.@%I:+0ZUP=2V>SZ!$"S/1*E]-36?18I`/LXS&0VJ*SJ
M'_D--PDN1_LXLBK`96-_58+'L=$3NEX\<C?3I>A\9Z/H[1;*!`JS5_#50Y&S
M+S;!P^QE>35XE-T3G8)E]#B2FX[5]L4GHIN],B\C^IN"!TN9!V8OL^5E+E?6
M(H&C;W07J*Q62)9;N,D:*PG^`Z.[HP[\)8H")>B8O=:L$IV==9\23`ZEK>*/
MW?7"6A75&4L%N:3,17%4ZBS@H+(X#XUY4>EQ9-LDXN?*FRUO'&,?D20;<VNU
ML>J:::;F6`7\_ZB;H92.#*V(IK$]#L3`B<R?4"/S&_P2?J68HBQ'44HPCJW.
M(WV&(4DBF>##IBAPZ<L%&*O^0@3WV)Q&UJJH"CN9K5V2$4.%FNK.EZF8&FW$
M%DLMI;B])?=YW9T$S,-XVKE!+GP,IV?0Q0(8Y3T3NZG5L(ND;I'T"Q0\<&(3
MZ!PKS*CNX=A"1+6OKT_'TKLR\I\MQ\#;E8$:$]?U[[>0DH)N@RP))O<D7!M[
MM>=B9Q>C4ITZ!<B(#0/;=ESL'M]45<6FTC>8HRZU7:)BX0T17<*Q(3]+T5TV
M0BJRD7GTLMI.Q3Y+]YP9&1.1%5G5LDYW3!B9ZJ\JMD+P2V'KDO9E_C1PW7`8
M3LFC1V;$$AD44;J7>'44Q!?.^LK6^Y6UU_3"O[P@>BWM"^BTX8$F42[I/7J]
M`^6S[O:$BU/L^Y$1I62"%Z&NN[*3.T>$19G`UU2,UF=L1XF;_\6.?4G99[6"
MQ)($]9<,S<YM@L9G@7--9DI"29%3KI61&:?YA%Z)&[B1Z]2-KOAAYE$T(TBO
M<8J2UUUW)A"SQF269#-.HT6(6JF<?"*J;^%WRKZFF:W2Z&X^IAFU.Z'\/&Q?
M(.9!LQQT9N`&XL0,D7P-2E.I$H\,-<T"Q?U0WDF6\Z!N-F%B+,;F^H.ZNP?R
M'K$ZDRN/U>"6*\]D/2RJ.M96'E)V&F^S@M3\:C*D*F5/W>LF2ZY6)YRBC%0!
M[F_<1:?0>6GF:-DC#]U;Q;`I4JI&C?`_2;G>9*4R1*;=/K6L*8;F3LJ&>\UD
MA5HWB%*_F+D.(G6=JV*YI@@8^5K+S#J;JXY]\`86?]E;5GFIX$;F0Y5YQT77
M[6F]$R-+/)7L"U(>&,-+G)2$0-*SEM;6:+#2G#80BKA0TRH0YB0*RCG"Q3'-
M=B#BA!?<)VYT-">UOKZI%1+OO-<87"C'RG[$'0K*J+D(NQ,NJ;&=724F9D7%
M82%+4;.SY5?LP;SNB.)`M@L=0:0`BY$=MZ_N*9(DJ-U5RS'H03&'CT5N.PVG
MJ<)"29'3?_P'Z-IT)T9\EKMZ+MU60C6X(.L1I"DQ5!V76\GH3FE,52W,"72!
M\12S9V+A;)T4JZQPBX28[$&)_X7MR/0-MP.HEX;6PX!FV*KA5<EUJZWINFM;
MZ\*.:N]4WZXCN1YU0"5UWAXYI&6F@-UB[V.^:)62&R*W5$TN"<.%*IJ->^(`
M5Q9><B%@N*N\QGE+=D58(.E6_Y;+C-W+/-YM*A((DUW)RXK=(S]Y9+-X=['-
MF-H8:-IKHD$RS;Z2T!N:\)!*HN0>R2=2UWD]JW@G,*K[#N3H-2#4)<-_!MBS
M%B5.9<HG5^=!5;4)5>=A45E<E#@R*I]<72)%U2NB4A,EAE$6F09$&%0CPJ!!
M$?K5B-!O4(>E,\1_"5B;8&M7-/!S"3>DU^H7M$Y=]Y:'L&>54'=;*>K.5Z8>
M7GQ"["OV+P//Y@42EW,HU'8`=VA]%3Y=)WR\[(&/%?-0Y[C]!N&K4QND;9=0
M`)M$ZGWW(\_>?DP5W'!#/;;V4I3#)Q4VN@?P%`J85-QPW>$2/;AEGD92N@M]
M^P&2Z@=Y]MFEF[IKCT(BN]5X?N>K=*XW(J:@>E1I<Y`9`IC",9"ZC"RZVPPW
M(61CG-+:NN)*8Q8-)@4K:S"99>F.$JY;_0A&E$]1U5$Z03$$$@4MI.2BR8(E
MRY&6@F!T&5XM(`S>@F#D[A*M(`S?@M!<.7CC9IK\4(816[&4IYF=D9X=ZC0C
M\I8"T>#^$]69I6(<#$&AF`K)BV/NFEG?!)8+5.XRP*ROWM&Q):&@P"'EVA-J
M1/4U$NTQ%/L0P[-"'J$_5%K1K%PC32?&%.1>L?Q&>CRF.*5D\N"0QY#:#9:J
M]K.;AF;/ZS6&CH]%PV+4B+.*'B--L<X4O\?,#4]X6C\#0,+%6K0%U4(H(X;1
M9':)K/!<Z>OHT!C)-Y#YK"H#G[#GT%O$OIXCAT"W\@A2K"^^A8+NK1Z18_57
M3!\9FC\1"SD%JG#G$:FCGKA6`6HX!B!.G%UM6[EZ>#X1W5J$<KZF895C57D4
MZF:\4!1I&Y6Z0T(2$M'=L'_[P9H=799*#:L]BKSLUC!44I,;$0F0*UM>B<R&
M2"Q1K7SG'$AW&QHF!"\D9)53<_G&W9[X4!6U>4%3VP0W8K7O?.N2*O5YF+.@
MCX[=N_(L>%WD&8L2.A6NY`M2;WH)K\JV7EMQI>)]5/)_$OC<1YX=GH<M;RUN
MIZ-[H9&],RW5%6>+])9;M!"71B^(V<M"7RG^$?.CP'^"P?,7EJIZ70L;FB%<
M>7]QD;>(!;&=DSUC4>3I,O"A^RX/2RC8.62)F]ICXJ.>5WIW]/)JZ2?YC9L*
MURVL6^`S>L23V0K;85>(*\O5@IP4'Z:"N%0/L5)XAEE!+.M@U/PJCF&O547E
M\J#J6$PV%XM7<!LPZPF:%).AHGMQ)QWEVM/IB>Z"S/T+O7^B`8<.<TD#YF.L
MRJ$\05565TC=@-6XT9`BFW+$ZBHS$[;^XH%I]43F@H&+Z>16_%5W@,K2K,&A
MVZ1X#0N7&L#\+"RFJ>H(+D2^MF)2.Q4KS].L)0I(E6[4U!FOD,.ZBM;J=FQ7
MB%!F-:C2/>3;]YE7/X9I2:6U1P[X,CI?&J;U*=H(O[64I[YF<`R!1J&ND*P5
M1)5,U#UQ]A=&07X]L2>)Y861V+GVVY-D2$U6@+:U?IH\:&2Y>T-AE?)!I2<)
M&)VZ:ABT^8[1]%`"HTOMZ<&S@-\]/;+`Z!"R8?U/)H"3(/ON.U2:V\.#*332
MVYZTQZYOL"]"\Z"T0X;7S@9/#G6XI;Z(XL+R?C$F3B#BN5.1GA]F\%^\6DY@
MPR@#?`66@1^7R0QOC4M>K@)1*`K>.)]-Q].;`T!S24G@UY;G=7DPV1*'D2O.
M&%'QGU74H/Y3+GQ&K.4)*9^AE_&[Z>="YUML(Z0:BXE-D'NZ7(>L=$/%2(P,
M*<TH9_>%&^1B]0#%+EHUQ%WJ%*<A8:3'Z=DBFX!J/$8K&[7%;4I*42)X4TW+
M9O>U0G&<ZMJL.YI3.5J9,9UJ.L[W%-BI=)#3FE3@'D6!ZIB1=L*^;E`8$0J1
MBA(9!IXAT.UV5$C;=%3!K-Z3V)&*[)+KG3TYDT3G%%O1`KB:LTH^=@5_#]!-
MX9__`U!+`P04````"``U@JM&.H<.FSPR``!7Q@(`%0`<`'9S87(M,C`Q-3`S
M,S%?;&%B+GAM;%54"0`#90Y1564.455U>`L``00E#@``!#D!``#E?7MOY#B2
MY_\'W'?@UAP6W3B[RBYW53]F>A99?LP:YW(:MFM[#XU#0Y:8MK:88HZD=#G[
MTQ]?4E)*/4B*E)C>P<QT.CL5$8I?1)`,!H-_^[>7)0+/,,UBG/SZYOCMT1L`
MDQ!'<?+XZYMU=AAD81R_`5D>)%&`<`)_?;.!V9M_^_O__!]_^Y?#0W![>P9F
M81X_P[,X"Q'.UBG\[N[S]^`_/]U>@:LX^?H09!"<X7"]A$D.#L%3GJ]^>??N
MV[=O;Q=Q$B1A'*"W:1J]#?'R'3@\+"B?IC#(B53@+,@A8/_Y!;P_.OYP>$3^
M^_'^^*=?WI_\\O[GMS]^/'K_XX<?__?1T2]'1Q*!_^!O!:3_$`)OC]Y^>"O_
M["8(OP:/$%R>23_[</;#AZ/9QX\GYT?GQV<?WW\X.3L].9O]>'S\\8?W)Q\_
M'AX=$4F.3WXZ_NF0?CKZ098<KS9I_/B4@^_"[YG(X/8M_>\93A*($-R`?P5W
M.,G(+Y>K(-F\!3.$P"U])`.W,(/I,XS>"HJHT"%!*LE^?2/I[^4A16]Q^OCN
M_='1R;OBAV_X+W^A?VO\_&7G]]].V*^/?_[YYW?LWY8_S>*F'Q*RQ^_^\_/5
M7?@$E\%AG%"K"2F#+/XE8U]>X9"!JB`7:/T%_>NP^-DA_>KP^/WAR?';ERQZ
M0U0&P-]2C.`M7`#ZSR^WEZWL?GY'?_$N@8_$R**KX`$B(BZE_<M3"A?-SZ$T
MK3Q&1?B9BG#\D8KPER9J^69%7">+ERM$%/)NB)37,+<K:)V@15EO8!KCZ#RQ
MK-IFLM;EOLN#U+*NVPA;E/V>Q#UH5^I=DC;EQ7F`+,N[0]*.O`;&D.^*J(`\
MHK^@HZ?X$276$3,9+Q&A):+P)8=)!$50I&1QV"0[(Y;!\.TC?GX7P9@0/?Z!
M?CBD'PZ/CD5P_0OYZH_S)(_SS2D9S-,`71+R+_\';JI\$8WR."V^9"_SZYN.
MA]^5`M*?TE&&/$1G(#`Y_'*G2N</]%#3:@HSO$[9$*2LQGQKZW_G;(#@`Q@C
M0#C][1V3I2+U+`TKO(,T+-B2CSV<Q2_>A9@,F*O\$,D6LDCQLE-]@BWNU<V[
M-D-XSH*4@OWAZ$1`3;_YHYBVS9*(4[U,%CA=LB%\]I`1!F&N`KT&,2U34*9K
MQS0BP8F1?O/W<E)+YL9DULQ,)=[R?CN%E>C#AK75Z#-$7"5;:`A'(+Q8X@E^
M+[C^OSI(%B)DP?R>O(5J8*P^HQT/Y<?MA\%2FY3\5+&O4:NX[?4]T&#=%)N4
M9\':9H1X1!E<H.!1U=QJ#VEKJ_*\?8,KR0-*?RJ+:]8L;M6`#UI$*@JT&./*
ME1C-TN@&N]K#QCY;H>,P_'$^9#R)6%)JZDC8K'O<JQN?]%P/DCTJMFBY%W$6
M!NC_PB"](-]DNK:[\[BQ5FN4'-HOYP0H*\!X36W!;1A@!0WYI>^Z'?>JVKHE
M<\\98,L5`@.U*]%R;\\B9GADT4U8--KTCIY\TWN+77>IW()EWZ<!W8&ZVRP?
M,%*UYMI#VIJL/&_?:@5YP.E/9:?-FL6M&O!!BTA%@=8RF[?P,::Y@22_#I;*
M4]KF9PWSFE4RSM*:6S:`\IDVJ=FB=MRG%X]4C'2U.VVBNRIN;X[;@H.=KM.T
M,@'37#>V/Z]M!6VD[#N;X%29$4Z]@NP%`JMHR3.E(WU]6QLT+F($TU/"X1&G
MFIMAM4<-XUF%BK,1@W$!!9MI!XQFE>,>I?BC7J2A67O;MGBYQ,E=CL.O=T\!
M$7N^SEEM%YE8:>[A=E(RW=#M(.IN=Y<Q!8SK`>!\@<1XXLU>%<2PGA*]10>U
M`J.`2X>3+(+L@;%:9X>/0;#BG@)1GA7?U%U&?/W'74Y<DJY\YXN+HEKQ!F>Q
M[@ZX'CTM@'1(6X6I9`CF"U"R!`7/CDW6,5S("$%LHL[6J@H[)CC+,IAG)L96
M?]+(K*I$'.SU,?I36DB+@G&W#KQ1)I+U:%;9,-0XQ9S;W$9W"`S0;HV6NQ6=
M+Y;;IOT=`V[4C&^:KIISH>N1S?HTR)YF243_<?[/=?P<(")$-LM/@S3=D+G'
M?P1HK92VT"1H!(82;0=N0/BQTK>0?H!;SE-ZA!YPV$B)OH.$)'QH_1O[(#$%
MLQP4;`'C.XI/W:1P%<31^<L*)ADD@LWS)YA6(HF.1RF1,X)*@;)];Q),`>1<
M,^99F#(&H8B!P>3CC0Z$V$"A?L.%JD@)ALS%&$M0';/&GW\9S[MLS`(LN<3V
MY,;?V2D.CZR_U\YM6;0[VYW`0B5OO"8ZUK?4%@)&FFVD93^8\W`PO<5VZQXK
MZ<4W/2-9Q<*>MSQ&FLG@%4SSS0U1!#O30.96*YHJNH::4Y@N.H:#83M)%Y,6
MSHV?@"E8'8`$[@`Q[C1%`1^LHS1/L4`U&!@G?N:EX`6N=[%P.!/1GX(,&B-=
M33JF#]TU=>[,,@9/+QS,*T:QLZLX>(A1G,<P(X;.-H>>,(I(5*(VGV],DI#J
M-(T4KDK>?H"6.!\`8G7/)$S$#PB"%4$$DA$S`AG;7J,!/),$^]=@A;._LIA.
MXLIW$5S$89Q_/Z5':`./31'8`Y#1#KXL[,ML`><[=NI4$FG`MD`7E:'PC+9!
M@+8\/7$<A:V"/D5YJ?T&=YAHYV`6AGB=Y-E-L`E(H#7)S+10,!OK&XDYV,45
M?(!@-.G4J1L"K*8=[]2-FC4];KHQ#-,UC';=6=/`VXB8*KV9GA,SIZQ\B>S]
M<&!E-?FH>E35>D-XGVA*,VPJ8VT0=;7\+<;.*S_,7,V^K1JV8XOVP)(-37BX
M/ET9K7_&VF.E=LS3E5V.4V>#E\LX7[)2B"0ZQ4D>)X\P"37MLY.,6;E&.T4'
MZ\4M,UY0([,#WUWC'(*/D^9>5'#"&MKS$Q.T"P>KGY$YC51U;B.K:3V/.6;F
M\JXM&3EM+;E.TM%)FG&DQ*('B<2;(D7-9-&NN&Q\W+3`J$[)2?V7G)`_`/_K
MZ"UM,@U600J>*<^_@@\'Y!OZ/Y#QTS#!.G_":?PG>2K(P6=BR4_@Y/B`]YRF
M(\D9#.'R`:;%MS\<`/+<"K*.W6CS5_`G3'%!+<XRNLIBA6?;8S9FE">N4FLU
M'*P`JU]&@NKVP<]#C5>W*1W[TB][WGG6>.27R;B9@N&DU?<.P(>CX<[W5_#^
MYX/W'WX\^.GD(_O%^Q\.WO_PX>"'DQ]?FP^V&@WN0]4C`T$5VQC;[V91Q`Z;
M!>@FB*/+Y#18Q62=JY5I;2-AENQKIN8@RUHR`K32]C!.0,AY39IL[<$#*VK*
M/]VC';53)N`R`:?-:G=B[[<P#^($1N=!FI"8E\W"<+U<(]K/_8R7'^B8O@HU
M(R3Z"3O9=BAX`%&*,:4G:""%]17G-2K"50IVH.`'9(C.FB$:*54P+$5@;5GJ
M*LW;6J7D5V)`+2%@-1'@.@'@17F?X;9%"RTGE5ZN+%_:=-ZMU_O+3^^/?_3!
M%90!U"C/<UB6-W8YW@2ILYL@G:>LG47$5B\W,&7=5,RS:>T4+>1.VHB/D',K
MU_O^I*]ZP6O-:'7KT7N@6O)>A"F8IX"SY:MQVHV6]P>:P+EX7Z)9F0LR=ZI=
M2A8PJA,=P8EVTF/^.%,K6*U.U*P_;X%I<1K1/&O6"LEHCG+)\IM#G:2@8@T'
M3G`\Y^!I7M\<HP9.CU/(.O,2B&YGN&R$8#1'T&R\J$S*&A).6R^V^06>MNVB
M+F`]'C*L\>*HX'3[RMA=%Z7M'!N+%R5R0_>=QENV5/<JO5BSZ`#6O`/H8+4R
M&CA-^X33KU-VVK6:+5(ZR0S%Q?WRI.HL7JU-5`!J=A:+JQ+G8#0YQS3KD9U7
MU5^,M)*PHWM7RY!&)YA^#=('2)?Q#UY].%5^A]&/N.X8VNU=C8X=[3M=;C3:
MOR=K#=4&[^J:\Q20#I^8L*O[91+B)63G"9:K%#[!)(N?H?AV6(-W-=)#>[VK
M<''7]IWS$<<D)/[%O_"N![P6WLWMX-4U[K@S_'P%TX`>31&M*(V:Q'<0,6O]
MUD;/09N]@E79-7729GN]:&!E+?FH>517>L%F[(,AMS"#M!B:>.`9?(8(LT9G
M0AH=T^\A9%B(UD'3O@L4[%A!2+1E.&UYH`H^6$MGOF*!:C#,6%E^R:OPD5'\
MXA\P(:Z)B`BS:!DG[/9!>A+`P#-Z21GAT4/5OG<(ALPY@@K+*?U#%2>LJ3E_
M,4%5.*B35+F-ZB<[X^2@Z9*MP=I5U2#V>Y*D-#FR.2ER/!D:UX+YHN,*9V8V
M+#\^3+M;2O;MF%(%U(P*6\:)'S;<H/TF*Z[KQB]-[UBR6+E3#J,8\V7R##/6
M;H%SODS($$Z^T;'H=AI&RFXC9W^&4E`&,6,TI5GWXH!5%>2ASE&A[H))8>8%
MFY%,G3,SF)'O/&JHY`J5@;K]F>LV@8]TD[MNT;!Y2C>N23?K&_=HQ`/=UNU6
M*'74>3*]8N$:)[@Z]!@8;Q\E\SLF6HFZNM2#QVGPG;#N[R>_[$`1I?IE'SV*
M\Q81)(,A\RH"^I@><@USLQEX[4$C;5=HV)]U$_(`T9DW[T@F[^V@AJGAF";?
MK';<J1I?5(RVVAU[HLU\IEI->A8_QQ%,HHSE?_YKS>=&>HM)#:KF446)@8OI
MS!F$2WKJ7G`$*>1GO',,'F#"#GK32\K8U0H9O?5Z`8-\G4*`%UT7+DP^8NC9
M07WTT(##;\R;1I5Z$73)620N2][CCS&SYR!&M.OW/98*-L0)TT]!%H?&HY`*
MZ>%!M)^+RY$LS]/X89VSMNG$@4.I+$B(X,VPIH%TV\"GJNO]0;5Y\`0E>W"/
M@5Q?5!R]9B*,XJU%/Y"BP)QQION/,5KG>K6FO:2,<.NA:@<G,NH]X'+A5/H?
MF:J#!\J/[U9SCKP<SW??5,45:VK:7PR%KY4-;LK#"]R;^$XW9SB*9_T&X\<G
MPFQ&C"MXA-=KVOENOF`B2?6#`QS.E(,1AF;,[&<U"CD.`RY(Z7B\,G.=\;DN
M70`2`1K<-Y&].VLZW3*FGPZT$FP'H+VS"%0U!B!D`%P(6NC)75^20SL,/&=!
M2IW[P]&)<&WZS1^W9'T59&3%Q(LK3P.$YBNZQT<H5U<`17<5I1Y`YK2UP#-E
M8P>V"(=KRI/MB=(J)$D.M@`ED@#,1&$^6[_UK^@HM'D[A<\.AA\/U7]K?6Z+
MK5XF<4Z6^S?K!Q2'\P4A3!SA%&=J&9->$OJ6UT[-B8$)=F#%^!$+XPS)Z$`X
M3F=#"K!@184YKMB6JLA/@^SI`N%O1D7;W72&'BG8(>GN_`!E!1@O_XX*M"/4
M?"Z@16UCF=0]73H9&9%X<IC9,"(N[H$HK.5WQL$/XZCJNLD<)'5XH]<=!VQ1
MJ1,[O0CBE!V#_[0I1^%3%&39["76VG#H(62D[4Z:[JYEW@#&9$J35H,%:ZG*
M5PB$_5-.HB/#IPVH84&&(<)O9)>0^D9^YC/9:)[<PG"=IF+%EWU)\$,&TV?J
ML)<)68N3?TW0)4^QN5E=:6=X&<2)D5NY$V:87;B2R[Y[2P;VL&-@7CB[<X-K
M"AAN`7S-QK4;N.1.LX7`8)Z`4F26GLF`+#1@4H.JV(TAD,O>%P1;%LFGVUWO
MZN)[NRXO&7YF]Y<H+YY-2.LOJO6Y.%ELG[97#U02.QXD<09`C@<J?7_@K3:D
M*.M%\$(-7?`[%Z9Q`>3S>R/YE;DYURLLJ`2`BR`%H[87'AB&?@O2-$ARZS&H
MC:Y%"VUF,7KT^<;%\#KR]*#<&W:Z5+TGB*H'G!U`W04;ER^L$&D$>_=1IE()
M8RO$-!*U:(T-]$</+K7:#P]#2Q>TO7&E5<7[`*-Z1*FAZ"Z>.'M7A6!2JS93
M#266\_Y7<0(OR4>M)&K3T\/RU"4AIWL`E`M@;/S8"-A5?M-F0$TW7BEZ=U.@
M0\>N*ISIUME-BFF==?1I\R6#T652GDB>T?M,6:J#W\2^)M_-RY/@)MNGMCB:
M5LY:8.X@H-.MV`7;BI4/V]/;9TN))BZ/MFDFV`TB>V\2(A[0HEUF$850-%%(
MQ:+7@FZ;!6PE`UO1P%:VGEW]"8^Z299?%"B/=*UO>7[D'A>Y6%AY0S*G4;,&
MD]CGAK_AI;;V17%Q&W$I)9W6IH6<V\I7\BW]'%)W806S<>)=]'1J=G@,3%^9
MB:%=ZR+KB5)$4#_D0A<;6O%XY*Z,9Y"L`4.^J40^(R@*,&=+3)9/?_*5OT:<
M4J-G9!0JI.W'$9DK[T@GL9LR-&@AATW4Z#E*J`&@DB,_]-D!E9O5O3C7`UF3
M89ADVO[31L%L\=E(S,5*'X=?#Q\H(W;DI.#D0S.9'DBPFK:\4W^Q_B^.=D'>
MR;M@8IJP&_],1./Q_=TC$;J[ZONC@'I+6OG-6:GU=I.5QK1Z-O.J[8W=UKYM
M)T#SA=B=,2L';28TK"RHB::+)LX:1KJS5^=%05DGBDW%8.V:]16QW2*L+2_J
M7P6WD3K)A2FQ&7@&^3^E!<MIL(KS`)GD!G2H&O9(4V7@(+_Y1,2C]QZ1V7>6
MP9QW-D+;0KII.]5IXXG-U;H7V`E_*]B"@F]UP2M8C[W:W54&&4Y701R=B6@M
MVI"1@98UE9DQBQOFBVH<+&&KPLS%A$WP+9M5,R?%K"\/]UJ_O%0+]4Z/55?X
M_B"LX,D%WH481?\^-D7E_9AFC;B/Y-:S,,1K,JK?!!O=\W4*Q"Q!6:/K(`<N
M&(`5Y^"7$[9AU.EOC3KS&8\N+RKQN6G&9SQG2=<DE&_G5$4X*0=LZ=\-]B4M
M7O:@U6#KQ!,I?WG>*@V1WLYF#2VCSX.UH=AC*^CQ?V85\K&@[0"ZG2U?M=N'
MAZ4]XY7T3%*WX:;3H=>[T);LP5KMSF0U.S[6ZDP9$?C%#&,6^VESM&DEFLS=
M%_O%A4!^!PI3,^D/&$:([+U)J`204K`AQ7Y.8@E9[(C*GEGXSW6<0B(^$2;?
MW!`4<C+_.2??LGL8=>*%#E4C`U!GX"3!1AY_HM-&=FJ#,V8K"%APG=+O#2#%
MYIKU&[ZJCQ9L:2&88`P*SH"Q9C/^\S841TH!W-$&!'&^.8,KG,5#4]Z[U"PM
MX.J$'92R"`X@XBS``J=@$83\U"&B8OBU1&]%KG,1WJQ(KU'J6DB7J!4L]V!2
M/-YD>)(9SPC+Y-<U^[4_ZYULMNOC+'?*B'`1)T$2#CX#8D+=)OH=C-PO=1<%
M<[^=707J?@?OU?1>P:KBR*40$YZ%('*%$$;9!0'Z,LO61"#8V'E8:UVJ3M1L
M7:-*W\4=(05SD8T2['DMI-1&@(W5C3VHV3V,]/?ELZPI]:1K66TKP,9H[`/B
MJ`8U90L*OJ#H+<XY@X+U9/XZ7TB-)8;Z:8V8-;0J=.T/G>I>N<"(C+"'K!G(
M7CED,\P]CMB@=I\A[78\>C1`ZF(RJ<.U-'FQX7ZMI*TBU\)E7-=L/3RP1S[9
M9PD*'MJ)Q?Z@KN"]K2V*1G=F<0CB_`6F89SIU7AUTQD,6)VD:Y^$@I'B@1YO
MO+`5PA:7:]:KIW`U.E/1%+#D-;K;,&?E9_.R0@JMN^L4B`U&I)'NN%XD33KY
M.4UOO*8;P1;7Z="HSV@U.A$_1"H8EJXTSMV0ZODH1_LGRIP<I]M&WC]9%?FW
MA\T>IU4'[J%HP;"W^!NG7J?;0Z%RSI*(_H-613P'B-9/W,`TQE%]KUDG!NC1
M-4)<AX4;_XZ+W?$XX;Y.2X38![@5:$K_-D(7#U'QGB")I&TO6A'$/DB\`6<.
M=NH?!C3H:W[+&0E;:;HAKL_.R]MYO163_BX/TES>X&LR3Q#DX`$^Q@F]P9K5
MN[%G]^D]SY-(Y2TA/0'4]G[.@BN][/":>"KYN-W/3Z*&<>DLSD*$:8L+D^WJ
MX;R,77<(6P<U9>O5"K$N(0$"4<F00I]P(4%,^_9.'9>M&`:VC<0>&X$<TZDT
M0(@CEZV0$-`X`=O*-/8V>-F4Y?.VO<UO<?ZT<Y-65KV3JGKOUF5"9&:W!V3L
M>JIX$=/9+VM8]8111/R#QN)\<Y\&2;8@?\[7^7QQ!9\A.M$),UZ(.ZS[S722
MN[Y@8'LU28Y!$$4QE9^6`=#F`6R.ROJ`>-$,R0-S;VJY-+5Q_/<V;1'"I?91
MTAL!^DH-E_5E]=OZZO?[22\&MF_&*IFE=P/\Y4#Y=H"\'MTZXB\XSH2Q=.?Y
M@N4*9TO:LD!L7L'H6&M&V$_,;+3OH^LTS-4O36%-8KT,=>I@8FWE^@P<VL&,
M.!'/?'.&8,O1M'%D8P76*=VGMV]\!7F%@@`?1!?J;RD5`Z=-LJO=XW6!TV4@
MNG-^6F=Q`K.,5>*L@F1S#U_R3TBQ#D6+G/ZE3VJ4G=S:5;)F@>E!,!<;<Y3]
M='=U:<*'#93YSNWP*#KX$#.^P<2H32]WZ*!BUC^_E:#=+O@E&U#PZ;DY9+1[
M$_IQP>KJ\MO?*W>85YS]D^3L^1,$@K_I.#'F2Z'Z^\SD]^'%CY0M^)TR!HSS
M2#>XQ8\)F:Z']-3PCMUHC3FZ%,V:D"L1=Y'T7"Z#=$--3Q(!-(2,2;O#ZX&)
MS?3J/7#"VWJ`&M_7YNECD(@+',@4/2."1$4$NB$O6LQRY@N10PU0>2.>T4AL
MB:$1X%9X6[4'62)0$:EH15\*14-R*1;8RN7)?,"N(6$GH#F>JLJ[4)\"1)>-
M=T\0YMN-!L/12XNN62C48&%_)!,<`6/)YATXF;J,P@A,/$2C>P)<,9+)6ZY5
M`"7>XP]H95Y<DL)DG.JF,RQEWT#252Z]@H47`X420$W;-*U:<QS6FP0PBN,]
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M7O<(PB+SU%#`1X<Q^:;>;:@:>P@[#U)ZJH:>9&("F0Q.[32,T&HC9Q65@@D]
M126@\&.8Z`4$JVK*<6BO,S>*X1U$K-B.PZA,3U=>X2RCI[6$!>'N%DQ3FE%G
M*.[1FH](=+BQ>@AM*2)D)=GSA;Q;1P+VEXQ,L\ZS/%Z2R97>C,6$JGZ)D18#
M)Y6%O):=74@@;033)?>:=_Z`A1S3E1B:@8O-=;P70%:W-P6*-W44OW`42R%,
MZ\8F>$$DO]N\]FXS\6YSZ=TFJ".#C]27;N$*IV5ISX;_O]D"28V@V91:A;:+
MVQ@>I[[:1`\F;*0RWR%!%31`R9)7AFV*?TRPP\/6R+P[R6V<?3U-813G])->
M5KR#C.FYEC:*3HXB;9FQ22EC!BBWB4\;]:*#-73F)Q*H"01*O@L&M8FI5(Y)
MB=!,_!?")<V#.*%GQ(U'C"'4]><W1HR<3%CE^M:4BL(GJ[(P8,7DF&[".@QT
M/%SG>P6P'`>9T[%YJ\S<=-(ZX4L5PZUDK4P$/G&M6.O4`W!SFR3S.:PB09L]
MG5R;9=D!J-[1:>IV+^K`]???LC:K'1$D).'3W'%K(J]JO9EP@&.ITS1M8:I$
MWDG?V>UEF"7;`W`-I[T14Q=#;*K,/<`+U:!JN/=R,F>[7*Z".*4BS-.S.%OA
M+$#SQ15.'J_B9QC-L@P.&M',Z)O=Q&C`RKY#;J6@:U'*_9"Q!YS_I+=G#L$:
MVU#TGN&*=B"=IZ`0@76B(4(`&=[)_+BL;Y9.6DEM=KA8.HZK2'!8,787;:?U
M\5@^KB>Q]J)67@G"IIKY?G7Z#A?:06K>@I3P-+/4TDT*0_(KLKA$=_DZH@4R
MI^+O^Y0PFH5AN@Z0R<`WC+Y^]L&0E9,$DR0+R*@PO/5K\55.Y0&!$&BZ'--0
M]+$-U>\9TM4UQQ9FMK(O_F!B@$(.T]33I.^)=E^1"<&7R,TO.MF@?PLS2(R>
M9@S.:$\\S-82YR^T-A;J#_E*Y(Q&$`7*#A*B@BFS48GME&.\#F+80']^HX-J
MP,RJP`#!4FUHM[3^34*\A/?!RY`U;BL-L_5."SD':U7&">3!R[0G@WI!P*K:
M\5#AJ*)KPF7">H'F4Q-#-BQ429H>PU*A[J#PAA:T'O)J]5`28N+C<UKH84,]
M^H]467/0>BYJ2@]+X1.1*GZ&W.,'U[6ITS1&3H6\DX.J6\ZLN'QJ]]*"#IOJ
M<`]@0DT(B1%LXCWW>J7]`,_J)67E*(!S/]JOHQD*[J2D07^Q$<[3<%AC*I^Y
MAM^D'HHI3C`M^I*2MP.<2)^VX6V">FQ<I!-HA6.E,61%C&FOC30$&`_5\!Z!
MB8IP^:T=Q*E'M[OP"49K1(^&+%<(;R"\@^ES3/O&%>=WY6GO##'G9`T6Z9T;
MCTG\)XSX57EL)FQVDL*=$&:E_J[D<;!P%*+*!X?$K?9B.5E9M8B$UZ0'/)Q;
M'!X-R==H7:AF6/34EI`3"$$KA^LK]K45ECZW%;>X39.OEL?O)`,7,$U%BN"4
M7PS#M)A">EW,+(GF^1-,>4G%P)Y/PWF9=9,9R-;)KAV[BT?$'%[\SX0`IVLB
M*IW;3%ZB9,TRL&TH]M@*1`@IA!%>+XD#"MN8E28ARIFF[#>U#<QLHQ5&5^(V
M/=H`GMXV-G!RTT]UX'C2Q\"^CPN.0&+IQ]Q"&<'&R8*:(O<"K8;AO`$TP%A/
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M)!*1M_`CXE@WQ.:5CU6<7Y71-:VD)`$;#>VB;FC-<6]X4[WJ9<)7<0(O<[C,
M5*).]_,&QP::2;DY`,)X$??ES"8\XM&C?ZRBG-:6HDJ@LZ'2$'#Q[%"P&9G_
M3D!7==X,LJ04C_1;R=2OJS>$_\[X-/;IG51FI"6NHUO]'C(2\LF$XRZ@0Q3;
M:9V]Q$J15H&(X;5O+?0<S+8"OM<\>9E7/Q!864$^*KV8;91<`%/]7*@>_$Y9
MC63SV_>[#I;DXWT:)%D0TLA\AI=!G&@9OP(U,T!Z";]F=U#'".NKS&L\D`1%
MZ1Z4(_U+X@E^YUP-9]AD>H^3B#AB,>Y\ALL'F*J8?O?S!@W@FDFYZ>%7\/)@
M[M4'`5;1CV?JKK;?+72]G=MP7L9S,:>R(V=B.UU#=DY]*2_`F/DI?-L<N$/N
MCDE!!L.WC_CY701C/A\@'^K3`/+5'^=)'N<;>B`C76'>=/4LR$E,KWRE$@MU
MJ&FYJCIA!SW=UQE1?Y:!N.0#(Q"1_Y\B5AH`AO7UYS4XPDLX2U!A`"A3.C6H
M?#O.1)I.32ZS;`VCLS5U6UX5R3/.U_`;^U=Z*TE%BF83."7B+H?!537K`S*>
MFR<3[I"?-LK89"]F,DXZ_=9#%ILIV7L4BPD!0X7S!)QI40`L=E?HF0C.V&"0
M+=[L)L4AA%%&D^R4&+UTGEW51RR#B6#GI9YA^H#E_I>,*=]#B@7;79,D'W9F
MS@<@@:Q+7_E82"LCS=8CO^'T*Z$IJBJ5ER'UQ_2GPU4*3A8=@@4(.8_I5APM
M2L8=JM!-XDMMIZ4S2O0X4`PS_8T<57*#VHYW4';>2#[8'J5:">9>=(]7`:^A
M77RO*JW:D]X>D0HIRW;D;@=I/VVH>8-)587^@E.9[TG(R`<E!=>AVU%CO1(:
M]#9N^K41S4#=W2GI(;/N7L7S#HY$4]*3ME/;42AN?7$?E(<DO8VY9<08JB?(
M&Q\SUY^K_*P?YK>;]&Y]>3]46#7"ELRP$S/\'"?Q<KW4-\3:@T9ZK-"P;XR"
M?&>J?2R[;-8S[M2%+SI%:NIT8Y_!BZ%]5A\TTZ5,PX%]<O)^V&>CGG&G+GS1
M*5)7IV^K>*U)?L<&EH_OICK;M_!:+A)N,C2U;)M/8J*JA*?-$KKI8;6F?C9?
MS%>0;A$EC^(Z5JVU5`<1LT9&;?0<='ECK&BV&A?,0#;]_<#]L&!E=?D(`:IH
M?[X`)1]0,#+;+VB^Z4T,*Y?),\SR)?\FI\<8-GS#1CE7:$I>/T5EQLE)3K&\
M:S"D'Z!TE]U2#-?Q5A[R'1>(]DTD$DV7<1QH"M@"$/L%>^/]D@V85_`U'4>G
M?%$DO6/C'8W%-%22`Q2"B#W>:>]L_)+!Q1I=Q0NE;0XM<G9O_MM2=GQ)(RSO
M_(-E@[@U8PY0_#QMPQ8=&%5N;*PKU6_(4`VMIGL:.4]`F8Y]/V/]RKM_ARBZ
MP"F12,>U%`D.O:FOG;;+*Q=9+1*B=RXB=BE?,'E#,SW\FB]9[-.E[UBA.DS-
M5R=2MH#PI3XV3BOQQ0*&>=E/_3YXN271F'9)3,(8Q6Q22;Z\@WF.H/9:TX2Z
M65-K;48.1CB8TN[(P2,$"X)@_@1!L*39%^J0#S"!BS@'*13MYM8KG(`UXJ,?
M6<46@DW:I]S<&/!P+/8*>.'/)7L@W6U#)0!5$=CWDA#[V4A9M5+'L0!^M+AU
M5'CBM,=M:]'*WG9:KM<BC0#W:S,_-)GE.;S-[BXG09B&VBLAGF[)42>9`5>L
M-5)T=JU=R0T4[*:_XZX;FIUK[CH4YB<,J`>!,8N>6EY6_XA\#R&;2+@Z&+]/
M+M%^/EY!:;Z"T>\8:J?A+=4#=MWX:E`GJ$+._M6TSNH*Y8N#(^E^6A]J9W2@
M4[U!>'B-XE@PH1I";3<(CUHV]@^8P#1`1)99M(R3.,OI#O$S-/8G18)&4"G1
MMN]3@BUSJ:#"V`NOTH,0&ZG3=[A0%2GJ6E6>TWB7G37CE<[)/6>LS=)\=J6P
M[]O65\Q7W45ZHZ6$'5D>=HSMZ[$R-+Z!.8EA0BP8-:M5Q%6=T*1*T<@6U(B[
MNG;]8>?:=0"GOR=/$T)LIDWOX1(>6;)L=\66NPT=E1^Q^ZL$R^JU6K,'.G\)
M<[WZ(Q5ZAM4L_:0ME[-4[GW;O>/K]X+MI(.M%H381)^M)_==V*"X4L_<Z$H"
M%JQ,T')RIV!('HQ#L;(K_O#'D.HXM%I.14>^Z;S%E06/44(L<ZO!-MY%Q4CI
M[03M6SOC-:5I*V"`U57CI;Z1I&J@:.^61E^[=H/S``F[N<?]AZ3:KA38!EA:
M@RX^WJ=Q@++="PLU''((=8.V^2:,W%Q<T#)B@9P)0UO1L,L8D70;6LCEF?"2
M@T%6@(>#X'KJ%&QHC02])8\)0@4RF;5WD3$;TMLIVAW8!1^>=!6<?)F8*X"#
M-53FV):*7-$M1'1]:A8=-8@-2K:UTG4P50\VY#L>]%+.UH?<:C],#=G2'K7Y
M#$D]HRG856[?-)_F3#W8FJX-/7\MM/M&[#1>\0<7HO$BYS&7:(+_38H7,,O(
M="=`%]`H[O51,DM3=A)U<NJN9`0ROG,PZ5D@17RPGLJ\Q:)(%0NOJ,!!F8V?
MOABT8E*E9+ZL'C$X^Y'*4%J[Z*C(6]U7TAH:XX2^2SNS'LV$AAVWU;U&G?S@
M&B?I[JWJ.AYND:F105KC;S]NF%X=3W\ERRCNDO?@5(Y]"\/.D'P-UH3&-"2W
M,>G3AHE^BH(LTSUBTT%D&,IU>O9C`*,/&`,O'+<5AB9';%:/CRK?=91/&R#I
M?LRC-+48TA`UF!M^2?`#76A17[Q,5NN\>A!8UI/^*1QW,M@(J];$>?W^ZLJ&
MVL==R^"\0GMI'96;1V$^Z,JR`B9L_>1_/6*-><;I,T[@YG.0?H7YQ3J),H.N
MOBT4S%K1-A)ST.>7\@%+Q@@L*"<O#ECTH('5%.6=YI&L=,X#7'0JW?64M/SX
M[S%,Z1FIS14]'S5@?MI)<>C,J8.XR]7K`2CY>3$FJN'6/*'M5:'W&#5.=:6_
M2KZ`,9YDYBL&0M;!9E<A`Z:S:H2'8:C"PVFRR"]OT\*RR>G4];DON.VZH,R[
MV1E'G<Z5K\\FFAD+!,?Z<[I.,L/`VJ5HWZ5X_#OV8DJG@DB3\[3IR4_M[SH&
MY\2'HG8D1G."]W:<X+UU)WCOU@G>>^L$=41ZG."]$R>PJOUN)VA'8C0G.+'C
M!"?6G>#$K1.<>.L$=41ZG.#$B1-8U7ZW$[0CX7K%+TW4+E+XSS5,PLV`Y7X[
MN:'KR#;*#I)@6TZ@9.6%ARC`U;S*[U:>W]`TKN\;,9IZ:5\*8F=!OT/.VG*P
M1MEMKLQ?=U*`KF?]WJA(OV'J7*O+OC3)^ES.&Y0[1@.F9YWT[*57:J1==)4K
M=L^\FK*IP-67`FO4G>?0]"2\^M'RMM[QRJ35E67&DU6J7;EK<V6[9.W*CRY7
M;DS.<A'DE84.5QZ:5VO9A3/+<G/PB`E=ZO<LSD*$J;PZ$:B#B-D1ES9ZCBJL
ML@.PH#@^4VZ3'C/J10,K:\E'S2-9Z?+.U):16;.%60J#^>(BH/5+^>:*N)R2
M`;<_J]\HH8&,DS8(E`^]FF<A.`%$64W7X:!+];A/-ZTGREMP+J]P933F#RA^
M9&JYANJM,SIIZ./>0<X)_MM;;!GP`)<<00(G['2A`@U6U9GC3@.,K5&CBOJ3
M1E&V2L1J:.6D/>D_T:)FW*T)U]CC+#O%[')YF-";Y;4/F;51,+.%1F(.-IT(
M'U!AY,,1KAXPL)J>O%,\TM6YFXO4BJLJ_@'Q8QJLGE@#!LWMI0XB9C=*M=%S
MT;A^RV'2V\-Z<<#*^O%1Y\+:MS>CR&S&W!:Z@X_UM]3?#.H@8J;\-GJOV.![
M<<#*^O%1YX7!<RXU<U?;N6E9WWR&"<(W0?KU-$#Q`J=)'*COO_11T%_;M!)S
MLK)AW,"*L`-;?M,M:/JQP&IJ\D[OU7H+JG3*ZT#2>N=&EP=O@.K"J\@^SG+"
M:`^GBXJ=V:W#W96F::XG.R0*Z'2M,6SL7;A&HF.MT0/"I%G-2DNC,J5536J"
M@'#W3O(BB4WSL/,%*#@`QF*<F`.S#$+*C^YUI2E1!-_[KN;5LGN8+N<+:A3Z
M:2XS#H;I,!-F(YHA^=%RVCS:(+RQ'57O';9E2I2*`(0,0!8";"$7B5,J!_7J
M0A+3Z.-\5T`V7-;42]X(6"<13+GQ>OL"J.YTC!'8<@*$U3AI@_*2\Y:KLR2+
M^;39_N8FV-#O9M^"--).(EMD.O!F]X'\'=PE)5WIWGY=F.S&GS:5'PH9`1/2
MAS2W?0O#SI!\#=:$QC0DMU=GTGO5YM\2XAY/\>J&('%^-[_9EDL0;=(O=;/Z
M1N2'74ZHSLGE-9=4"E"*`2A+\!V5Y'MP'2PG+?X9`GG3O92Z"M\O>)$*LN?@
M#LS!C51>Q%R<_;L1]R6ZE43_J;]-H4[3`:Y;\M/XZ@'[PU]G;8!4V4/KNMT#
M^+1\D3O?H%V2^V_X_@FOLR")KN-$O.2*CN:4N.:&B1HQ_1R^"ETGVRB$,<@%
M9Y#0%&#&\,",.5@1[M-MJFA!A[55Z3-,<I`CW_XL/&'@1LMX\@LOI^95<`24
M9>'NW+PZ7TK-O6OO(+WA!1$ZAU#7Q=4)ZMN/*FTGKGY7=VR0R\Z_$!),Y^[:
M4&(CM?H.6]7UCW^PX_KCOD-9Y5-W]DI`*#@/#`&5^<L-$?6)K,<-!O=>.OJ6
MTT/2B9^7,RL^DJ\$UXG'<E60L([F/`6D8X52L+3CU*.\3?.$7>U%W*3@^[*&
M;4G#W?U\E=R[!6YF:=+!C!UDVQ42HSUYT9XZ@]&R[/:,"-O';*\-!HUA*WY%
MENLU#7]B0R.;/0<QHNG_"YS^@SRK54WA3H9QC:I''/NQB<BW)-;%9SV$&$R?
M(5W6I&"QSM?$Q.(L6P<D,.QEV%&U,!O!2`FZ5VA-U@(7E[;<2<Q`*3!9\Z2`
MB>QW0+N!1'=D2?$(YXOY.L]RLEZ+DT<V]_L<O,3+]7*4H*8DQ[BFJ""2@TM.
M2Z;T.'<HASH:UH@%T@4UWHH#XB1,>5UDDJP#A"9MY#6*'=H(?<K@OE*;LQ8"
M)8,E85"26:P?A=1^1T&>N<HDZ7ED'R7TM3,?U_;:Y+`?Y,2P60]P&1]#L_7#
M?\$P!SFNQ+F`RCCIC5?NS,M&1.N&[S69DK78)<2L1"TNZ"CABB]D6)@\#59Q
M'B`^B[P5:QHRA;Q@*YI+L:#1"4<&Q(UL1)N/RW`B(DBQ*)PR6)B#BP<K=Y^`
M1)5%/9\S"/[%HJJ0@*VIN`S@LF6-[]>\HEC-SJ(HIH\4.IVM\R><QG_":-2,
M49<8TRSSVR5RT-6MY%7$";ZBVLLIA89EV<P4]>'U.JW(0;Y(,L8B=50*;;!+
M6*CR&N:7"9E40WKRLTQ&W6,IN#]A%!&OH*TE0P=C,<P!HJ=.@SQ/XX=USI)A
M9"HOS_2%".`0/%`I6$HCBM$ZWWUW)_'\-Q@_/A%FLV>8DH5K->=XR8("4X].
M<%:G:>0CJN0M(4K/C@E$"\Z'`6==!$]I;39E!-7&$ILJ=0]P0U7(@."ZFZ?F
MG%E_V7!`N.EZ.VE1Q=C,DNB,^[B==R4L'W`9=]JL=$V#,`\_*\)[-^#0_H@\
M8JV(AMA3`Q1R'J0)>>'L!J;%D&7_S>5X^ZG[?8JHV_1:CH]-SI(\9C+%S_".
M=C1FG8_/7T*TCLAJ@CCQ*<.$#:'S15US`\Y.VN$\\,B;#2'<GJ*4)01;$4$A
M(Z!"`DE*^E`A)\W[BHF.5T<IK5I=XWE*>\"^&@M#HQN7F[;GPQ3Z:=-,0/<8
MIE,QS!J`NY/(P3*_V?(F[>`^@F'A$>%ZG4:$.NU'.W)]VK0&P1%/F38KC9YJ
MUC]=VD_+HF%LR8X6(@XF/^VMC%:OM]?5YS$R/7Y'V0T\&BKV^>YQ4<PNI<,T
MSXZHD#*Y+J"/JJ-;`_C^)UD?EZ='Y#S=E/<&*".&-77H+SK5MF/=T`P^4C+6
M2Z'J^]SC[8F2RI[?J"=+;F&6IW&8PX@Q_Y+$>79[]T7_5L,>0D91MY.FBWL,
M"W;"LM:4H1>7&JK!A+54YRLD:`<-[A>,%[@%=^#+N#XR<+Y^97(&RQ[/*98H
M5^[.8_4N2A;U10EN3J=<^7$JR[IQV5O^7EDXH>67(5E>V(Y_'>$P;<Z6>*UW
M-,L2PRE,A_-V<"X!YV3=$-/S!:`THFQK1+`2B,)J("JVIOS:.;9K5O8"D`SA
MOIN0Y=##19.-1GPF(>DK^9O\13X\D,4%^>/_`U!+`P04````"``U@JM&;>6J
M(\P<```%[@$`%0`<`'9S87(M,C`Q-3`S,S%?<')E+GAM;%54"0`#90Y1564.
M455U>`L``00E#@``!#D!``#M75MOXSJ2?E]@_X,G`RQF,$CB7/N"TSMPXN1,
ML.DX2-+3LT\-1:)C;<NB1Y=T?'[]DI0L2K8N+$JD',D'C1/'D8K%C\5BL5BL
M^NWO;W-G\(H\W\;NE[VC@^'>`+DFMFSWY<M>Z.\;OFG;>P,_,%S+<+"+ONPM
MD;_W]__^S__X[4_[^X.'A_%@9`;V*QK;ONE@/_307QZ__G7PKXN'V\&M[?Y\
M-GPT&&,SG",W&.P/9D&P^'QX^.O7KX.I[1JN:1O.@>=9!R:>'P[V]U>4+SUD
M!(2KP=@(T(#]]WEP/#PZVQ^2?^=/1Q\_'Y]\/OYT\.%\>/SA[,/?AL//PV&*
MP#^C7@U2_Q$"!\.#LX/T8_>&^=-X08.;<>JQL_'IV7!T?GYR-;PZ&I\?GYV,
M+T_&HP]'1^>GQR?GY_O#(>'DZ.3CT<=]^FEXFN8<+Y:>_3(+!G\Q_\I8'CP<
MT']C[+K(<=!R\%^#1^SZY,GYPG"7!X.1XPP>Z"O^X`'YR'M%UD%,T5EA2$;*
M];_LI?![>_:<`^R]'!X/AR>'JP?WHB<_T]\!C[]M//_KA#U]].G3IT/VU^11
MW\Y[D)`].OS7U]M'<X;FQK[M4JDQ:0.^_=EG7]YBDPVJ`%^#PB?H;_NKQ_;I
M5_M'Q_LG1P=OOK5'(!L,?O.P@Q[0=$!_?GNXR31'I=WP`MMG$D>'9WAR<G1(
M'SU\0O.%0^3M-NHM;>3SS$/3+WNOY)W]U<.TI3_G/1LL%V2&^#;Y"^GWH30S
M@?&&73Q?1ERM9L_JY\BUKMS`#I8W[A1[<X9H%;</A-`/"*'<KBP\(IUNP!ZD
M_<X\B]X"Y%K(6E&@O"OJ+..&\.-@,]/ON#$F+SXR#U[PZZ&%;-K6*?U`,3G=
M'Q[%TO)G\M6/B#J9BG/L/@;8_/DX,T@W)V'`M![1A%E('"K#V%M]Z1C/R/FR
M)TKIL'G6KVT'>9=$$E^PMX3QNO9JH\Q=AIY'QN^:K`N&\[_(\*Y<B^IR40Z+
MWU>`X25IR3.<&R*_;_^#@"ANO*R`P0?T8OND%3>X,^;"&.:_VRA[3YY!)?MQ
M.7_&CBA?:R\URM!*<42"<X\\&UO7Y#M?E+D2`@H9I1)>@\W4ZTJ8C&``3N&"
MEQME<$0:L!@.CB&LJ==>4H+8$^$!"E3T3B$[F\LZ_>9'V5(Y>J8SWPQ$.`$0
M2UA,6P0CS\RT8GCFJ@7R<<,<R%IU\1.'"X-J_7US9CN))3'U\!S$7LP%SD,7
M>Q;RR%Z'6*O#@R'9\"R(<'J$TI>]X[U!Z!,F\8*2,QSZ-S1%9!VR;B.("MEG
MO`?$P$'LR7>&T-I\X!!]V$&$2W59`M71R0XJ7+$R<;`^[<#*!2MC;21P'9_M
MX,*YEF,"T<E.F:\@RC?Z.5([G9Y%:F/[ED!UNM/I*ZB*=^,<K9U2SPK6FG<E
M`>ILI\[79F"IRRS![5R#CO_M<-W'V9`3]Y%01!2>2TP4C>LCBWSPL6-;Y'OK
MPG"HK_QQAE#@?W.-T+(#[DDM=>K6(=R6DU>*9Y%-^M3PG]D8A_[^BV$LHITZ
M<@)_]<WZECW^^L>M;3S;CAW8R"<"S&1QAATB>?[5OT,B;"(;:'%:0AX'^<[4
M8[\%AA]08-@NLJX,SR63WA^91)>$]'C%&J.I;=I"#@P(-<4=&EE$:)E.NC=L
MZ\:]-!9V8`@Y2"M)*&8]I8W_:3BAD!.K^%W%S-ZO]+T<O[FO:Y^<$">="!4-
M`F('5'U3]48T=T`F&7)-HNZ@LE)(1G$74AI:4K'K9#$VOB4Y3=Y6K?),TPN)
MX56+[Q(BZMG'(9'%>V-I/#M(CO=<"MH%14:?E%'1UX%<<ZEF=RIHJA8KWR=6
M+$B,XC>4KYQX@;Q@>4^,;;9G([@LJ#:^0R"DR^DH[L0DF"$O`NP.NR9\SA80
MT"(4,BHF^Z)ZXVI!3,^KMP7=HY&Q3:$EP;P0.=6VB^'/J+5!?E!!?34<9G\$
MEX;G+8G]`;=XQ0CJ%"@9?5E`0`O;\OQJ8S1Q6$RFUZNHU7OLV]`C=AB]-EQY
M4CW&Q0/#S_S.N^;UK)#B#5`V9A<_X#OM-C9%B@F#]2@_QCKN/61"ZRD_GAGV
M'K!":#XV#@T.#&=KH"G#I,``YH=5/5;;Y5L;?B[5<>U=/:528'QH7B]OR5R2
MM8C$71$)B!\[JZO!OIY\((M-J8_-Z_+M@TYDK2MP1B9`?>JL8@<#5>1Q7F%%
MC:<=5@6G"@E(1YW5_`TIK116Q\TK^`Y@57HBR+'K@X8'8R=B5QR==%;GP\#*
M/?9/4#KMK+:'3\=L,$<"T5EGO2\PB`IC=!*DSCMKRL.0$HG)XJ!U5L775>HI
MD#XTK\P[8$-4QUXF`'YL7L]O`+A5\<3W#/D9"FR3AR(V'ER<V\I[BC3.=D!;
ML*54W@DQ.OHB1J/&;WP_7(\R!_*_(J&;]5$8S(@V^*,F^VDR^KI`)'?B,9&W
MF,5VCSS&CF17BLEIC>JM-3$J2;70%?CT**/20@?D)DD5):T=:6*JB%+<!:=L
MR5&,Z(!U.$=$LQ!N3F(.7>>N@ZJ`;J7$>9A4YZYGJX`M_X)H]_(DU,5.R)CC
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M1*OV83P7T5`M,-GAA4IW[NNZ6(X'6(YA_K)B=G]'+FG28?IJ;KLLQ1PM_R`A
MV96DE.><\1&QZNFMHS%Z10YFH?T2':D@I%N`9%R^)43T.:^C6;=NI\;?UO-C
MBY'>DETC"`<L-(C<O=C9<*3J>8"%IRR'J[.!2""X*E4U=\%V-L(4!%C.PLR]
MK!K"CMZ_#DN;8-QIV-DK!@U`5VQU<]]A9[5_(_BM[;14W(']%,'FHA?JJ>L&
M<%6;:WY1=B=^Q2BNN58X:)V]G-Z4Z`GZU/@5Y=UT%A9$$6\LOWN[6YZ+8:WT
MW_.;N8VKR5?D/>.N*$K9HQZ.KX9-W1:<H-)4.M<._J7LL+2X@>T_%\WA'5AU
MZ\:U`WJR'SX[MCF9$FDA0G>)?;%#H4H2RH/&W;CL+YDY5*6/YC1=0/0U0>,(
M%C)>24QQ=ZX-VV-135^106L0TU'^;@>S;RY^IO5TZ0IVXRZ(=GA`)G9-V[&9
M')+?0L^+M85_XQ*MPVH8^)>.X?OVU$;6C<LT2^82T9-GN#X9+AJB,9G>4@_2
M"02PK6!70Z9%.L-H5B'R,=J=$M:)2H[#8LAG6CJ:W=7BY:-E/+WUV^IDVLD?
MCCUTCCO:N9:Z%57H(E:*1Z8N&J/H9_W>%=%5'PE`&;GW,-TU61?+;S[5(3FS
M)DK'$)+O>$P1,'2@5DOJTR&;"%G^-3%7V1HV8;:@?_6&/-/VH3==*HEI[,YW
M,FT,>KH1-0X:M7(Z&CM!`TCI74UBND5FA4W6R.S.7[9?0J1;ZFJRY6ZB<REB
M+70GU]JMVZT"HENC-66L&1GJ[728&UJJEPGAEI2'1V47:&)N4YN<&-ECM*!!
MWJ#.BE!3/5.-)=M!/.&12:P1#Q4FO01-50#5K1;=!N<ON,5V@$E.8)7/:>&6
MM,_IS9R`J^S*"<^2%83JM]4&&.E,DK5[FR6FO3MQUNQQ;-[E9L^NUT>Q%K1W
M/!&G.$F5C&J#4-7E\N.'?)-IO$4!#6`%H<)N%/B%']"<._6HH]EQHMT?$8#L
MIF(UK86*,\K35AW`&1]F(7:.0R2=:6U0G&8!!<6,$Q/+0V;D6"6?'10#.9IC
ML@7\`]P-,7K*ZTXF)]Y/>.4\1IDCW2<LN!A+U651TO[N.DQ],ZI!2Q;<HJX8
M\EO;13?D(V@0\]Z&*OU"QU$F;.(KHD?5PMH>1K0QEN.E+UE!FN*ZB&YCC//E
ML''>2TCK,G-2FX#XU-":K!T(;AP?9D\/+Y8)\^R\<(SGA@U:XC0PHPO.]?9'
M;[:<U9A/2)?&>X)NR=;?U'>])PFYJ'F7)X?.ED0T%?<0%P\`OSK1_>C8K+1B
MX=G$,>ILIA4QQ90'F3I=S&'O;&(@?<LKKF%C]"##U18-1)&ARD>ALSG:MF@4
M<C<Y?`BZGSZJ<+',V[#RVX6=72%+=OFX>9=%#PJ--NQ/$KC+U-T:I.JP5.-1
MY4/2V6(W2EWA&.KWYY=).ZM/=`%>=%[4@WNFJB&6/V54<5]UZVY7ZI+PBB-I
M?I-UI[QK(@T):.A!>5Z)J)%2,,5"8504[]TZW=$TM!N15#VH[*L`0U#L70\*
M`BO=%-:*`NU!H>%:+@YP?+'*:L3;+<VRP=_IJA2`"'<5I8NW;GU3![7(+8D>
ME#A6!W#=.S>\<G)GRYK7TLRE-[<X>)W--5GCNERF#I#P]3]>I[IQ;;`]J734
MH;IV5Y279>ZLZU(MEH67BGM0\+IY9#>OH?.2V'W;EM6`L2`O`:^.W;=-`1#+
MNODL.-#=3_!8:C3!\J$DL"GP<G4`MHTD.2N\CIMW62W8$!%NO:!;J*WR)B78
M-9\U/\+NRMV&G;LX<O5R;'$X.[M';RSI6=YA8)O)XI*Q.^ZLB:5B[`0R(R;(
M=M=SU22RE8DS$SP5%`O0E^:5@W"-O;D11U]<A#Y1T;[/-N@+PTUNCI=F=`72
M:BMYJRB;P.N"I<2>".L7CF!Z+1`YU?>\H]-?(O;WF,P!V=O:)51:C?ZH[AT&
MC@>O2Z\A0%J#6G@,YW/#6Y)EQ7YQR6)NTE.G#=B`^@%&M'U%(<BOXBN.96V#
M%`R4XD['*-<QT"'IFIJY,!SJQ7Z<(110I8I=E$JO(ZA6RHFTKT8*^%.L-L(%
MZ3#=D!E.F@'.EJ3R`-%579S2>S'<.`:>I^)/0HF3(9Y,XXV`X?`L_5*%+)MI
ML-5"<XUBAF4EHVN:+,^-`E5DI33:UV/Y[&E*J%%7;U40TI47)-6ZC/XII[,5
M5WO+>ICG=NR'>J`1#W9TX8"5)&(&'G(E-E$"E-I7%65,JJX\4]@R9T]*@T`I
M*R^Q(\".5+43&.%6/;]2&&#Y,>V:6HK.9&Z(J>;2@LLTN!BJC\I(M*^(<KG3
MD+$T<^9%1(M?*DTBNZ5V7V#:JK.<)DA'7M'5==D'Y-#`<79HPOA[3O,GHY;J
MMM2FGFH(I?5+RB!!Z)KJND,!O::YJG>96\U$4(6)D&I?E95RJ7:6KQ<7E=)=
M)404*ZGUEF743S&--A5+9<]**L1V6#>('=PH/<5ZKZ=9FDZU[M"O5-L>83@D
M-AI;LQ@'R^C_4HH&3ENS_JG1MTI2ZG>=B[5BRK7'2YRFAL[EF68U^R9$4GV]
M#@+KD_%6HR_%-!0S_T"T)%D3:63MF`8,8G;Q-<[V$#$#Z8<0.6C:\'L/F>0I
MHE6=QR"TJ#E^&?_^Y-F&PW(!&(Z,+-6CK\NSG3HO2@6#PD='D*#J^3)?$#Y8
M9AR/+*$+[!O.9'J+:<:&5V1%J47JS"4I^NK+*N;?,:_147&:[=3;K:':Q0A"
M%4G*.GNP_9_4+_F-F"]>8-ANL#+09);;.M35EXNG#KKH\A+EZY)L+VS&(6RQ
M+2&C.A,]>J%2_8`6-"U?;$_7L8H$"4+%BT7K3Z;IDWXJ`SY1MU=^8,^)A0)S
M3<I0W466Z8E>!0Z+5C?`-H,'G(,<M\XFLH?A5JJ(.5J=S38/F**2"S('L;/)
MXH$B)V:-<=PZF^$=AINX?9Y`=[1;'6KLX3B,N\4"LN'GN.V6C1KN(`[C;N$0
M]P9RU';+1H4ON`?%M*#&L.`10`_J8<&1$SL8ZD$%*QATE>>$/:@V!4,,?FJL
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M\NK-=$+289J0GFYGPM42W<B%-A6MJXY2Y'O_-1[H;#7I&1CM!K*:4/C`)G:7
M`#5<`I0>G1Y8^'(X-C?W.V?<E^5.'5F6'?7EQIVN'ARCP+`=J.5?LYGVUU'I
M'BB_#E)5NTE<=0H04[WVT59HT\@:A]1`C7S8;!;Z=^@7^Y,/6NH$*0IUS$?F
MP0M^/;20'?6)?%CO"OGJQQ71-RRC"?86.(JP'1L!P3+SE4@W(-3`U^$RN=-O
M-RH_5%YW*WH??)V&%BVPV"E>1.LKFC\C3YB1PO=52ZM!%Q<F87?&G'QDA1/(
M:D1'",\-6VB((=14=RA\]LE"29!,,3-ZLV$SKIA(/0E]BHI<2TEG_.[.8]Y]
MCWGQZ'/CK7-5#"NG"Q::H#VX)5.MXS!,)_?@K@Q@H<-5:W*';\6(3,)RRZG#
M]S>$3$X,LW@Y7'U0Z+EP0?<Y'8Z2AT(&J'NL(-P[KXKTU@20-N?Y::R]]EU`
M];NBV'M.A)Z64$/)Q8\'HC2S%0')EX\H")R\O/45?G4)ZOH2P*Q?Z?L'<JQK
M['WSA3:,0()MI7@AC4]#Y]:>@CHE1`ZZ,\^_ROO5>+/GX3RJ[C>/O@FHMWT9
MK4;"FW=9\HI'YBZD-NQD&A=Q=E_BY`.@B51"!#H*W['WDY8]C,+!A-%=?TUY
M:C!Z41Y9JV,5HC/#><@N68T14:,VR.4A0JU&/I]-A0YWC(J24XQ[/%W$G:D%
M+ZIFTW8EV<R^J%J*#?<%P9G,O*:#1:B[-O52H],&YJT5(;6[?Z(]W4GA6'3=
ME0H0;9P[EWK@2=U4-^M0;/K\.NLBS5L><.%:U6$GJ"@@61NCPSE_)/0)R(KD
M'KW.58^7,<XQ;*O0X5PKDNCE;A&[[C:6%[*2[3SW'N]F9DJV9)T["9PGG3.I
M:LJ@D(LO@>]TN(.O*$E<F=LW`?"LFX>S\@#*G`TD:)YKV$%NS<%:*K8_3NYK
ML:/&C90.<7(SA6=N]5AY+\=QDKU4[&J*\G4@*S^=1\P*R.TD2%'U!9Y&LI6`
M/.[*FE8,U>_()0:C0U;KD36W7=MGJ9A?43Q4<$^S(,$VZ\!(N,]%R&FIRY,$
MG=[&$@2/\*X@U$XWH.<%I63T78UL)BV2Z!F%8@9V!6"WX(1$00%8-=+2X;,7
M/1-](T=N@3;KP1F.R*)0#5>/0N'%C`'1W-4].@\"`R=HSW;XY$B[-FQ\#]7A
M^PRJM[P8OKG7>AVBM=2><<:[N-?^*O/=9>C1H8H3X,FXS9IJKGW76.V>J`YP
M3C.235T8<P,+<!8@I_KF+VTRRXA$3\JH*`\ZK\G[-K"='7N9#:P8O3;7&U"/
M<>7X]&"/(XM8V6SL@6'3C*`5J&.5\20X,)SM,%4VD\4V:)A4$=]6,Z20;^7A
MW6O-2BQR)41T&!B-]*&*DOHP>]KRO8>GR/?9#+]&=0:CD!(XVPROU[9>JBU'
M:`$,UZ&NZ<`V=G+7DRP!8JK-06/)<II2IU%<74_*"BPCT^J:+-"_''].R8#T
MP&4K"%J=6=J#@J%`T:M2SCTH00A$K&I=UEK*[%T@)@+62?,'*FWL+W*K$N25
MXETE>1\%O&;O6KYWN0RNRAAH?Y^BH&^*;6BVF<XI$P`RGXN)Z*K@(%BE@#QP
MAUTO@_/F@0FDY$,S#>N"*2V6"6_P6#HQ>BUTZMI#_PZ1:R[A(75"Y'1UZ6*9
MQP4TP$Z(G*XNW;B+,/!O:>#"20V)RR/30A>.F^G"<8M=.&JF"T<M3G>^YOS#
M1AZ-C6EHXI<0UJ<"-GE@@-?0`J4452=GP2Y:?C6\GRBX#EW+E\C24D!!KXU1
M5/OHFXN??>2]TFT'FQ[92TL72_;ZI6/X?@T9;9P'?>+,VZXAP>M$WH%]"0X-
M;[#170&UFGX$:`&U!L>N!\'9S4^OO*'8U!H]"%6H5KS%4MO@\M*#0P'E]@&N
M-H%Z$/6M2U>4VLA9Q7'<:9S%-B!Y((IMI#J<<KW>GC4/TKP--P?P=`<@`,#C
M30`[EU5'*8`GFP!^[#R`BI>=8@=M=LTY[33(`G[OB@5GPV7?@_``R$E(U7J]
M<8JCL'#%UN&G=(XW<U+(PQ&Z+\Z-'NJFHSV*SZLYO-VX^$9KT-A1$CP:A899
M1B.B%AJMS%*OD?:C-B3Y!P8%)VD=;XD(H\FS8[\P:G=(//2WE(9B9^\M(M,&
MT8;IG/,\FI67899ERG]"WISFO7#!;F#9%J#AV2,/&9/IM4&=+\&2T10>@=QW
M52./?3\CE5(A*V54H`A^1:Z#[PWOYZ7AV&1>N+8!K+1;0D%UZI\HJ^KO"+]X
MQF)&HW(E2NP6$U%>V#K.>Y!N&UQ9MYB(;ED&'X\545"N_JCJD3G=6G^S3=NJ
MH!>X&MX>'$=5R"86FC\].%NJ5D%82%/VX'"H>K'!U0MB#TYWQ*=>F1G3@\LS
M`K8@+C-5>W!H(`91W4U'#WS?`%DKW9AR%V(WG"HT*3XK*DU:L5\1S97?H#=%
MDGK[;A0HXVKM]53UY:AT]20,_,!P+2*D$.N]G([JS5Y^#C"NI2Z6_)$XD>CH
ME^%9JUHB'/^(^5$8S,C4^X./NM!V424;BB%,C5]<@R9B@693]%X1K<EP'09$
M?%>%NR6%0Y3XMDK,A&G@M'1'@Z=%3HH;WU:X[I%']9SQ@B;3%-M,%.("-%J0
M$^)C6T%<J8=8*;R258&:_636_$[>!3E9U/&PK>!).8&;:`WJ+$[R6E*9O`\]
M<T:(4^L`Z#*NI`.N.DL)1:J'DGGZA9]F./3)#+K&H1<@!.50G""4U12I.S(2
M:PT!V10CIJO`!VO]ETMLS9F]H`Q</4[NZ4^X5UZ<9JN=2]TEN&"5MJ#N>RGR
MVBHJ5.H8OTC)U*BB4+O17>6$+3B>4%DYH;:$].`$I/E)G)<3'**U>G"<4F>Q
M$(8WO?CUX-P%;%U@D&W4@Q,9:03%C>`>W`"11K%RL].#N&:EJU$3.^$>)%)K
MT#W1!/B5WAH>P-NYVL1;.B1"'DA>,KJS9MR6#4NQ2YV/Q4YK@<9"XK2'UZ;N
M;+C%ELF]R)%C,BH?=HN$[`S(.0SGL&JX3ZLASN,.!30$ABQPK+/,)95T?U4S
MG,(;!G%%+GKWR*3U^6PG#)"U1D`J'$0M$^U'C2CJGV+_ON&Y1.231M=8`OGR
MJT@I=DQ_1_;+C#0T(N-&;+B,@9V:W35Z*-M"BQWWZ0J.+,924UW-TE3<.3(I
MHC*9=&HDVZ0GG)I<,^P0=>V#^P@FK?JL;6T"R9R9%--HU7E4U3-<8U1Z<)H!
MP4]\YG+@FK=R-A+"OV_@RK2[PD!TPLDS?G<26&D(:(TXWQ;S^AX'-)S8<)PE
M`\)^18_TIC]+!G#U9CHAL46O">@9$S'&;&./HLX"5\GG.S'2E4"@N/P!X=<2
MYW5C.L]Q"*PTUDR#JBNKU>-RTX6@'IE;;<44'A#1X;9)99:*_S?7#OR'QV_P
M?-85A*`A@K'#]PFO3@M3<Q08("A"JA41O#/F"!X66$UKN^?3Q3*?`#1L4"D;
MVL(+:_:B1HQA,RWOML,:C.FF!ZT'NV5%,PQKTC\]"!34L8Q4#E=ZV>Q!(*&P
M'8(!ME,/P@<AN`D:Q!RU[L8M;+L.S@M^.^IL`&+C^^#F!F+E"=`:0YOK%/SM
MD/:-7L@@O_P_4$L#!!0````(`#6"JT8GJBC.-`L``!-B```1`!P`=G-A<BTR
M,#$U,#,S,2YX<V155`D``V4.455E#E%5=7@+``$$)0X```0Y`0``[5Q;;]LX
M%GY?8/\#UP^+%+N^Q4G:&,D,TC@9!$AKPW%GYJV@)3HF2E$>DDKB?[^'U,62
M)>OB2^/!JBA:R3Q7?D?G')*6KWY]<QAZ(4)2EU\WNJU.`Q%NN3;ES]<-3S:Q
MM"AM_/K+/_]Q]:]F$XW'`W1C*?I"!E1:S)6>("=/7SZ@/S^/']&3-2<.1@/7
M\AS"%6JBN5*+?KO]^OK:FE&.N44Q:PEAMRS7::-F,Y1[*PA68`(:8$60^=-'
MIYWN>;,#?R\FW4_]TU[_]++U\:)S^O'\XW\ZG7ZG$Q/PN^\"BOT!`:U.Z[P5
M)QMAZP=^)NAA$",['YR==VXN+GIWG;ONX.+TO#>X[0UN/G:[%V>GO8N+9J<#
MEG1[G[J?FOJJ<Q:WW%TL!7V>*W1B?3`FHW%+_QVXG!/&R!+]&SVY7`*EL\!\
MV4(WC*&Q9I%H3"01+\1N!1*E/X,`"I=]#A(\Y[H1F\2WJ6`M5SRW;27::KD@
M;2!J`A41U&H$?)2_$*DB/L,CB=5Z=E_:_E@;[.PU.]UFKQLR`=9:GHS89EA.
MC:IP1#.=)9FD6HAL/7I$,W23#"7\2?HBJ;5!`;4RY&L2>\UU+?ZTTSEO^X,Q
MAY\Q7F3ZJP<RW+4)S38&!C+(-0G-=A?LZ0$64L$C04)ZR_6X$LML%<%@!G*,
M\A\Y6O3P%,M(RUN*_K5GJ+N7EY=M,QJAA:DEL\TQ0QD`6)X0D$`V.1&,9DP6
M>;/FV4QZ)(/A16*1<$-G,2P4E2:YZ">QT]/D6"E!IYXB]ZYP!F2&/081XO&_
M/,SHC!(;4AXC.F$E"&+#"HMGHKYBA\@%MD@IK<;(K&D&4+KM/[\\^LFR`4\]
M0E?46;A"(?_Q?W0MDPQS0-5WS3!^FOJC9O<4)J?U)L%>GFGIIN!K[V!"&%Q;
MF;"*S*U,"!]HK?M\D];L#%!=WWI^TDHOM</=BU(.I_/;+C:X_.NN9L3+1BE3
MC(S,)-DF3,FH3#17C^HFD_)+R[ZLT9]4-":5]\O;LEX*]$4)[;EEI+KV>)4(
M;YJKDE'*BJQ*LX4E\50?W56=D<R"4=V8J(28JZI&I`I0=0-B;5=P7165C,:M
MNAFKJNU?-E<%O)01Z:I?W8:P<=,75?6O-WU;:`_[4G-56?]Z5QL8@#EWE=%J
M[O4GBP7E,S>XA0]TL>L+EY$))#Q$[>O&A#@+!LN=1]-QZ:%OXX<2O45;D[:3
MW-4ZP<BJT"Z;P.J,&OL[^@^LW&*+N%`5TKJNVNL<Z\(\2>PA_\5<+P0L<+@_
M-3'N@"2/T\+,\M@6C"O+-O,%GX9PK*$4SM.8S)#IA_M86)HVOVMN+X2[(``7
MU+-8TVT$S`6973=TR]H,8?P.'K8`MY`DI2`)G@%];5("(T,)BBHMXG9%9!"3
M_T6816ITO;UN2'AD&#GD"J+]/I,*Z%>=U&3`9,_I(*(IG-)W<ISA:57'@86P
MS3X_ZN%C=1<22U5WUW-1MM>C&%5EYZ/\7B&;*_SF<M=9^D:&:3?\_X;;=QQ,
M6SY`-1&.,:MARL<8R+^7(L]+]]V,?!]=8FXC7QR*R:M6`;;.X]N7CMTKP.XX
M/H'A9D_AUN4VX:`<+J3+J`V?VY\QTVOOISDA2G[CV+.ITAL-$:Y;L1?AW-4X
M1Y*1WKL,A*.X=!2(1[Y\=!)I^%!#?R#H1QB6.6I.%(5)VS$.DK**@N)TYZ!`
M)PF-=9#L'B31J!S.AE`6C9,2DKL^0Q!D#@STA3RZ<HODL8WLHB#JE0RBE6[D
MSM!*NZDT"?U(&U"GGH-%U2V6\WOFONX80!EBBF+E;*M8T8J0T50'1=66,CJI
MO0];.'C:/WN2<B(UAOZY9+RK+,E1!/6Y:2PC87`3R3-/?"A1`PSE(SPAK5&M
MA.J3YSA8+(>S)_K,Z0QJ,*P#++.+2_GS"!XH"U95F?"69"W"^2*%<R!8`QL3
MC5:R42B\!KL2V/&63S\N+M<9,A/<#:1%8'Y,@9EH_=!*5`U=M>R+J?@=,X]\
M(5C?.QN1RZ8L`NY3.MN"'&0$H;BD&K=*N$'`.U29F3-=LLE?A&],JGGT11A>
MIC",20NZY)B\&LE*2-[]Y9FM,0N<@37&"-):-H29A`78=3LI['PQ*)*#C*`:
MM$J@?25*KP5'1#S-L2"F^W1<_J1<ZT<F>+D,12!V4R"".'\Q"JM59"2:]8B1
MB8S0&M`#]*M[Z%O+]J_=TQWZ5W027M6KT4/$P01/V4Y1$`@HBH'>3C'@*ZDC
M8!^+F1S$<QF*$#XKO;"I\=SC"B<'SCSZ(C0S]I:R5SLUF/OONW(P+<%6!&UZ
M.ZFX!ZM1/L"6\(UM&T,QBQW_#XC"E%7?+<X35A01Z3VI4AO)0+?2&O\*`SKQ
M%=?1<HB6K6K8["ZU*'[26V,5FKLZB-XCB/3K,;;'H(#<244=_^`1$OUG;(XC
MG07ATDS%W9N^)#O'UY8*BT(OO:-7*?1"JS1U9)=?\IK&,A0W#06VU:&YSP7)
M2)`%IG8PMWI3=PA%1MR:=Q/4C91$R9SPVUEH08B=IC<>-RYLFBC0&T:*OZEL
M5*-`-_*5US&TSQB"IUMXQ'ZD>$H9U5]SK1PQ&T44Q4=Z3S,G/@(M**:FCH0]
M+H?OP]?@'[A4PGS/5@;C]HV*6(9\3/3+3U`.(,W3O&@Y@)JBB$IOF&Y:?,-(
M:`F*F1(2V0BK."^4L,@@9"RJ@V_OIY95^_,M114%47K'-?>LL^[#]QPA68><
M54.CJHRBF$COT6:?H=;!\!-W^Z+UDVX4/-_7X4QG9PORP8`R#]8D:P)R8N9`
MJHI"*[UA7&)7,;%:B]FD;XU5)D\%=JT$CB*!=3@>+AQ'KM(Y`3.V-`A`=GC2
MS8-I6N_>+.;9Q+X7KI,(I@`L(U<./:5_!D/_W-&N$7L0:XJ">JNM\D10Q\Q&
MH=UH93@*+4<S,'W]$0@#WS<?Q>S_?PC\JW;\+6^X2[X%?A7\JHR)*/WVXO>\
MM_1NIM`<8TOY[Z!?-\K1^J\CFA\:ZL-G,/$/BCC:Q@:2'I!1Y6F.WX3K+4)"
M"B0-Y%]#E%#7GA@QMB>"]PLY94P?IUPWH&$'43A0&-ZW-S@XAONH^==O!S`V
M7`0'`B-!9D2(8%<M7%XN0W^W8HV[#_$-$2>6!YZ`&6;FS53#//77T=<-"XRC
M:O/$/.@(PVSD31FUAC/P!J"Z=:7^`JCO?Q[%W\9-:-A?]$N\(#*)V0K."+TO
MQ)D2$;J_#:<_+?ZOI/5MU\&4OVOT;_3A#RP$YJJJZYO8_C9^3]Q8H2SI=";/
ML7F<>]`Y(6_J,S/?3O1]+4N=\%*%G_^<!WV3IV8/!IJ;6'D%+[[)V#&)3#E<
MD>D8_8Z=S(RI_*$W/KY!"A30TW`5?K=PZ?^;\G]+YF.<!\#0@MY'O]C[I#Q[
MJ3>`@ON)@'IEMHM!Q(:9V)K]*.<B49NA6R3:GJB";QP^LB8M::?YVDRV"\'0
M%N;;JC^'<6%Y4S,)AW$$5BDNM\WBRS<X66(V#A];-?G#%3]TLX<75.FW_WWS
MUS_=<Q/H__ZCVD^*3)^FIYZ.LM1']K`4?[6XE(/'_BCIUZMU;H;_](;K"V;F
MP`B_4<=S'LQ/S_E'2%CIC8'ER&B/FKDMN7\ZUN6+W7JARCA]#8[+,TI=%>9W
M>ZPK+NUN!,'#V3VVS%+DD9C?9_(]SQP*DBQD6`S#[XMK\$,34)2U;4.H<<]&
MY%<2H9=+\G?!Z`OAS!UAH1?-=.8*3G&R).80'%M1G+RZD[GK2<SMKU`=S'+0
MWP?0!T!)M\K1'IN':V;&G+AW/:$(6?.R//VQ>7KG+)B[)#XP(T]8<WC&TC`6
MDAV;7SX8<N*&QF[<[BA#^9[>7;7]'T^%R_\!4$L!`AX#%`````@`-8*K1GT7
M+1+@<```B:(&`!$`&````````0```*2!`````'9S87(M,C`Q-3`S,S$N>&UL
M550%``-E#E%5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`-8*K1EV36'91
M"0``VFX``!4`&````````0```*2!*W$``'9S87(M,C`Q-3`S,S%?8V%L+GAM
M;%54!0`#90Y1575X"P`!!"4.```$.0$``%!+`0(>`Q0````(`#6"JT9W>F".
MBA$``"#Q```5`!@```````$```"D@<MZ``!V<V%R+3(P,34P,S,Q7V1E9BYX
M;6Q55`4``V4.455U>`L``00E#@``!#D!``!02P$"'@,4````"``U@JM&.H<.
MFSPR``!7Q@(`%0`8```````!````I(&DC```=G-A<BTR,#$U,#,S,5]L86(N
M>&UL550%``-E#E%5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`-8*K1FWE
MJB/,'```!>X!`!4`&````````0```*2!+[\``'9S87(M,C`Q-3`S,S%?<')E
M+GAM;%54!0`#90Y1575X"P`!!"4.```$.0$``%!+`0(>`Q0````(`#6"JT8G
MJBC.-`L``!-B```1`!@```````$```"D@4K<``!V<V%R+3(P,34P,S,Q+GAS
M9%54!0`#90Y1575X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"``#)YP``
"````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Balance Sheet Components </p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets (in thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and clinical <sup style="font-size:85%; vertical-align:top">(1)</sup></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,669</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,216</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">517</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,186</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,398</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">(1)</sup></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><sup style="font-size:85%; vertical-align:top"></sup>A substantial majority of these prepayments consist of advances to our contract manufacturers. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Liabilities (in thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and related</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,143</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,737</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and clinical</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,489</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,259</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional services</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">411</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,219</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,666</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EPUAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 230,261</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 170,566</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">4,186</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">2,398</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">234,447</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">172,964</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">284</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">616</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">664</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">714</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">235,395</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">174,294</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">601</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">1,259</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">7,219</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">5,666</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">7,820</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">6,925</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">7,820</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">6,925</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 5,000,000 shares authorized at March 31, 2015 and December 31, 2014, respectively; zero shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 50,000,000 shares authorized at March 31, 2015 and December 31, 2014; 29,257,836 and 24,245,437 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively</a></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">360,838</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">278,626</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(133,266)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(111,259)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">227,575</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">167,369</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#x2019; equity</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 235,395</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 174,294</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Assets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Liabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Formation and Business of the Company<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vsar_FormationAndBusinessOfCompanyTextBlock', window );">Formation and Business of the Company</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Formation and Business of the Company </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Versartis, Inc. (the &#8220;Company&#8221;) was incorporated on December&#160;10, 2008 in the State of Delaware. The Company is an endocrine-focused biopharmaceutical company initially developing long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. The Company is developing drug candidates that it has licensed from Amunix Operating Inc. (&#8220;Amunix&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s headquarters and operations are in Menlo Park, California. Since incorporation, the Company has been primarily performing research and development activities, including early clinical trials, filing patent applications, obtaining regulatory approvals, hiring personnel, and raising capital to support and expand these activities. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Unaudited Interim Financial Information<font style="font-style:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial information as of March 31, 2015 is unaudited. The condensed consolidated financial statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that management considers necessary for the fair presentation of the results of operations for the interim periods covered and of the financial condition of the Company at the date of the interim balance sheet. The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December&#160;31, 2014 included in the Company&#8217;s annual report on Form 10-K filed on March&#160;6, 2015 with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Secondary Offering </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2015, we completed a secondary public offering of common stock, pursuant to which we issued 4,999,999 shares of common stock, which includes shares issued pursuant to the underwriters&#8217; exercise of their over-allotment option, and received net proceeds of approximately $80.2 million, after underwriting discounts, commissions and estimated offering expenses. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3.5pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vsar_FormationAndBusinessOfCompanyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Formation and business of company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">vsar_FormationAndBusinessOfCompanyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>vsar_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6GAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Balance Sheet Components - Accrued Liabilities (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related</a></td>
        <td class="nump"><a title="us-gaap_EmployeeRelatedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 1,143</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeRelatedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_EmployeeRelatedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 1,737</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeRelatedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent', window );">Preclinical and clinical</a></td>
        <td class="nump"><a title="vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">5,489</a><span style="display:none;white-space:normal;text-align:left;">vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">3,259</a><span style="display:none;white-space:normal;text-align:left;">vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
        <td class="nump"><a title="us-gaap_AccruedProfessionalFeesCurrent" onclick="toggleNextSibling(this);">188</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedProfessionalFeesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedProfessionalFeesCurrent" onclick="toggleNextSibling(this);">411</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedProfessionalFeesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
        <td class="nump"><a title="us-gaap_OtherAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">399</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">259</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 7,219</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 5,666</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Preclinical and clinical trials accrued liabilities current.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">vsar_PreclinicalAndClinicalTrialsAccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>vsar_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EMJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) (Menlo Park, California [Member], USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>sqft</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Menlo Park, California [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vsar_AreaOfFacilityLease', window );">Operating facility lease area</a></td>
        <td class="nump"><a title="vsar_AreaOfFacilityLease[us-gaap_StatementGeographicalAxis=vsar_MenloParkCaliforniaMember]" onclick="toggleNextSibling(this);">12,943</a><span style="display:none;white-space:normal;text-align:left;">vsar_AreaOfFacilityLease<br>/ us-gaap_StatementGeographicalAxis<br>= vsar_MenloParkCaliforniaMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Operating facility lease term</a></td>
        <td class="text">39 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vsar_OperatingLeaseObligationNet', window );">Total obligation under lease</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="vsar_OperatingLeaseObligationNet[us-gaap_StatementGeographicalAxis=vsar_MenloParkCaliforniaMember]" onclick="toggleNextSibling(this);">$ 1.9</a><span style="display:none;white-space:normal;text-align:left;">vsar_OperatingLeaseObligationNet<br>/ us-gaap_StatementGeographicalAxis<br>= vsar_MenloParkCaliforniaMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vsar_AreaOfFacilityLease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Area of facility lease.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">vsar_AreaOfFacilityLease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>vsar_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:areaItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vsar_OperatingLeaseObligationNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Operating lease obligation net.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">vsar_OperatingLeaseObligationNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>vsar_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation and Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The preparation of the accompanying condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements are consolidated for the quarter ended March 31, 2015 and year ended December 31, 2014 and include the accounts of Versartis, Inc. and its wholly-owned subsidiary, Versartis Cayman Holdings Company, established in 2014. All intercompany accounts and transactions have been eliminated. The U.S. dollar is the functional currency for all of the Company's consolidated operations. All other accompanying condensed financial statements for the quarter ended March 31, 2014 include only the accounts of Versartis, Inc.</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, the Company has incurred net losses and negative cash flows from operations. At March&#160;31, 2015, the Company had an accumulated deficit of $133.3&#160;million and working capital of $226.6&#160;million. The Company expects to continue to incur losses from costs related to the continuation of research and development and administrative activities for the foreseeable future. Although management has been successful in raising capital in the past, most recently in January 2015, there can be no assurance that the Company will be successful or that any needed financing will be available in the future at terms acceptable to the Company. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segments </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. All long-lived assets are maintained in the United States of America. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of <font style="text-transform:uppercase;">c</font>redit <font style="text-transform:uppercase;">r</font>isk </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. All of the Company&#8217;s cash and cash equivalents are held at five financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risk and Uncertainties </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#8217;s potential drug candidates, uncertainty of market acceptance of the Company&#8217;s products, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Products developed by the Company require clearances from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the products will receive the necessary clearances. If the Company was denied clearance, clearance was delayed or the Company was unable to maintain clearance, it could have a materially adverse impact on the Company. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be at terms acceptable by the Company. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and <font style="text-transform:uppercase;">c</font>ash <font style="text-transform:uppercase;">e</font>quivalents </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. At March 31, 2015 and December 31, 2014 the Company&#8217;s cash and cash equivalents were held in five institutions in the United States and include deposits in money market funds which were unrestricted as to withdrawal or use.</p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and <font style="text-transform:uppercase;">e</font>quipment, Net </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, generally between three and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of their useful life or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by the comparison of the carrying amount to the undiscounted future net cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value (i.e. determined through estimating projected discounted future net cash flows or other acceptable methods of determining fair value) arising from the asset. There have been no such impairments of long-lived assets as of March 31, 2015 or December&#160;31, 2014.</p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying value of the Company&#8217;s cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to the short-term nature of these items. Convertible preferred stock call option liability and convertible preferred stock warrant liability were carried at fair value. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4.5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:91%;">
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;I</p></td>
<td valign="bottom" style="width:0.94%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:92.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unadjusted quoted prices in active markets for identical assets or liabilities;</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;II</p></td>
<td valign="bottom" style="width:0.94%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" style="width:92.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;III</p></td>
<td valign="bottom" style="width:0.94%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:92.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial instruments consist of Level I assets. Level I securities are comprised of a highly liquid money market fund. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preclinical and Clinical Trial Accruals </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s clinical trial accruals are based on estimates of patient enrollment and related costs at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and clinical research organizations (&#8220;CROs&#8221;) that conduct and manage clinical trials on the Company&#8217;s behalf. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates preclinical and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of patient enrollment and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and <font style="text-transform:uppercase;">d</font>evelopment </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are charged to operations as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, laboratory supplies, consulting costs, external research and development expenses and allocated overhead, including rent, equipment depreciation, and utilities. Costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use are expensed to research and development costs when incurred. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income <font style="text-transform:uppercase;">t</font>axes </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i)&#160;the factors underlying the sustainability assertion have changed and (ii)&#160;the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based <font style="text-transform:uppercase;">c</font>ompensation </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For stock options granted to employees, the Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair value. The value of the portion of the award that is ultimately expected to vest is recognized as expense ratably over the requisite service period. The fair value of stock options is determined using the Black-Scholes option pricing model. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions regarding a number of complex and subjective variables. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense, net of estimated forfeitures, is reflected in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">604</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,384</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,988</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">426</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:3pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company&#8217;s comprehensive loss was the same as its reported net loss. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Share of Common Stock </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, convertible preferred stock, stock options and convertible preferred stock warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss for all of the periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. </p>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#8217;s financial position or results of operations upon adoption. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-10<font style="font-style:italic;">, Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation</font>, or ASU 2014-10, which eliminates the definition of a development stage entity, the development stage presentation and disclosure requirements under ASC 915, <font style="font-style:italic;">Development Stage Entities</font>, and amends provisions of existing variable interest entity guidance under ASC 810, <font style="font-style:italic;">Consolidation</font>. As a result of the changes, the financial statements of entities which meet the former definition of a development stage entity will no longer: (1)&#160;present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2)&#160;label the financial statements as those of a development stage entity, (3)&#160;disclose a description of the development stage activities in which the entity is engaged, and (4)&#160;disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. Furthermore, ASU 2014-10 clarifies disclosures about risks and uncertainties under ASC Topic 275, <font style="font-style:italic;">Risks and Uncertainties</font> that apply to companies that have not commenced planned principal operations. Finally, variable interest entity rules no longer contain an exception for development stage entities and, as a result, development stage entities will have to be evaluated for consolidation in the same manner as non-development stage entities. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2014, the FASB issued new guidance related to the disclosures around going concern. The new standard provides guidance around management&#8217;s responsibility to evaluate whether there is substantial doubt about an entity&#8217;s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The Company will apply the guidance and disclosure provisions of the new standard upon adoption.</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASU 2014-10, entities are no longer required to apply the presentation and disclosure provisions of ASC 915 during annual periods beginning after December&#160;15, 2014. In addition, the revisions to the consolidation standards are effective for annual periods beginning after December&#160;15, 2015 for public companies and are effective for annual periods beginning after December&#160;15, 2016 for nonpublic entities. Early adoption is permitted for any annual reporting period or interim period for which the entity&#8217;s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). The Company has adopted ASU 2014-10, effective January 1, 2015, but there was no impact on its financial position, results of operations or cash flows. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6NAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">50,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">50,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">29,257,836</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">24,245,437</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">29,257,836</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">24,245,437</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Loss per Share of Common Stock (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Computation of Basic and Diluted Net Loss Per Share</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except per share data): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders - basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,006</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,985</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,810</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,788</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares used to compute basic and diluted net</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; loss per share</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,810</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,788</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per common share</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.79</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16.13</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Shares Outstanding</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:9pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following potentially dilutive securities outstanding at the end of the periods presented have been excluded from the computation of diluted shares outstanding: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,761,967</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,188,896</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185,514</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:13.3%;">
<tr>
<td valign="bottom" style="width:100%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:4pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1CAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vsar_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,  2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">VSAR<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Versartis, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001513818<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding" onclick="toggleNextSibling(this);">29,260,236</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_AmendmentFlag</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentType</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityFilerCategory</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityRegistrantName</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_TradingSymbol</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vsar_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">vsar_DocumentAndEntityInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>vsar_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQPAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Formation and Business of the Company - Additional Information (Detail) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vsar_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Business incorporated date</a></td>
        <td class="text">Dec. 10,  2008<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in secondary offering, net of issuance costs</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">$ 80,208</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vsar_SecondaryOfferingMember', window );">Secondary Offering [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vsar_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Secondary public offering shares of common stock issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_SubsidiarySaleOfStockAxis=vsar_SecondaryOfferingMember]" onclick="toggleNextSibling(this);">4,999,999</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= vsar_SecondaryOfferingMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in secondary offering, net of issuance costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock[us-gaap_SubsidiarySaleOfStockAxis=vsar_SecondaryOfferingMember]" onclick="toggleNextSibling(this);">$ 80,200</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= vsar_SecondaryOfferingMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when an entity was incorporated</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vsar_PublicOfferingLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">vsar_PublicOfferingLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>vsar_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vsar_SecondaryOfferingMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vsar_SecondaryOfferingMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E4EAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 17,100</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 4,869</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">5,181</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">2,714</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">22,281</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">7,583</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(22,281)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(7,583)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump"><a title="us-gaap_InvestmentIncomeInterest" onclick="toggleNextSibling(this);">49</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentIncomeInterest</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingIncomeExpense" onclick="toggleNextSibling(this);">226</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncomeExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_OtherNonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(11,843)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncomeExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(22,006)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(19,426)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPreferredStockDividendsAndAdjustments', window );">Deemed dividend related to beneficial conversion feature of convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_OtherPreferredStockDividendsAndAdjustments" onclick="toggleNextSibling(this);">(25,559)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherPreferredStockDividendsAndAdjustments</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" onclick="toggleNextSibling(this);">$ (22,006)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" onclick="toggleNextSibling(this);">$ (44,985)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per basic and diluted share attributable to common stockholders</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.79)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (16.13)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares used to compute basic and diluted net loss per share</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">27,810</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">2,788</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPreferredStockDividendsAndAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other preferred stock dividends and adjustments, not otherwise defined in the taxonomy, that are necessary to adjust net income to obtain net income applicable to common stockholders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section Q<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherPreferredStockDividendsAndAdjustments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Loss per Share of Common Stock<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share of Common Stock</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. Net loss per share of Common Stock </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except per share data): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders - basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,006</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,985</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,810</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,788</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares used to compute basic and diluted net</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; loss per share</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,810</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,788</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per common share</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.79</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16.13</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss attributable to common stockholders per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period, determined using the treasury-stock method and the as-if converted method, for convertible securities, if inclusion of these is dilutive. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive securities outstanding at the end of the periods presented have been excluded from the computation of diluted shares outstanding: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,761,967</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,188,896</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185,514</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:13.3%;">
<tr>
<td valign="bottom" style="width:100%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:4pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Equity Incentive Plans </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Board of Directors, or Board, and stockholders previously approved the 2009 Stock Plan, or the 2009 Plan. In March 2014, the stockholders approved the 2014 Equity Incentive Plan, or the 2014 Plan. As of March&#160;21, 2014, the effective date of the 2014 Plan, the Company suspended the 2009 Plan and no additional awards may be granted under the 2009 Plan. Any shares of common stock covered by awards granted under the 2009 Plan that terminate after March&#160;21, 2014 by expiration, forfeiture, cancellation or other means without the issuance of such shares, will be added to the 2014 Plan reserve. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2015, the total number of shares of common stock available for issuance under the 2014 Plan was approximately 2,031,000.  Unless the Board provides otherwise, beginning on January&#160;1, 2015, and continuing until the expiration of the 2014 Plan, the total number of shares of common stock available for issuance under the 2014 Plan will automatically increase annually on January&#160;1 by 4.5% of the total number of issued and outstanding shares of common stock as of December&#160;31 of the immediately preceding year. As of March 31, 2015, approximately 2,947,000 shares of common stock were subject to outstanding awards under the 2014 Plan. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2014, the Board and stockholders approved the 2014 Employee Stock Purchase Plan, or the ESPP, which became effective as of March&#160;5, 2014. The Company has reserved a total of approximately 392,000 shares of common stock for issuance under the ESPP. Unless the Board provides otherwise, beginning on January&#160;1, 2015, and continuing until the expiration of the ESPP, the total number of shares of common stock available for issuance under the ESPP will automatically increase annually on January&#160;1 by the lesser of (i)&#160;1% of the total number of issued and outstanding shares of common stock as of December&#160;31 of the immediately preceding year, or (ii)&#160;300,000 shares of common stock. As of March 31, 2015, the Company has approximately 9,000 shares of common stock under the ESPP. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for accounts comprising shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income, and compensation-related costs for equity-based compensation. Includes, but is not limited to, disclosure of policies, compensation plan details, equity-based arrangements to obtain goods and services, deferred compensation arrangements, and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E3JAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Fair Value Measurements - Financial Instruments Measured at Fair Value on Recurring Basis (Detail) (Money market funds [Member], Recurring [Member], USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
        <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure" onclick="toggleNextSibling(this);">$ 160,162</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure" onclick="toggleNextSibling(this);">$ 160,125</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
        <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">$ 160,162</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_MoneyMarketFundsMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">$ 160,125</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_MoneyMarketFundsMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6LAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015

</div>
          <div>Segment</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vsar_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">$ (133,266,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">$ (111,259,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vsar_WorkingCapital', window );">Working capital</a></td>
        <td class="nump"><a title="vsar_WorkingCapital" onclick="toggleNextSibling(this);">226,600,000</a><span style="display:none;white-space:normal;text-align:left;">vsar_WorkingCapital</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
        <td class="nump"><a title="us-gaap_NumberOfOperatingSegments" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NumberOfOperatingSegments</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vsar_CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod', window );">Cash and cash equivalents maturity period</a></td>
        <td class="text">Three months or less<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairments of long-lived assets</a></td>
        <td class="nump"><a title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</span><span></span></td>
        <td class="nump"><a title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vsar_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vsar_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Percentage for the amount of benefit realized upon ultimate settlement</a></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements[us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">50.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2420-110228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 958<br><br> -SubTopic 225<br><br> -Section 45<br><br> -Paragraph 11<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28367520&amp;loc=d3e92212-112881<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Impairment<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vsar_CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash and cash equivalents maximum investments maturity period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">vsar_CashAndCashEquivalentsMaximumInvestmentsMaturityPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>vsar_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vsar_SignificantAccountingPoliciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">vsar_SignificantAccountingPoliciesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>vsar_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vsar_WorkingCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Working capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">vsar_WorkingCapital</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>vsar_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets (in thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and clinical <sup style="font-size:85%; vertical-align:top">(1)</sup></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,669</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,216</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">517</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,186</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,398</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">(1)</sup></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><sup style="font-size:85%; vertical-align:top"></sup>A substantial majority of these prepayments consist of advances to our contract manufacturers. </p></td></tr></table></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Liabilities</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Liabilities (in thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and related</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,143</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,737</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and clinical</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,489</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,259</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional services</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">411</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,219</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,666</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of accrued liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EABAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vsar_BasisOfPresentationAndUseOfEstimatesTextBlock', window );">Basis of Presentation and Use of Estimates</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation and Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The preparation of the accompanying condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements are consolidated for the quarter ended March 31, 2015 and year ended December 31, 2014 and include the accounts of Versartis, Inc. and its wholly-owned subsidiary, Versartis Cayman Holdings Company, established in 2014. All intercompany accounts and transactions have been eliminated. The U.S. dollar is the functional currency for all of the Company's consolidated operations. All other accompanying condensed financial statements for the quarter ended March 31, 2014 include only the accounts of Versartis, Inc.</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, the Company has incurred net losses and negative cash flows from operations. At March&#160;31, 2015, the Company had an accumulated deficit of $133.3&#160;million and working capital of $226.6&#160;million. The Company expects to continue to incur losses from costs related to the continuation of research and development and administrative activities for the foreseeable future. Although management has been successful in raising capital in the past, most recently in January 2015, there can be no assurance that the Company will be successful or that any needed financing will be available in the future at terms acceptable to the Company. </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segments </p>
<p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. All long-lived assets are maintained in the United States of America. </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of <font style="text-transform:uppercase;">c</font>redit <font style="text-transform:uppercase;">r</font>isk </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. All of the Company&#8217;s cash and cash equivalents are held at five financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vsar_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock', window );">Risk and Uncertainties</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risk and Uncertainties </p>
<p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company&#8217;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#8217;s potential drug candidates, uncertainty of market acceptance of the Company&#8217;s products, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Products developed by the Company require clearances from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the products will receive the necessary clearances. If the Company was denied clearance, clearance was delayed or the Company was unable to maintain clearance, it could have a materially adverse impact on the Company. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be at terms acceptable by the Company. </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and <font style="text-transform:uppercase;">c</font>ash <font style="text-transform:uppercase;">e</font>quivalents </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. At March 31, 2015 and December 31, 2014 the Company&#8217;s cash and cash equivalents were held in five institutions in the United States and include deposits in money market funds which were unrestricted as to withdrawal or use.</p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and <font style="text-transform:uppercase;">e</font>quipment, Net </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, generally between three and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of their useful life or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized. </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by the comparison of the carrying amount to the undiscounted future net cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value (i.e. determined through estimating projected discounted future net cash flows or other acceptable methods of determining fair value) arising from the asset. There have been no such impairments of long-lived assets as of March 31, 2015 or December&#160;31, 2014.</p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The carrying value of the Company&#8217;s cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to the short-term nature of these items. Convertible preferred stock call option liability and convertible preferred stock warrant liability were carried at fair value. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4.5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:91%;">
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;I</p></td>
<td valign="bottom" style="width:0.94%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:92.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unadjusted quoted prices in active markets for identical assets or liabilities;</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;II</p></td>
<td valign="bottom" style="width:0.94%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" style="width:92.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</p></td>
</tr>
<tr>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;III</p></td>
<td valign="bottom" style="width:0.94%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:92.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial instruments consist of Level I assets. Level I securities are comprised of a highly liquid money market fund. </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vsar_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock', window );">Preclinical and Clinical Trial Accruals</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preclinical and Clinical Trial Accruals </p>
<p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company&#8217;s clinical trial accruals are based on estimates of patient enrollment and related costs at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and clinical research organizations (&#8220;CROs&#8221;) that conduct and manage clinical trials on the Company&#8217;s behalf. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates preclinical and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of patient enrollment and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and <font style="text-transform:uppercase;">d</font>evelopment </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are charged to operations as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, laboratory supplies, consulting costs, external research and development expenses and allocated overhead, including rent, equipment depreciation, and utilities. Costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use are expensed to research and development costs when incurred. </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income <font style="text-transform:uppercase;">t</font>axes </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i)&#160;the factors underlying the sustainability assertion have changed and (ii)&#160;the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based compensation</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based <font style="text-transform:uppercase;">c</font>ompensation </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For stock options granted to employees, the Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair value. The value of the portion of the award that is ultimately expected to vest is recognized as expense ratably over the requisite service period. The fair value of stock options is determined using the Black-Scholes option pricing model. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions regarding a number of complex and subjective variables. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense, net of estimated forfeitures, is reflected in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">604</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,384</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,988</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">426</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:3pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company&#8217;s comprehensive loss was the same as its reported net loss. </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share of Common Stock</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Share of Common Stock </p>
<p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, convertible preferred stock, stock options and convertible preferred stock warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss for all of the periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:13pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#8217;s financial position or results of operations upon adoption. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-10<font style="font-style:italic;">, Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation</font>, or ASU 2014-10, which eliminates the definition of a development stage entity, the development stage presentation and disclosure requirements under ASC 915, <font style="font-style:italic;">Development Stage Entities</font>, and amends provisions of existing variable interest entity guidance under ASC 810, <font style="font-style:italic;">Consolidation</font>. As a result of the changes, the financial statements of entities which meet the former definition of a development stage entity will no longer: (1)&#160;present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2)&#160;label the financial statements as those of a development stage entity, (3)&#160;disclose a description of the development stage activities in which the entity is engaged, and (4)&#160;disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. Furthermore, ASU 2014-10 clarifies disclosures about risks and uncertainties under ASC Topic 275, <font style="font-style:italic;">Risks and Uncertainties</font> that apply to companies that have not commenced planned principal operations. Finally, variable interest entity rules no longer contain an exception for development stage entities and, as a result, development stage entities will have to be evaluated for consolidation in the same manner as non-development stage entities. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2014, the FASB issued new guidance related to the disclosures around going concern. The new standard provides guidance around management&#8217;s responsibility to evaluate whether there is substantial doubt about an entity&#8217;s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The Company will apply the guidance and disclosure provisions of the new standard upon adoption.</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASU 2014-10, entities are no longer required to apply the presentation and disclosure provisions of ASC 915 during annual periods beginning after December&#160;15, 2014. In addition, the revisions to the consolidation standards are effective for annual periods beginning after December&#160;15, 2015 for public companies and are effective for annual periods beginning after December&#160;15, 2016 for nonpublic entities. Early adoption is permitted for any annual reporting period or interim period for which the entity&#8217;s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). The Company has adopted ASU 2014-10, effective January 1, 2015, but there was no impact on its financial position, results of operations or cash flows. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13279-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 60<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6390181&amp;loc=d3e202-110218<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for segment reporting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vsar_BasisOfPresentationAndUseOfEstimatesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Basis of presentation and use of estimates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">vsar_BasisOfPresentationAndUseOfEstimatesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>vsar_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vsar_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Preclinical study and clinical trial accruals.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">vsar_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>vsar_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vsar_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Significant risks and uncertainties policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">vsar_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>vsar_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Estimated Stock-Based Compensation Expense</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:9pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Stock-based compensation expense, net of estimated forfeitures, is reflected in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">604</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,384</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,988</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">426</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Financial Instruments Measured at Fair Value on Recurring Basis</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table sets forth the Company&#8217;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at March 31, 2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,162</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,162</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,125</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,125</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3.5pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6CAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Balance Sheet Components - Prepaid Expenses and Other Current Assets (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense And Other Assets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Preclinical and clinical</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseCurrent" onclick="toggleNextSibling(this);">$ 3,669</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseCurrent" onclick="toggleNextSibling(this);">$ 2,216</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
        <td class="nump"><a title="us-gaap_OtherPrepaidExpenseCurrent" onclick="toggleNextSibling(this);">517</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherPrepaidExpenseCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherPrepaidExpenseCurrent" onclick="toggleNextSibling(this);">182</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherPrepaidExpenseCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">$ 4,186</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">$ 2,398</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Assets<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5879-108316<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2GAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Loss per Share of Common Stock - Summary of Computation of Basic and Diluted Net Loss Per Share (Detail) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders - basic and diluted</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" onclick="toggleNextSibling(this);">$ (22,006)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" onclick="toggleNextSibling(this);">$ (44,985)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted-average shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" onclick="toggleNextSibling(this);">27,810</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" onclick="toggleNextSibling(this);">2,788</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used to compute basic and diluted net loss per share</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">27,810</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">2,788</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.79)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (16.13)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e2646-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EC3AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (22,006)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (19,426)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump"><a title="us-gaap_DepreciationDepletionAndAmortization" onclick="toggleNextSibling(this);">54</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationDepletionAndAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepreciationDepletionAndAmortization" onclick="toggleNextSibling(this);">5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationDepletionAndAmortization</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">1,988</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">426</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vsar_RemeasurementOfCallOptionAndPreferredStockLiability', window );">Remeasurement of convertible preferred stock call option liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="vsar_RemeasurementOfCallOptionAndPreferredStockLiability" onclick="toggleNextSibling(this);">9,560</a><span style="display:none;white-space:normal;text-align:left;">vsar_RemeasurementOfCallOptionAndPreferredStockLiability</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Remeasurement of convertible preferred stock warrant liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAdjustmentOfWarrants" onclick="toggleNextSibling(this);">2,279</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAdjustmentOfWarrants</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">(1,456)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">(127)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsPayable" onclick="toggleNextSibling(this);">(657)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayable</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayable" onclick="toggleNextSibling(this);">665</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayable</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued liabilities and other liabilities</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" onclick="toggleNextSibling(this);">1,553</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" onclick="toggleNextSibling(this);">810</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(20,524)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(5,808)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(5)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(38)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(5)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(38)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock in initial public offering, net of issuance costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceInitialPublicOffering" onclick="toggleNextSibling(this);">132,188</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in follow-on offering, net of issuance costs</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">80,208</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" onclick="toggleNextSibling(this);">64,793</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of convertible preferred stock warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromWarrantExercises" onclick="toggleNextSibling(this);">570</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromWarrantExercises</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">16</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">4</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">80,224</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">197,555</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">59,695</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">191,709</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">170,566</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">13,288</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">230,261</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">204,997</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash items</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vsar_InitialPublicOfferingCosts', window );">Offering issuance costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="vsar_InitialPublicOfferingCosts" onclick="toggleNextSibling(this);">1,293</a><span style="display:none;white-space:normal;text-align:left;">vsar_InitialPublicOfferingCosts</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=vsar_ConvertiblePreferredStockCallOptionLiabilityMember', window );">Conversion of preferred stock call option liability [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash items</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3', window );">Conversion of liability to additional paid in capital</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3[us-gaap_FairValueByLiabilityClassAxis=vsar_ConvertiblePreferredStockCallOptionLiabilityMember]" onclick="toggleNextSibling(this);">9,581</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= vsar_ConvertiblePreferredStockCallOptionLiabilityMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=vsar_ConvertiblePreferredStockWarrantLiabilityMember', window );">Conversion of preferred stock warrant liability [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash items</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3', window );">Conversion of liability to additional paid in capital</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3[us-gaap_FairValueByLiabilityClassAxis=vsar_ConvertiblePreferredStockWarrantLiabilityMember]" onclick="toggleNextSibling(this);">2,752</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= vsar_ConvertiblePreferredStockWarrantLiabilityMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=vsar_ConvertiblePreferredStockToCommonStockMember', window );">Conversion of preferred stock to common stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash items</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion to common stock and additional paid in capital</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConversionOfStockAmountConverted1[us-gaap_FairValueByLiabilityClassAxis=vsar_ConvertiblePreferredStockToCommonStockMember]" onclick="toggleNextSibling(this);">$ 122,290</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConversionOfStockAmountConverted1<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= vsar_ConvertiblePreferredStockToCommonStockMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 480<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transfers of financial instrument classified in shareholders' equity out of level 3 of the fair value hierarchy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersOutOfLevel3</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of accrued expenses and other operating obligations not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vsar_InitialPublicOfferingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Initial public offering costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">vsar_InitialPublicOfferingCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>vsar_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vsar_RemeasurementOfCallOptionAndPreferredStockLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Remeasurement of call option and preferred stock liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">vsar_RemeasurementOfCallOptionAndPreferredStockLiability</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>vsar_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=vsar_ConvertiblePreferredStockCallOptionLiabilityMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=vsar_ConvertiblePreferredStockCallOptionLiabilityMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=vsar_ConvertiblePreferredStockToCommonStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=vsar_ConvertiblePreferredStockToCommonStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=vsar_ConvertiblePreferredStockWarrantLiabilityMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=vsar_ConvertiblePreferredStockWarrantLiabilityMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Commitments and Contingencies </p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Facility Leases </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2014, the Company entered into an operating facility lease agreement to lease 12,943 square feet in Menlo Park, California for its new headquarters building for a period of thirty-nine months. The total obligation for the Company under this lease is approximately $1.9 million as of March&#160;31, 2015. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E3NAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Loss per Share of Common Stock - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Shares Outstanding (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vsar_OptionsToPurchaseCommonStockMember', window );">Options to purchase common stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vsar_OptionsToPurchaseCommonStockMember]" onclick="toggleNextSibling(this);">2,761,967</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= vsar_OptionsToPurchaseCommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vsar_OptionsToPurchaseCommonStockMember]" onclick="toggleNextSibling(this);">2,188,896</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= vsar_OptionsToPurchaseCommonStockMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">185,514</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vsar_OptionsToPurchaseCommonStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vsar_OptionsToPurchaseCommonStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.1.9</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>32</ContextCount>
  <ElementCount>121</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>17</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Disclosure - Formation and Business of the Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureFormationAndBusinessOfCompany</Role>
      <ShortName>Formation and Business of the Company</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureEquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Net Loss per Share of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStock</Role>
      <ShortName>Net Loss per Share of Common Stock</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Net Loss per Share of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStockTables</Role>
      <ShortName>Net Loss per Share of Common Stock (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Formation and Business of the Company - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetail</Role>
      <ShortName>Formation and Business of the Company - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedStockBasedCompensationExpenseDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Stock-Based Compensation Expense (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Balance Sheet Components - Prepaid Expenses and Other Current Assets (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Balance Sheet Components - Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureBalanceSheetComponentsAccruedLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Accrued Liabilities (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Fair Value Measurements - Financial Instruments Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Financial Instruments Measured at Fair Value on Recurring Basis (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Equity Incentive Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail</Role>
      <ShortName>Equity Incentive Plans - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Net Loss per Share of Common Stock - Summary of Computation of Basic and Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStockSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail</Role>
      <ShortName>Net Loss per Share of Common Stock - Summary of Computation of Basic and Diluted Net Loss Per Share (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Net Loss per Share of Common Stock - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Shares Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.versartis.com/20150331/taxonomy/role/DisclosureNetLossPerShareOfCommonStockSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedSharesOutstandingDetail</Role>
      <ShortName>Net Loss per Share of Common Stock - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Shares Outstanding (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_ProceedsFromIssuanceOfCommonStock had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">'Monetary' elements on report '100180 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2013'</Log>
    <Log type="Info">Process Flow-Through: 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 100040 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>vsar-20150331.xml</File>
    <File>vsar-20150331.xsd</File>
    <File>vsar-20150331_cal.xml</File>
    <File>vsar-20150331_def.xml</File>
    <File>vsar-20150331_lab.xml</File>
    <File>vsar-20150331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2BAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Stock-Based Compensation Expense (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 1,988</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 426</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">604</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">124</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">$ 1,384</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">$ 302</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
